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Abstract 
The overall contribution of this thesis is to advance both methodology and 
practice. This thesis contributes to Bayesian spatial and spatiotemporal 
methodology by investigating techniques for spatial imputation and joint disease 
modelling, and identifies high-risk individual profiles and geographic areas for 
type II diabetes mellitus (DMII) outcomes. This research is of particular 
significance to researchers involved in public health and epidemiological 
modelling who are seeking to expand their understanding of hierarchical, spatial, 
spatiotemporal and joint modelling methods for health applications. 
 
This thesis focuses primarily on spatiotemporal modelling of DMII, and 
secondarily on other related chronic conditions. DMII is increasing in every 
country of the world, and diabetes complications are the leading cause of hospital 
admissions in Australia (25.6%) (Page et al. 2007). DMII and related chronic 
conditions including hypertension, coronary arterial disease, congestive heart 
failure and chronic obstructive pulmonary disease are examples of ambulatory 
care sensitive conditions for which hospitalisation for complications is potentially 
avoidable with quality primary care. 
 
Many areas around the world, including the US and the UK, are suffering from a 
shortage of primary care services for DMII (Bono et al. 2004, Diabetes U.K. 
2012b). Bayesian spatial and spatiotemporal studies highlighting small areas 
most at risk for DMII prevalence, incidence and adverse outcomes are useful for 
identifying those areas that would benefit from additional services to detect and 
manage DMII early, thus avoiding costly sequelae. Furthermore, they have the 
potential to detect underlying geographic factors specific to one or common to 
multiple diseases that are amenable to health promotion programmes. A problem 
is that there are as yet few such studies examining DMII outcomes across small 
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areas. This thesis directly addresses this gap in knowledge and develops new 
methodology and new applications for DMII-specific and joint disease spatial and 
spatiotemporal modelling within a Bayesian generalised linear mixed model 
framework. 
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Chapter 1: Introduction 
The rising prevalence of chronic diseases worldwide and subsequent 
hospitalisation has led to great economic strain on healthcare systems around the 
world and high social and quality of life costs (Byrd 2009, Clancy 2005, Kirby et 
al. 2010, Longman et al. 2012). Diseases such as type II diabetes mellitus, chronic 
obstructive pulmonary disease, coronary arterial disease, hypertension and 
congestive heart failure are classified as ambulatory care sensitive conditions, for 
which hospitalisation for complications can be avoided with quality primary care 
(Billings et al. 1990). Thus hospitalisation for these conditions is often used as a 
proxy for avoidable hospital admissions (Longman et al. 2012). Both the 
prevalence and hospitalisation rates for these chronic diseases can potentially be 
reduced by targeting geographic regions most at risk for aetiological factors of 
these diseases for early detection and disease management (Billings et al. 1990). 
Thus spatial analysis is useful to inform public policy and resource allocation 
(Elliot et al. 1992). The overall purpose of this thesis is to develop methodology 
for the spatial analysis of chronic disease outcomes and underlying aetiology. 
 
The term spatial data can refer to geo-referenced data that is aggregated over 
defined geographic regions such as Local Government Area (LGA) and 
Statistical Local Area (SLA) in Australia, or aggregated to small areas on a grid 
or lattice structure, or it can refer to point-referenced data which pinpoint the 
exact latitude and longitude of each individual datapoint for both the cases and 
the population or control data (Best et al. 2005). The data may be continuous or 
discrete, and their spatial locations may be regular or irregular (Besag 1974, 
Cressie 1993). It is more common for spatial data to be routinely available in 
aggregated form at defined geographic levels and this avoids the ethical and 
confidentiality issues associated with point-level data (Best et al. 2005). 
Furthermore, by aggregating measurements over multiple persons, data may be 
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associated with less measurement error than individual data (Elliot et al. 1992). 
When collected over multiple timepoints, spatiotemporal analysis is possible to 
examine temporal trends and for future prediction specific to individual regions 
(Bernardinelli et al. 1995b). 
 
Spatial data aggregated to defined LGA and SLA geographic levels have been 
commonly used in spatial analyses of disease risk in Australia and is the focus of 
this thesis (Longman et al. 2012). Some sources of geo-referenced spatial data at 
LGA and SLA level include survey data, Census data, routinely collected hospital 
data and data from registries, all of which have been utilised in this thesis. Full 
descriptions of these sources of data are provided in Appendix A. 
 
Spatial analyses of interest to this thesis include generalised linear mixed models 
(GLMMs) formulated as hierarchical models, joint analysis of multiple diseases 
and spatiotemporal models. All of these methods are useful to highlight regions 
most at risk for chronic disease outcomes and underlying aetiological factors. 
However, two common problems with spatial data aggregated to small area levels 
are sparse data and missing data (Best et al. 2005). Bayesian GLMMs are well-
suited to modelling spatial variations in disease outcomes accounting for different 
sources of uncertainty (Best et al. 2005). For sparse data, incorporation of 
spatially correlated priors for residual error allows for more robust inferences by 
“borrowing strength” across neighbouring regions to reduce the variance using 
shrinkage estimators (Banerjee et al. 2004, Besag et al. 1991, Best et al. 2005). 
Use of spatially correlated priors can also be a useful method for imputation of 
missing outcome or covariate information (Williams 1998). 
 
GLMMs formulated as hierarchical Bayesian models allow the exploration of 
individual- and group-level risk factors nested within spatial and temporal effects 
(Gelman et al. 2013). The incorporation of spatial and temporal effects allowing 
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for various types of spatiotemporal interaction allows us to (a) identify regions 
most at risk of increasing temporal trends in disease outcomes that would benefit 
most from additional resources and interventions, and (b) build future predictive 
models specific to both region and time (Bernardinelli et al. 1995b). Furthermore, 
Bayesian methods lend themselves well to model comparison through a suite of 
posterior predictive fit checks (Carlin et al. 2009). 
 
Several chronic diseases share common aetiological factors, and the joint 
modelling of these diseases within a Bayesian framework allows distinction 
between shared and disease-specific risk factors (Tzala et al. 2008). The resulting 
identification of regions with a large shared risk component for multiple diseases 
is useful to inform resource allocation, with the potential to reduce the burden of 
multiple disease outcomes simultaneously by targeting these regions and shared 
risk factors (Tzala et al. 2008). 
 
By harnessing the power of this diverse array of methods for modelling chronic 
disease outcomes accounting for underlying aetiology, the decision-maker is 
well-placed to identify ways to improve health outcomes accounting for spatial, 
temporal and shared effects. 
1.1 Aims and objectives 
The overarching purpose of this thesis is to develop methodology for the spatial 
analysis of chronic disease outcomes and underlying aetiology. The aims and 
objectives underlying this thesis have a dual focus. 
 
There are two-fold aims, to understand the statistical background behind the 
development of models and methods, and to understand the applications of these 
methods. 
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Congruent with these two aims, there are two sets of objectives: objectives with 
a methodological focus, and objectives with an applied focus. 
 
The methodological objectives are as follows: 
M1: To develop an understanding of and to extend upon generalised linear mixed 
modelling methods used for Bayesian spatial modelling 
M2: To develop an understanding of and to extend upon the methods used for 
Bayesian spatiotemporal modelling 
M3: To develop an understanding of and to extend upon the methods used for 
multiple outcome modelling 
M4: To develop an understanding of and to extend upon the methods used for 
dealing with missing data 
M5: To develop an understanding of the methods used for model comparison 
 
This thesis aims to explore spatial and temporal patterns of chronic disease 
prevalence and hospitalisation incidence in Australia, and their association with 
each other and with geographical risk factors, focussing initially on type II 
diabetes mellitus (DMII) and related disorders. To this end, four applied 
objectives are defined as follows: 
 
A1: To apply the methodology developed in meeting objectives M1-M5 to 
identify geographical patterns and inequalities in prevalence and hospitalisation 
incidence of DMII, and changes in spatial patterns over time 
A2: To apply the results of M3 to the modelling of multiple disease outcomes, 
specifically DMII, chronic obstructive pulmonary disease, coronary arterial 
disease, hypertension and congestive heart failure 
A3: To identify individual and geographic risk factors associated with DMII and 
related chronic diseases 
4
A4: To develop spatially and temporally specific predictive models for the next 
five years of DMII prevalence 
 1.2 Thesis overview 
The structure of this thesis is described as follows. Chapter 2 comprises a review 
of the literature pertaining to methodologies relevant to this thesis. 
Methodologies reviewed include the Bayesian framework, Bayesian GLMMs for 
spatial, spatiotemporal, and joint disease modelling, dealing with missing spatial 
data and model comparison. Chapters 3, 4, 5, 6, and 7 each represent a paper that 
has been published or submitted to a journal for publication. 
 
Chapter 3 addresses methodological objectives M1 and M3, and presents a  
comprehensive systematic review of the literature, identifying all spatial studies 
that examine DMII outcomes, with a descriptive summary of methodologies used 
in these studies. This work has been published in Royal Society Open Science: 
 
Baker J, White N, Mengersen K. Spatial modelling of type II diabetes outcomes: 
a systematic review of approaches used. Royal Society Open Science. 
2015;2(6):140460 
 
Chapter 4 addresses methodological objectives M1, M4 and M5, and applied 
objectives A1 and A3. Methodology is described and compared for the 
imputation of missing spatially correlated data. Using the selected method, 
individual and spatial factors associated with DMII prevalence across 
Queensland Local Government Areas (LGAs) are examined using Bayesian 
spatial generalised linear mixed models. This work has been published in 
International Journal of Health Geographics: 
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Baker J, White N, Mengersen K. Missing in space: an evaluation of imputation 
methods for missing data in spatial analysis of risk factors for type II diabetes. 
International Journal of Health Geographics. 2014;13:47 
 
Chapter 5 addresses methodological objectives M1 and M5, and applied 
objectives A1 and A3. An application to real clinical practice is presented using 
routinely collected New South Wales (NSW) hospital data. Individual 
demographic and clinical factors nested within spatial effects are modelled, and 
the associations between DMII and four other chronic diseases are explored for a 
range of hospital outcomes. 
 
Chapter 6 addresses methodological objectives M2, M3 and M5, and applied 
objectives A1, A2 and A3. Three variant formulations of a shared component 
model are developed that are useful for future prediction of disease outcomes 
specific to region, time and disease. A shared component can be defined as the 
spatially-varying latent risk factors that are common to multiple diseases included 
in the model (Knorr-Held et al. 2001). 
 
Chapter 7 addresses methodological objectives M2, M4 and M5, and applied 
objectives A1 and A4. A variety of spatiotemporal models are compared 
accounting for non-linear temporal trends and different types of space-time 
interaction. The prediction of DMII prevalence in Queensland specific to region 
and year is used as a case study,  
 
Finally, Chapter 8 provides a summary and discussion of the outcomes of this 
research and the implications for public health. Furthermore, the contributions of 
this thesis are discussed. The chapter concludes with recommendations for future 
work and applications of the methodology described. 
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Thus, the thesis leads from an overview of the current state of knowledge of 
Bayesian spatiotemporal modelling for chronic disease, through extensions on 
these methodologies for the purposes of imputation, multilevel hierarchical 
modelling, joint disease modelling and spatiotemporal modelling, to a discussion 
of the applied and methodological implications of this research and 
recommendations for further work. 
  
7
  
8
Chapter 2: Literature Review and 
Background 
This section of the thesis presents an overview of the current state of literature 
pertaining to the global burden of type II diabetes mellitus and related chronic 
disease, followed by a review of statistical models relevant to this research. This 
includes a description of the Bayesian framework for inference and a comparison 
to frequentist inference, followed by a description of methodology for sensitivity 
analyses, hierarchical models, spatial GLMMs, spatiotemporal models, and a 
critique of joint disease models. Following this are sections on dealing with 
missing data and model comparison. Finally, the section concludes by 
highlighting gaps in the literature that are addressed by this thesis. 
 
A number of sections in this Chapter are related to background material necessary 
for understanding more complex models presented in this thesis. For these 
sections, a seminal textbook in statistical inference (Barnett, 1999) has been used 
as the key reference and will be cited at the beginning of each relevant section. 
2.1 The global burden of type II diabetes 
The emerging pandemic of type II diabetes mellitus (DMII) in both developed 
and developing countries is evidenced by increasing prevalence in every country 
of the world (International Diabetes Federation 2014). The costs from 
hospitalisation for DMII sequelae are a growing concern (International Diabetes 
Federation 2014). Service provision cannot keep up with increasing numbers of 
DMII cases in some parts of the world, and a “state of crisis” in diabetes care was 
recently reported in the United Kingdom (Diabetes U.K. 2012b). One study 
examining temporal trends in hospitalisation incidence for diabetes found an 
exponential increase between 1981 to 2000 (Premaratne et al. 2005). 
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The estimated number of people with diabetes worldwide was 387 million people 
in 2014, projected to increase to 592 million by 2035, affecting 11.3% of the US 
and 4.45% of the UK adult population, with DMII accounting for 90-95% of all 
diabetes cases (Diabetes U.K. 2012a, Holden et al. 2013, International Diabetes 
Federation 2014). In Australia, the number of people diagnosed with DMII has 
increased from ~200,000 to almost 1 million cases from 1989 to 2014, and 4.1% 
of men and 2.9% of women are currently estimated to suffer from 
DMII(Australian Bureau of Statistics 2009). It is estimated that the direct and 
indirect costs of diabetes combined exceeded USD 612 billion in the US in 2014, 
£23.7 billion in the UK in 2011 and AUD 14.6 billion in Australia in 2010, and 
DMII represents 90-95% of diabetic cases (American Diabetes Association 2008, 
American Diabetes Association 2013, Lee et al. 2013, National Diabetes 
Information Clearinghouse 2011). 
 
This disabling chronic condition is associated with enormous social and 
economic costs and health care burdens (Askew et al. 2009). The management of 
DMII is time-consuming and complicated. Management may require complex 
medication plans, regular general practitioner and specialist appointments, 
modification of lifestyle, frequent blood glucose tests and podiatry consultations 
(Australian Bureau of Statistics 2009). DMII is a progressive disorder and may 
lead to secondary cardiovascular, renal, neuropathic and retinal sequelae which 
are functionally debilitating and costly to treat (Elley et al. 2010, Stewart et al. 
2006). DMII is reported to be the seventh leading cause of death in the US, and 
the leading cause of renal failure, nontraumatic lower-limb amputation, new cases 
of blindness, and a major cause of heart disease and stroke (Centers for Disease 
Control and Prevention 2011).  
 
Regions identified as being at high risk for DMII prevalence and underlying risk 
factors stand to benefit from screening programmes for early detection, and 
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additional resources for closer management of DMII at a primary care level 
(Billings et al. 1990). Through early detection of DMII, management of 
glycaemic control and cardiovascular risk factors, the potential exists to improve 
treatment effects and reduce the risks of long-term complications and 
hospitalisation (Harris et al. 2000, Liese et al. 2010). Furthermore, by screening 
for undiagnosed cases of DMII with fasting plasma glucose tests, it may be 
possible to decrease the overall health costs of DMII (Harris et al. 2000). Indeed, 
there is increasing evidence from around the world that around 60% of DMII 
cases are preventable with medications and/or lifestyle changes (Palmer et al. 
2012). 
 
Several demographic and clinical factors and metabolic markers have been found 
to be associated with DMII risk for individual patients (Bocquier et al. 2011, 
Egede et al. 2011, Green et al. 2003, Noble et al. 2011, Weng et al. 2000). These 
are summarised in Table 2.1. Many of the factors listed are modifiable. Individual 
risk factors for diagnosis with DMII are known to include increasing age, BMI 
and waist:hip ratio, male gender, indicators of low socio-economic status, 
sedentary lifestyle, physical inactivity, smoking history, and low levels of fruit 
and vegetable consumption (Bocquier et al. 2011, Egede et al. 2011, Green et al. 
2003, Noble et al. 2011, Weng et al. 2000). 
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Table 2.1 Demographic, clinical and metabolic factors associated with increased 
risk of developing type II diabetes mellitus 
Demographic factors Clinical factors Metabolic markers 
Male gender Hypertension Elevated fasting plasma glucose 
Increasing age Cardiovascular disease 
Elevated two-hour post-prandial 
glucose 
Increasing BMI Tachycardia Elevated random glucose 
Indicators of low socio-economic 
status (education, income, occupation) 
Family history of diabetes in first 
degree relative 
Elevated triglyceride:high density 
lipoprotein ratio 
Increasing waist.hip ratio History of gestational diabetes White cell count 
Increasing waist:height ratio Corticosteroid use Elevated HbA1c 
Black/Hispanic ethnicity   Elevated Ga-glutamyl transpeptidase 
Sedentary lifestyle/physical inactivity   Elevated adiponectin 
Smoking history   Elevated C-reactive protein 
Excessive alcohol use   Elevated ferritin 
Low levels of fruit and vegetable 
consumption   
Elevated interleukin-2 receptor A 
Poor environmental quality   Elevated insulin level 
 
 
In addition, there is increasing evidence from spatial studies conducted in the US, 
UK, Canada and Europe of spatial variation in DMII outcomes due to geographic 
factors (Bocquier et al. 2011, Chaix et al. 2011, Congdon 2006, Geraghty et al. 
2010, Green et al. 2003, Kravchenko et al. 1996, Lee et al. 2008, Liese et al. 2010, 
Noble et al. 2011, Weng et al. 2000). To date, these studies represent only a small 
number of countries (Baker et al. 2015). Furthermore, there is a gap in the 
literature of spatial studies that examine the contribution of other lifestyle factors, 
such as overweight/obesity, physical activity levels and fruit and vegetable 
consumption to DMII risk at a regional level (Baker et al. 2015). 
 
No geographical studies mapping DMII prevalence and incidence, and associated 
risk factors, have previously been undertaken in Australia (Baker et al. 2015). 
The spatiotemporal exploration of these factors would be useful in building 
geographically and temporally specific predictive models for DMII in the 
Australian population. Analysis of regional differences in DMII incidence may 
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be useful in providing information for more targeted management, resource 
allocation and policy decisions. This gap in the literature is addressed in Chapter 
4, which examines geographic risk factors for DMII prevalence in Queensland. 
 
Although factors associated with DMII diagnosis have been described in the 
literature, little is known about individual, clinical and geographic risk factors 
(including comorbidity with related diseases) associated with hospitalisation for 
DMII complications and adverse inpatient outcomes for these patients, and this 
is the subject of Chapter 5. 
 
Joint geographical patterns of hospital admissions for DMII, chronic obstructive 
pulmonary disease (COPD), coronary arterial disease (CAD), hypertension (HT) 
and congestive heart failure (CHF) are further explored with the addition of 
temporal components for each disease in Chapter 6. Identifying areas most at risk 
for multiple diseases admissions allows targeting of risk factors shared across all 
diseases (Tzala et al. 2008). 
 
In Chapter 7, spatial models are expanded upon by building predictive 
spatiotemporal models for DMII prevalence in Queensland specific to region and 
year, with the aim of identifying regions with the most rapidly increasing 
prevalence rates that would benefit most from additional services. 
 
Thus, a range of applications are presented for spatiotemporal modelling of DMII 
outcomes and associated chronic disorders, in order to inform public policy and 
resource allocation for improved outcomes of DMII in Australia. 
2.2 The global burden of chronic disease 
The prevalence of chronic disease worldwide is increasing, and placing a growing 
burden to health services in Australia and internationally (Byrd 2009, Clancy 
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2005, Kirby et al. 2010, Longman et al. 2012). Costs are both economic and 
social, in terms of decreased quality of life and decreased productivity (Byrd 
2009). There is evidence that complications of chronic diseases such as DMII, 
COPD, CAD, HT and CHF, which are classified as ambulatory care sensitive 
(ACS) conditions, can be largely prevented with quality primary care (Billings et 
al. 1990). These five conditions are often used as a proxy for avoidable hospital 
admissions (Billings et al. 1990, Longman et al. 2012). The concept of using ACS 
conditions as a proxy for avoidable hospital admissions was first introduced in 
1990 (Billings et al. 1990). Residents of areas with indicators of socio-economic 
deprivation have been shown to be at significantly greater risk of avoidable 
hospital admissions (Laditka et al. 2005, Roos et al. 2005) and emergency 
admissions after adjusting for other risk factors (Purdy 2010). Individuals of 
lower socioeconomic status (SES) are also more at risk for preventable 
hospitalisation even after adjusting for severity of illness (Blustein et al. 1998). 
 
In Australia, the leading cause of avoidable hospitalisations are diabetes 
complications, and together with COPD and angina due to CAD, these conditions 
account for almost one half (44.5%) of all avoidable hospital admissions (Page et 
al. 2007). Type II diabetes mellitus (DMII) accounts for 90-95% of all cases of 
diabetes (Diabetes U.K. 2012a, Holden et al. 2013, International Diabetes 
Federation 2014) and has been shown to be associated with other ACS conditions 
including COPD (Mannino et al. 2008, Rana et al. 2004), CAD (Bartnik et al. 
2004, Kannel et al. 1979, Turner et al. 1998), HT (Sowers et al. 2001) and CHF 
(Kannel et al. 1974, Nichols et al. 2004), and hospitalisation for these conditions 
may be for secondary complications of DMII. Early detection and management 
of DMII and other ACS conditions has the potential to reduce long-term 
complications and hospitalisation (Billings et al. 1990). 
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2.3 Statistical models 
This section begins with a discussion of statistical models in general, followed by 
a description of the characteristics of the traditional frequentist and newly-
popular Bayesian approaches to inference, ending with a summary of the 
important distinctions between these two approaches to statistical inference. 
 
Firstly, statistics may be defined as “the study of how information should be 
employed to reflect on, and give guidance for action in, a practical situation 
involving uncertainty” (Barnett 1999). A practical situation involving uncertainty 
is one where multiple outcomes are possible, and it is impossible to know in 
advance what the actual outcome will be. Construction of a theory to help guide 
action in situations such as these depends on building a formal model of the 
situation, and formulation of the concept of probability. The model is an 
approximation of the practical situation and is a statement of the set of possible 
outcomes and the probabilities that describe the pattern of outcomes that might 
be seen. The validity of the model thus depends on how appropriate the 
assumptions made are, for example, assumptions of random and independent 
processes, and assumed probability distributions of random effects and 
parameters in the model. Effects can be “fixed” or “random”, where a fixed effect 
is assumed to be measured without error, and a random effect is a source of 
random variability, eg. a random sample drawn from a larger population. After 
fitting the model, a comparison of observed values to predicted values from the 
statistical model can be used to test the model’s goodness of fit, as well as to 
estimate parameters of interest. The value of a statistical analysis for a given 
situation depends upon the adequacy of the model. 
 
For a given dataset, let us define the observed data as (𝑦: 𝑧), where 𝑦 is the 
observed value of a vector random variable 𝑌, and 𝑧 is treated as fixed (Cox 
2006). Let us define 𝜓 as a vector of parameters in the model, which can be 
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separated into parameters (𝜃, 𝜑) where 𝜃 is the parameter of interest and 𝜑 are 
the nuisance parameters completing the specification of the model (Cox 2006). 
The parameter of interest should have a clear interpretation in terms of the 
research question and subject matter, for example, as a rate of change, difference, 
or properties such as energy, mass etc. (Cox 2006). 
 
A statistic 𝑆(𝜃) is said to be sufficient for 𝜃 if the entirety of information about 
𝜃 that is contained in the dataset can be obtained from the sampling distribution 
of 𝑆(𝜃) alone (Barnett 1999). The conditional distribution of 𝑌, given 𝑆(𝜃), does 
not depend on 𝜃 (Barnett 1999, Cox 2006). 𝑆(𝜃) is generally of a lower 
dimension than 𝑌, leading to a reduction in the dataset without losing any 
information about 𝜃 (Cox 2006). The Fisher-Neyman Factorisation Criterion can 
be used to show that 𝑆(𝜃) is sufficient for 𝜃 as follows (Barnett): 
 
𝑝(𝑦) = 𝑔(𝑆)ℎ(𝑦) 
 
If the likelihood 𝑝(𝑦) can be factorized into the product of two functions, of 
which one is a function of 𝑆(𝜃) alone, and the other is a function of 𝑦 not 
involving 𝜃 then the criterion is satisfied (Barnett 1999). 𝑆(𝜃) is defined as 
minimally sufficient if two criteria are met: first, if 𝑆(𝜃) is sufficient and second, 
if no statistic of a lower dimension is sufficient. If 𝑆(𝜃) is minimally sufficient 
then the elements of 𝑆(𝜃) make up the the minimal set of sufficient statistics 
(Barnett 1999). 
 
Two major approaches to statistical inference are frequentist and Bayesian 
methods. There are several distinctions between the two methods, which are the 
subject of the following section. A description of frequentist followed by 
Bayesian methods ensues, then a summary of distinctions between the two. 
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2.3.1 Bayesian vs frequentist inference 
Frequentist methods 
The foundations of frequentist approaches to statistical inference were laid 
through the work of Fisher, Neyman, Pearson and others. These approaches 
depend on a frequency interpretation of probability and are designed for the 
processing of sample data alone (Barnett 1999). They are also termed classical 
due to their earlier origin and wider application than Bayesian inference (Barnett 
1999). Linear regression was first described by Galton in the late 1800s, followed 
by correlation and goodness-of-fit measures by Karl Pearson in the 1900s (Carlin 
et al. 2009). The use of likelihood for general estimation appeared from the work 
of Fisher and classical hypothesis testing from Jerzy Neyman and Egon Pearson 
in the late 1920s-30s (Carlin et al. 2009). 
 
Frequentist theory is free from subjective assessments and is based entirely on 
quantifiable sample data (Cox 2006). The initiators chose not to incorporate prior 
information, believing that such information would seldom be objective (Barnett 
1999). Therefore, sample data is used as the only source of relevant information 
in making inferences (Barnett 1999). 
 
The outcomes that are observed in the sample data are assumed to stem from 
independent repeated trials of the situation under identical circumstances (Barnett 
1999). Thus, the observed data for any particular situation is viewed as one of a 
hypothetical infinite sequence of similar samples, and is viewed as representative 
or typical of a larger population. Thus, probability is related to inferences in the 
larger population, and arguments involving probability are via their long-run 
frequency. 
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The parameter of interest, 𝜃, is regarded as an unknown constant (Cox 2006). In 
a hypothetical long run of statements about 𝜃 with significance level 𝛼, a 
proportion 1 − 𝛼 are expected to be correct (Barnett 1999, Cox 2006). A fallacy 
is that it is impossible to know for any one given sample if 𝜃 falls within the 
proportion that are correct or not (Barnett 1999). 
 
Frequentist methods include a set of “stylised procedures”. These include 
procedures for point or interval estimation or hypothesis testing. These 
procedures have been constructed to satisfy or optimize ad hoc criteria (Barnett 
1999, Bernardo et al. 1994). These procedures generally use sufficient statistics 
(Barnett 1999). The performance of methods used in these procedures are 
assessed by setting criteria based on sampling distributions. For example, there 
may be a requirement for point estimators to be unbiased or consistent.  Sample 
data are represented through their likelihood, and hypothesis tests are based on 
the tail-area probabilities of the likelihood. Measures of reliability and accuracy 
are in the form of standard errors or efficiency determinations.  
 
The procedures for assessing evidence using point or interval estimation or 
hypothesis testing are based on how they would perform if used repeatedly over 
an infinite number of trials, and this raises issues regarding the relevance of 
inferences about the long run to a particular application (Cox 2006). The 
probability interpretation of a frequentist confidence interval is as a random 
region containing the fixed value of 𝜃 - the probability of this interval containing 
𝜃 is in terms of repeated trials of the experimental situation (Cox 2006). It is 
impossible to judge whether or not a particular frequentist confidence interval 
does or does not contain 𝜃 (Barnett 1999, Cox 2006). 
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Bayesian methods 
The Bayesian approach to statistical inference originates from the theory of 
inverse probability introduced by Thomas Bayes in 1763, known as Bayes 
Theorem (Barnett 1999). Interest in Bayesian inference spread from the 1950s 
with the work of Ramsey, Jeffreys, Lindley, Savage and others, and Bayesian 
methods for inference received new impetus since the 1990s with the advent of 
more efficient computing technology. The formulation for Bayes Theorem is as 
below: 
𝑝(𝜃|𝑌) =
𝑝(𝑌|𝜃)𝑝(𝜃)
𝑝(𝑌)
 
               =
𝑝(𝑌|𝜃)𝑝(𝜃)
∫ 𝑝(𝑌, 𝜃)𝑑𝜃
 
                        =
𝑝(𝑌|𝜃)𝑝(𝜃)
∫ 𝑝(𝑌, 𝜃)𝑝(𝜃)𝑑𝜃
 
   (2.1) 
where  𝑝(𝜃|𝑌) is defined as the posterior probability of 𝜃 given the random 
variable of interest 𝑌, 𝑝(𝑌|𝜃) as the likelihood of 𝑌 given 𝜃, 𝑝(𝜃) as the prior 
probability of 𝜃, and 𝑝(𝑌) is a normalising constant representing the probability 
of 𝑌, which is not dependent on 𝜃. The likelihood is the probability of observing 
the events when the hypothesis/model is the correct specification (Barnett 1999). 
Equation (2.1) can be simplified as follows: 
 
   𝑝(𝜃|𝑌) ∝  𝑝(𝑌|𝜃)𝑝(𝜃) 
 
That is, the posterior distribution is proportional to the likelihood and the prior 
(Gelman et al. 2013). 
 
In the context of Bayesian inference, Bayes’ theorem can be interpreted as a way 
of using sample data to update an earlier state of  knowledge expressed as the 
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prior probabilities (Barnett 1999). Thus the inferential process incorporates both 
prior information and sample data. The prior information is updated by the sample 
data, resulting in a combined assessment of all knowledge relevant to the practical 
application. Final inferences are made solely through the posterior probability 
distributions, which carry their own measure of accuracy in the form of posterior 
credible intervals.  Bayesian inference is also known as the Inverse Probability 
approach due to the inversion of the order of target and conditioning events. 
 
Inferences about the posterior distribution can be computed either directly (ie. 
mathematically) or indirectly using Markov chain Monte Carlo (MCMC) 
stochastic simulation (Barnett 1999). Since the conception of the inverse 
probability approach of Bayesian inference, an initial problem has been the 
frequent mathematical intractability of posterior distributions. Even in simple 
situations, deriving the explicit form of 𝑝(𝜃|𝑌) and other useful summary 
measures, such as Bayesian point estimates and credible intervals, involves 
tedious and difficult calculations. Furthermore, a common feature of modern 
Bayesian methods is incorporation of a hyperprior structure which increases the 
dimensionality of the parameter space. In complex problems involving many 
parameters and possibly a hyperprior structure, the difficulties of mathematical 
computation of the posterior distribution are even more severe. It used to be very 
difficult or even impossible to evaluate integrals in the model, necessitating the 
use of approximations (Carlin et al. 2009). 
 
The development of more efficient computing technology since the 1990s has 
overcome the major obstacle to Bayesian inference – that although the detailed 
form of posterior distributions are often intractable, they can be estimated  
with MCMC simulation techniques through the use of computers (Barnett 1999). 
Over recent years, simulation techniques, especially the Gibbs sampler, 
Metropolis-Hastings algorithm and other sampling algorithms for the MCMC 
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approach, have been used to determine summary measures of 𝑝(𝜃|𝑌) in complex 
problems. The evaluation of integrals has historically been performed using 
simulation and Monte Carlo methods for quite some time, by re-formulating a 
deterministic problem in terms of probabilities. Due to the ergodicity properties 
of the Markov chain, accurate estimation and analyses are possible for very 
complex systems involving multiple parameters (Bernardo et al. 1994, Carlin et 
al. 2009). These methods will be described in detail in a later section. 
 
Within the framework of Bayesian inference, the parameter of interest, 𝜃, is now 
regarded as a random variable and is regarded as having a probability distribution 
both with and without the data (Cox 2006). Thus, different values of 𝜃 are 
associated with different probabilities, weights, or subjective degrees-of-belief 
(Cox 2006). Random variables can also be fit to nuisance parameters completing 
the specification of the model (Cox 2006). This allows the incorporation of 
different sources of uncertainty within the model (Cox 2006). In contrast, the 
frequentist framework regards 𝜃 as a fixed and unknown constant value (Cox 
2006). 
 
A direct probability assessment can be made of the parameter of interest for a 
specific situation without having to relate it to a long-run notion of probability 
(Barnett 1999). Bayesian point estimation of the most likely value for any 
parameter uses the mode of the corresponding posterior distribution. The 
posterior probability of the parameter of interest, 𝜃, measures in straightforward 
terms our inference about the probability expression of 𝜃. Thus a Bayesian 
credible interval may be interpreted as a region within which 𝜃 lies with 
prescribed probability, which has an appealing simplicity that cannot be 
attributed to the interpretation of frequentist confidence intervals. Inferences from 
all Bayesian analyses relate directly to the posterior without the need for separate 
theories of multiple comparison, testing and estimation. (Carlin et al. 2009). 
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 The prior information, based on earlier experience can be in the form of a past 
record, prior or expert knowledge or subjective degree-of-belief or value 
judgements (Barnett 1999). Often, in the presence of incomplete objective 
information, it is necessary to incorporate subjective or arbitrary values to 
complete a model specification. This is where a Bayesian model is useful. As 
quoted by Barnett (1999): “If prior information exists, it must surely be important 
to incorporate it through the methods of Bayesian inference”. Prior information 
must be quantified and expressed in terms of a prior probability distribution. It is 
important to observe rules of coherence to obtain a rational set of prior 
distributions, which is described in detail by Bernardo and Smith (1994).  Three 
broad categories of prior information include substantial prior knowledge, vague 
prior knowledge and prior ignorance (Barnett 1999). If no tangible prior 
information is available, prior ignorance can be expressed through the choice of 
uninformative/vague prior distributions. Detailed discussions on these subsets are 
provided by Barnett (1999) and Bernardo and Smith (1994) . This thesis focuses 
on the use of uninformative and conjugate priors. 
 
Often there is a lack of reliable prior information that is available for the 
parameters of the model, or inferences based solely on the sample data observed 
is desired. In these situations, using noninformative priors that do not favour any 
value of the parameter over another is appropriate (Gelman et al. 2013). The 
uniform distribution is an example of a noninformative prior, as a large range can 
be specified with equal probability for all values within the range (Bernardo et al. 
1994). When a vague prior distribution is used, it can always be outweighed in 
principle by a sufficiently large sample size of data whatever the extent of the 
prior information (Bernardo et al. 1994), leading to an asymptotic approach. This 
approach is known as the principle of precise measurement, which allows the 
interpretation of the normalised likelihood function as a representation of all 
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information about 𝜃 available from the sample, regardless of prior information 
about 𝜃 (Bernardo et al. 1994). Therefore, if the prior distribution is mis-specified 
in any way, this will not affect inferences about 𝜃, adding to the robustness of a 
Bayesian analysis where the principle of precise measurement is in effect 
(Bernardo et al. 1994). 
 
If the posterior distribution and the prior distribution are in the same family, then 
the prior and posterior are termed conjugate distributions, and the prior is termed 
a conjugate prior for the likelihood function (Barnett 1999). Mathematical 
computation is facilitated by using conjugate families of prior distributions, and 
they also allow a comparison between the contribution of the sample data and the 
prior information. Expression of prior information through conjugate families of 
prior distribution is of mathematical and interpretive convenience as it gives a 
closed form of the posterior without a difficult numerical integration. 
Furthermore, it allows an intuitive grasp of to what degree the likelihood updates 
the prior distribution leading to the posterior distribution. 
 
As an example, the Gaussian family is conjugate to itself (self-conjugate), thus if 
the likelihood is Gaussian, selecting a Gaussian prior for the mean will result in 
a posterior distribution that is also Gaussian (Barnett 1999). Similarly, a prior of 
the Gamma distribution is a conjugate prior for the Poisson likelihood and leads 
to a posterior distribution of the same type as the prior (Gamma distribution), 
eg: for the conjugate prior Gamma distribution with parameters 𝛼, 𝛽, that is 
𝜃~𝐺𝑎(𝛼, 𝛽), the posterior distribution takes the following form: 
 
𝑝(𝜃|𝑌) ∝ 𝑝(𝑌|𝜃)𝑝(𝜃) 
             ∝ (𝑒−𝜃𝜃𝑦)(𝜃𝛼−1𝑒−𝜃𝛽) 
                       ∝ 𝜃𝑦+𝛼−1𝑒−𝜃(1+𝛽) 
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 where the posterior distribution is a Gamma distribution with parameters 𝐺𝑎(𝑦 +
𝑎, 1 + 𝛽). 
 
Despite the mathematical convenience of conjugate priors, it is important to 
ensure that the selected prior accurately represents the true situation (Barnett 
1999). If a small set of sufficient statistics exists, this serves to reduce the 
dimensionality of the problem and the computational effort required to apply 
Bayesian methods, and is a prerequisite for using conjugate prior distributions 
(Barnett 1999, Carlin et al. 2009). 
 
The method of sampling in Bayesian inference (for example, a predetermined 
sample size vs. continued sampling until a certain criterion is met), does not affect 
the posterior distribution of 𝜃 after normalization, as the likelihood is unchanged. 
In contrast, estimates from frequentist approaches vary depending on the method 
of sampling (Barnett 1999, Carlin et al. 2009). For example, consider a coin-
tossing experiment where nine heads are obtained in twelve throws. Two possible 
methods of sampling that could result in this outcome are to do a predetermined 
set of twelve throws (Binomial distribution), or continue throwing until nine 
heads are obtained (Negative binomial distribution). The two sampling methods 
would lead to the same posterior estimates using Bayesian inference, but under 
the Neyman-Pearson testing structure of frequentist hypothesis testing, would 
lead to different interval estimates and different decisions from the hypothesis 
test using the usual 𝛼 = 0.05 (Carlin et al. 2009). 
 
Another advantage of Bayesian inference is the use of sequential learning for 
sequentially designed experiments, which can incorporate the information of 
newly observed data from each new experiment through a simple reweighting 
step using sequential Monte Carlo (Drovandi et al. 2013). A sequential Monte 
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Carlo approach to Bayesian sequential design is also useful for the incorporation 
of model uncertainty, where a parallel algorithm can be run for each rival model 
and subsequently combined for design selection (Drovandi et al. 2014). 
Comparison of methods 
This section discusses criticisms and controversy surrounding first frequentist 
then Bayesian methods of inference, and concludes with a summary of 
differences between the two approaches. 
 
Frequentist approaches to inference are often criticized for not incorporating prior 
information, even when this is available (Barnett 1999). Although they do not 
allow for formal incorporation of prior information, a consideration of such 
information is often necessary in order to decide what hypothesis to test or which 
significance levels to select. The choice of significance levels in the hypothesis 
test and consideration of consequences has been criticised for being arbitrary and 
subjective. Thus, claims of frequentist procedures being “objective” can be 
viewed as illusory as they depend on many assumptions about the data-generating 
mechanism, such as it being a simple (and often normally distributed) model free 
from confounding, selection bias, measurement error, etc. (Carlin et al. 2009). 
 
In addition, the frequency-based concept of probability in the form of long-run 
probabilities assumes that any given sample is one of an infinite number of similar 
trials, and that basic conditions do not change over repeated samples, which may 
not be a realistic assumption depending on the situation (Barnett 1999). Another 
assumption that is criticised is that sample size is predetermined. Inferences made 
from statistical procedures such as point and interval estimation and hypothesis 
testing are assessed in terms of their long-run behaviour. How valid is it to 
attribute aggregate properties over many trials to a specific situation? 
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An example of one such difficulty is the interpretation of confidence intervals. 
When a statistician reports a 95% confidence interval for a parameter in a 
particular problem, it may bear some relevance to the statistician’s accuracy in 
the long run (in the long run his advice is correct on 95% of occasions) (Barnett 
1999). However, the confidence interval is not relevant for assessing what we 
really know about that particular problem or situation. Similarly for prediction, 
95% confidence intervals for predictive inferences also cannot be interpreted in 
terms of what is expected to occur 95% of the time in the future – instead, the 
frequency interpretation is that in the long run, 95% similar sets of sample data 
would yield a predictive confidence interval that would accurately include future 
observations. 
 
In a one- or two-sided hypothesis test, the significance level 𝛼 provides upper 
and/or lower bounds for the long-run estimate of the parameter of interest, but 
cannot be interpreted as expressing the probability of incorrect acceptance or 
rejection for the current sample, nor does it measure the overall proportion of 
samples where the hypothesis is rejected or accepted (Barnett 1999). 
 
In contrast, Bayesian approaches to inference have been criticised for 
incorporating intangible prior information, often based on subjective information 
or degrees-of-belief, which can be viewed as a lacking objectivity (Barnett 1999). 
In addition, they demand that prior information be included even when it is vague, 
subjective or non-existent. The quantification of subjective prior information can 
be criticised as arbitrary, and the use of non-informative or reference priors is 
also criticised. 
 
Bayesian approaches often require a higher-dimensional parametric specification 
than a frequentist analysis, which can lead to difficulties in determining what the 
required posterior probability distributions are (Barnett 1999). However, methods 
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such as the Gibbs sampler and other MCMC procedures can be used to 
circumvent this problem. Caution is required with transformations of the data, as 
point estimates are not invariant with respect to transformation of the parameter 
space within the Bayesian framework. Therefore, alternative parameterisations of 
the model can lead to different inferences being drawn from the same sample 
data. 
 
In summary of the above section, the main distinctions between the two 
approaches can be categorized as follows: 
- Incorporation of prior information: the frequentist framework incorporates data 
from the current sample only, whereas the Bayesian framework requires the 
incorporation of both prior information and sample data. 
- View of probability: the frequentist framework takes a long-run view of 
probability, whereas the Bayesian framework allows a more direct interpretation 
of estimated probability for one particular situation. 
- Properties of parameters: the frequentist framework views the parameter of 
interest as a fixed, unknown constant, whereas the Bayesian framework views 
parameters as random variables – thus it can incorporate different sources of 
uncertainty within a model 
- Structure: the frequentist approach focuses on a set of stylized procedures 
designed to satisfy an ad hoc criterion, whereas the Bayesian approach can easily 
structure specific problems within a tailored framework with tailored solutions to 
problems 
- Dimensionality: frequentist models generally have a lower-dimensional 
parametric specification than Bayesian models, especially those with a hyperprior 
structure. In view of this, Bayesian models can take longer computational time 
compared with frequentist models. 
- Effect of sampling method: different methods of sampling often lead to different 
inferences under the frequentist, but not the Bayesian framework. 
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Markov chain Monte Carlo (MCMC) 
This section describes MCMC methods overall, details the steps of the popular 
Metropolis-Hasting algorithm and Gibbs sampler, and concludes with a 
description of tests of chain convergence. A Markov chain, named after Andrey 
Markov, is a random process that transitions from one state to another on a state 
space containing a finite number of states (Markov 1906). The probability 
distribution of the next state depends only upon the value of the current state and 
not on the values of any of the preceding states (Markov 1971). This property of 
“memorylessness” is also known as the Markov property (Markov 1971). Monte 
Carlo sampling, named after the city famous for its casinos, refers to random 
sampling from a wide variety of probability distributions (Carlin et al. 2009). 
 
Combining the two concepts results in Markov chain Monte Carlo methods 
(Carlin et al. 2009). These use Monte Carlo random sampling to sequentially 
sample parameter values from a Markov chain which has the property that its 
stationary distribution matches the desired joint posterior distribution of interest 
(Carlin et al. 2009). The Markov chain begins at assigned or arbitrary initial 
values for parameters of interest, and generally converges to posterior values for 
each parameter, building upon previous values to generate the next sets of values 
(Carlin et al. 2009). Several MCMC algorithms are available including the 
Metropolis-Hastings algorithm (Hastings 1970, Metropolis et al. 1953) and the 
Gibbs sampler (Geman et al. 1984), which are the most popular. Other methods 
including reversible jump MCMC are available to model situations involving 
dimension changes (Gelman et al. 2013, Green 1995). It is important to test 
convergence of the chain, and various tests of convergence are available – these 
are discussed later in this section (Carlin et al. 2009). 
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The Metropolis-Hastings Algorithm 
The Metropolis-Hastings Algorithm is an MCMC method which is used to 
produce a sequence of random samples from a probability distribution from 
which it is difficult to obtain direct samples (Hastings 1970, Metropolis et al. 
1953). The value of this sequence is that is allows an approximation of the 
distribution and the generation of a histogram of the distribution (Hastings 1970, 
Metropolis et al. 1953). The algorithm was first described by Nicolas Metropolis 
et al. in 1953 for a canonical ensemble and extended to a more general case by 
W.K. Hastings in 1970 (Hastings 1970, Metropolis et al. 1953). At each new 
iteration 𝑤, an arbitrary candidate generating function 𝑄(𝜃𝑤, 𝜃∗) is used to 
generate candidate sample value 𝜃∗ for parameters to be estimated, 𝜃, based on 
the current sample value (Hastings 1970, Metropolis et al. 1953). The distribution 
of the next sample depends only on the current sample value, producing a Markov 
chain (Hastings 1970, Metropolis et al. 1953). All parameters 𝜃 = (𝜃1, … , 𝜃𝛥) are 
updated by the algorithm simultaneously (Hastings 1970, Metropolis et al. 1953). 
𝑄(𝜃𝑤, 𝜃∗) gives the probability of the new sample 𝜃∗ being observed given the 
current sample 𝜃𝑤 (Hastings 1970, Metropolis et al. 1953). The next candidate 
sample value is then accepted or rejected (Hastings 1970, Metropolis et al. 1953). 
The acceptance ratio is represented by min (1,
𝑓(𝜃∗)𝑄(𝜃∗,𝜃𝑤)
𝑓(𝜃𝑤)𝑄(𝜃𝑤,𝜃∗)
) (Hastings 1970, 
Metropolis et al. 1953). 
 
The steps of the Metropolis-Hastings Algorithm are outlined below (Hastings 
1970, Metropolis et al. 1953). 
 
1. Initialisation: select an initial value for 𝜃1, for iteration 𝑤 = 1. 
2. Generation: Generate 𝜃∗ from function 𝑄(𝜃𝑤, . ) and 𝜖 from 𝑈𝑛𝑖(0,1). 
3. Acceptance or rejection: Let 𝜃𝑤+1 = 𝜃∗ if 𝜖 ≤ min (1,
𝑓(𝜃∗)𝑄(𝜃∗,𝜃𝑤)
𝑓(𝜃𝑤)𝑄(𝜃𝑤,𝜃∗)
), 
otherwise let 𝜃𝑤+1 = 𝜃𝑤. 
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4. Next iteration: increment 𝑤 = 𝑤 + 1. If 𝑤 < 𝑊, where 𝑊 is the total 
number of iterations to be performed, then return to Step 2. 
 
Samples from the beginning of the chain (known as the burn-in period) may not 
accurately represent the desired distribution and are typically discarded (Hastings 
1970, Metropolis et al. 1953). A good review on the algorithm is provided by 
(Chib et al. 1995). 
 
Gibbs Sampler 
The Gibbs Sampler is an MCMC method for obtaining a sequence of observations 
which are approximated from the joint probability distribution of two of more 
random variables and the observed data 𝑦 (Geman et al. 1984). This sequence can 
be used to approximate the joint distribution and the marginal distribution of one 
or more of the variables (Geman et al. 1984).  
 
For some of the variables, values may already be known from the observations 
they relate to, and therefore do not need to be sampled (Geman et al. 1984). A 
Markov chain of samples is generated through Gibbs sampling, with the property 
that each sample is correlated with its neighbouring samples (Barnett 1999, 
Geman et al. 1984). If independent samples are desired, care must be taken to 
thin the resulting chain, eg. by taking every 𝑛th value only, such as every 100th 
value (Barnett 1999). If the thinning factor is large enough then the resulting 
MCMC samples are roughly uncorrelated. As with other MCMC algorithms, 
samples from the burn-in period may not accurately represent the desired 
distribution and are typically discarded (Barnett 1999). The Gibbs sampler was 
first described by brothers Stuart and Donald Geman in 1984 and is named after 
the late physicist Josiah Gibbs (Geman et al. 1984). 
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The steps of the Gibbs sampler are outlined below (Geman et al. 1984). 
 
1. Initialisation: select initial values for 𝜃1
1, … , 𝜃𝛥
1, for iteration 𝑤 = 1. 
2. For 𝑤 = 1, … , 𝑊, 
(a) Sample 𝜃1
𝑡+1 from the conditional distribution 𝑓(𝜃1|𝜃2
𝑤, … , 𝜃𝛥
𝑤 , 𝑦). 
(b) Sample 𝜃2
𝑡+1 from the conditional distribution 𝑓(𝜃2|𝜃1
𝑤+1, 𝜃3
𝑤 … , 𝜃𝛥
𝑤, 𝑦) 
(c) ⋮ 
(d) Sample 𝜃𝛥
𝑡+1 from the conditional distribution 𝑓(𝜃𝛥|𝜃1
𝑤+1, … , 𝜃𝛥−1
𝑤+1, 𝑦). 
3. Next iteration: increment 𝑤 = 𝑤 + 1. If 𝑤 < 𝑊, where 𝑊 is the total 
number of iterations to be performed, then return to Step 2. 
 
The ability of the Gibbs sampler to reduce a multivariate problem (ie. sampling 
from a posterior distribution of large dimension) to a series of simple lower-
dimensional problems is the key that finally led to Bayesian analysis being 
computationally feasible (Carlin et al. 2009, Gelfand et al. 1990). The popular 
programme WinBUGS for Bayesian MCMC procedures uses Gibbs sampling, 
and BUGS is an abbreviation for Bayesian inference Using Gibbs Sampling 
(M.R.C. Biostatistics Unit 2008). 
 
Bayesian data analysis can be split into the following three steps: 
1. Setting up a joint probability distribution for all observable and unobservable 
parameters in the problem 
2. Calculating the posterior distribution, which is the conditional probability 
distribution of the unobserved parameters of interest given the observed data. 
3. Evaluating model fit and sensitivity analysis. If necessary given evaluation 
results, the model can be altered and the three steps repeated (Gelman et al. 2013). 
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Prior Distributions 
There are many ways to represent the prior probability distributions required for 
the first of the three steps. For example, one approach is to limit values of 
parameters to what is possible and assign probability masses to “possible” values 
to sum to one, reflecting expert opinion (Carlin et al. 2009). Another approach is 
to assume that the prior for an estimated parameter belongs to a parametric 
distributional family, choosing parameters for this family so that the distribution 
matches expert opinion as closely as possible (Carlin et al. 2009). A disadvantage 
of this approach is that the prior beliefs may not easily fit any standard 
distribution, and two distributions that look practically identical, may have quite 
different properties leading to different posterior distributions (Berger 1985). 
Berger (1985, p 79), points out as an example that the Cauchy(0,1) and Normal 
N(0, 2.19) distributions have the same 25th, 50th and 75th percentiles (-1, 0 and 1) 
and appear similar when plotted, however, they may result in rather different 
posterior distributions (Berger 1985). 
 
One approach to developing priors is to elicit expert information (Kynn 2005, 
Low Choy et al. 2009). Methods for eliciting priors are described for an unknown 
proportion in normal linear models with unknown variance parameters (Kadane 
et al. 1980, Nichols et al. 2004, Winkler 1967). Reviews of prior elicitation 
philosophies and methods for a range of situations have also been described 
(Chaloner 1996, Garthwaite et al. 2005, Kadane et al. 1996, Kadane et al. 1998, 
O’Hagan et al. 2006). 
 
Assessing convergence 
Iterative simulations run using MCMC methods are expected to eventually 
converge to the stationary distribution, which is the target distribution (Little et 
al. 2002). However, if a sufficient number of iterations have not been run, then 
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simulations may not be representative of the target distribution (Gelman et al. 
2013). It is vital to establish whether or not the chain has converged after a certain 
number of iterations (Gelman et al. 2013). Convergence of models can be 
assessed via visual inspection, and through diagnostic measures including the 
Gelman and Rubin diagnostic, Geweke diagnostic and Raftery and Lewis 
diagnostic. Both visual plots and convergence diagnostics are available through 
R package ‘coda’ to assess convergence (Plummer et al. 2015). However, none 
of the diagnostic tests are foolproof and have on occasion failed to detect lack of 
convergence, thus a combination of both diagnostics and visual inspection is 
recommended by authors who tested a number of these methods (Cowles et al. 
1996). The various methods of assessing convergence are described below. 
 
Visual inspection 
One way to check for convergence is to visually inspect traceplots of individual 
chains, discarding the initial transient phase, or burnin (Gelman et al. 1992). A 
traceplot is a plot of the iteration number (x axis) against the value of the 
parameter drawn at each iteration (y axis). If several chains are run in parallel, 
each from a different point in a range of initial starting values, then comparing 
the traceplots of each chain gives an idea of how well the chains are mixing 
(Brooks et al. 1998). If the output is indistinguishable when compared between 
chains, then this is a sign of good mixing and an indication of convergence 
(Brooks et al. 1998). 
 
Autocorrelation 
The degree of autocorrelation between draws for each chain is another indication 
of mixing (Cowles et al. 1996). For lag 𝜋, where 𝜋 is the difference between two 
iteration numbers, the correlation between every draw and its 𝜋th lag is: 
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𝜌𝜋 =
∑ (𝜃𝑤 − ?̅?)𝑊−𝜋𝑤=1 (𝜃
𝑤+𝜋 − ?̅?)
∑ (𝜃𝑤 − ?̅?)2𝑊𝑤=1
 
 
where 𝑊 is the total number of iterations. As 𝜋 increases, we would expect 𝜌𝜋 to 
be smaller. High autocorrelation for larger values of 𝜋 is indicative of slow 
mixing. 
 
Gelman and Rubin Multiple Sequence Diagnostic 
Although methods have been proposed for the purpose of assessing single 
sequence convergence, these methods are only recommended for straightforward 
datasets and well-understood models (Geyer 1992). A more reliable and popular 
approach is to simulate 𝑓 > 1 chains for each random variable with initial values 
dispersed throughout the parameter space (Carlin et al. 2009, Little et al. 2002). 
Gelman and Rubin (1992) have developed a multiple sequence diagnostic based 
on this idea (Gelman et al. 1992). For each scalar estimand 𝜃, which includes all 
parameters of interest in the model and any other quantities of interest (such as 
the ratio of two parameters or the value of a predicted observation), the individual 
draws from 𝐹 parallel sequences across 𝑊 iterations are labelled as 𝜃𝑓
𝑤 (𝑓 =
1, … , 𝐹, 𝑤 = 1, … , 𝑊). Let ?̅?𝑓. be defined as the mean value of 𝜃𝑓
𝑤 across all 
iterations within sequence 𝑓, ?̅?.. as the mean value of 𝜃𝑓
𝑤 across all iterations and 
all sequences, and 𝑌 as the observed data. After discarding the burn-in, the 
between and within sequence variances, 𝐵 and 𝑄 respectively, are then computed 
as follows (Gelman et al. 1992): 
 
𝐵 =
𝑊
𝐹 − 1
∑(?̅?𝑓. − ?̅?..)
2
𝐹
𝑓=1
  
where  
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?̅?𝑓. =
1
𝑊
∑ 𝜃𝑓
𝑤
𝑊
𝑤=1
                              
?̅?.. =
1
𝐹
∑ 𝜃𝑓.
𝐹
𝑓=1
                        
 
𝑄 =
1
𝐹
∑ 𝑠𝑓
2
𝐹
𝑓=1
                          
where 
𝑠𝑓
2 =
1
𝑊 − 1
∑(?̅?𝑓
𝑡 − ?̅?𝑓.)
2
𝑊
𝑤=1
   
 
The marginal posterior variance of the estimand, 𝑣𝑎𝑟(𝜃|𝑦) can be estimated by 
a weighted average of 𝐵 and 𝑊 as follows: 
 
𝑉𝑎?̂?+(𝜃|𝑦) =
𝑇 − 1
𝑇
𝑄 +
1
𝑇
𝐵                                      
 
Assuming that the starting distribution is appropriately overdispersed, this 
overestimates the marginal posterior variance but has the advantage of being 
unbiased under stationarity – ie. if the distribution started with is equal to the 
target distribution (Gelman et al. 2013, Little et al. 2002). The within variance 𝑄 
should be an underestimate of 𝑣𝑎𝑟(𝜃|𝑦) as individual chains have had 
insufficient time to range over the entirety of the target distribution, and should 
have smaller variance than the between variance 𝐵 (Little et al. 2002). As 𝑊 →
∞, the expectation of 𝑄 approaches 𝑣𝑎𝑟(𝜃|𝑦) (Little et al. 2002). The 
convergence is assessed through estimation of by what factor might the current 
distribution for 𝜃 be decreased if simulations were to continue to the limit 𝑊 →
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∞ (Little et al. 2002). The potential decrease in scale is estimated by (Little et al. 
2002): 
√?̂? = √
𝑉𝑎?̂?+(𝜃|𝑦)
𝑄
            
 
√?̂? declines to 1 as 𝑊 → ∞ (Little et al. 2002). If the potential decrease in scale 
is high, further simulations may improve inferences about the target distribution 
(Little et al. 2002). Once ?̂? is close to 1 for all scalar estimands of interest, then  
any subsequent draws from each of the multiple chains should collectively be 
treated as being representative of the target distribution (Little et al. 2002). 
Generally, values of √?̂? below 1.2 are acceptable; however, a higher level of 
precision may be required for an important analysis (Little et al. 2002). The 
diagnostic can be computed within R using the gelman.diag function (Plummer 
et al. 2015). 
 
Geweke Diagnostic 
The Geweke diagnostic, developed by Geweke (1991) assesses convergence by 
comparing values early in the Markov chain with those late in the Markov chain 
(Geweke 1991). Geweke suggests using the first 0.1 and last 0.5 proportions 
(Geweke 1991). If the chain is stationary, then the means of the two segments 
will be similar. A difference of means test is used to assess whether the two parts 
of the chain are from the same distribution (Geweke 1991). The standard errors 
in the test statistic are adjusted for autocorrelation (Geweke 1991). The diagnostic 
can be computed within R using the geweke.diag function (Plummer et al. 2015). 
 
Raftery and Lewis Diagnostic 
The Raftery and Lewis diagnostic developed in 1992, assumes that the goal is to 
estimate a posterior quantile of interest 𝑞 to within tolerance level ±𝑟 units with 
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probability 𝑠 of being within that tolerance level (Raftery et al. 1992). For 
example, if 𝑞 = 0.025, 𝑟 = 0.005, and 𝑠 = 0.95, the reported 95% credible sets 
would then have a true coverage between 0.94 and 0.96 (Carlin et al. 2009). The 
diagnostic will test the required number of iterations, required number of burn-
ins and thinning necessary to satisfy the specified conditions by first running and 
testing a shorter pilot chain (Raftery et al. 1992). A longer chain can also be tested 
to see if it has satisfied the results that the diagnostic suggests (Raftery et al. 
1992). The full statistical theory behind the diagnostic has been described 
(Raftery et al. 1992). The diagnostic can be computed within R using the 
raftery.diag function (Plummer et al. 2015). 
2.3.2 Sensitivity Analysis 
Sensitivity analysis forms the foundation of robust Bayesian analysis, requiring 
an examination of the effect of selection of uncertain inputs such as prior 
distribution and likelihood function on resulting inferences from the model 
(Berger 1994, Berger et al. 2000, Gill 2002). Methods for examining sensitivity 
to the prior distribution have been described (Berger 1994) and other studies have 
described examination of sensitivity to the prior and likelihood (Dey et al. 1996, 
Sivaganesan 1993), loss function (Martin et al. 1998), prior and utility function 
(Martin et al. 2003), form of the link function (Draper 1995), and implications 
for missing data (Kong et al. 1994). Approaches to robust Bayesian analysis have 
been classified into three categories: informal, global and local (Rios Insua et al. 
2000). 
 
An informal approach utilises a selection of prior distributions and examines the 
effect of these on resulting posterior estimates (Rios Insua et al. 2000). This type 
of approach has the disadvantage of potentially overlooking priors that produce 
dissimilar posterior estimates (Rios Insua et al. 2000). A global approach utilises 
priors of the same class, allowing identification of the priors that result in the 
37
extreme (maximum and minimum) posterior means (Moreno 2000). Local 
approaches are concerned with the rate of change in posterior estimates in 
connection with changes in the prior, using differential methods to assess this rate 
(Gustafson 2000, Sivaganesan 1993). This type of approach may be simpler to 
calculate than global approaches, especially for complex models, but are usually 
difficult to interpret and calibrate (Gustafson 2000, Sivaganesan 1993). 
2.3.3 Hierarchical Models 
The term “hierarchical model” refers to a model that extends the basic Bayesian 
structure given in Equation (2.1) to a hierarchy of multiple levels (Carlin et al. 
2009, Chen 2013). This broad class of model includes random effects, mixed 
(both random and fixed) effects, variance components and generalised linear 
mixed models (GLMMs) (Chen 2013). This approach is useful for complex 
datasets where information is available for different levels of observational units, 
each of which can be fit with their own distribution (Chen 2013). The multiple 
parameters that specify these distributions are connected by the structure of the 
problem (Chen 2013). As they are related, the joint probability model for these 
parameters must reflect the dependencies between them. The nomenclature 
“multilevel hierarchical model” is often used to refer to models with a nested data 
structure, while “hierarchical model” is often used to refer to a broader class of 
model including non-nested data structures (Chen 2013). 
 
A multilevel hierarchical model accounts for different levels of effects nested 
within each other, eg. marks from students from different schools, where 
individual effects are nested within school effects, or disease outcomes for 
patients treated at different hospitals, where individual effects are nested within 
hospital effects (Gelman et al. 2007). Considering the students example, three 
ways of modelling this are (Gelman et al. 2007): 
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1. A model with different coefficients for each school 
2. A model with different variance components for each school 
3. An indicator variable for each school as predictors within the model 
 
The hyperparameters of the model, relating to the second layer of effects (eg. 
school in this example) are also estimated from the data. 
 
Advantages of hierarchical modelling include the ability to describe complex 
systems with multiple sources of uncertainty (Gelman et al. 2013). The approach 
allows efficient modelling of complex multiparameter  problems, and facilitates 
computation for model fitting (Chen 2013). They are also useful in studies with 
stratified or cluster sampling (Gelman et al. 2013). In cluster sampling situations, 
it is necessary to use hierarchical modelling to be able to generalise to the 
unsampled clusters (Gelman et al. 2013). 
 
Within the context of disease modelling, multilevel hierarchical Bayesian models 
allow disease risk to be evaluated as a function of individual level risk factors 
nested within regional factors (Chaix et al. 2011). Chaix et al. (2011) describe a 
Bayesian GLMM to explore the effect of individual covariates nested within 
neighbourhood determinants of DMII prevalence in 2218 census-block groups in 
metropolitan Paris. Data from the RECORD Cohort Study were used (Chaix et 
al. 2011). Diagnosis with diabetes, 𝐷ℎ𝑖, for each individual ℎ nested within their 
area of residence 𝑖, was modelled as a Bernoulli distribution with probability of 
diagnosis 𝑝ℎ𝑖. The log odds of diagnosis, logit(𝑝ℎ𝑖), was modelled as a linear 
function of individual and neighbourhood sociodemographic explanatory 
variables, as follows: 
 
𝐷ℎ𝑖~𝐵𝑒𝑟𝑛(𝑝ℎ𝑖) 
𝑙𝑜𝑔𝑖𝑡(𝑝ℎ𝑖) = 𝑋ℎ𝑖
𝑇 𝛽 + 𝑈𝑖               
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𝑈𝑖~𝑁(𝜇, 𝜎
2)   
 
where 𝐵𝑒𝑟𝑛 is the Bernoulli distribution with probability of diagnosis 𝑝ℎ𝑖, 𝑋ℎ𝑖 is 
a vector of individual and area-level risk factors for individual ℎ within area 𝑖, 𝛽 
is a vector of regression parameters, and 𝑈𝑖  is the uncorrelated random effect for 
each neighbourhood 𝑖, assumed to follow a Normal distribution (𝑁) with mean 𝜇 
and variance 𝜎2. Congdon (2006) used a similar model to estimate the risk of 
diabetes across areas in England based on individual age, gender, ethnicity and 
neighbourhood quintile (Congdon 2006). 
2.3.4 Spatial Generalised Linear Mixed Models 
The use of georeferenced health data which locate cases in space, makes it 
possible to analyse spatially varying patterns of disease using spatial models 
(Chen 2013). The approaches used for modelling spatial data are part of the broad 
family of hierarchical or multilevel models (Chen 2013). Compared with studies 
examining disease outcomes and exposure at an individual level, spatial studies 
have the advantage that they may be less prone to the effects of random 
measurement error, and account for correlation between neighbouring areas using 
smoothing methods (Elliot et al. 1992). Moreover, they avoid ethical and consent 
issues associated with the collection and distribution of identifiable individual 
data, allowing more ready availability of aggregate or point-level spatial data 
covering large areas (Earnest et al. 2012). Spatial studies also allow visualisation 
of geographical patterns of disease outcomes and exposure patterns through 
mapping software, and through smoothing methods allow identification of high-
risk areas (Earnest et al. 2012). Maps generated by spatial studies may provide a 
useful starting point for hypothesis formulation and further exploratory analysis 
concerning aetiology of disease (Earnest et al. 2012). 
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Spatial studies have been useful for mapping relative risk and prevalence over 
small areas, incorporating spatial and/or individual-level covariates for DMII in 
the US, UK, Canada and Europe, and an overview of methods used in these 
studies is provided in the systematic review in Chapter 3 (Baker et al. 2015). 
When fitted within a Bayesian framework, they have the advantage of being able 
to nest individual demographic and clinical effects within geographic and 
environmental factors (Chen 2013). Furthermore, they are able to “borrow 
strength” across neighbouring regions for more robust inferences, which is 
particularly useful for the common problem of sparse and missing data within 
aggregated survey data (Chen 2013). They allow epidemiologists to explore 
questions such as: how do population rates of disease vary across space? To what 
extent is this variation driven by spatially varying exposures and characteristics 
of residents living in those areas? And which geographic areas exhibit unusually 
high or low rates of disease after taking known exposures into account? (Chen 
2013). 
 
Bayesian spatial methods have successfully been used to model several diseases 
including DMII (Chaix et al. 2011, Congdon 2006, Liese et al. 2010), anaemia 
(Magalhaes et al. 2011), dental caries (Stromberg et al. 2011), leprosy (Joshua et 
al. 2008), multiple sclerosis (Cocco et al. 2011), cancer mortality risk (Cramb et 
al. 2011, Goovaerts 2006, Hegarty et al. 2010), and malaria (Haque et al. 2010, 
Stensgaard et al. 2011, Zayeri et al. 2011). A review of Bayesian spatial models 
for disease mapping is provided by Best et al. (2005). Models described in this 
review include GLMMs with proper or intrinsic conditional autoregressive 
(CAR) priors for correlated spatial residual error, semi-parametric models 
including mixture modelling and spatial partition models, and spatial moving 
average models for continuous spatial processes. In this thesis, the focus is on 
spatial GLMMs for Binomial and Poisson likelihoods with intrinsic CAR spatial 
priors, which are described in more detail below (Besag et al. 1991). A GLMM 
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can be formulated as a hierarchical model with multiple levels of effects (Chen 
2013). 
 
Binomial GLMMs 
Besag, York and Mollie (1991) describe a GLMM approach formulated as a 
Bayesian hierarchical model for Binomial and Poisson likelihoods, known as the 
BYM model (Best et al. 2005, Chen 2013). This is one of the most popular ways 
of accounting for spatial autocorrelation, ie. similarity in outcomes between 
neighbouring regions (Chen 2013). The Binomial model described takes the 
general form: 
 
𝑌𝑖~𝐵𝑖𝑛(𝑝𝑖 , 𝑛𝑖) 
𝑙𝑜𝑔𝑖𝑡(𝑝𝑖) = 𝛼 + 𝛽𝑋𝑖 + 𝑈𝑖 + 𝑉𝑖 
 
where 𝐵𝑖𝑛 is the Binomial distribution with parameters 𝑝𝑖 and 𝑛𝑖; 𝛼 is a fixed 
intercept and 𝛽 is a vector of coefficients. For area 𝑖, 𝑝𝑖 is the estimated proportion 
with the outcome of interest, 𝑛𝑖 is the population at risk, 𝑋𝑖 is vector of covariate 
data,  𝑈𝑖 is the uncorrelated error and 𝑉𝑖 is the correlated error with an intrinsic 
CAR prior for spatial structure. 
 
The intrinsic CAR prior assumes that the correlated random effect in area 𝑖, given 
the correlated random effect in area 𝑗, is given by (Besag et al. 1991): 
 
𝑉𝑖|𝑉𝑗 = 𝑣𝑗 , 𝑗 ≠ 𝑖 ~𝑁 (
∑ 𝑣𝑗
𝑚𝑖
𝑗=1
𝑚𝑖
,
𝜎𝑉
2
𝑚𝑖
)   (2.2) 
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where the Normal (𝑁) distribution with mean 
∑ 𝑣𝑗
𝑚𝑖
𝑗=1
𝑚𝑖
 and variance 
𝜎𝑉
2
𝑚𝑖
; 
∑ 𝑣𝑗
𝑚𝑖
𝑗=1
𝑚𝑖
  is 
the average correlated random effect for the adjacent neighbours of area 𝑖, 𝑚𝑖 is 
the total number of such neighbours, and 𝜎𝑉
2 is the conditional variance of 𝑉 
(Pascutto et al. 2000). Hyperpriors are also fitted to 𝛼, 𝛽 and 𝑈. This 
parameterisation leads to an intuitive interpretation for the conditional mean 
∑ 𝑣𝑗
𝑚𝑖
𝑗=1
𝑚𝑖
 as a weighted average of the random effects, 𝑣𝑗, for all adjacent neighbours, 
but forces the conditional variance 
𝜎𝑉
2
𝑚𝑖
 to be nonconstant across areas (Best et al. 
2005). The univariate conditional prior distributions in this parameterisation 
(Equation 2.2) are well defined; however, the joint prior distribution for 𝑉 is 
improper with an undefined mean and infinite variance (Best et al. 2005). 
Nonetheless, a proper posterior distribution will still be obtained, as long as the 
general requirement in hierarchical formulations is met for proper hyperprior 
distributions on the variance components (Best et al. 2005). The 𝑉𝑖 follow an 
intrinsic autoregression, and can be interpreted as representing the spatial 
between-area variation in disease risk (Best et al. 2005). An advantage of the 
BYM model is that the conditional independencies can be modelled in MCMC 
estimation approaches, and allows spatial smoothing (Best et al. 2005). The 
marginal variance of both the spatially structured component, 𝑉𝑖, and the spatially 
unstructured component, 𝑈𝑖, can be estimated empirically at each MCMC 
iteration (Best et al. 2005). The benefit of including these two components of 
spatial error is that posterior inference about the degree of spatial dependence can 
be made from the proportion of total (marginal) spatial variation captured by 𝑉𝑖 
out of the total captured by both 𝑈𝑖 and 𝑉𝑖 (Best et al. 2005). 
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Poisson GLMMs 
The BYM model with a Poisson likelihood provides a useful framework for rare 
disease counts, and takes strata such as age, gender and other distributions of 
interest in each area into account through the calculation of expected counts in 
each area based on external or internal standardization (Best et al. 2005). 
Standardisation of aggregate spatial data is commonly performed to account for 
age and gender distributions within each region and these strata will be used as 
an example in the description below (Earnest et al. 2012). In external (direct 
standardisation), external population data on disease risk for each age- and 
gender-stratum is used to compute expected disease counts based on the age and 
gender distribution for each region within the study dataset. Alternatively, 
internal (indirect) standardisation utilises the stratified rates of disease risk within 
the entire dataset to compute expected disease counts for individual regions 
(Earnest et al. 2012). 
 
Using either external or internal standardization, given (as an example) gender 𝑔 
and agegroup 𝑙, the expected disease count 𝐸𝑖 in region 𝑖, can be computed using 
the following equation:  
𝐸𝑖 = ∑ ∑ 𝑁𝑖𝑔𝑙𝑝𝑔𝑙
𝐿
𝑙=1
𝐺
𝑔=1
 
 
where 𝑁𝑖𝑔𝑙 is the population fitting age-gender stratum 𝑔𝑙 in area 𝑖, and 𝑝𝑔𝑙 is the 
direct or indirect prevalence of disease in age-gender stratum 𝑔𝑙. 𝐺 is the total 
number of gender groups (generally two) and 𝐿 is the total number of agegroups. 
This can be extended to a more general example with 𝑅 strata, with 𝜅𝑟 levels for 
strata 𝑟. 
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The standard Poisson model using CAR priors for correlated random effect 
described by Besag et al. (1991)   assuming a Poisson distribution for the number 
of cases 𝑌𝑖  in each area 𝑖, takes the following form: 
 
𝑌𝑖~𝑃𝑜(𝐸𝑖µ𝑖)       
 
where 𝑃𝑜 is the Poisson distribution, 𝜇𝑖  represents the relative risk of diabetes 
and offset 𝐸𝑖  denotes the expected number of cases in area 𝑖. 
 
𝑙𝑜𝑔(𝜇𝑖) = 𝛼 + 𝛽𝑋𝑖 + 𝑈𝑖 + 𝑉𝑖 
 
where 𝛼 is a fixed intercept, 𝛽 is a vector of coefficients, and for area 𝑖, 𝑋𝑖 is 
vector of covariate data, 𝑈𝑖 is the uncorrelated error and 𝑉𝑖 is the correlated error 
with an intrinsic CAR prior for spatial structure. 
 
The BYM model requires a well-defined set of geographic boundaries in order to 
determine adjacency (Chen 2013). Some authors have suggested that the BYM 
model may result in oversmoothing, and have developed semiparametric spatial 
models that make fewer distributional assumptions (Best et al. 2005, Richardson 
et al. 2004). 
2.3.5 Spatiotemporal models 
This section provides a review of Bayesian spatiotemporal methods described in 
the literature. Epidemiological data often include information about geographic 
and temporal factors (Bernardinelli et al. 1995b). Incorporating spatiotemporal 
patterns into disease modelling allows us to characterise the evolution of disease 
over time specific to individual regions, thus identifying regions that are at higher 
risk of increasing incidence or prevalence of disease outcomes (Bernardinelli et 
al. 1995b). 
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 Bernardinelli et al. (1995a and 1995b) describe a Poisson GLMM for 
spatiotemporal modelling of disease risk allowing for spatiotemporal interactions 
where the temporal trends in disease risk may be different for different regions 
(Bernardinelli et al. 1995a, Bernardinelli et al. 1995b). In this model, the variation 
in observed disease count 𝑌𝑖𝑡 in region 𝑖 at time 𝑡 is modeled as a function of the 
population at risk 𝑛𝑖𝑡, and the underlying rate of disease 𝜃𝑖𝑡 in region 𝑖 at time 𝑡: 
 
𝑌𝑖𝑡~𝑃𝑜(𝑛𝑖𝑡𝜃𝑖𝑡)      
 
The log-rate of disease is modeled as a linear function of space and time: 
 
log(𝜃𝑖𝑡) = 𝜇 + 𝑉𝑖 + (𝛽 + 𝛿𝑖)𝑡 
 
where 𝜇 is the mean log-rate over all regions, 𝑉𝑖 is the random regional error, 𝛽 
is the mean linear time-trend over all regions, and 𝛿𝑖 is the interaction between 
the regional and time effects. Sum-to-zero constraints are applied for 𝑉𝑖 and 𝛿𝑖 so 
that 𝑉𝑖 represents the difference between a regional error and the fixed intercept 
𝜇, and 𝛿𝑖 represents the difference between each regional trend and the mean 
time-trend 𝛽.  
 
Three different types of prior distribution for 𝛿𝑖 are described (Bernardinelli et al. 
1995a, Bernardinelli et al. 1995b). First, in the model for unstructured 
heterogeneity of regional trend, 𝛿𝑖 are assumed to be sampled from a Normal 
distribution with mean 0 and variance 𝜎2, so for each region 𝑖 given neighbouring 
region 𝑗, 
 
𝛿𝑖|𝛿𝑗 , 𝑗 ≠ 𝑖~𝑁(0, 𝜎
2)         
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 Second, in the clustering model, the mean of 𝛿𝑖 depends on the trends of 
neighbouring regions: 
 
        𝛿𝑖|𝛿𝑗 , 𝑗 ≠ 𝑖~𝑁 (
∑ 𝛿𝑗
𝑚𝑖
𝑗=1
𝑚𝑖
,
𝜎𝛿
2
𝑚𝑖
) 
 
where 𝑗 are adjacent areas and 𝑚𝑖 is the total number of such areas for area 𝑖. 
This type of prior allows the borrowing of information from neighbouring regions 
thus estimates are pulled towards the local mean, with variance in the 𝛿𝑖 
controlled by the variance parameter 𝜎𝑖
2. A chi-square distribution is 
recommended as a prior distribution for the precision 1/𝜎2 (Bernardinelli et al. 
1995a, Bernardinelli et al. 1995b). 
 
Third, when the random effects 𝑉𝑖  and the random time effects 𝛿𝑖 are assumed to 
be a priori correlated, such as in situations like growth curves (Rutter et al. 1994) 
and patient monitoring (Berzuini 1995), in both the heterogeneity and clustering 
models described above, a bivariate normal distribution can be used to allow for 
correlation between the intercept 𝑉𝑖  and time trend 𝛿𝑖 for each region 𝑖 
(Bernardinelli et al. 1995a, Bernardinelli et al. 1995b). A Wishart prior 
distribution can be specified for the variance-covariance matrix for this bivariate 
normal distribution (Bernardinelli et al. 1995a, Bernardinelli et al. 1995b). 
 
Waller et al. (1997) describe an alternate method to nest spatial effects within 
temporal effects to accommodate spatiotemporal interactions. A limitation with 
the modelling approaches described by Bernardinelli et al, is that all temporal 
trends are assumed to be linear, and may be restrictive even using priors for a 
priori correlated random effects (Waller et al. 1997). Providing a less restrictive 
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temporal approach, Waller et al. describe a nested model where a purely spatial 
model is applied to each timepoint separately. Time is treated interchangeably – 
that is, spatial patterns at each timepoint are independent of each other, and there 
is less emphasis on evaluating the development in disease risk over time (Waller 
et al. 1997). 
 
Knorr-Held and Besag (1991) propose an intermediate approach that combine the 
spatial model described by Besag et al. (1991) with dynamic models (Fahrmeir 
et al. 1997, West et al. 1989). The log-odds of disease risk, 𝜃𝑖𝑡 for region 𝑖 at time 
𝑡, is formulated as (Knorr-Held et al. 1997): 
logit(𝜃𝑖𝑡) = 𝛼𝑡 + 𝛽𝑡𝑋𝑖𝑡 + 𝑈𝑖 + 𝑉𝑖           
 
where 𝛼𝑡 is the effect of time 𝑡, 𝛽𝑗 is a vector of coefficients at time 𝑡, 𝑋𝑖𝑡 is 
vector of covariate data for area 𝑖 at time 𝑡, 𝑈𝑖 is the uncorrelated error for area 𝑖, 
and 𝑉𝑖 is the correlated error with spatial structure for area 𝑖. For 𝛼1 … 𝛼𝑇, a 
random walk with independent Gaussian increments is applied, conditional on a 
highly dispersed variance 𝜎𝛼
2. This dynamic modelling approach allows 
nonparametric estimation of temporal trends in disease risk and trends in 
covariate effects over time (Knorr-Held et al. 1997). 
 
Furthermore, Knorr-Held proposes an extension of the above model for log-odds 
of disease risk, 𝜃𝑖𝑡, including structured and unstructured a priori temporal 
effects, and structured and unstructured a priori spatial effects, which is 
formulated as follows (Knorr-Held 2000): 
 
logit(𝜃𝑖𝑡) = 𝜇 + 𝛼𝑡 + 𝛾𝑡+𝑈𝑖 + 𝑉𝑖 + 𝛿𝑖𝑡 
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where 𝜇 is the overall risk of disease, 𝛼𝑡 is the uncorrelated random temporal 
effect, 𝛾𝑡 is the correlated random temporal effect with dynamic temporal 
structure, 𝑈𝑖 is the uncorrelated error for area 𝑖, 𝑉𝑖 is the correlated error with 
spatial structure for area 𝑖, and 𝛿𝑖𝑡 is the interaction term between space and time. 
Knorr-Held describes four different types of spatiotemporal interaction between 
one of the two types of spatial and one of the two types of temporal main effects, 
and proposes four corresponding types of priors for 𝛿𝑖𝑡 for each situation (Knorr-
Held 2000). 
 
Spatiotemporal methods have successfully been used to model the risk of 
colorectal cancer (Ugarte et al. 2012), ambulatory asthma (Lawson et al. 2010) 
and joint analysis of six diet-related cancers over time using latent factors (Tzala 
et al. 2008). A problem with linear or dynamic random-walk temporal effects 
described in the models above, is that they may not be accurate for future 
prediction. This problem is addressed in Chapter 7 by developing a methodology 
to compare spatiotemporally predictive models accounting for non-linear 
temporal trends and four different potential types of spatiotemporal interactions 
as described by (Knorr-Held 2000). 
2.3.6 Joint disease modelling 
Many diseases share common risk factors, such as demographic and lifestyle 
choices, and joint spatial analysis of related diseases can assist in identifying 
clustering of underlying disease risk if similar patterns of geographical variation 
are present (Knorr-Held et al. 2001). Much recent work in Bayesian disease 
modelling has focused on the role of joint modelling of two or more diseases. 
Joint disease modelling has the benefits of borrowing strength across both 
neighbouring regions and across diseases with common aetiological factors for 
more reliable risk estimates, especially in situations with sparse or missing data 
(Best et al. 2005, Knorr-Held et al. 2001). This is particularly useful when 
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uncertainty is present due to sparse disease counts or under-reporting of disease 
(Earnest et al. 2010, Held et al. 2006), as well as adjusting for unmeasured 
confounders (Best et al. 2009, Mezzetti 2012).  
 
Incorporating both shared and disease-specific spatial and temporal components 
has the advantage of highlighting regions most at risk for aetiological factors of 
disease and increasing temporal trends in disease outcomes (Best et al. 2005). 
These regions would be expected to benefit most from additional resource 
placement and health promotion programmes to decrease risk for multiple disease 
outcomes in one simultaneous step (Best et al. 2005). It also allows exploration 
of the differences between diseases in terms of spatial and temporal trends 
respectively (Best et al. 2005). A popular approach to joint modelling of multiple 
outcomes is the Bayesian hierarchical shared component model (Best et al. 2005). 
 
This section provides a review of Bayesian joint disease models described in the 
literature and highlights a gap in predictive spatiotemporal joint disease 
modelling for three or more diseases that is addressed by the proposed new 
research in Chapter 6. Each model is broken down into its component parts and 
the advantages and disadvantages of each model formulation are discussed. A 
summary is presented in tabular format in Table 2.2. For each model, for area 𝑖, 
disease 𝑑 and time 𝑡, 𝑌𝑖𝑑𝑡 and 𝐸𝑖𝑑𝑡 are the observed and expected counts 
respectively and 𝑝𝑖𝑑𝑡 is the true incidence rate of a given disease outcome. 
 
Two-disease cluster model 
Early work in Bayesian joint disease modelling includes the two-disease shared 
component model proposed by Knorr-Held and Best (2001) which is an extension 
of a single-disease cluster model (Knorr-Held et al. 2000).  This model partitions 
the relative risk of each of the two diseases into three spatial components allowing 
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for spatial clustering: one shared by both diseases and two disease-specific 
components reflecting residual spatial variation particular to each individual 
disease. 
 
Assuming a Poisson distribution for counts of disease 1, 𝑌𝑖1 and disease 2, 𝑌𝑖2 in 
each area, the formulation of this model is as follows: 
 
𝑌𝑖1~𝑃𝑜(𝐸𝑖1𝑠𝑖
𝛿𝑣𝑖1)    
𝑌𝑖2~𝑃𝑜(𝐸𝑖2𝑠𝑖
1/𝛿
𝑣𝑖2) 
 
where 𝐸𝑖1 and 𝐸𝑖2 are expected counts for disease 1 and 2 respectively, 𝑠𝑖 is a 
shared component, and 𝑣𝑖1and 𝑣𝑖2 are disease-specific components for disease 1 
and 2 respectively, each partitioned into 𝜗 clusters using reversible jump MCMC. 
The three spatial components, 𝑠𝑖, 𝑣𝑖1and 𝑣𝑖2 are assumed to be independent. The 
loading factor 𝛿 with a log-normal prior distribution is applied to each disease, 
allowing differential weighting to be placed on the shared spatial component for 
each disease. 
 
Prior to this, multivariate models had been suggested for joint spatial analysis of 
two diseases (DeSouza 1992, Mollie 1990). The advantages of the shared spatial 
component model described by Knorr-Held and Best (2001) over these include 
that the identification of similar patterns of geographic clustering across two 
diseases provides more convincing evidence of real spatial clustering of the 
underlying risk factors for both diseases. Furthermore, areas at high risk of 
common risk factors to both diseases are clearly identified and can be targeted to 
jointly reduce disease risk for both diseases. In addition, each spatial component 
has a direct interpretation in terms of geographic factors that are either shared by 
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both diseases or specific to one or other disease.  A multivariate model ignores 
possible spatial correlation in the relative risks across regions. 
 
A limitation of this model is that shared and disease-specific spatial components 
are assumed to be independent, ignoring the possibility of interactions between 
underlying covariates, and assumed to have significant spatial structure. Thus this 
type of model is most useful when there is evidence of geographic variability in 
risk factors for the diseases under study. 
 
Two-disease bivariate Poisson 
Kim et al. (2001) propose an alternative formulation using a bivariate Bayesian 
Poisson mixed model to jointly model two diseases. They include a covariate for 
age, which is defined as 𝑙. The formulation for this model is (Kim et al. 2001): 
(𝑌𝑖1𝑡𝑙 , 𝑌𝑖2𝑡𝑙)~𝑃𝑜(𝑝𝑖1𝑡𝑙 , 𝑝𝑖2𝑡𝑙)                                
              log(𝑝𝑖𝑑𝑡𝑙) = 𝑣𝑖𝑑 + (𝑊𝑖𝑑 + 𝜇𝑑𝑙)(𝑡 − 𝑡̅)+𝑢𝑑𝑙 + 𝜀𝑖𝑑𝑡𝑙 
 
where 𝑣𝑖𝑑 is the disease-specific spatial variation for each disease which is 
assumed to follow a CAR prior, and correlation between the two diseases is 
modelled within the bivariate Poisson distribution. 𝑊𝑖𝑑(𝑡 − 𝑡̅) is the 
spatiotemporal interaction term, 𝑢𝑑𝑙 is the disease-specific effect of age, and 𝜀𝑖𝑑𝑡𝑙 
is the uncorrelated residual error term. 
 
Advantages of this model over the cluster model proposed by Knorr-Held and 
Best (2001) include that the CAR prior placed on each disease-specific spatial 
component allows spatial smoothing and borrowing of strength across 
neighbouring regions for more robust inferences. The model also allows 
examination of temporal patterns for each region as well as the effect of 
covariates (in this example, age). Additionally, compared with univariate models 
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for disease, the bivariate model results in better estimates in terms of mean 
squared error (MSE) and narrower ranges with more precision in posterior 
estimates of mortality rates than the univariate estimates (Kim et al. 2001). 
 
A limitation of this joint disease model is that the lack of a shared spatial 
component means that possible spatial correlation in the relative risks across 
regions is ignored. 
 
Multiple disease CAR Model 
A shared spatial component model which builds upon the two-disease 
formulation proposed by Knorr-Held and Best (2001) is extended to three or more 
diseases by Held et al. (2005). In Table 2.2, this model is referenced as Held, 
2005 Model 1. The formulation of this model is as follows (Held et al. 2005): 
 
𝑌𝑖𝑑~𝑃𝑜(𝐸𝑖1exp (𝜃𝑖𝑑)) 
           𝜃𝑖𝑑~𝑁(𝛼𝑑 + 𝑠𝑖𝛿𝑑 + 𝑣𝑖𝑑 , 𝜏𝑑) 
∑ log (𝛿𝑑)
𝐷
𝑑=1
= 0                                             
 
This model includes a disease-specific intercept, 𝛼𝑑 and disease-specific 
uncorrelated error, 𝜏𝑑, allowing for larger differences in the relative risk 
parameter 𝜃𝑖𝑑 and variance of observed values between diseases. A sum-to-zero 
constraint is applied to the log of the loading factors, 𝛿𝑑, which similar to the 
model proposed by Knorr-Held and Best (2001), are assumed to follow log-
normal priors. However, the shared and disease-specific spatial components in 
this model, 𝑠𝑖 and 𝑣𝑖𝑑 are assumed to follow a CAR prior. 
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An advantage of this model is that it allows examination of geographic patterns 
in underlying risk factors common to three or more diseases, for example 
smoking, alcohol consumption, etc. which are common risk factors for many 
diseases. 
 
A limitation of this model is the assumption that the shared spatial component 
has spatial structure and that the shared and disease-specific spatial components 
are independent of each other, which does not allow for the possibility of 
interaction between the “true” but unobserved covariates. Furthermore, the model 
does not include a temporal component thus is not useful for spatiotemporal 
prediction. 
 
Multiple disease CAR model with multiple shared components 
The multiple joint disease above is further developed by Held et al. (2005) to 
include multiple shared components and this is applied to a four-disease case 
study accounting for spatial variation in smoking and alcohol consumption. This 
model is referenced in Table 2.2 as Held, 2005 Model 2, and the formulation is 
as follows: 
𝑌𝑖𝑑~𝑃𝑜(𝐸𝑖1𝑒𝑥𝑝(𝜃𝑖𝑑))              
                     𝜃𝑖𝑑~𝑁(𝛼𝑑 + 𝑢1𝑖𝛿1𝑑 + 𝑢2𝑖𝛿2𝑑 + 𝑣𝑖𝑑 , 𝜏𝑑) 
 
This model differs from Held, 2005 Model 1 above as it has two shared 
components: one for smoking, 𝑢1𝑖, and one for alcohol, 𝑢2𝑖. Each of these shared 
components is associated with disease-specific and risk-factor-specific loading 
factors, 𝛿1𝑑 and 𝛿2𝑑 respectively. These loading factors provide the additional 
ability to measure the effect of specific risk factors for each disease separately. 
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Advantages of this model include that a direct interpretation is possible of the 
shared components and their related risk factors, which are shared either by 
several diseases or particular to just one individual disease. In addition, the model 
has the ability to estimate the weight of each shared component for each disease, 
which allows a comparison of the importance of the related risk factors for each 
disease. Also, compared with individual disease analysis of underlying risk 
factors, the joint disease model has been shown to achieve substantial 
improvement in DIC values and also increase precision in the (log) relative risk 
estimates. 
 
A limitation of this model is the assumption that spatial structure exists in the 
shared latent risk factors, and that the components are independent of each other, 
which does not account for possible interaction between the underlying “true” 
covariates. Also, the model does not include a temporal component thus is not 
useful for spatiotemporal prediction. 
 
Multiple disease CAR model with differential shared components 
Further work by Held et al. (2006) that jointly models four infectious diseases, 
includes three shared and four disease-specific spatial components to account for 
differential risk for diseases with related aetiological factors. The aim of the 
analysis is to adjust for under-reporting in notification rates by borrowing 
information across multiple diseases (Held et al. 2006). The authors argue that 
two of the diseases share raw poultry consumption (modelled as one shared 
component specific to these diseases, 𝑢1𝑖) and the remaining two share raw pork 
consumption (modelled as a second shared component specific to these diseases, 
𝑢2𝑖) as common aetiological factors. The third spatial component, 𝑢3𝑖, is common 
to all four diseases. The formulation for this model is as follows: 
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𝑌𝑖𝑑~𝐵𝑖𝑛(𝑛𝑖𝑑 , 𝑝𝑖𝑑)                              
    𝑙𝑜𝑔𝑖𝑡(𝑝𝑖𝑑)~𝑁(𝛼𝑑 + 𝑢1𝑖𝛿1𝑑 + 𝑢2𝑖𝛿2𝑑 + 𝑢3𝑖𝛿3𝑑 , 𝜏𝑑) 
 
Advantages of this model include its ability to separate aetiological factors 
common to some diseases but not others and measure the effect of these factors 
for each disease. The model also allows the identification of specific risk patterns 
and variables relevant to each disease, which is possible due to the inclusion of 
information about multiple diseases, and may not be possible in a smaller joint 
model with only two diseases. Furthermore, the model has the ability to adjust 
for under-reporting, borrowing strength across multiple diseases. 
 
Again, the model is limited to spatial modelling; without a temporal component 
it is not useful for studying temporal patterns in disease outcomes or for temporal 
prediction. 
 
Two-disease spatiotemporal model 
Temporal effects were introduced to Bayesian joint disease models by 
Richardson et al. (2006) in a two-disease model with disease-specific linear 
temporal effects and an exchangeable hierarchical structure for spatiotemporal 
interaction, 𝜑𝑖𝑡. The formulation of this spatiotemporal model is as follows 
(Richardson et al. 2006): 
 
𝑌𝑖1𝑡~𝑃𝑜(𝐸𝑖1𝑡𝑒𝑥𝑝(𝜃𝑖1𝑡))     
𝑌𝑖2𝑡~𝑃𝑜(𝐸𝑖2𝑡𝑒𝑥𝑝(𝜃𝑖2𝑡))     
𝜃1𝑑𝑡 = 𝑠𝑖𝛿 + 𝑐𝑡𝛾 + 𝜑𝑖𝑡 + 𝜀𝑖𝑑𝑡 
              𝜃1𝑑𝑡 =
𝑠𝑖
𝛿
+
𝑐𝑡
𝛾
+ 𝜑𝑖𝑡 + 𝑣𝑖 + 𝑏𝑡 + 𝜀𝑖𝑑𝑡 
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Mirroring the shared and disease-specific spatial components, this model also has 
shared and disease-specific temporal components, 𝑐 and 𝑏 respectively, and a 
loading factor for the temporal component, 𝛾. 
 
Advantages of this spatiotemporal model over purely spatial approaches include 
that compared with a purely spatial analysis, the model has the following 
additional abilities: 
- It allows the simultaneous examination of the persistence of spatial patterns over 
time and highlighting of unusual patterns. The persistence of a pattern indicates 
that risk factors, environmental or economic effects are stable over time. 
- The ability to identify localised clusters that could be linked to emerging 
environmental hazards. 
- The ability to examine temporal patterns that are common to all diseases and 
disease-specific, and to identify high-risk areas for increasing incidence or 
prevalence. 
- The identification of spatial patterns of joint disease risk that persist or evolve 
in a systematic fashion over time provides stronger evidence than a single cross-
sectional study of true variation. 
- Finding similar geographic or temporal trends in disease risk for multiple 
diseases provides more convincing evidence that common sources of influence 
exist that reflect underlying shared risk factors. 
- The ability to borrow strength across space, time and diseases is especially 
useful for diseases that have less clear aetiology or for rare diseases. 
- Potential to improve precision in the estimation of the underlying disease risks 
by borrowing strength not only from neighbouring areas and timepoints, but also 
from other diseases. 
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A limitation of this model is the inflexibility of the exchangeable hierarchical 
structure for spatiotemporal interactions which may limit the accuracy of future 
predictions for disease outcomes specific to region and timepoint. 
 
Multiple disease spatiotemporal model with spatiotemporal interaction 
An alternative formulation is proposed by Tzala and Best (2008) for joint 
spatiotemporal modelling of three or more diseases. The authors propose a model 
with an individual shared spatial component for each time period in the analysis 
(Tzala et al. 2008). In Table 2.2, this model is referenced as Tzala, 2008 Model 
1. The formulation is as follows: 
 
𝑌𝑖𝑑𝑡~𝑃𝑜(𝐸𝑖𝑑𝑡𝑒𝑥𝑝(𝜃𝑖𝑑𝑡))              
               𝜃𝑖𝑑𝑡~𝑁(𝑢1𝑖𝛿1𝑑 + 𝑠𝑖𝑡𝛿2𝑑 + 𝜀𝑖𝑑 + 𝜀𝑑𝑡 , 𝜏𝑑) 
 
where 𝑢1𝑖 is a proxy for smoking for each area with associated loading factor 
 𝛿1𝑑 for each disease, 𝑠𝑖𝑡 is the shared spatial component for each timepoint, 
assumed to be independent between timepoints, with associated loading factor 
𝛿2𝑑 for each disease common to all timepoints, 𝜀𝑖𝑑 and 𝜀𝑑𝑡 are residual spatial 
and temporal error respectively for each disease, and 𝜏𝑑 is a disease-specific term 
for uncorrelated residual error. 
 
This model has flexible nonparametric structure for spatiotemporal interaction, 
allowing different spatial patterns of disease at each timepoint. This is 
advantageous when the focus is on examination of spatiotemporal patterns of 
disease within the study period rather than on prediction. 
 
A limitation of the model is that only one or two latent factors can be reliably 
estimated based on results from a previous simulation study (Tzala 2004). 
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Additional common factors may be identified if data are available for a larger 
number of areas, time points and/or diseases, but this would increase the 
computational burden considerably. Another limitation is that the nonparametric 
structure for spatiotemporal interaction limits the model’s usefulness for future 
prediction of disease patterns specific to region and timepoint. 
 
Multiple disease spatiotemporal model without spatiotemporal interaction 
Tzala et al. (2008) further describe a simpler model for joint spatiotemporal 
modelling of three or more disease outcomes without a spatiotemporal interaction 
term. In Table 2.2, this model is referenced as Tzala, 2008 Model 2. The 
formulation is as follows: 
 
𝑌𝑖𝑑𝑡~𝑃𝑜(𝐸𝑖𝑑𝑡𝑒𝑥𝑝(𝜃𝑖𝑑𝑡))              
                           𝜃𝑖𝑑𝑡~𝑁(𝑢1𝑖𝛿1𝑑 + 𝑠𝑖𝛿2𝑑 + 𝑐𝑡𝛿3𝑑+𝜀𝑖𝑑 + 𝜀𝑑𝑡 , 𝜏𝑑) 
 
where 𝑠𝑖 is the shared spatial component common to all timepoints, 𝑐𝑡 is the 
overall linear temporal trend with associated disease-specific loading factor 𝛿3𝑑, 
and all other terms are as defined in the previous model. 
 
The advantage of this model over the previous model depends upon the 
application, and this model is useful when there is no evidence of spatiotemporal 
interaction. 
 
A limitation of this model is that it assumes an overall linear temporal trend, albeit 
weighted by a loading factor for each individual disease. This may be an 
appropriate assumption for some applications. However, some applications may 
show divergent temporal trends for specific diseases and require more flexibility 
in the modelling of disease-specific temporal trends. 
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 This section has described the evolution of shared component models for joint 
disease modelling in the literature, with each new model described building upon 
previous research and providing additional capabilities. The final models 
described by Tzala and Best (2008) have the advantage of allowing both spatial 
and temporal modelling of two or more diseases, allowing for spatiotemporal 
interaction. However, they do not allow for spatial variation in disease risk to 
change over time.  
 
Multiple disease spatiotemporal predictive model 
There is a gap in the literature, highlighted by this review, for a joint disease 
model that is useful for future prediction of disease outcomes specific to region 
and timepoint for three or more diseases, allowing for spatial variation in disease 
risk to change over time. This gap is addressed in Chapter 6 by developing a 
variant formulation for joint spatiotemporal disease modelling. The formulation 
is as follows: 
 
𝑌𝑖𝑑𝑡~𝑃𝑜(𝐸𝑖𝑑𝑡𝑒𝑥𝑝(𝜃𝑖𝑑𝑡))              
                 𝜃𝑖𝑑𝑡~𝑁(𝑠𝑖𝛿𝑑𝑡 + 𝜈𝑖𝑑 + 𝑏𝑑𝑡 + 𝛼𝑑 + 𝜀𝑖𝑑𝑡 , 𝜏) 
 
where 𝑠𝑖 is a shared spatial component, 𝛿𝑑𝑡 is the associated disease-specific 
loading factor that may differ over time, 𝜈𝑖𝑑 is the disease-specific spatial 
component, 𝑏𝑑 is a disease-specific temporal component, 𝛼𝑑 is a disease-specific 
intercept and 𝜏 is the uncorrelated residual error. 
 
This model has the following advantages: 
- It allows for shared spatial underlying disease risks to change over time, and for 
these changes to be different for each disease. 
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- The influence of underlying spatial risk factors on each disease and how this 
changes over time can be estimated for each disease. 
- The parametric structure of the temporal effect allows for future prediction of 
disease outcomes specific to disease, area and time. 
- The formulation improves model fit, as measured by DIC, compared with a 
model with a disease-specific loading factor common across all timepoints (see 
Chapter 6). 
 
Application 
Shared component models have been successfully applied to jointly model risk 
of oral and oesophageal cancer (Knorr-Held et al. 2001), male and female lung 
cancer (Richardson et al. 2006), COPD and lung cancer (Best et al. 2009), and 
birth defects and caesarean sections accounting for sparse data (Earnest et al. 
2010). So far, there is a gap in the literature pertaining to joint disease modelling 
to identify spatial risk factors for potentially avoidable hospitalization for chronic 
disease. This gap is addressed in Chapter 6. 
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Table 2.2: A comparison of shared component models for joint disease modelling through the literature 
 
Paper No. 
diseases 
Covariate
s 
Form of model Shared spatial 
component 
Factor loading for 
shared spatial 
component 
Disease-specific 
spatial component 
Shared 
temporal 
component 
Factor 
loading for 
shared 
temporal 
component 
Disease-
specific 
temporal 
component 
Spatio-
temporal 
interaction 
Uncorrelate
d error 
Knorr-
Held , 
Best 
2001 
2 - 𝑌𝑖1~𝑃𝑜(𝐸𝑖1𝑠𝑖
𝛿𝑣𝑖1)    
𝑌𝑖2~𝑃𝑜(𝐸𝑖2𝑠𝑖
1/𝛿
𝑣𝑖2) 
𝑠𝑖 partitioned 
into 𝑘 clusters 
log(𝛿) ~𝑁(0, 𝜔2) 𝑣𝑖𝑑 partitioned into 𝑘 
clusters 
- - - - 𝜀𝑖𝑑 
Kim 
2001 
2 Age 𝑙                (𝑌𝑖1𝑡𝑙 , 𝑌𝑖2𝑡𝑙)~𝑃𝑜(𝑝𝑖1𝑡𝑙 , 𝑝𝑖2𝑡𝑙) 
log(𝑝𝑖𝑑𝑡𝑙) = 𝑣𝑖𝑑 + 
(𝑊𝑖𝑑 + 𝜇𝑑𝑙)(𝑡 − 𝑡̅) + 𝑢𝑑𝑙 + 𝜀𝑖𝑑𝑡𝑙  
- - 𝑣𝑖𝑑~𝐶𝐴𝑅 
𝑝𝑟𝑖𝑜𝑟 
- - - 𝑊𝑖𝑑(𝑡 − 𝑡̅) 𝜀𝑖𝑑𝑡𝑙 
Held 
2005 
Model 1 
3+ - 𝑌𝑖𝑑~𝑃𝑜(𝐸𝑖1exp (𝜃𝑖𝑑)) 
          𝜃𝑖𝑑~𝑁(𝛼𝑑 + 𝑠𝑖𝛿𝑑 + 𝑣𝑖𝑑 , 𝜏𝑑) 
∑ log (𝛿𝑑)
𝐷
𝑑=1
= 0                                             
𝑠𝑖~𝐶𝐴𝑅 
prior 
log(𝛿𝑑)~𝑁(0, 𝜔
2) 𝑣𝑖𝑑~𝐶𝐴𝑅 
𝑝𝑟𝑖𝑜𝑟 
- - - - 𝜏𝑑 
Held 
2005 
Model 2 
4 Smoking 
𝑢1, 
alcohol 
𝑢2 
𝑌𝑖𝑑~𝑃𝑜(𝐸𝑖1𝑒𝑥𝑝(𝜃𝑖𝑑)) 
𝜃𝑖𝑑~𝑁(𝛼𝑑 + 𝑢1𝑖𝛿1𝑑 + 
𝑢2𝑖𝛿2𝑑 + 𝑣𝑖𝑑 , 𝜏𝑑) 
𝑢1𝑖 , 𝑢2𝑖~ 
CAR prior 
𝛿1𝑑, 𝛿2𝑑 - - - - - 𝜏𝑑 
Held 
2006 
4 Raw 
poultry 𝑢2 
and pork 
𝑢3 
consumpt
ion 
𝑌𝑖𝑑~𝐵𝑖𝑛(𝑛𝑖𝑑 , 𝑝𝑖𝑑)           
𝑙𝑜𝑔𝑖𝑡(𝑝𝑖𝑑)~𝑁(𝛼𝑑 + 𝑢1𝑖𝛿1𝑑 + 𝑢2𝑖𝛿2𝑑 +
𝑢3𝑖𝛿3𝑑, 𝜏𝑑)  
𝑢1𝑖 , 𝑢2𝑖 , 𝑢3𝑖~
CAR prior 
𝛿1𝑑, 𝛿2𝑑, 𝛿3𝑑 
 
- - - - - 𝜏𝑑 
Richards
on 2006 
Full 
model 
2 - 𝑌𝑖1𝑡~𝑃𝑜(𝐸𝑖1𝑡𝑒𝑥𝑝(𝜃𝑖1𝑡))                        
𝑌𝑖2𝑡~𝑃𝑜(𝐸𝑖2𝑡𝑒𝑥𝑝(𝜃𝑖2𝑡))                        
𝜃1𝑑𝑡 = 𝑠𝑖𝛿 + 𝑐𝑡𝛾 + 𝜑𝑖𝑡 + 𝜀𝑖𝑑𝑡                  
𝜃1𝑑𝑡 = 𝑠𝑖/𝛿+𝑐𝑡/𝛾 + 𝜑𝑖𝑡+𝑣𝑖 + 𝑏𝑡 + 𝜀𝑖𝑑𝑡 
𝑠𝑖~CAR prior log(𝛿) ~𝑁(0, 𝜔
2) 𝑣𝑖~𝐶𝐴𝑅 
𝑝𝑟𝑖𝑜𝑟 
𝑐 𝛾 𝑏 𝜑𝑖𝑡 – 
exchangeab
le 
hierarchical 
structure 
𝜀𝑖𝑑𝑡 
Tzala 
2008 
Model 1 
6 Proxy for 
smoking 
𝑢1 
𝑌𝑖𝑑𝑡~𝑃𝑜(𝐸𝑖𝑑𝑡𝑒𝑥𝑝(𝜃𝑖𝑑𝑡))                                               
𝜃𝑖𝑑𝑡~𝑁(𝑢1𝑖𝛿1𝑑 + 𝑠𝑖𝑡𝛿2𝑑 + 𝜀𝑖𝑑 + 𝜀𝑑𝑡 , 𝜏𝑑) 
𝑠𝑖𝑡~CAR 
prior 
𝛿1𝑑, 𝛿2𝑑 𝜀𝑖𝑑 - - 𝜀𝑑𝑡 - 𝜏𝑑 
Tzala 
2008 
Model 2 
6 Proxy for 
smoking 
𝑢1 
𝑌𝑖𝑑𝑡~𝑃𝑜(𝐸𝑖𝑑𝑡𝑒𝑥𝑝(𝜃𝑖𝑑𝑡))                                          
𝜃𝑖𝑑𝑡~𝑁(𝑢1𝑖𝛿1𝑑 + 𝑠𝑖𝛿2𝑑 + 𝑐𝑡𝛿3𝑑+𝜀𝑖𝑑
+ 𝜀𝑑𝑡 , 𝜏𝑑) 
𝑠𝑖~CAR prior log(𝛿1𝑑, 𝛿2𝑑)~N(0,1
03) 
 
𝜀𝑖𝑑 𝑐𝑡 log(𝛿3𝑑)~N(0
,103) 
𝜀𝑑𝑡 - 𝜏𝑑 
Baker et 
al. 2015 
5   𝑌𝑖𝑑𝑡~𝑃𝑜(𝐸𝑖𝑑𝑡exp (𝜃𝑖𝑑𝑡)) 
𝜃𝑖𝑑𝑡~𝑁(𝑠𝑖𝛿𝑑𝑡 + 𝜈𝑖𝑑 + 𝑏𝑑𝑡 + 𝛼𝑑, 𝜏)           
𝑠𝑖~CAR prior log(𝛿𝑑𝑡) ~𝑁(0, 𝜔
2) 𝑣𝑖𝑑~𝐶𝐴𝑅 
𝑝𝑟𝑖𝑜𝑟 
- - 𝑏𝑑 - 𝜏 
Where for area 𝑖, disease 𝑑 and time 𝑡, 𝑌𝑖𝑑𝑡 and 𝐸𝑖𝑑𝑡 are the observed and expected counts respectively and 𝑝𝑖𝑑𝑡 is the true incidence rate 
of a given disease outcome. CAR=conditional autoregressive prior 
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2.3.7 Dealing with missing data 
Routinely collected data can be a useful source of information about the 
distribution of lifestyle factors at a small area level, but often a problem with such 
data is the presence of missing covariate or outcome information (Little et al. 
2002). This is an issue as standard statistical methods have been developed to 
analyse rectangular datasets with complete cases (Little et al. 2002). Observations 
with any missing values are called incomplete cases. Little and Rubin (2002) 
provide a good review of different patterns of missing data and mechanisms that 
lead to missing data. Of importance is whether or not missingness is dependent 
upon the underlying values of the variables in the dataset (Rubin 1976). If 
missingness is completely independent of the values of the data, then the missing-
data mechanism is termed missing completely at random - this does not 
necessarily mean that the pattern of missingness is random, but that missingness 
does not depend on the data values (Little et al. 2002). If missingness depends 
only on the data that are observed and not on the data that are missing then the 
mechanism is termed missing at random (Little et al. 2002). If missingness 
depends on the values of the missing data, the mechanism is called not missing 
at random (Little et al. 2002). 
 
Three common approaches to dealing with missing data include deletion of 
incomplete cases, imputation methods and model-based procedures (Little et al. 
2002). These are described in more detail below. 
 
Deletion 
A common method for dealing with missing data is deletion of incomplete cases. 
This is generally simple to perform and may be a satisfactory solution in 
applications with small amounts of missing data (Little et al. 2002). However, for 
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applications with substantial missing data, this method can lead to reduced power 
by decreasing the sample size (S.A.S. 2011). Two popular methods of dealing 
with missing data are listwise deletion and pairwise deletion (S.A.S. 2011).  
 
Listwise deletion is also known as “complete case analysis” (S.A.S. 2011). In 
listwise deletion, any cases with one or more missing value are deleted and 
excluded from analysis, leaving a simple rectangular dataset for analysis (S.A.S. 
2011). Advantages of this approach include simplicity and comparability of 
univariate statistics which are all computed on a common sample of cases (Little 
et al. 2002). A disadvantage is the loss of covariate or outcome information that 
is present in the incomplete cases leading to loss of precision (S.A.S. 2011). In 
the case where the data are missing completely at random, listwise deletion does 
not affect the sample means or add any bias, but it reduces the power of the 
analysis by reducing the effective sample size (S.A.S. 2011). In addition, if there 
are systematic differences between the complete and incomplete cases (eg. if data 
are not missing completely at random), then the sub-sample of cases remaining 
after listwise deletion are not representative of all cases, and bias is introduced, 
especially if the number of complete cases is small (Little et al. 2002). 
 
Pairwise deletion is also known as “available case analysis”, and requires the 
deletion of a case when it is missing a variable that is needed for a particular 
analysis, but inclusion of that case for other analyses for which all required 
variables are present (S.A.S. 2011). Some examples are for univariate analyses 
or measures of correlation (Little et al. 2002, S.A.S. 2011). Thus, the total number 
of cases used across analyses will not be consistent. When used for repeated 
measures or temporal analyses, because of the inconsistent numbers of values at 
different points in time, mathematical anomalies may be seen such as correlations 
that are greater than 100% (S.A.S. 2011). 
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As an alternative to deletion of incomplete cases, imputation of missing data with 
plausible values allows inferences to be made about outcomes and covariates 
using statistical methods suited to complete data (S.A.S. 2011). Single and 
multiple imputation methods are briefly described below. 
 
Single imputation 
Single imputation methods replace each missing value with a single value (S.A.S. 
2011). Imputed values are either means or draws from a predictive distribution of 
the missing values (Little et al. 2002). Standard statistical procedures for 
complete data analysis can then be applied to the imputed dataset (S.A.S. 2011). 
Single imputation methods have an advantage over deletion in that they preserve 
effective sample size and power, are easy to implement and allow use of statistical 
methods suited to complete data (S.A.S. 2011). However, they treat missing 
values as if they were known and have the disadvantage that they do not reflect 
the uncertainty around the predictions of the unknown missing variables (S.A.S. 
2011). This leads to the estimated variances of the parameter estimates being 
biased towards zero (Rubin 1987). 
 
Approaches to single imputation can be categorised into explicit modelling, 
where the predictive distribution of the missing values is based on a formal 
statistical model, and implicit modelling, where the focus is on an algorithm 
which implies an underlying model (Little et al. 2002). Explicit modelling 
methods include mean imputation, stratified mean imputation and regression 
imputation. Implicit modelling methods include hot deck imputation, cold deck 
imputation and substitution (Little et al. 2002). These are briefly described below. 
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Explicit modelling 
Mean imputation replaces the missing value for a particular variable with the 
mean of observed values for that variable (Little et al. 2002). This has the 
advantage of not changing the sample mean, and the disadvantage of reducing 
sample variance and attenuating any correlations involving the variables that are 
imputed (Little et al. 2002). This is because, for cases with imputed values, it is 
guaranteed that no relationship will exist between the imputed variable and any 
other measured variables (Little et al. 2002). Thus, mean imputation has attractive 
properties for univariate analysis but poses problems for multivariate analysis 
(Little et al. 2002). 
 
Stratified mean imputation, also known as mean imputation within classes, is 
similar to mean imputation, with the difference that data are first categorised or 
stratified by another variable or variables (Kalton et al. 1982). Following this, the 
missing value for a particular variable is replaced by the mean of the non-missing 
values for that variable for the sample belonging to the same stratum (Kalton et 
al. 1982). This has an advantage over mean imputation if the variable(s) stratified 
by has a relationship with the response variable (Kalton et al. 1982). Stratified 
mean imputation allows different values for each stratum allowing for non-
parametric relationships between the stratified variable(s) and the response 
variable (Kalton et al. 1982). 
 
Regression imputation predicts values for missing data based on a 
regression model that estimates relationships between variables (Little et al. 
2002). It has the opposite problem to mean imputation, as it fits predictions 
perfectly along a straight line without any residual variance, thus overestimating 
relationships and suggesting greater precision in the imputed values than is 
justified (Little et al. 2002). The regression model predicts the most likely value 
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for missing data, but does not estimate uncertainty about the predicted value 
(Little et al. 2002). 
 
Implicit modelling 
Implicit modelling methods include “last observation carried forward”, hot-deck 
and cold-deck imputation, which are described below. 
 
 “Last observation carried forward” for longitudinal, repeated measures data first 
orders the data for each case by time at which it was measured, and replaces 
missing values for each case at a particular time with the last observed value for 
that case at a previous time (Shao et al. 2003). It depends on the assumption that 
a measurement has not changed from the last time it was measured (Shao et al. 
2003). 
 
Hot-deck replaces missing values with observed values from a “similar” case 
within the same dataset (Little et al. 2002). This method is common in survey 
practice and many different schemes are available for selecting observations that 
are similar for imputation (Marker et al. 2002). 
 
Cold-deck imputation replaces missing values with a constant value from an 
external source (Little et al. 2002). External sources commonly used include other 
surveys or a previous realisation of the same survey (Little et al. 2002). 
 
The disadvantage of single imputation methods, that they do not reflect the full 
uncertainty created by missing data, motivated the development of multiple 
imputation methods, which are described in the following section. 
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Multiple imputation 
Multiple imputation offers a distinct advantage over single imputation methods, 
which typically lead to biased parameter estimates and invalid inferences (Rubin 
1987). Multiple imputation, developed by Rubin (1987), replaces each missing 
value with a set of plausible values that exemplify the uncertainty around the 
correct value to be imputed. Following 𝑓 rounds of multiple imputation, each of 
the 𝑓 imputed datasets is separately analysed using standard statistical procedures 
suited to complete data (S.A.S. 2011). The results are then combined from these 
analyses (S.A.S. 2011). Multiple imputation aims to represent a random sample 
of the missing values, resulting in valid statistical inferences that reflect the 
uncertainty from the missing values (Rubin 1996, S.A.S. 2011). Frequently, three 
to five imputations are sufficient for multiple imputation (Rubin 1996). 
 
Several algorithms have been described in the literature for multiple imputation 
of missing values under multivariate normality (Rubin et al. 1990, Tanner et al. 
1987), the multivariate t-distribution (Lange et al. 1989, Liu 1996), an iterative 
Gibbs sampler (Geman et al. 1984), sequential imputation (a variation of 
importance sampling) (Kong et al. 1994, Rubin 1987), sequential regression 
multivariate imputation (Raghunathan et al. 2001), and variations of the general 
location model (Raghunathan et al. 1995, Schafer 1997). 
 
Model-based procedures 
Within Bayesian models, data can be imputed directly within the model through 
iterative simulation methods (Little et al. 2002, Williams 1998). Two common 
approaches are data augmentation and the Gibbs sampler, which are described 
below. 
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Data augmentation, first described by Tanner and Wong (1987), is an iterative 
method of simulating the posterior distribution of parameters 𝜃. The algorithm 
has an imputation step and a posterior step. Starting with an initial value for 
parameters 𝜃1, subsequent values for missing data 𝑦𝑚𝑖𝑠 are imputed based on 
observed data 𝑦 and 𝜃𝑤 at iteration 𝑤 (Tanner et al. 1987): 
 
Imputation step: Draw 𝑦𝑚𝑖𝑠
𝑤+1 with density 𝑝(𝑦𝑚𝑖𝑠|𝑦, 𝜃
𝑤) 
Posterior step: Draw 𝜃𝑤+1 with density 𝑝(𝜃|𝑦, 𝑦𝑚𝑖𝑠
𝑤+1) 
 
Often the distributions in these two steps are considerably easier to draw from 
than either 𝑝(𝑦𝑚𝑖𝑠|𝑦) and 𝑝(𝜃|𝑦) or the joint posterior distribution 𝑝(𝜃, 𝑦𝑚𝑖𝑠|𝑦) 
(Little et al. 2002). As the total number of iterations 𝑊 → ∞, the sequence 
converges to a draw from the joint distribution 𝑝(𝜃, 𝑦𝑚𝑖𝑠|𝑦) (Little et al. 2002). 
 
Multivariate normal data augmentation, which fits a multivariate normal 
distribution to covariates, accounting for correlations between covariates, is an 
example of data augmentation and is a popular approach for the imputation of 
missing data in rectangular continuous datasets without long tails (Liu 1995, 
Rubin et al. 1990). Within a Bayesian framework, Tanner and Wong (1987) 
outline a data augmentation method based on a multivariate normal distribution 
utilising the algorithm above. 
 
The Gibbs sampler 
Imputation of missing values can be performed within iterative simulations using 
the Gibbs sampler (Geman et al. 1984). The Gibbs sampler described previously 
is extended to a more general case for a set of 𝛥 random variables, denoted by 
𝑋1, … , 𝑋𝛥. Thus 𝜃1
1, … , 𝜃𝛥
1 in the previous example on page 31 are replaced by 
𝑋1, … , 𝑋𝛥 where 𝑦𝑚𝑖𝑠 takes the place of 𝑋1 (Little et al. 2002). 
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 In the case where 𝛥 = 2, the Gibbs sampler is essentially the same as data 
augmentation if 𝑋1 = 𝑦𝑚𝑖𝑠 and 𝑋2 = 𝜃 (Little et al. 2002). For multiple 
imputation, the Gibbs sampler can be run independently 𝐹 times to generate 𝐹 
independent and identically distributed (iid) draws from the approximate joint 
posterior distribution of 𝑝(𝜃, 𝑦𝑚𝑖𝑠|𝑦) (Little et al. 2002). Where 𝛥 > 2, the Gibbs 
sampler can be used in more complex problems where data augmentation is 
difficult to compute (Little et al. 2002). 
2.3.8 Model comparison 
Three major approaches to model comparison have been described in the 
literature, and include: 
 
1. Calibration and resampling techniques including cross-validation (Franklin et 
al. 2000, Geisser 1975), leave-one-out jack-knife (Efron et al. 1993), and 
bootstrapping (Efron et al. 1993). 
 
2. Partitioning data into training and test datasets. The training set is used to 
calibrate the model and the test set to evaluate the predictive performance of the 
model. Methods for partitioning include resubstitution (Osborne et al. 1992, 
Stockwell 1992), bootstrap samples (Buckland et al. 1993, Verbyla et al. 1989), 
randomisation (Capen et al. 1986) and k-fold partitioning or hold-out or external 
approaches (Stockwell 1992). There is a trade-off when selecting the size of the 
training and test datasets, as model accuracy is reduced when the size of the 
training set is smaller (Fielding et al. 1997). Although data partitioning is valuable 
for model evaluation, a model performs better on average when all available data 
are included for calibration, thus when developing the final model it is 
recommended that all available data are included (Rencher 1995). 
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3. Measures of Bayesian model complexity and fit, including Bayes Factors, 
Bayesian Information Criteria (BIC), Deviance Information Criteria (DIC), root 
mean squared error (RMSE) and posterior predictive checks (Gelman et al. 2013). 
 
An overview of the above model evaluation methods is provided by Hastie et al. 
(2001) (Hastie et al. 2001). The third category, measures of model complexity 
and fit, is described in more detail below. 
 
Bayes Factors 
The posterior probability 𝑃(𝑀|𝑦) of a Bayesian model M given data y is given 
by Bayes’ Theorem (Kass et al. 1995): 
 
𝑃(𝑀|𝑦) =
𝑃(𝑦|𝑀)𝑃(𝑀)
𝑃(𝑦)
                       
 
The key data-dependent term 𝑃(𝑦|𝑀) is a likelihood, representing the probability 
that certain data are produced under the assumption of this model, 𝑀 (Kass et al. 
1995). Thus, given a model selection problem in which two models must be 
selected between based on observed data y, the plausibility of the two different 
models M1 and M2, parameterised by model parameter vectors 𝜃1 and 𝜃2 is 
evaluated by the Bayes factor K given by (Kass et al. 1995): 
 
𝐾 =
𝑃(𝑦|𝑀1)
𝑃(𝑦|𝑀2)
=
∫ 𝑃(𝜃1|𝑀1)𝑃(𝑦|𝜃1𝑀1)𝑑𝜃1
∫ 𝑃(𝜃2|𝑀2)𝑃(𝑦|𝜃2𝑀2)𝑑𝜃2
       
 
where 𝑃(𝑦|𝑀𝑖) is called the marginal likelihood for model 𝑖. A value of 𝐾 >  1 
indicates that 𝑀1 is more strongly supported by the data under consideration than 
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𝑀2, whereas a value of 𝐾 <  1 indicates that the data support 𝑀2 over 𝑀1 (Kass 
et al. 1995). 
 
A drawback of using Bayes factors for model comparison is that models with 
informative priors are typically favoured over models with non-informative priors 
– this is “Bartlett’s paradox” (Gelman et al. 2013). This effect can be 
compensated for by evaluating over a range of possibilities and several classes of 
priors if necessary (Gelman et al. 2013). 
 
Bayesian information criterion (BIC)  
BIC can be used as a criterion to select between a finite set of models (Gelman et 
al. 2013). It is partly based on the likelihood function, similar to Akaike 
information criterion (AIC) (Gelman et al. 2013). The value of the likelihood can 
be increased by adding parameters, but a problem with this approach is the 
possibility of overfitting (Gelman et al. 2013). This problem is resolved when 
using the BIC, as it introduces a penalty term for the number of parameters in the 
model (Gelman et al. 2013). The penalty term is larger in BIC than in AIC 
(Gelman et al. 2013). The BIC is derived under the assumption that the data 
follow a distribution within the exponential family, and is an asymptotic 
derivation. Let: 
𝑦 = the observed data; 
𝜃 = the maximum likelihood estimate  
𝑛 = the number of data points in y, the number of observations, or equivalently, 
the sample size; 
𝑘 = the number of free parameters to be estimated; 
𝑝(𝑦|𝜃) = the maximized value of the likelihood function for the estimated model, 
the likelihood of the observed data given 𝜃; 
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Then the formula for the AIC is: 
𝐴𝐼𝐶 = −2 log 𝑝(𝑦|𝜃) + 2𝑘      
 
The formula for the BIC is: 
𝐵𝐼𝐶 = −2 log 𝑝(𝑦|𝜃) + 𝑘 log 𝑛 
 
Models with smaller values of AIC and BIC are preferred to models with larger 
values. 
 
Deviance information criterion 
The Deviance information criterion (DIC) first introduced by Spiegelhalter 
(2002)(Spiegelhalter et al. 2002) is a Bayesian generalization of the Akaike 
information criterion (AIC) that makes two changes, replacing the maximum 
likelihood estimate 𝜃 with the posterior mean 𝜃𝐵𝑎𝑦𝑒𝑠 = 𝐸(𝜃|𝑦) and replacing 𝑘 
with a data-based bias correction, 𝑝𝐷 as the effective number of parameters 
(Gelman et al. 2013).  
 
The DIC is of particular use in Bayesian model selection problems involving 
MCMC simulation to obtain the posterior distributions of the models (Gelman et 
al. 2013). It is an asymptotic approximation as sample size increases, similar to 
the AIC and BIC (Gelman et al. 2013). It is a valid measure only when the 
posterior distribution is approximately multivariate normal (Gelman et al. 2013). 
The DIC has been defined by Gelman et al (2013) as: 
𝐷𝐼𝐶 = −2 log 𝑝(𝑦|𝜃𝐵𝑎𝑦𝑒𝑠) + 2𝑝𝐷 
𝑝𝐷 = 2𝑣𝑎?̂?(log 𝑝(𝑦|𝜃))             
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where 𝑝𝐷 is the effective number of parameters in the model, 𝜃𝐵𝑎𝑦𝑒𝑠 is the 
posterior mean, 𝑣𝑎?̂?(log 𝑝(𝑦|𝜃)) is the variance of the posterior log likelihood, 
and the other terms are as previously defined (Gelman et al. 2013). The similarity 
of the form of the DIC to the AIC is apparent. 
 
Models with smaller DIC are preferred over models with larger DIC. The DIC 
penalises the deviance, −2 log 𝑝(𝑦|𝜃𝐵𝑎𝑦𝑒𝑠) – which favors a good fit – by the 
effective number of parameters 𝑝𝐷 (Gelman et al. 2013). The deviance can be 
decreased by increasing the number of parameters in the model, and 𝑝𝐷 
compensates for potential overfitting by favoring models that have a smaller 
number of parameters (Gelman et al. 2013). Spiegelhalter (2002) suggests that 
models with DIC values >7 higher than that of the “best” model are substantially 
inferior (Spiegelhalter et al. 2002). 
 
In the case of Bayesian model selection, DIC has an advantage over other criteria 
in that the DIC can be easily computed from the samples generated by MCMC 
simulation, eg. within software such as WinBUGs (M.R.C. Biostatistics Unit 
2008). In contrast, AIC and BIC require calculation of the likelihood at its 
maximum over 𝜃, which is not directly obtained from the MCMC simulation 
output. 
 
Root mean square error 
The root mean squared error (RMSE) can be used to measure the differences 
between predicted values ?̂?𝑤 of a model at each iteration 𝑤 to observed values 𝑦 
for 𝑊 different predictions as follows (Gelman et al. 2013): 
𝑅𝑀𝑆𝐸 = √
∑ (?̂?𝑤 − 𝑦)2𝑊𝑤=1
𝑊
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 The RMSE is scale dependent, thus it is useful for comparing prediction accuracy 
for a particular variable between different models, but not for comparing different 
variables with each other (Gelman et al. 2013). 
 
Posterior predictive checks 
Comparing the predictive distribution 𝑦𝑟𝑒𝑝(replicate data) based on estimated 
parameters of the model to the observed data 𝑦 is generally termed a posterior 
predictive check and can be used for model evaluation and model comparison 
(Gelman et al. 2013, Rubin 1984). This approach has three advantages over 
standard applications of goodness-of-fit statistics: 
1. Unlike frequentist measures of model evaluation, posterior predictive checks 
have the advantage of being able to measure the uncertainty associated with 
estimated parameters of a model. 
2. A very wide range of goodness-of-fit statistics can be defined and calculated 
from the distribution of predictions, without being confined to various forms of 
residual sums of squares.  
3. The calculation of p-values is possible through the Bayesian framework for the 
statistic. These assess the probability of the data arising by chance, given model 
assumptions. 
 
Several different types of posterior predictive checks have been described in the 
literature, including Bayesian p-values associated with test quantities, predictive 
concordance, log likelihood and the conditional posterior ordinate (Gelman et al. 
2013). 
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Bayesian p-values 
Posterior Bayesian p-values associated with test statistics can be estimated for a 
range of statistics by comparing predicted values generated from parameter 
estimates with observed data (Gelman et al. 2013). Typically, the minimum or 
maximum observed value 𝑦 is compared with the minimum or maximum 
simulated 𝑦𝑟𝑒𝑝. The p-value associated with the test statistic is the probability 
that the test statistic 𝑦𝑟𝑒𝑝 falls outside the test statistic for observed data over 
repeated iterations. 
 
Predictive concordance 
The predictive concordance uses the quantiles and credible intervals of the 
predicted data 𝑦𝑟𝑒𝑝, for example the 2.5% tail area of 𝑦𝑟𝑒𝑝 or the 95%, 80% or 
50% credible interval for 𝑦𝑟𝑒𝑝, and estimates the probability of individual values, 
𝑦𝑖 , of observed data falling into the extreme range outside the test quantile or test 
credible interval, which can be considered outliers (Gelman et al. 2013). The 
predictive concordance is the percentage of 𝑦𝑖  for all observations 𝑖 that are not 
outliers. 
 
Gelfand (1996) suggests that in the case of the 2.5% tail area, the goal is to 
achieve 95% predictive concordance, as lower concordance suggests that the 
model does not fit the data well, and higher concordance may suggest overfitting 
(Gelfand 1996). 
 
 
Log likelihood 
The log likelihood provides a measure of the log predictive density and is 
considered a reasonable choice to assess predictive accuracy (Gelman et al. 
2013). Let 𝐿𝐿𝑖 be the log likelihood for each observation 𝑦𝑖  over 𝑊 iterations 
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given the estimated parameters of the model 𝜃. The log likelihood is then defined 
as follows for each observation: 
 
𝐿𝐿𝑖 =
∑ log 𝑝(𝑦𝑖|𝜃
𝑤)𝑊𝑤=1
𝑊
           
 
The log likelihood for the model overall, for n observations over T iterations is 
defined as: 
 
             𝐿𝐿 =
∑ (𝑛−1 ∑ log 𝑝(𝑦𝑖|𝜃
𝑤)𝑛𝑖=1 )
𝑊
𝑤=1
𝑊
 
 
Larger values of log likelihood are favoured over smaller values (Gelman et al. 
2013). 
 
Conditional posterior ordinate 
The conditional posterior ordinate for each observation 𝑦𝑖  (𝐶𝑃𝑂𝑖) is the inverse 
of the likelihood for each observation 𝑖 given the estimated parameters of the 
model 𝜃 (Chib et al. 1998). By considering the inverse likelihood across 𝑊 
iterations, the 𝐶𝑃𝑂𝑖 is defined as: 
 
𝐶𝑃𝑂𝑖 =
1
𝑊−1 ∑ 𝑝(𝑦𝑖|𝜃
𝑤)−1𝑊𝑤=1
     
 
The conditional posterior ordinate for the model overall, for n observations over 
𝑊 iterations is defined as: 
 
                𝐶𝑃𝑂 =
1
𝑊−1 ∑ (𝑛−1 ∑ (𝑛𝑖=1 𝑝(𝑦𝑖|𝜃
𝑤)−1)𝑊𝑤=1
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 Similar to the log likelihood, the conditional posterior ordinate measures model 
fit by measuring the probability of observed data being observed under the 
estimated parameters of the model 𝜃. 
2.4 Gaps in the literature 
The literature review in this section highlights the following gaps in the literature 
which are addressed by this thesis. 
 
The first problem and gap in the literature that this thesis addresses is the lack of 
spatial studies in many parts of the world examining DMII outcomes. A review 
of methodology used and geographic factors included in the few such spatial 
studies that have been conducted would provide information immediately 
applicable to small area analysis of DMII in other parts of the world. This is 
addressed in Chapter 3, which presents an overview of spatial methods used 
throughout the literature to examine DMII outcomes through a systematic review. 
 
The second problem and gap in the literature that this thesis addresses is dealing 
with missing covariate data that may be spatially correlated. An advantage of 
spatial disease modelling is that aggregated survey data of disease outcomes and 
covariates are readily available and avoid ethical and confidentiality issues 
associated with individual-level data. However, a frequent problem with survey 
data is the presence of missing data. This is addressed in Chapter 4, where the 
concept of spatial smoothing of disease outcomes is extended to modelling spatial 
correlation between covariate information for the purpose of imputation of 
missing spatial data. We compare the accuracy of this novel imputation method 
with two other well-known methods. Chapter 4 also addresses a third problem 
and gap in the literature, in that as yet little is known about geographic factors 
associated with DMII. In this chapter, the associations between seven geographic 
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lifestyle-related factors and DMII prevalence are examined across 71 Local 
Government Areas in Queensland. 
 
The fourth problem and gap in the literature that this thesis addresses is that there 
is a lack of knowledge around individual- and geographic risk factors associated 
with hospitalisation for DMII complications, and adverse inpatient outcomes for 
patients hospitalised for DMII complications. This is addressed in Chapter 5 
using hierarchical Bayesian GLMMs, with extension of this standard 
methodology to a novel application: the estimation of risks of each inpatient 
outcome to a range of patient profiles, which is useful to inform management of 
specific types of patients in both primary and inpatient settings. 
 
The fifth problem and gap in the literature that this thesis addresses is that among 
joint spatiotemporal disease models described thus far in the literature, there is a 
lack of a model that examines changes in underlying shared factors over time 
while retaining sufficient temporal structure to examine temporal trends in 
disease outcomes. In Chapter 6, this problem is addressed by proposing three 
variant formulations of a shared component spatiotemporal model. The proposed 
models are evaluated in the context of a New South Wales case study examining 
hospitalisation rates over time for five chronic diseases, accounting for both 
known and unknown underlying shared and disease-specific spatial factors. 
 
The sixth problem and gap in the literature that this thesis addresses is that among 
spatiotemporal disease models described thus far in the literature, there is a lack 
of a model that allows for non-linear temporal patterns across different areas 
while still retaining sufficient temporal structure for future prediction of disease 
outcomes specific to area and year. In Chapter 7, this problem is addressed by 
presenting an approach to compare spatiotemporal predictive models with both 
linear and non-linear relationships between log disease rates and calendar time, 
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accounting for four different types of spatiotemporal interaction. This novel 
methodology is presented within the context of a case study which builds a 
predictive model for DMII prevalence specific to year and to 71 Local 
Government Areas in Queensland. 
 
The review of literature in this chapter has provided a summary of the current 
state of knowledge pertaining to Bayesian spatial and spatiotemporal modelling 
relevant to this thesis. The chapter has highlighted the importance of addressing 
the global burden of type II diabetes and related chronic diseases. Furthermore, it 
has covered a breadth of knowledge and understanding relating to current 
principles of statistical modelling, including a comparison of Bayesian and 
frequentist methods for inference. The role of sensitivity analysis and methods 
for performing this have been discussed.  Hierarchical models have been 
described, including the class of spatial GLMMs. The current state of knowledge 
for both spatial and spatiotemporal models has been discussed. 
 
A review has been provided of the development of spatial and spatiotemporal 
modelling approaches for joint modelling of multiple diseases throughout the 
literature, with a discussion of the relative advantages and disadvantages of each. 
Following this, a review of techniques for dealing with missing data and methods 
for model comparison has been provided. Finally, gaps in the literature 
highlighted by this literature review have been summarised in the final section of 
this chapter. The subsequent chapters of this thesis serve to extend upon 
methodology described in this chapter, and to address and fill all gaps in the 
literature that have been described. 
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Chapter 3: Spatial modelling of type II 
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ABSTRACT 
 
Background: With the rising incidence of type II diabetes mellitus (DM II) 
worldwide, methods to identify high-risk geographic areas have become 
increasingly important. In this comprehensive review following Cochrane 
Collaboration guidelines, we outline spatial methods, outcomes and covariates 
used in all spatial studies involving outcomes of DM II. 
 
Methods: 1,894 potentially relevant citations were identified. Studies were 
included if spatial methods were used to explore outcomes of DM II or type I and 
2 diabetes combined. Descriptive tables were used to summarise information 
from included studies.  
 
Results: Ten spatial studies conducted in the US, UK, Canada and Europe met 
selection criteria. Three studies used Bayesian generalised linear mixed 
modelling (GLMM), three used classic generalised linear modelling (GLM), one 
used classic GLMM, two used Geographic Information Systems (GIS) mapping 
tools and one compared case:provider ratios across regions. 
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 Conclusions: Spatial studies have been effective in identifying high-risk areas 
and spatial factors associated with DM II outcomes in the US, UK, Canada and 
Europe, and would be useful in other parts of the world for allocation of additional 
services to detect and manage DM II early. 
 
Keywords: diabetes; spatial; geographic; mapping; systematic review 
 
1. BACKGROUND 
Type II diabetes mellitus (DM II) is on the rise worldwide, and is reported to be 
increasing in every country of the world (1). Costly sequelae of DM II, including 
hospital admission, can be prevented with quality primary care (2), however, 
many areas suffer from insufficient primary care services to meet the growing 
epidemic of DM II. Indeed, diabetes care has been reported to be “in a state of 
crisis” in a recent report from Diabetes UK (3). An estimated 50% of DM II cases 
are undiagnosed (1). Spatial studies that identify high-risk areas for DM II 
outcomes can highlight regions that would most benefit from additional primary 
care services to detect, manage and monitor DM II early. In addition, spatial 
studies have the potential to identify geographic factors that are important to DM 
II aetiology. We define spatial studies as studies involving aggregate or point-
level spatial information. This broad definition includes ecological and multilevel 
studies, and models with correlated and uncorrelated spatial effects. 
 
A spatial approach to disease modelling is relevant to any chronic disease with 
elements of environmental causation, and is especially relevant to DM II as recent 
research has demonstrated associations between DM II prevalence and 
geographic factors such as green space, walkability, increased fast-food 
availability, car-dominated transport and reduced opportunities for exercise (4, 
5). Many of these factors are amenable to health promotion programmes, and 
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spatial analysis can provide useful information to inform resource allocation and 
public policy decisions (6). As yet, there are few spatial studies in the literature 
examining DM II outcomes, and a review of the findings and methodologies used 
in these studies would be useful as a basis for further studies in other parts of the 
world to identify areas in need for DM II management, and associated geographic 
factors amenable to modification. 
 
Currently 11.3% of the US and 4.45% of the UK adult population are estimated 
to have diabetes, and DM II accounts for 90-95% of these cases (7, 8). Diabetes 
is the leading cause of renal failure, nontraumatic lower-limb amputation, and 
new cases of blindness, the major cause of heart disease and stroke, and the 
seventh leading cause of death in the US (7). The direct and indirect costs of 
diabetes are estimated to exceed USD 612 billion in the US in 2014, £23.7 billion 
in the UK in 2011 and AUD 14.6 billion in Australia in 2010 (9-11). 
 
The management of DM II is complex and time-consuming, and may involve 
regular health consultations, lifestyle modification, frequent blood glucose and 
podiatry checks, and complex medication regimes (12). Fortunately, there is 
evidence that around 60% of DM II cases are preventable with lifestyle change 
and/or medications (13). Early detection and management of glycaemic control 
and cardiovascular risk factors should lead to more effective treatment while 
reducing the risk of diabetic complications (14). Screening for undiagnosed cases 
using a fasting plasma glucose test thus has the potential to significantly reduce 
the healthcare burden of DM II (14). Effective placement of screening services 
can be determined using spatial analysis of DM II outcomes to identify areas of 
high risk. 
 
Numerous studies, including a systematic review, suggest that a number of 
demographic and clinical factors and metabolic markers are associated with 
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increased risk of developing DM II (15-19). In addition, there is some evidence 
of geographic factors associated with DM II prevalence (4, 5, 17) These are 
summarised in Table 1. Several of these factors are modifiable, including lifestyle 
choices and associated cardiovascular risk, and neighbourhood factors are 
amenable to health promotion programmes. Due to spatial clustering of lifestyle 
factors, identification of areas with higher prevalence of lifestyle-related risk 
factors would allow provision of targeted health promotion programmes. 
 
Diagnosis of DM II appears to be associated with diagnosis of several other 
disorders, including hypertension (20), coronary arterial disease (21-23), 
congestive heart failure (24, 25), chronic obstructive pulmonary disease (26, 27), 
colorectal cancer (28-31), pancreatic cancer (32-34), endometrial cancer (35), 
acute pancreatitis (36), biliary disease (36), psoriasis (37), urinary tract calculi 
(38) and diagnosis with high-grade prostate cancer (39). Spatial analyses allow 
examination of joint spatial correlations between multiple diseases, and 
describing these methodologies would be useful for future research into 
geographical associations between these diseases. 
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Table 1. Risk factors associated with increased risk of developing type II diabetes mellitus 
Demographic factors Metabolic markers 
Male gender Elevated fasting plasma glucose 
Increasing age Elevated two-hour post-prandial glucose 
Increasing BMI Elevated random glucose 
Indicators of low socio-economic 
status (education, income, 
occupation) 
Elevated triglyceride:high density 
lipoprotein ratio 
Increasing waist.hip ratio White cell count 
Increasing waist:height ratio Elevated HbA1c 
Black/Hispanic ethnicity Elevated interleukin-2 receptor A 
Sedentary lifestyle/physical inactivity Elevated adiponectin 
Smoking history Elevated C-reactive protein 
Excessive alcohol use Elevated ferritin 
Low levels of fruit and vegetable 
consumption 
Elevated Ga-glutamyl transpeptidase 
- Elevated insulin level 
  
Clinical factors Environmental factors 
Hypertension Reduced green space/walkability 
Cardiovascular disease Increased fast-food availability 
Tachycardia Decreased access to healthy food 
Family history of diabetes in first 
degree relative 
Car-dominated transport 
History of gestational diabetes Reduced opportunities for exercise 
Corticosteroid use Lower socioeconomic status 
- Higher proportion of daily smokers 
 
 
87
Historically, geographical studies have been effective in finding associations 
between incidence and mortality of disease and exposure to risk factors, such as 
lifestyle and environmental factors (40). Software packages, such as BUGS, R, 
MapInfo are available for performing spatial mapping of disease outcomes and 
their relationship with exposure to lifestyle and environmental factors (41-43). 
Based on a small range of standard algorithms, these software provide smoothed 
estimates and colour-coded geographical maps. Maps provide a powerful visual 
tool for identification of geographical patterns of occurrence of disease, and are 
potentially useful in the formulation of hypotheses of DM II aetiology. 
 
Both purely ecological and multilevel studies are useful for ascertaining risk 
factors underlying spatial variation in DM II outcomes. Purely ecological studies 
using aggregate spatial data have the advantage that they avoid ethical and 
confidentiality considerations associated with the identifiability of individuals. 
Survey data for DM II outcomes and geographic factors aggregated to small area 
level are readily available, and by aggregating measurements over multiple 
persons, data may be associated with less measurement error than individual data 
(44). Ecological studies are thus able to identify associations between disease 
outcomes and geographic factors at a small area level. 
 
In contrast, multilevel studies that account for individual-level factors nested 
within geographic factors have the advantage of being able to identify the residual 
effects of geographic factors on DM II outcomes after accounting for individual 
factors, and to measure the relative importance of each. However, obtaining data 
at both an individual and geographic level requires more effort and ethical 
consideration. 
 
Bayesian models are particularly well-suited to spatial modelling as the 
information specific to each region can naturally be represented as priors, and 
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both correlated and uncorrelated spatial effects can be examined (45). The 
Bayesian framework accounts for different sources of uncertainty and 
compensates for sparse and missing data. For sparse data, incorporation of 
spatially correlated priors for residual error allows “borrowing of strength” across 
neighbouring regions allows for more robust inferences. Use of spatially 
correlated priors can also be a good method for imputation of missing outcome 
or covariate information (46). In addition, uncertainty around notification rates 
and measurement error can be incorporated into a Bayesian model. Furthermore, 
hierarchical Bayesian models allow the exploration of individual-level risk 
factors nested within correlated and uncorrelated spatial effects. 
 
Type I diabetes mellitus (DM I) and DM II differ in underlying aetiological 
factors, however, many spatial studies analyse both in combination. As the vast 
majority of diabetic cases (90-95%) are accounted for by DM II, inclusion of 
these studies is still useful for examination of DM II outcomes, as the remaining 
small proportion of DM I cases is unlikely to bias results very much. Thus 
inferences from spatial studies combining DM I and DM II are also useful for the 
purpose of this review. 
 
This systematic review aims to perform a comprehensive search of the literature 
in accordance with Cochrane Collaboration guidelines to identify all spatial 
studies available involving aggregate or point-level spatial information, and 
examining outcomes of DM II or DM I and DM II combined. This review aims 
to summarise: (a) risk factors for DM II identified by spatial studies, (b) general 
spatial methods used, and (c) to describe in detail statistical analyses used in these 
studies. 
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2. METHODS 
2.1 Ethics Statement: No ethics approval was required for this systematic 
review. 
 
2.2 Role of Funding Source: The funding source had no involvement in study 
design, in the collection, analysis or interpretation of data, in the writing of the 
report and in the decision to submit this article for publication. 
 
2.3 Search Strategy 
A systematic review was conducted to identify all articles published between 
January 1950 and June 2013 involving spatial methodology to examine outcomes 
of DM II or DM I and DM II combined. The eight steps of the Cochrane 
Collaboration guidelines for a systematic review below were followed (47). 
 
Step 1: Defining the review questions and developing criteria for including 
studies 
Step 2: Searching for studies 
Step 3: Selecting studies and collecting data 
Step 4: Assessing risk of bias in included studies 
Step 5: Analysing data and undertaking meta-analyses 
Step 6: Addressing reporting biases 
Step 7: Presenting results and "summary of findings" tables 
Step 8: Interpreting results and drawing conclusions 
 
The review questions (Step 1) were: 
“What health outcomes and covariates have been examined in spatial studies 
involving outcomes of type II diabetes mellitus?” 
“What spatial methods have been used in these studies?” 
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Systematic searches (Step 2) were performed using MEDLINE, Science Direct, 
Web of Science, CINAHL, and Cochrane Library of Systematic Reviews. A 
combination of Medical Subject Headings (MeSH) and keyword searches were 
used. For MEDLINE, which allowed the most tailored search strategy, two 
subsets of citations were generated, to identify studies using spatial or Bayesian 
methodology. The MeSH term “diabetes mellitus type 2” was used for participant 
type, combined with 1. keywords “map*”, “geographic”, “spatial”, “areal” or 
“belt” to identify spatial studies, and 2. truncated keyword “bayes*” to identify 
Bayesian studies (* indicates truncation). Searches were limited to English 
literature and human studies. The search terms “type 2 diabetes mellitus” 
combined with “map*”, “geographic”, “spatial”, “areal” or “belt” were also used 
to search Science Direct, Web of Science and CINAHL. Searches were restricted 
to abstract, title or keywords for Science Direct, topics for Web of Science, and 
abstract for CINAHL. The Cochrane Library of Systematic Reviews was 
searched using the term “type 2 diabetes mellitus”. Reference lists of relevant 
articles identified by this method were scanned for other studies not identified 
through the electronic search.  
 
2.4 Selection of Studies 
Pre-defined inclusion and exclusion criteria were set for study selection prior to 
conducting the literature search (Step 3). Studies were included if they used 
spatial methods to explore aggregate or point-level spatial data examining 
outcomes of DM II or DM I and DM II combined, and excluded if only non-
spatial methods were used or only involved participants with DM I. A two-stage 
process was used to select relevant studies for the review (Figure 1). One author 
(J.B.) independently examined abstracts of all articles identified through 
electronic searches and excluded those not meeting the selection criteria. 
Following this, three authors (J.B., N.W., K.M.) independently examined full 
manuscripts obtained and made decisions about inclusion and exclusion of 
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studies. Any disagreement was resolved through discussion. Where more than 
one article was found describing the same study, only the most recent or most 
complete publication was included unless methodology used differed 
significantly. 
 
2.5 Data Extraction 
Data extraction was performed by one author (J.B.) and entered into a 
predesigned spreadsheet. For each included study, information was extracted 
about geographic location, sample size, outcome measures examined, statistical 
methods used, covariates included, and results found. Characteristics and results 
of each study are summarised into a table. 
 
3. RESULTS 
The electronic search identified a total of 1,938 potentially relevant citations from 
all databases searched, and after removal of 44 duplicates, abstracts of 1894 
citations were screened. Overall, 1,857 citations were excluded on the basis of 
abstract information (Figure 1). Full manuscripts were obtained and examined for 
37 articles, and ten studies met selection criteria, of which three used Bayesian 
spatial methodology and seven used classical modelling techniques. Risk of bias 
was assessed (Step 4), and coverage bias was a possibility with all studies 
included but difficult to assess. Other types of bias described in the Cochrane 
Handbook, including selection, performance, detection, attrition, and reporting 
bias, relevant to studies comparing two arms, were less relevant to the spatial 
studies included. 
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Figure 1: Study selection and exclusion process 
 
A descriptive analysis was performed (Step 5). Due to large differences in 
outcomes measured and methodology used between studies, meta-analysis was 
not possible, nor was publication bias able to be assessed via funnel plots and 
sensitivity analyses (Step 6). Table 2 outlines characteristics of studies included 
in this systematic review, including details of study location, sample size, 
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outcome measures, methodology used, covariates included, and results found 
(Step 7). 
 
The statistical methods used in the ten included papers are examined in detail in 
this section. Three studies used Bayesian generalised linear mixed modelling 
(GLMM), three used classic generalised linear modelling (GLM), one used 
classic GLMM, two used GIS mapping tools and one compared case provider 
ratios across regions. For Bayesian analyses involving Normal prior distributions, 
these were parameterised in terms of variances, unless otherwise specified. 
 
3.1 Bayesian Generalised Linear Models:  
 
3.1.1 Multilevel logistic modelling: 
The paper by Chaix et al. used Bayesian multilevel logistic modelling to perform 
separate and joint modelling of neighbourhood determinants of both DM II 
prevalence and study participation, in 2218 census-block groups in Paris 
metropolitan area (48). Data from the RECORD Cohort Study were used. A 
GLMM was used to model the outcome of diagnosis with diabetesfor each 
individual nested within their area of residence as a Bernoulli distribution with 
probability parameter 𝑝𝑖𝑘. The logit(𝑝𝑖𝑘)  was modelled as a linear function of 
individual and neighbourhood sociodemographic explanatory variables.  
Formulae for this multilevel logistic model are provided in Appendix A. 
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Table 2: Characteristics of included studies 
Primary 
author, 
Year  Country  
Sample 
size  
Outcome 
measures  Methods  
Covariates in 
model  Results  
Liese, 
2010 
[49]  
US  4 US 
regions  
Geographical 
variation, joint 
spatial 
correlation 
b/w DM I and 
DM II, 
smoothed risk 
estimates  
Sparse Poisson 
CAR, MCAR  
Age,  gender, 
ethnicity  
Evidence for 
small area 
variation in 
incidence of 
and joint 
correlation 
between DM 1 
and DM II  
Geragh
ty, 
2010 
[54]  
US  7288 
DM (1 
or 2) pts  
DM 
prevalence, 
distance to 
primary care 
provider, 
glycaemic 
control 
(HbA1c)  
Regression, 
geographical 
information 
software (GIS) 
mapping   
Demographic and 
laboratory 
characteristics  
SES barrier to 
optimal 
glycaemic 
control  
Lee, 
2008 
[61]  
US  9 US 
regions  
Disparities 
between 
estimated 
paediatric DM 
prevalence 
and 
endocrinologis
t supply  
Mapping of DM 
prevalence:paediatri
c endocrinologist 
ratio  
-  Up to 19-fold 
difference in 
case: provider 
ratio across 
regions  
Green, 
2003 
[17]  
Canada 230 
Manitob
a areas  
DM 
prevalence 
estimation  
Spatial scan statistic, 
spatial 
autoregressive 
linear regression  
Sociodemographi
c, environmental 
and lifestyle 
factors  
Low SES, poor 
environmental 
quality, poor 
lifestyles +ve 
correlated with 
DM prevalence  
Noble, 
2012 
[59]  
England  130 
areas in 
London  
Small-area 
mapping of10-
year risk of 
developing 
DM II  
GIS mapping  Age, gender, 
ethnicity, 
deprivation,  
family hx, CVD, 
smoking, HT, 
steroid use, 
height, weight  
Small-area 
geospatial 
mapping 
feasible  
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Table 2: Characteristics of included studies (continued) 
Primary 
author, 
Year  Country  
Sample 
size  
Outcome 
measures  Methods  
Covariates in 
model  Results  
Congdon, 
2006 [52]  
England  8,000 
electoral 
wards  
DM prevalence 
estimation  
Regression, 
aggregate 
data  
Age, gender, 
ethnicity, area 
deprivation, 
adverse 
hospitalisation 
indicators  
Diabetic 
ketoacidosis 
and coma 
+ve 
correlated 
with DM 
prevalence  
Weng, 2000 
[19]  
England  332 DM 
(type 1 
or II) pts  
Metabolic 
control, access 
to healthcare, 
clinical 
outcomes 
(neuropathy, 
retinopathy, 
proteinuria) 
and mortality  
GIS 
mapping  
Age, gender, 
ethnicity, BMI, 
smoking, 
glycaemic 
control 
(HbA1c), 
Underprivileged 
Area Score  
↑morbidity 
and 
mortality in 
DM pts 
related to 
SES and 
ethnicity  
Bocquier, 
2011 [16]  
France  16 
Marseilles 
cantons  
Prevalence 
estimation of 
treated DM  
Multilevel 
Poisson 
regression  
Area 
deprivation, 
population 
density, 
adjusted for 
individual level 
factors (age, 
gender, low 
SES)  
DM 
prevalence 
higher in 
more 
deprived 
and 
population-
dense areas  
Chaix, 2011 
[48]  
France  2218 
Paris 
census 
blocks  
DM II 
prevalence, 
joint spatial 
correlation 
with study 
participation  
Multilevel 
logistic 
modelling  
-  DM 
prevalence 
highest in 
areas with 
low 
educational 
attainment  
Kravchenko, 
1996 [58]  
Ukraine  27 admin 
regions  
Spatiotemporal 
estimation of 
DM 1 and DM 
II prevalence  
Regression, 
aggregate 
data  
-  Small area 
variation 
and general 
increase in 
prevalence 
over time  
US=United States, b/w=between, DM=diabetes mellitus, DM I=type I diabetes mellitus, DM II=type II 
diabetes mellitus, CAR=conditional autoregressive, MCAR=multivariate conditional autoregressive, 
HbA1c=glycated haemoglobin, GIS=geographic information science, SES=socio-economic status, 
+ve=positive, hx=history, CVD=cardiovascular disease, HT=hypertension 
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The authors also performed coupled modelling of DM II and study participation, 
in order to identify selective participation related to neighbourhood, and account 
for potential bias on the associations with diabetes. A Markov chain Monte Carlo 
(MCMC) approach was used to simultaneously model study participation and 
diabetes prevalence using a Poisson model. 
 
Separate modelling of DM II showed evidence that a low neighbourhood 
education was associated with higher odds of diabetes, controlling for individual 
education and self-reported financial strain. Joint modelling showed evidence that 
the odds of diabetes were slightly higher in high-participation areas. 
 
3.1.2 Sparse Poisson Convolution conditional autoregression: 
Liese et al. utilised a variation of a Bayesian conditional autoregressive (CAR) 
and multivariate conditional autoregressive (MCAR) methods to separately 
evaluate geographic variation in DM I and DM II incidence, and to estimate joint 
spatial correlation between DM I and DM II, in youth aged 10-19 years in four 
US states(49). Data from the SEARCH for Diabetes in Youth Study were used. 
CAR priors can be defined as a spatial structure in which the correlated random 
error of each region on a map of interest is described by a lattice of neighbouring 
regions, with 𝑖~𝑗 denoting that regions 𝑖 and 𝑗 are neighbours (45, 50). 
 
Sparse Poisson Convolution model: 
A challenge with the data used in this study was the presence of sparse count data 
in some areas, violating assumptions of traditional Poisson models due to 
excessive amount of zeros. The authors selected a sparse Poisson convolution 
(SPC) model to account for the sparseness of data. The SPC model is a variation 
of the CAR model with an added indicator variable denoting zero or non-zero 
count in any area. The SPC models used in this study to model DM I and DM II 
prevalence are described by the authors.   
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 Joint spatial correlation between DM I and DM II was evaluated using a sparse 
Poisson MCAR model, which is a variation of the model with MCAR priors 
described by Gelfand and Vounatsu (51). This type of model simultaneously 
models joint correlation between multiple outcomes while accounting for 
correlated error between spatial neighbours. In the model adapted by Liese et al., 
DM I and DM II were considered components of a vector of outcomes and a 
multivariate model applied. Joint spatial correlation between DM I and DM II 
was examined by calculating an empirical correlation between the RR estimates 
obtained for the sparse Poisson convolution models using the Pearson correlation 
coefficient. Formulae for the sparse Poisson convolution model and Sparse 
Poisson MCAR model are provided in Appendix A. 
The study found evidence of geographic variation in DM I and DM II incidence, 
and evidence for joint spatial correlation between the two types of DM. 
 
3.1.3 Stratified generalised linear modelling: 
Congdon reported Bayesian generalised linear modelling using MCMC in 
WINBUGS to estimate prevalence and mortality of clinically diagnosed diabetes 
(DM I and DM II combined) based on individual and neighbourhood 
sociodemographic factors in a small area prevalence study in England (52). Data 
from 354 local authority areas from the Health Survey for England study were 
used. Furthermore, variations between areas in adverse hospitalisation indicators 
were compared to estimated diabetic prevalence rates. The authors considered 
three models, briefly described here. 
 
In the first model, the stratified observed counts of diagnosed diabetes cases, 
stratified by gender, eighteen 5-year age bands, and seven ethnic groups, were 
modelled assuming a Poisson distribution. 
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Two GLMs were modelled, one with and one without age-ethnic group 
interactions. The coefficient for age was modelled using a random walk prior that 
assumes diabetes rates for successive age groups will tend to be similar.(53). 
 
In the second model, the prevalence gradient of diabetes (DM I and DM II 
combined) over neighbourhood deprivation quintiles was modelled using logistic 
regression. For each gender separately, the impact of age), ethnicity in four 
categories and neighbourhood deprivation quintile were assessed using a 
Bernoulli trial model for the presence of diabetes in each individual.   
 
In the third model, diabetes mortality was modelled separately for each gender 
using Poisson regression.  Formulae for the three models above are provided in 
Appendix A. 
 
The results showed evidence that diabetes prevalence rates varied from 2% to 5% 
across local authority areas. Male and female prevalence was comparable. For 
males, the area mortality rate from diabetes rose as area prevalence increased, but 
was more regular over prevalence quintiles for females. 
 
Further analysis was undertaken to assess health performance indicators of DM. 
Rankings were compared between 28 strategic health authority areas based on 
age-standardised rates of diabetic-ketoacidosis (DKA) coma and amputations, 
ratios of DKA coma episodes and amputation operations to estimated prevalent 
populations, and correlation of these indicators with prevalence rates. Results 
showed evidence that DKA and coma were positively correlated with prevalence, 
while diabetic amputation was not. 
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3.2 Classic generalised linear models and generalised linear mixed models: 
 
3.2.1 Multilevel Poisson regression: 
Bocquier et al. used an age- and gender-adjusted multilevel Poisson GLM to 
model neighbourhood characteristics associated with prevalence of treated 
diabetes among beneficiaries, using data from drug reimbursement data from the 
General Health Insurance Scheme in Southeastern France (16). Individual gender 
and age characteristics were nested within geographic characteristics. Patients 
were classified as treated diabetic cases if they had oral antidiabetic medication 
or insulin dispensed three times or more within the year.  
 
Results from this study found a crude prevalence of treated diabetes of 5.4%, and 
evidence that prevalence was significantly higher in more deprived and 
population-dense cantons independent of individual-level factors (age, gender, 
low socioeconomic status (SES)). 
 
3.2.2 Generalised linear mixed modelling (GLMM): 
Geraghty et al. used a GLMM approach to model HbA1c and LDL cholesterol 
based on individual demographic and lab characteristics and neighbourhood SES 
quintile (54). Registry data from 13 primary care clinics in Sacramento, 
California were used, and Euclidean distance from patients’ homes to their 
primary care clinic calculated. GIS tools (ArcInfo) were used to analyse outcome 
disparities in a population of patients with DM II (55). 
 
The first regression model assessed HbA1c level as a linear mixed model with 
random intercept and slope based on individual sociodemographic and lab 
characteristics, with practice characteristics or their primary care physician and 
clinic specialty as fixed effects and neighbourhood SES quintile as a random 
effect. 
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 The second model dichotomised low-density lipoprotein (LDL) cholesterol using 
a cutpoint of 100mg/dL, using mixed logistic regression. The same fixed and 
random effects were included as in the HbA1c model, with the addition of statin 
prescription. Formulae for both models are provided in Appendix A. 
 
Results of this study showed evidence of an association between neighbourhood 
SES quintile and HbA1c level. SES was not found to be associated with LDL 
control. 
 
3.2.3 Linear regression 
Green et al. used analysis of variance and linear regression to identify 
sociodemographic, environmental and lifestyle factors associated with 
geographical variation in DM prevalence (DM I and DM II combined) in 
Winnipeg, Manitoba, using Census, Health Epidemiology Unit, and hospital and 
physician claims data (17). The authors used two methods to aggregate predictor 
and outcome data into high risk areas for diabetes prevalence, firstly by 
aggregating to existing health administrative areas, and secondly by using a 
spatial scan statistic (SaTScan software (56)), both methods generating very 
similar results.  
 
The spatial scan statistic places a circular window of varying size on a map 
surface, allowing its centre to move so that the window includes different sets of 
neighbouring areas at any given position and circle size. The window is placed 
alternatively at the centroid of each area and the radius varied continuously from 
zero, up to a maximum size including 50% of the population, using MCMC 
simulation to test for elevated risk of DM prevalence. The statistic assumes the 
number of cases in each geographic region to be Poisson distributed and tests the 
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null hypothesis that within each age/gender group, the risk of DM is the same as 
in all regions combined (57). 
 
With both aggregation methods, linear regression was used to model standardised 
DM prevalence as a function of socioeconomic, environmental and lifestyle 
factors ecologically associated with the variability in prevalence, including self-
reported Aboriginal status, education, income, family structure, unemployment, 
housing conditions, crime and smoking rates. Variables were log-transformed 
when necessary to meet assumptions of normality and homoscedascity (specific 
variables that were transformed were not given). 
 
Results from this study showed evidence that higher DM prevalence was strongly 
associated with indicators of low SE status, poor environmental quality and poor 
lifestyles. 
 
3.2.4 Linear regression including temporal component: 
Kravchenko et al. used mixed linear regression to separately model time trends 
in DM I and DM II prevalence, and the effect of smoking on prevalence of DM 
complications, in various administrative regions of the Ukraine (58). Statistical 
reports collected in 1990-1993 by specialized endocrinologic institutions were 
used in this study. For each region, the time trends for prevalence of DM I and 
DM II were separately interpolated by mixed linear regression. Formulae for this 
model are provided in Appendix A. 
 
Student t-tests were used to test for differences in DM complications between two 
groups: smokers (10-30 cigarettes/day over 10 years) and non-smokers who had 
received preventative efforts for five years to correct nutrition, promote a healthy 
lifestyle, normalise body weight, metabolism and arterial pressure. 
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Results showed significant variation in the prevalence of DM II across regions, 
an overall increase in prevalence of both DM I and DM II over time, and evidence 
that prophylactic measures directed at a decrease in patient weight, the 
normalization of metabolism, arterial pressure and the elimination of pernicious 
habits promoted a decrease in diabetic complications. 
 
3.3 Studies using GIS mapping: 
Weng et al. investigated differences in metabolic control, access to healthcare, 
clinical outcomes (neuropathy, retinopathy, proteinuria) and mortality rates in a 
cohort of 610 diabetics living in different geographical areas of central London 
(19). Patients were clustered into prosperous, intermediate or deprived areas by 
electoral ward using UPA score (“Underprivileged Area Score”).  GIS software 
(MapInfo) was used to analyse the geographical distribution of UPA of a sample 
of 332 patients (43). 
 
Results showed evidence that patients in deprived areas were older, had higher 
BMI and worse glycaemic control than those in prosperous areas. Smoking was 
more prevalent in deprived areas. Prevalence of microvascular complications was 
related to geographical location, and age-gender adjusted mortality rate was 
significantly higher in deprived than prosperous areas. 
 
Noble et al. performed a feasibility study of geospatial mapping in Tower 
Hamlets, London, using ArcGIS, to examine 10-year risk of developing DM II as 
measured by QDScore (55, 59, 60). Data from general practice electronic records 
on all non-diabetic individuals were used, and for each individual the QDScore 
instrument was used to calculate 10-year risk of developing DM II, and data were 
geocoded into areas. 
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Basic and smoothed visual maps were produced to identify areas of high and low 
10-year risk. A ring map also visually illustrated availability of fast food outlets, 
population density and percentage of green spaces for each area. A basic map of 
index of area multiple deprivation scores visually corresponded very closely with 
the basic map of 10-year DM risk. 
 
The authors concluded that producing geospatial maps of DM risk from general 
practice electronic records was feasible and useful for public health and urban 
planning, but challenging due to data governance issues and technical challenges. 
 
3.4 Study comparing case:provider ratio: 
 
Mapping of child DM prevalence:paediatric endocrinologist ratio: 
Lee et al. examined variations across US regions in the ratio of paediatric DM 
cases (types 1 and 2, aged <18yrs) to number of paediatric endocrinologists, and 
similarly, the ratio of obese children to paediatric endocrinologists (61). Data 
from the American Board of Pediatrics were used to estimate the number of 
board-certified paediatric endocrinologists by state, and data from the National 
Survey of Children’s Health were used to estimate the number of children with 
diabetes and obesity by state. 
 
Results showed evidence of geographic disparities in DM cases:endocrinologist 
supply, with a two-fold difference between states. 
 
4. DISCUSSION 
This review has shown that spatial studies have successfully been used to identify 
areas of high risk for DM II prevalence or incidence, to show disparities in 
case:provider ratio, metabolic control, access to healthcare, clinical outcomes and 
mortality rates across areas, and to compare temporal trends between areas. The 
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two hierarchical models included, found evidence that spatial information 
influenced outcomes after adjusting for individual level risk factors. Each 
included study found evidence for small area variation, and in addition, five found 
area-level indicators of lower socioeconomic status, and two found area 
deprivation level to be positively correlated with outcomes, building on findings 
from several studies that find low area SES and deprivation to be risk factors for 
diabetes at an individual level (62-67). One study found the clinical outcomes of 
ketoacidosis and coma to be positively correlated with area-level DM prevalence, 
indicating that areas of high prevalence are also prone to higher complication 
rates (52). 
 
Joint modelling of multiple outcomes was shown to be useful in finding 
correlations between DM I and DM II, and between diagnosis with DM and study 
participation. These methods could usefully be extended to jointly model and 
examine correlations between incidence of DM II and DM II complications, or 
DM II and other chronic conditions, at either a mixed level (individual and area 
level factors) or purely aggregate level. A full meta-analysis was not possible, 
due to large differences in methodology, covariate inclusion and outcomes 
between the included studies. 
 
In interpreting results and drawing conclusions from this review (Step 8), a 
variety of area-level risk factors were confirmed by the included studies, the 
usefulness of including spatial information to describe geographic variation and 
identify regions of high excess risk was highlighted, and joint modelling of 
conditions was shown to be useful. 
Three of the included studies used Bayesian methodology, which allowed several 
distinctive advantages over classical statistical methods. Individual effects nested 
within spatial effects were able to be described using hierarchical multilevel 
modelling and nested random effects (48, 49, 52). Non-standard distributions 
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were able to be fitted to these complex models, and the methods were suitable for 
situations with sparse or missing data. Different sources of uncertainty, such as 
spatial and non-spatial random error, were able to be incorporated and described 
within these types of models. 
 
The study by Kravchenko et al. included a temporal component in their model, 
allowing these authors to compare changes in DM prevalence over time between 
areas, identifying areas at higher risk for increases in prevalence (58). Information 
from spatiotemporal studies of this type may provide useful results influencing 
health policy and resource allocation decisions. 
 
Standard linear models were used by Kravchenko et al. to model DM prevalence 
as a function of year, and Geraghty et al. to model HbA1c level as a function of 
multiple covariates (54, 58). However, a generalised linear modelling approach 
may be more appropriate in situations where the outcome variable is not normally 
distributed. 
 
Our review methodology is based on the Cochrane collaboration guidelines for 
review methodology; however, the Cochrane model is implicitly based on the 
conventional medical model to exclusively identify patient-level risks from 
randomised clinical trials. Our review provides a template for a more holistic 
evidence review approach that also includes environmental risk factors, which is 
immediately applicable to other diseases. 
 
The strengths of this systematic review include that Cochrane collaboration 
guidelines were followed in setting predefined aims, inclusion and exclusion 
criteria, selection of studies and assessment of bias. Selection of included studies 
was based on careful examination of modelling approaches used, and nonspatial 
studies were excluded. Transparent descriptions of models used in included 
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studies are included in this review, with a view to outline methods that have been 
useful in examining spatial associations with DM II. Weaknesses of this review 
are that it does not account for bias from possible coverage and measurement 
errors, and that many of the included studies reported outcomes on both DM I 
and DM II, affecting the reliability of estimated outcomes purely for DM II. Other 
weaknesses are that an examination of reporting bias was not possible, and that 
there were insufficient studies similar enough to perform a meta-analysis. 
 
In conclusion, findings of this review show that incorporation of spatial 
information is useful and effective in modelling DM II, and can identify spatial 
risk factors associated with DM II, and areas at high risk for DM outcomes and 
increasing DM burden over time. Several of the geographic risk factors associated 
with DM II outcomes, including green space, availability of healthy food, car-
dominated transport and opportunities for exercise are amenable to modification. 
Bayesian methods allow joint modelling and examination of correlations between 
multiple outcomes. Although several spatial studies have been conducted 
examining DM II in the US, UK, Canada and Europe, there is a lack of similar 
studies in other parts of the world. Spatial models conducted in these regions 
would be useful for identifying spatial risk factors associated with DM II and 
areas at high risk for DM outcomes, which would be beneficial in guiding public 
policy and management decisions. 
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Appendix A: Formulae for spatial models included in systematic review 
 
3.1.1 Multilevel logistic modelling (48): 
A generalised linear mixed model (GLMM) was used to model the outcome of 
diagnosis with diabetes, 𝐷𝑖𝑘, for each individual 𝑖 nested within their area of 
residence 𝑘, as a Bernoulli distribution with probability parameter 𝑝𝑖𝑘. The 
logit(𝑝𝑖𝑘)  was modelled as a linear function of individual and neighbourhood 
sociodemographic explanatory variables, as follows: 
𝐷𝑖𝑘~𝐵𝑒𝑟𝑛(𝑝𝑖𝑘) 
𝑙𝑜𝑔𝑖𝑡(𝑝𝑖𝑘) = 𝑋𝑖𝑘
𝑇 𝛽 + 𝑈𝑘               
𝑈𝑘~𝑁 (𝜇,
1
𝜏
)     
 
where 𝑋𝑖𝑘 is a vector of individual and area-level risk factors for individual 𝑖 
within area 𝑘, 𝛽 is a vector of regression parameters, and 𝑈𝑘  is the uncorrelated 
random effect for each neighbourhood 𝑘, with mean 𝜇 and variance 
1
𝜏
 (an inverse 
of the precision 𝜏). 
 
Priors distributions were specified for the precision and regression coefficients as 
follows: 𝜇 = 0, 𝜏~𝐺𝑎(0.5,0.0005), 𝑁(0,10000) for each coefficient within 
vector 𝛽  with the exception of the intercept and coefficient for age, for which 
flat prior distributions were specified. A flat prior is a uniform prior distribution 
where the probability of any value within the distribution is a constant. The mean 
of the uncorrelated random effect was assumed known and set to zero. 
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3.1.2 Sparse Poisson Convolution conditional autoregression (49): 
For a lattice of neighbouring regions, with 𝑖~𝑗 denoting that regions 𝑖 and 𝑗 are 
neighbours, the standard Poisson model using conditional autoregressive (CAR) 
priors for correlated random effect described by Besag et al. (1991) assuming a 
Poisson distribution for the observed number of cases 𝑌𝑖  in each area 𝑖, takes the 
following form: 
 
𝑌𝑖~𝑃𝑜(𝐸𝑖𝑝𝑖)   
 
where 𝑃𝑜 is the Poisson distribution, offset 𝐸𝑖  denotes the expected number of 
cases in area 𝑖, and 𝑝𝑖  represents the relative risk of diabetes in area 𝑖. Log (𝑝𝑖) is 
modelled as a linear equation as follows: 
 
log (𝑝𝑖) = 𝑋𝑖
𝑇𝛽 + 𝑈𝑖 + 𝑉𝑖  
 
where for area 𝑖, 𝑋𝑖  is a vector of area-level risk factors, 𝛽 is a vector of regression 
parameters, 𝑈𝑖  represents an uncorrelated random effect with no spatial structure, 
and 𝑉𝑖  represents a correlated random effect with CAR spatial structure. 
 
The CAR prior assumes that the correlated random effect in area 𝑖, given the 
correlated random effect in area 𝑗, is given by: 
 
                            𝑉𝑖|𝑉𝑗 = 𝑣𝑗 , 𝑗 ≠ 𝑖 ~𝑁 (𝜇(𝑣𝑗),
𝜎𝑉
2
𝑚𝑖
) 
 
where 𝜇(𝑣𝑗) is average correlated random effect for the neighbours of area 𝑖, 𝑚𝑖 
is the number of such neighbours, and 𝜎𝑉
2 is the conditional variance of 𝑉. An 
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advantage of using the CAR prior is that the conditional independencies can be 
modelled in MCMC estimation approaches, and allows spatial smoothing. 
 
Sparse Poisson Convolution model: 
The sparse Poisson convolution (SPC) model used in this study to model DM I 
and DM II prevalence is described by the authors as follows: 
 
𝑃(𝑦𝑖) = 𝑃𝑜(µ𝑖) 
                                       log(µ𝑖) = log(𝐸𝑖) + α(j) + 𝑢𝑖 + 𝑣𝑖 , 𝑗 = 1,2 
 
where for census tract 𝑖, 𝑦𝑖  is the observed count, 𝑃(𝑦𝑖) is the probability of 
observing 𝑦𝑖 , 𝐸𝑖 is the expected number of cases and 𝑗 is a binary factor indicating 
zero and non-zero observed counts (ie. 𝑗 = 1 if 𝑦𝑖 = 0 and 𝑗 = 2 if 𝑦𝑖 > 0. α(j) 
is a factored intercept for modelling zero and non-zero counts, 𝑢𝑖 is the 
uncorrelated random effect in and 𝑣𝑖 is the correlated random effect. The priors 
described for this model include a CAR prior for 𝑣𝑖 controlled by adjacent areas 
with common boundaries (first-order neighbours), intercept α~𝑁(0,1000), 
standard deviation of uncorrelated random error σ𝑢~𝑈𝑛𝑖𝑓(0,10) and standard 
deviation of correlated random error  σ𝑣~𝑈𝑛𝑖𝑓(0,10). 
 
Sparse Poisson MCAR model: 
 In the model adapted by Liese et al., DM I and DM II were considered 
components of a vector of outcomes and a multivariate model applied as follows: 
𝑃(𝑌𝑖) = 𝑃𝑜(𝛍𝑖) 
                                        log(𝛍𝑖) = log(𝑬𝑖) + 𝛂(j) + 𝑼𝑖 + 𝑽𝑖 , 𝑗 = 1,2 
where for census tract 𝑖, 𝑌𝑖 is a vector of multivariate observed counts for DM I 
and DM II following a Poisson distribution with mean 𝛍𝑖, and 𝛍𝑖 is a vector of 
the means of the Poisson distribution of the multivariate health outcomes. 𝑬𝑖 is a 
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vector of the expected number of cases for multivariate outcomes, 𝛂(j) is a vector 
of factored intercepts for the multivariate outcomes where 𝑗 denotes the class of 
the observed count (zero or positive), 𝑈𝑖 is a vector of uncorrelated random effects 
and 𝑉𝑖 is a vector of correlated random effects. 
 
Joint spatial correlation between DM I and DM II was examined by calculating 
an empirical correlation between the RR estimates obtained for the sparse Poisson 
convolution models using the Pearson correlation coefficient. The priors 
described for this model include a CAR model for 𝑉𝑖 controlled by adjacent areas 
with common boundaries, intercept α~𝑁(0,1000), standard deviation of 
uncorrelated random error σ𝑈~𝑈𝑛𝑖𝑓(0,10) and standard deviation of correlated 
random error  σ𝑉~𝑈𝑛𝑖𝑓(0,10). 
 
3.1.3 Stratified generalised linear modelling (52): 
The authors considered three models, briefly described here. 
In the first model, the stratified observed counts, 𝑌𝑖𝑗𝑘, of diagnosed diabetes cases, 
stratified by gender 𝑖, eighteen 5-year age bands 𝑗, and seven ethnic groups 𝑘, 
were modelled assuming a Poisson distribution, as follows: 
𝑌𝑖𝑗𝑘~𝑃𝑜(𝐸𝑖𝑗𝑘𝜇𝑖𝑗𝑘) 
 
where µ𝑖𝑗𝑘 models the impact of gender, age and ethinicity, and 𝐸𝑖𝑗𝑘 is the 
expected count in stratum (𝑖𝑗𝑘). In this model, 𝐸𝑖𝑗𝑘 =  2.3 ∗ 𝑁𝑖𝑗𝑘 , where 2.3 is the 
external standardisation rate of diabetic prevalence and 𝑁𝑖𝑗𝑘 is the population 
number in stratum 𝑖𝑗𝑘. 
 
𝑙𝑜𝑔(𝜇𝑖𝑗𝑘) = (𝑋𝑖𝑗𝑘)
𝑇
𝛽                
 
122
where (X𝑖𝑗𝑘) is a vector of area-level risk factors, and 𝛽 is a vector of regression 
parameters. 
 
Two GLMs were modelled, one with and one without age-ethnic group 
interactions. The coefficient for age, 𝛽𝑗 , was modelled using a random walk prior 
that assumes diabetes rates for successive age groups will tend to be similar, as 
follows: 
 
𝛽𝑗~𝑁 (𝛽𝑗−1,
1
Ƭ𝑗
) for 𝑗 = 2, … ,18   
𝛽𝑗=1~𝑁(0,1000) and precision Ƭ𝑗 ~𝐺𝑎(1,1) 
 
The coefficients for gender, 𝛽𝑖, and ethnicity, 𝛽𝑘, were assigned fixed effect 
priors with corner constraints, 𝛽𝑖=1 = 𝛽𝑘=1 = 0, 
𝛽𝑖=2~𝑁(0,1000), 𝛽𝑘~𝑁(0,1000) for 𝑘 = 2, … ,7 
 
Additional priors used for the GLM with an age-ethnic group interaction term 
include: 
 
𝛽𝑗𝑘~𝑁(0,
1
Ƭ𝑗𝑘
), where Ƭ𝑗𝑘~𝐺𝑎(1,1). A sensitivity analysis was performed on the 
prior distribution for each precision, Ƭ𝑗 and Ƭ𝑗𝑘, with  𝐺𝑎(1,0.1) and 𝐺𝑎(1,0.001) 
priors also trialled. 
 
In the second model, the prevalence gradient of diabetes (DM I and DM II 
combined) over neighbourhood deprivation quintiles m was modelled using 
logistic regression. For each gender separately, the impact of age (𝑗 = 1, … ,18), 
ethnicity in four categories (𝑘 = 1, … ,4) and neighbourhood deprivation quintile 
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(𝑚 = 1, … ,5) were assessed using a Bernoulli trial model for the presence of 
diabetes 𝐷𝑖 in each individual 𝑖, with probability parameter 𝑝𝑖 , as follows: 
 
𝐷𝑖~𝐵𝑒𝑟𝑛(𝑝𝑖) 
𝑙𝑜𝑔𝑖𝑡(𝑝𝑖) = 𝑋𝑖
𝑇𝛽                       
 
where 𝑋𝑖 is a vector comprising ethnic group, age group and deprivation quintile 
for each individual 𝑖, and 𝛽 is a vector of regression parameters, including 
coefficients for 𝑗, 𝑘, 𝑚. Priors used were similar to Model 1, including a random 
walk prior on age categories 𝑖: 
 
𝛽𝑗~𝑁 (𝛽,
1
Ƭ𝑗
) for 𝑗 = 2, … ,18 
𝛽𝑗=1~𝑁(0,1000) and precision Ƭ𝑗 ~𝐺𝑎(1,1) 
 
The deprivation effects were assumed to follow truncated normal distributions, 
constraining sampling to produce a monotonic gradient as follows: 
 
𝛽𝑚~𝑁(0,1000)𝐼(𝛽𝑚−1, 𝛽𝑚+1), 𝑚 = 2,3,4 
𝛽𝑚=1~𝑁(0,1000)𝐼(−∞, 𝛽𝑚=2) 
𝛽𝑚=5~𝑁(0,1000)𝐼(𝛽𝑚=4, ∞) 
 
where 𝐼(𝑎, 𝑏) is the interval from 𝑎 to 𝑏. 
 
For ethnic group 𝑘, a normal prior with corner constraints was used: 
 
 𝛽𝑘=1 = 0, 𝛽𝑘~𝑁(0,1000) for 𝑘 = 2,3,4  
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In the third model, diabetes mortality was modelled separately for each gender 
using Poisson regression. For males, let 𝑌𝑖1 = observed deaths in area 𝑖, and 
𝐸𝑖1=expected deaths in area 𝑖. 
 
For females, let 𝑌𝑖2 = observed deaths in area 𝑖, and 𝐸𝑖2=expected deaths in area 
𝑖. 
 
𝑌𝑖1~𝑃𝑜(𝐸𝑖1𝑚𝑖1);  log(𝑚𝑖1) = 𝐵(𝑄𝑀𝑖) 
𝑌𝑖2~𝑃𝑜(𝐸𝑖2𝑚𝑖2);  log(𝑚𝑖2) = 𝐵(𝑄𝐹𝑖) 
 
where 𝑄𝑀𝑖 = male-prevalence quintile to which area 𝑖 belongs to and 𝑄𝐹𝑖  = 
female-prevalence quintile to which area 𝑖 belongs to. A Poisson regression was 
assessed to be satisfactory for this model due to the absence of overdispersion. 
 
3.2 Classic generalised linear models and generalised linear mixed models: 
 
3.2.2 Generalised linear mixed modelling (GLMM) (54): 
The first regression model assessed HbA1c level as a linear mixed model with 
random intercept and slope based on individual sociodemographic and lab 
characteristics, with practice characteristics or their primary care physician and 
clinic specialty as fixed effects and neighbourhood SES quintile as a random 
effect: 
 
𝐻𝑖 = 𝑋𝑖
𝑇𝛽 + 𝑍𝑖𝑊𝑖 + 𝑈𝑖 
 
where 𝐻𝑖  is the haemoglobin level for individual 𝑖, 𝑋𝑖  is a vector of risk factors 
with fixed effects for individual 𝑖, 𝛽 is a vector of fixed regression parameters, 
𝑍𝑖  is a vector of risk factors with random effects for individual 𝑖, 𝑍𝑖  is a vector of 
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random regression parameters for individual 𝑖, and 𝑈𝑖  represents an uncorrelated 
random effect with no spatial structure. 
 
The second model dichotomised LDL cholesterol using a cutpoint of 100mg/dL, 
using mixed logistic regression. The same fixed and random effects were 
included as in the HbA1c model, with the addition of statin prescription: 
𝐿𝑖~𝐵𝑒𝑟𝑛(𝑝𝑖)               
                                 𝑙𝑜𝑔𝑖𝑡(𝑝𝑖) = 𝑋𝑖
𝑇𝛽 + 𝑍𝑖𝑊𝑖 + 𝑈𝑖  
 
where for individual 𝑖, 𝐿𝑖  represents the outcome LDL>100, 𝑝𝑖 is the probability 
of having LDL>100, 𝑋𝑖  is a vector of risk factors with fixed effects, 𝛽 is a vector 
of fixed regression parameters, 𝑍𝑖  is a vector of risk factors with random effects, 
𝑊𝑖  is a vector of random regression parameters, and 𝑈𝑖  represents an uncorrelated 
random effect with no spatial structure. 
 
3.2.4 Linear regression including temporal component (58): 
For each region, the time trends for prevalence of DM I and DM II were 
separately interpolated by mixed linear regression: 
 
𝑌𝑖 = 𝑎𝑖 + 𝛽𝑖𝑥𝑖 + 𝑈𝑖 
 
where for area 𝑖, 𝑌𝑖 is the estimated prevalence, 𝑥𝑖 is the year, 𝑎𝑖 is the intercept, 
𝛽𝑖 is the coefficient for year, and 𝑈𝑖  is an uncorrelated random effect with no 
spatial structure. 
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ABSTRACT 
 
Background: Spatial analysis is increasingly important for identifying 
modifiable geographic risk factors for disease. However, spatial health data 
from surveys are often incomplete, ranging from missing data for only a 
few variables, to missing data for many variables. For spatial analyses of 
health outcomes, selection of an appropriate imputation method is critical 
in order to produce the most accurate inferences. 
 
Methods: We present a cross-validation approach to select between three 
imputation methods for health survey data with correlated lifestyle 
covariates, using as a case study, type II diabetes mellitus (DM II) risk 
across 71 Queensland Local Government Areas (LGAs). We compare the 
accuracy of mean imputation to imputation using multivariate normal and 
conditional autoregressive prior distributions. 
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Results: Choice of imputation method depends upon the application and 
is not necessarily the most complex method. Mean imputation was selected 
as the most accurate method in this application. 
 
Conclusions: Selecting an appropriate imputation method for health 
survey data, after accounting for spatial correlation and correlation 
between covariates, allows more complete analysis of geographic risk 
factors for disease with more confidence in the results to inform public 
policy decision-making. 
 
Keywords: imputation,missing;spatial;prevalence;diabetes 
 
BACKGROUND 
Spatial analysis is being used increasingly to identify geographic risk 
factors associated with disease and areas at high excess risk of disease 
beyond what would be expected given the prevalence of these risk factors. 
Many geographic risk factors are modifiable and amenable to health 
promotion programmes, thus spatial analysis can provide useful 
information to inform resource allocation and public policy decisions. 
Maps of spatial models have been useful for highlighting differential risk 
across regions. They are particularly useful for small area estimation, since 
the accuracy and precision of estimates based on small counts in a region 
can be improved by “borrowing strength” from estimates in neighbouring 
regions [1]. Bayesian models are particularly well suited to spatial 
modelling since the information provided by neighbouring regions can be 
naturally represented as priors [2]. 
 
Routinely collected survey data can provide useful information about the 
distribution of covariates at a regional level, but frequently a problem with 
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such data is the presence of missing covariate information. Often the data 
are spatially correlated and/or there are correlations between covariates. In 
these cases, imputation of missing data with plausible values allows 
inferences to be made about outcomes and covariates using statistical 
methods suited to complete data. Several methods of imputation are 
available and it is important to select the one best suited to a particular 
dataset. 
 
In this paper, we address this challenge by considering a case study of 
geographic risk factors associated with type II diabetes (DM II). 
 
The prevalence of DM II is increasing worldwide, with a report from 
Diabetes UK reporting a “state of crisis” in diabetes care [3]. Diabetes is 
reported to affect 11.3% of the US and 4.45% of the UK adult population, 
of which DM II accounts for 90-95% of cases [3, 4]. Diabetes is reported 
to be the leading cause of renal failure, nontraumatic lower-limb 
amputation, and new cases of blindness, the major cause of heart disease 
and stroke, and the seventh leading cause of death in the US [4]. 
 
Despite the rising shortage of service provision for DM II, there is evidence 
that DM II is preventable in 60% cases with lifestyle change and/or 
medications [5]. Thus long-term consequences of DM II can be prevented 
through early detection and management of glycaemic control and 
cardiovascular risk factors [6]. Evidence shows that DM II is associated 
with both environmental and individual factors [7]. Therefore, analysis of 
geographic differences in DM II incidence may provide important 
information for more targeted intervention and management, and hence 
may be useful for informing resource allocation decisions. 
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Demographic and lifestyle factors associated with increased risk of 
developing DM II include male gender, increasing age, increasing BMI, 
increasing waist:hip ratio, indicators of low socio-economic status, 
sedentary lifestyle, physical inactivity, smoking history, and low levels of 
fruit and vegetable consumption [8-12]. In addition, spatial studies of DM 
II that aim to describe changes in DM II outcomes over a set of 
neighbouring regions have shown DM II to be associated with deprivation 
[12], socioeconomic status [9, 11, 13, 14] and smoking prevalence [11] at 
a regional level. However, these studies have only been conducted in a very 
limited number of countries to date. Moreover, there is a lack of spatial 
studies examining the association of DM II relative risk (RR) with the 
distribution of other candidate lifestyle factors such as overweight/obesity, 
physical activity levels and fruit and vegetable consumption at a regional 
level. 
 
Spatial studies examining DM II outcomes over regions have been 
developed in the US, England and Europe [7, 9, 11-18]. Spatial models 
estimated by Bayesian methods have successfully been used to model 
several diseases including DM II (Liese, Chaix, Congdon, Bayesian 
GLMMs), anaemia [19], dental caries [20], leprosy [21], multiple sclerosis 
[22], cancer incidence and mortality risk [23-25], malaria [26-28], and 
childhood leukaemia and lymphoma [29]. In our case study, we fit 
Bayesian spatial models to DM II prevalence data across Queensland 
regions, accounting for significant missing data. 
 
This study has four objectives: a) to trial and select an appropriate 
imputation method to account for missing survey data from a number of 
relevant choices, b) to examine geographic disparities in DM II RR in 
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Queensland, b) to identify areas with high DM II RR in this region, and d) 
to identify environmental risk factors for DM II RR at a regional level. 
 
METHODS 
For clarity, we first introduce the case study, then consider imputation 
methods, and finally evaluate these alternative methods in the context of 
the case study. 
 
Case study 
This case study examines disparities in the RR and relative excess risk 
(RER) of DM II across 71 Queensland LGAs, accounting for seven 
geographic lifestyle factors, after selection of the most appropriate 
imputation method out of three alternative methods. RR is defined as the 
ratio of the estimated risk in a particular LGA to the mean estimated risk 
across all LGAs; thus LGAs with a larger RR are estimated to be more at 
risk for DM II prevalence than LGAs with smaller RRs. RER is defined as 
the estimated excess risk for DM II prevalence in a particular LGA after 
taking into account the effect of lifestyle covariates in that region. Thus 
LGAs with a larger RER have unexplained higher risk for DM II 
prevalence than would be expected and may benefit more from 
programmes for early detection and management of DM II. 
 
Sources of Data 
Our analysis of the region-level determinants of DM II relative risk relied 
on three databases, briefly described below. 
 
(1) The National Diabetes Services Scheme (NDSS) database for 2011 
diabetic notification data [30].The NDSS delivers diabetes-related 
products, information and support services to almost 1.1 million Australian 
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with diabetes and monitors the prevalence of diabetes including DM II 
across regions in Australia. This database also contains 2011 data 
originally from the Australian Bureau of Statistics (ABS) for a) 
socioeconomic status (SES) measured by average income scored 1-10 (1 
indicating lowest and 10 indicating highest income decile across Australia) 
and b) proportion over the age of 45 years for the general population in 
each LGA in Queensland, which were used as covariates in this case study. 
 
(2) The 2011 census information from the ABS for estimated resident 
population (ERP) per LGA [31].The ABS collects and publishes census 
data and monitors population counts across regions in Australia. 
 
(3) The Queensland self-reported health status 2009-2010: Local 
Government Area summary report weighted by age and gender distribution 
[32]. This survey estimates the prevalence of key population health 
indicators for those aged 18 years and older for each Queensland LGA 
based on self-report, including body mass index (BMI) from self-reported 
height and weight, proportion of daily smokers, proportion with 
insufficient physical activity for health benefit, adequate fruit intake (2+ 
serves/day), and adequate vegetable intake (5+ serves/day). The proportion 
overweight or obese in each LGA, defined as BMI≥25kg/m2, was 
estimated from self-reported height and weight.  
 
The survey provides a total of 16,530 completed computer-assisted 
telephone  interviews across Queensland, with a response rate of 56.7% in 
2009 and 64.5% in 2010. The telephone numbers selected for this survey 
were reportedly sourced by random digit dialling (RDD) using a specific 
sample frame from the Association of Market and Social Research 
Organisations RDD sample database. Data are reported for LGAs that had 
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a sample of 60 or more completed interviews (Brisbane LGA had the 
largest number of interviews at 2,561). Data are not reported from this 
survey for 28 LGAs with a sample size smaller than 60 due to potential 
inaccuracy of estimates.  
 
The reported overall prevalence of DM II across all Queensland LGAs 
from NDSS data were combined with ERP data to compute estimated 
counts for each LGA. Three island LGAs (Mornington, Palm Island and 
Torres Strait Island) were excluded, leaving 71 Queensland LGAs included 
in this spatial analysis. 
 
Spatial Model 
Multivariable models including all seven lifestyle covariates were fitted to 
the DM II prevalence data.  
 
Bayesian generalised linear mixed models (GLMMs) using Markov chain 
Monte Carlo (MCMC) were used to model RR and prevalence across 
regions. Two general models were considered: a Binomial model and a 
Poisson model. The Binomial GLMMs took the form: 
 
𝑌𝑖~𝐵𝑖𝑛(𝑝𝑖 , 𝑛𝑖)     
𝑙𝑜𝑔𝑖𝑡(𝑝𝑖) = 𝛼 + 𝑥𝑖𝜷 + 𝑈𝑖 + 𝑆𝑖    (1) 
 
where for region 𝑖, 𝑌𝑖 is the observed number of DM II cases, 𝑝𝑖 is the 
estimated prevalence of DM II, and 𝑛𝑖 is the estimated resident population. 
𝛼 is a fixed intercept, 𝜷 is a vector of coefficients, and 𝑥𝑖 is the 𝑖th row of 
the design matrix 𝑿, containing covariate data for region 𝑖. The 
uncorrelated error for region 𝑖 is denoted 𝑈𝑖, and 𝑆𝑖 is the correlated spatial 
error based on neighbourhood information; this is described in more detail 
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below. Separating the residual error into spatial (𝑆𝑖) and non-spatial (𝑈𝑖) 
components provides an indication of how much variation in DM II 
prevalence can be attributed to the effect of geographical region, after 
accounting for the effect of the covariates. 
 
The Poisson GLMMS took the general form: 
 
𝑌𝑖~𝑃𝑜(λ𝑖)                    
𝑙𝑜𝑔(λ𝑖) = log(𝐸𝑖) + 𝛼 + 𝑥𝑖𝜷 + 𝑈𝑖 + 𝑆𝑖  (2) 
 
where for region 𝑖, 𝑌𝑖 is the reported number of DM II cases, λ𝑖 is the 
estimated RR of DM II, 𝐸𝑖 is the expected count and the other terms are as 
defined above. The expected DM II count in each region was computed as 
a product of the average DM II prevalence across Queensland (internal to 
the dataset) and the ERP for each LGA. 
 
The intrinsic conditional autoregressive (CAR) prior, first described by 
Besag in 1974, was fit to the spatially correlated residual terms in equations 
(1) and (2) [33]. This prior assumes that the value of 𝑆𝑖 is normally 
distributed around the values of 𝑆𝑖 in the neighbouring regions, ie: 
𝑆𝑖|𝑆𝑘 = 𝑠𝑘, 𝑘 ≠ 𝑖 ~𝑁 (𝜇(𝑠𝑘),
𝜎𝑆
2
𝑚𝑖
)  (3) 
 
where 𝜇(𝑠𝑘) is average correlated random effect for the neighbours of 
region 𝑖, 𝑚𝑖 is the number of such neighbours, and 𝜎𝑆
2 is the conditional 
variance of 𝑆 [34]. A neighbour is defined as any region adjacent in space 
to region 𝑖. It can be seen that this type of prior induces a form of local 
smoothing across regions, where the degree of smoothing is controlled by 
the spatial correlation between regions [1]. An advantage of the CAR 
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model is that the conditional dependencies can be modelled as part of the 
usual Bayesian MCMC analysis [34]. 
 
Results are reported from a baseline model, to which models with other 
choices of priors were compared in sensitivity analysis. The baseline model 
has CAR priors fit to both correlated random effects, 𝑉𝑖, and to covariate 
data 𝑿, and Gamma(1,0.01) priors for the precisions of 𝑈𝑖. 
 
For both Binomial and Poisson models, RER was computed for each LGA 
based on residual error after accounting for the variation attributed to the 
effects of covariates as follows: 
 
𝑅𝐸𝑅 = exp (𝑈𝑖 + 𝑆𝑖) 
 
The RER provides an indication of regions where the estimated risk is 
greater or smaller than would be expected after accounting for the 
influence of lifestyle risk factors in that region. 
 
Estimation of model parameters and mapping of results was performed 
using R 2.15.0 and WinBUGS 14[35, 36]. Results presented for each 
model are based on 100,000 iterations, following a burn-in of 50,000 
iterations. The number of iterations and burn-in used in each model were 
selected based on the appearance of trace plots for parameters. Covariates 
representing proportion over 45 years of age, proportion overweight or 
obese, proportion of daily smokers, proportion with insufficient physical 
activity, proportion with adequate fruit intake and proportion with 
adequate vegetable intake were centred around their mean to improve 
model convergence. Correlations between covariates were assessed using 
Pearson’s R. Model fit was compared between models using deviance 
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information criteria (DIC) [37]. DIC consists of two components, a term 
that measures goodness of fit (?̅?) and a term that penalises models for the 
number of parameters (𝑝𝐷), thus favouring simpler models: 
 
𝐷𝐼𝐶 = ?̅? + 𝑝𝐷 
                   ?̅? =
1
𝑇
∑ 𝐷(𝑦, 𝜃(𝑡))
𝑇
𝑡=1
 
                𝐷(𝑦, 𝜃) = −2log (𝑝(𝑦|𝜃)) + C 
 
where ?̅? is expected deviance over the course of MCMC, 𝑇 is the total 
number of iterations, 𝐷(𝑦, 𝜃) is the deviance of the unknown parameters 
of the model 𝜃, y are the data, 𝑝(𝑦|𝜃) is the likelihood function of 
observing the data given the model, and 𝐶 is a constant that cancels out in 
calculations comparing different models. The expectation, ?̅? is a measure 
of how well the model 𝜃 fits the data – the smaller the value of ?̅?, the better 
the fit. Smaller values of DIC values are indicative of an improved model. 
 
In addition to multivariable models, the effect of each covariate 
individually on DM II RR was evaluated with univariate models. It was 
also considered that SES may potentially be a more distal factor 
influencing levels of the other lifestyle covariates: thus, potential 
mediation between SES and DM II RR by the other covariates was 
explored through mediation analysis. The mediation analysis took results 
from the univariate model for SES as a baseline, and examined the 
percentage change to the estimated coefficient for SES when each of the 
other covariates was added to the model to form a bivariate model. A 
change of more than 10% was considered indicative of potential mediation. 
  
138
Dealing with missing data 
Three imputation methods that may be appropriate for spatial analysis of 
health survey data and are considered in this study include: 
 
a) Mean imputation. This method substitutes each missing observation 
with the mean of the non-missing observations for each particular 
covariate; 
 
b) Imputation using a multivariate normal (MVN) prior distribution for 
covariate data. This method estimates the correlations between covariates 
in the model and uses these covariate relationships to predict missing 
observations based on the non-missing observations for each region; 
 
c) Imputation using a CAR prior distribution for each covariate. This 
method estimates the spatial correlation for each covariate individually, 
and uses these spatial relationships to estimate missing observations for 
each covariate based on non-missing observations in neighbouring regions. 
 
The appropriateness of each of these methods depends on the particular 
application. Here we evaluate these alternative methods in the context of 
the case study. 
 
Imputation methods 
A cross-validation approach was used to compare the accuracy of three 
imputation methods in producing estimates close to observed values. 
Results from mean imputation were compared to results from imputation 
using multivariate normal and conditional autoregressive prior 
distributions. The aim of imputation was to improve the model in terms of 
a) estimating unobserved covariate information based on known covariate 
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information, and b) estimating associations between DM II RR and 
covariates included in the model. 
 
Six of the seven covariates included in models had missing data and for 
five of these this was substantial. Of the 71 Queensland LGAs included in 
this analysis, data were missing for three LGAs (4%) for proportion aged 
45 years and older. Data were missing for 28 LGAs (39%) for four 
covariates: proportion overweight/obese, proportion daily smokers, 
proportion with insufficient physical activity, and proportion with adequate 
fruit intake. For proportion with adequate vegetable intake, data were 
missing for 32 LGAs (45%), including the 28 LGAs with missing data for 
other covariates. 
 
The common practice of removal of cases with missing values would have 
resulted in an unacceptable reduction of the data (45%) of cases removed) 
and potential bias in the results. Imputation of the missing data was 
considered instead. 
 
Methods for each of the three imputation approaches are detailed below: 
(1) Mean imputation. For covariates 𝑗 = 1 𝑡𝑜 6 for the six covariates 
requiring imputation for missing values and regions 𝑖 = 1 𝑡𝑜 𝑤𝑗  where 𝑖 
are the regions with missing values and 𝑤𝑗  are the total number of regions 
with values to be imputed for covariate 𝑗, each missing observation for 
each covariate was replaced with the mean of the non-missing observations 
for that covariate. This preserves the mean of the observed data but does 
not account for correlations among variables and underestimates standard 
deviation of data after imputation. 
 
140
 (2) Imputation using a MVN prior distribution for covariates. A variance-
covariance matrix was fit to account for variance of and correlations 
between each of the seven explanatory variables. An inverse Wishart 
distribution with inverse variances of 0.01 for all covariates, and inverse 
covariances of 0.001 between covariates was fit as a prior to the variance-
covariance matrix. Posterior estimates of the missing data were then 
obtained based on the observed data. The form of the multivariate normal 
prior for the design matrix 𝑿, containing covariate data was: 
 
𝑿~𝑁(𝑴, 𝜮) 
𝜮~𝐼𝑊(𝝍, 𝜈) 
 
where 𝑴 is a vector of mean values and 𝜮 is a variance-covariance matrix 
with an inverse Wishart distribution; ie. the inverse of 𝜮 has a Wishart 
distribution with parameters 𝝍, 𝜈. The Wishart distribution is a 
generalisation to multiple dimensions of the chi-squared distribution. 
 
(3) Imputation using CAR prior distributions for covariate data for each 
covariate 𝑗. The expected value of a missing datum for region 𝑖 was 
estimated using a Normal prior distribution around the average of the 
observed values for that covariate in neighbouring regions. This approach 
borrows strength from neighbouring regions and accounts for spatial 
correlation between neighbours in covariate values. 
 
 The form of CAR priors fit separately for each covariate was: 
 
                        𝑉𝑖|𝑉𝑘 = 𝑣𝑘, 𝑘 ≠ 𝑖 ~𝑁 (𝜇(𝑣𝑘),
𝜎𝑉
2
𝑚𝑖
) 
                  𝜎𝑉~𝑈𝑛𝑖𝑓𝑜𝑟𝑚(0.01,5.0) 
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where for region 𝑖, 𝑉𝑖|𝑉𝑘 is the correlated random effect given the 
correlated random effect in neighbouring region 𝑘, 𝜇(𝑣𝑘) is average 
correlated random effect for all adjacent neighbours, 𝑚𝑖 is the number of 
such neighbours, and 𝜎𝑉
2 is the conditional variance of 𝑉. The same 
neighbours are defined as for equation (3). 
 
Multiple rounds of cross-validation were used to assess how accurately the 
imputation models performed on an independent dataset. Cross-validation 
was performed using only the 39 Queensland LGAs with full information 
for all seven covariates. For each of ten rounds of cross-validation, the data 
were split into two complementary subsets: 90% of data (35 LGAs) were 
randomly selected to form the training dataset, and the remaining 10% (4 
LGAs) formed the test dataset. A conundrum with cross-validation 
approaches for spatial data is that estimation is improved by including as 
much data as possible in the training dataset, thus our decision to include 
90% of data in the training dataset. However, the consequence is that a 
small sample remains for testing the results of imputation against the 
observed values. Due to this difficulty, imputation results for this case 
study should be treated with caution – however, the methodology is 
applicable to other datasets with larger sample sizes. 
 
For each round of cross-validation, the observed covariate information in 
the test dataset were assigned missing values for the purpose of imputation. 
Each of the three imputation models were fit to the training dataset and 
used to impute values for the test dataset. The imputed values were then 
compared to observed values for each covariate in the test dataset by 
computing the root mean squared error (RMSE) for each covariate. For 
covariates 𝑗 = 1 𝑡𝑜 6 for the six covariates requiring imputation for 
missing values and 𝑖 = 1 𝑡𝑜 𝑤𝑗  where 𝑖 are the regions with missing values 
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and 𝑤𝑗  are the total number of regions with values to be imputed for 
covariate 𝑗, the RMSE for each covariate 𝑗 is computed as follows for an 
estimated parameter 𝑥: 
 
𝑅𝑀𝑆𝐸[𝑥𝑗] = √
∑ (𝑥𝑖𝑗 − 𝑥𝑖𝑗)2
𝑤𝑗
𝑖=1
𝑤𝑗
;     𝑅𝑀𝑆𝐸[𝑥] =
∑ 𝑅𝑀𝑆𝐸[𝑥𝑗]
6
𝑗=1
6
 
 
where 𝑥𝑖𝑗 is the imputed value for region 𝑖 and covariate 𝑗, and 𝑥𝑖𝑗 is the 
observed value of the parameter for region 𝑖 and covariate 𝑗. The overall 
RMSE was computed giving each covariate equal weighting; however an 
alternative possibility would be to give each missing value equal 
weighting. 
 
Imputation using MVN and CAR priors were compared to each other with 
respect to bias, defined as the average difference between predicted values 
and the mean observed value for a covariate, adjusted by the size of that 
mean observed value. By definition, mean imputation assigns the mean 
observed value for each covariate to missing values, resulting in a bias of 
zero. For each value imputed by MVN or CAR prior for covariates, bias 
was computed as follows: 
 
𝐵𝑖𝑎𝑠[𝑥𝑖𝑗] =
𝑥𝑖𝑗 − ?̅?𝑗
?̅?𝑗
;      𝐵𝑖𝑎𝑠[𝑥𝑗] =
∑ |𝐵𝑖𝑎𝑠[𝑥𝑖𝑗]|
𝑛𝑗
𝑖=1
𝑤𝑗
 
 
where 𝑥𝑖𝑗 is the predicted value for region 𝑖 and covariate 𝑗, and ?̅?𝑗is the 
mean observed value across all observations for covariate 𝑗.  
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The overall bias was computed as an average of biases for each covariate 
as follows: 
𝐵𝑖𝑎𝑠[𝑥] =
∑ 𝐵𝑖𝑎𝑠[?̂?𝑗]
6
𝑗=1
6
 
 
For imputed missing values, the following information was collected and 
compared between MVN and CAR prior imputation methods: 
 
1. RMSE – this measures how close imputed values are to the observed 
values for each covariate and overall; 
 
2. Mean bias – averaged over imputed observations for each covariate and 
overall. This measures whether or not a particular imputation method tends 
to overestimate or underestimate values overall for a particular dataset; 
 
3. Mean width of 95% credible intervals for bias – averaged over imputed 
observations for each covariate and overall. In Bayesian statistics, a 95% 
credible interval (CI) is a two-tailed interval containing 95% of the 
posterior probability distribution. A wider interval for a particular 
imputation method indicates that estimated values fluctuated from the 
expected value of zero bias to a greater degree than an imputation method 
with a narrower interval; 
 
4. Proportion of 95% CIs including zero bias for each covariate and overall. 
A smaller proportion for a particular imputation method indicates that 
more of the intervals missed the expected value of zero for bias. 
The imputation method providing the smallest overall RMSE and bias was 
selected for further analyses. 
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Sensitivity Analysis 
Sensitivity analysis was used to evaluate the impact of different priors on 
the posterior estimates of the model. The models were compared in terms 
of posterior estimates of the coefficients, and posterior inferences. The 
following priors were considered for both Binomial and Poisson models: 
 
1. CAR priors fit to both covariate data 𝑿 and correlated random effects, 
𝑆𝑖; Gamma(1,0.01) priors for precisions of components of 𝑈𝑖 (Baseline 
model) 
 
2. Gamma(1,0.01) priors for precisions of all components of the vectors 𝛽 
and 𝑈𝑖; CAR priors for 𝑆𝑖 
 
3. Uni(0.01,5) priors for standard deviations of all components of the 
vectors 𝛽 and 𝑈𝑖; CAR priors for 𝑆𝑖 
 
4. Half normal priors, N(0,0.0625)I(0,) for standard deviation of 
components of 𝑈𝑖; gamma(1,0.01) priors for precisions of components of 
𝛽; CAR priors for 𝑆𝑖 
 
5. Log normal priors, N(0,4) for standard deviation of components of 
log(𝑈𝑖); gamma(1,0.01) priors for precisions of components of 𝜷, CAR 
priors for 𝑆𝑖 
 
More detailed information on priors included in the sensitivity analyses is 
provided in Table 1. 
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Table 1: Prior distributions used for parameters in Sensitivity analysis 
Parameter Model 1 Parameter Model 2 Parameter Model 3 Parameter Model 4 Parameter Model 5  
α N(0,0.01) α N(0,0.01) α N(0,0.01) α N(0,0.01) α N(0,0.01)  
βj;j=1,...,7 CAR(1/Ƭβj,R) βj;j=1,...,7 N(0,1/ Ƭβj) βj;j=1,...,7 N(0,σ2βj) βj;j=1,...,7 N(0,1/ Ƭβj) βj;j=1,...,7 N(0,1/ Ƭβj)  
Ui;i=1,...,N N(α,1/ƬU) Ui;i=1,...,N N(α,1/ ƬU) Ui;i=1,...,N N(α,σ2U) Ui;i=1,...,N N(α,1/ ƬU) Ui;i=1,...,N N(α,1/ ƬU)  
Si;i=1,...,N CAR(1/ƬS,R) Si;i=1,...,N CAR(1/ƬS,R) Si;i=1,...,N CAR((σ2S,R) Si;i=1,...,N CAR(1/ƬS,R) Si;i=1,...,N CAR(1/ƬS,R)  
Ƭβj Ga(1,0.01) Ƭβj Ga(1,0.01) σβj U(0.01,5) Ƭβj Ga(1,0.01) Ƭβj Ga(1,0.01)  
ƬU Ga(1,0.01) ƬU Ga(1,0.01) σU U(0.01,5) σU N(0,0.0625)I(0,) log(σU) N(0,4)  
ƬS Ga(1,0.01) ƬS Ga(1,0.01) σS U(0.01,5) ƬS Ga(1,0.01) ƬS Ga(1,0.01)  
α=intercept, j=covariates 1 to 7, βj=vector of coefficients for covariates 1 to 7, i=Local Government Areas (LGAs) 1 to 71, Ui=uncorrelated residual error for LGAs 1 to 71, 
Si=correlated residual error for LGAs 1 to 71, Ƭβj=vector of precisions for covariate coefficients, ƬU=vector of precisions for uncorrelated residual error, ƬS=vector of 
precisions for correlated residual error, σβj=vector of standard deviations for covariate coefficients, σU=vector of standard deviations for uncorrelated residual error, 
σS=vector of standard deviations for correlated residual error, Ga=Gamma distribution, U=Uniform distribution, CAR= CAR normal prior centred around zero, denoted 
CAR(variance, adjacency neighbourhood weight matrix), R= adjacency neighbourhood weight matrix with diagonal entries equal to number of neighbours; ie. 𝑅𝑖𝑖 = 𝑚𝑖  
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Results of sensitivity analysis were compared across models in terms of 
posterior means and 95% credible intervals of coefficient values, size of 
residual errors and DIC and significance of included covariates. Covariates 
were defined to be significantly associated with outcomes if the 95% 
credible interval of their coefficient did not include zero. 
 
RESULTS 
The results of our evaluation of the described imputation methods in the 
context of the case study are presented in this section.  
 
Descriptive Analysis 
Of the 71 Queensland LGAs included in this analysis, SES data were 
available for all LGAs. DM II prevalence data were missing for four 
smaller LGAs, three of which were also missing data for proportion over 
45 years of age. These four LGAs also had missing data for other covariates 
apart from SES. Overall, data were missing for 28 LGAs (39%) for four 
covariates: proportion overweight/obese, proportion daily smokers, 
proportion with insufficient physical activity, and proportion with adequate 
fruit intake. For proportion with adequate vegetable intake, data were 
missing for 32 LGAs (45%), including the 28 LGAs with missing data for 
other covariates. The reason for missing lifestyle data for these 28 LGAs 
is that they had a sample size smaller than 60 in the Queensland self-
reported health status survey and were not reported due to potential 
inaccuracy of results. 
 
SES ranged from 1 to 7 across Queensland LGAs with mean 3.8 (standard 
deviation (SD) 1.8). Of observed values, the mean proportion over 45 years 
of age was 35% (SD 8%), mean proportion overweight or obese was 62% 
(SD 6%), mean proportion of daily smokers was 19% (SD 5%), mean 
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proportion with insufficient physical activity was 49% (SD 7%), mean 
proportion with adequate fruit intake was 54% (SD 5%) and mean 
proportion with adequate vegetable intake was 12% (SD 4%). 
Of the 71 LGAs, 22 (31%) had missing covariate information for 50% or 
more of their immediate neighbours. Of the 28 LGAs with missing 
information for all self-reported lifestyle covariates, 14 (50%) also had 
missing covariate information for 50% or more of their immediate 
neighbours. 
 
Pearson’s correlation estimates returned an absolute value greater than 0.2 
among 52% (11/21) of covariate pairs among the seven explanatory 
variables, indicating reasonably highly correlated covariate data. This 
motivates the investigation of a multivariate imputation approach, but the 
presence of substantial structured missing data supports the possible 
preference for mean imputation. 
 
Imputation 
Mean imputation was found to have the lowest overall RMSE (32.5) for 
this dataset. The RMSE values for each covariate separately and overall, 
for each of the three imputation methods, are summarised in Table 2. 
Imputation using CAR priors for the covariates had the second lowest 
overall RMSE, of 46.1 from both Poisson and Binomial GLMMs. 
Imputation using MVN produced the overall highest RMSE, 71.1 from 
Poisson and 72.7 from Binomial GLMM. 
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Table 2: Comparison of imputation methods by root mean squared error (RMSE) and bias from cross-validation 
Covariate 
N 
missing 
RMSE, mean(sd) 
Average bias Average width of CI 
% of CIs including 
zero bias 
Mean imputation 
MVN CAR prior 
Poisson Binomial Poisson Binomial 
MVN 
CAR 
prior MVN 
CAR 
prior MVN 
CAR 
prior 
% over 45yrs of age 3 49.7 
108.7 
(21.2) 
109.6 
(19.5) 
46.3 
(17.8) 
46.2 
(17.9) 0.012 0.041 0.897 0.345 100% 100% 
% Overweight/obese 28 26.3 73.7 (22.3) 73.1 (20.6) 
45.4 
(18.5) 
45.4 
(18.4) 0.016 0.081 0.413 0.200 100% 75% 
% Daily smokers 28 25.8 53.2 (18.1) 54.4 (19.3) 
49.8 
(21.1) 
49.8 
(21.0) 0.153 0.271 1.144 0.640 100% 68% 
% Insufficient physical activity 28 36.7 90.7 (37.5) 91.4 (37.1) 
67.0 
(41.3) 
67.1 
(41.3) 0.048 0.047 0.535 0.246 100% 93% 
% Adequate fruit intake 28 34.4 67.4 (14.3) 68.6 (14.7) 
37.5 
(22.7) 
37.6 
(22.7) 0.069 0.052 0.382 0.221 100% 91% 
% Adequate vegetable intake 32 21.9 39.1 (18.5) 39.2 (18.4) 
30.4 
(19.6) 
30.6 
(19.9) 0.157 0.185 1.144 0.973 100% 94% 
Overall - 32.5 71.1 (11.4) 72.7 (11.1) 
46.1 
(11.7) 
46.1 
(11.7) 0.076 0.113 0.752 0.438 100% 87% 
 RMSE=root mean squared error, sd=standard deviation, MVN= Multivariate normal imputation, CAR prior=conditional autoregressive prior 
imputation; CI=95% credible interval for bias  
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Bias statistics for each covariate separately and overall are summarised in 
Table 2. The overall average bias from the imputation methods was largest 
for imputation using CAR priors (0.11) and smallest for MVN and mean 
imputation (estimated 0.08 for MVN and zero for mean imputation by 
definition). MVN imputation produced greater uncertainty of bias 
compared with imputation using CAR priors (average width of 95% 
credible interval (CI) was 0.75 and 0.44 respectively overall). Imputation 
using MVN consistently produced 95% CIs that included a bias value of 
zero, whereas only 87% of 95% CIs from imputation using CAR priors 
included a bias value of zero. A graphical comparison of estimate bias 
distribution between MVN and CAR prior imputation methods for one 
covariate, the proportion over 45 years of age, is provided in Figure 1. Bias 
plots for other covariates are available in the appendix. 
 
Figure 1: Bias for estimated % over 45 years for Local Government Areas (LGAs) with missing 
data, by 1. Multivariate normal imputation, and 2. Conditional autoregressive (CAR) priors 
for covariates; eg. LGA 23-1 indicates multivariate normal imputation for LGA number 23 
and LGA 23-2 indicates imputation with CAR priors for covariates for LGA number 23. 
 
LGA=Local Government Area) 
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 As the imputation method providing both the smallest RMSE and bias for 
this dataset, mean imputation was selected and was adopted for further 
analyses, including sensitivity analysis. Although there is some built-in 
circularity favouring mean imputation as an unbiased method of 
imputation by definition, overall it appears an appropriate choice for this 
dataset given a) it produced estimates that were closest to observed 
estimates, and b) the other two methods produced significant bias for two 
covariates in particular: proportion of daily smokers and proportion with 
adequate vegetable intake. 
 
Sensitivity Analysis 
Mean estimates of selected parameters resulting from Binomial and 
Poisson GLMMs with different priors are displayed in Table 3. Each of the 
GLMMs included in sensitivity analysis produced similar coefficient 
estimates and resulted in the same conclusions.  
 
Results 
SES was found to be the only variable associated with DM II RR based on 
the Poisson models and prevalence based on the Binomial models, from 
both univariate and multivariate models. Of the other covariates included 
in the models, none were found to be significantly associated with DM II 
outcomes. From the baseline Poisson model (model 1), each one unit 
increase in SES was estimated to decrease the log(relative risk) of DM II 
by 0.18 (95% credible interval 0.13 to 0.23). 
Mediation analysis did not find a significant mediating effect (defined by 
a change of 10% or more to the SES coefficient) between SES and DM II 
RR by any of the other covariates included in this study.  
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Table 3: Estimates for selected parameters from models included in sensitivity analysis: mean (95% credible intervals). Prior distributions used 
in models 1-5 are summarised in Table 1. 
Binomial  α  β1  β2  β3  β4  β5  β6  β7  σ S
 2
  σ U
 2 DIC  
1 -2.158 -0.194 0.009 -0.004 0.008 -0.008 -0.013 -0.005 0.013 0.073 667 
  (-2.368,-1.963) (-0.240,-0.143) (-0.001,0.020) (-0.019,0.012) (-0.010,0.027) (-0.022,0.006) (-0.036,0.011) (-0.033,0.022)       
2 -2.147 -0.197 0.009 -0.005 0.008 -0.007 -0.015 -0.004 0.013 0.074 667 
   (-2.415,-1.911) (-0.253,-0.129) (-0..002,0.021) (-0.024, 0.013) (-0.013, 0.027) (-0.023, 0.008) (-0.040,0.008) (-0.031,0.025)       
3 -2.158 -0.194 0.01 -0.005 0.008 -0.007 -0.014 -0.005 0.012 0.079 666 
  (-2.374,-1.939) (-0.248,-0.1416) (-0.002,0.021) (-0.022,0.011) (-0.010,0.026) (-0.022,0.006) (-0.038,0.007) (-0.032,0.022)       
4 -2.155 -0.194 0.009 -0.003 0.008 -0.007 -0.014 -0.004 0.012 0.076 668 
  (-2.384,-1.951) (-0.242,-0.138) (-0.002,0.0196) (-0.020,0.016) (-0.010,0.026) (-0.022,0.008) (-0.038,0.009) (-0.030,0.023)       
5 -2.203 -0.183 0.008 -0.004 0.008 -0.006 -0.013 -0.003 0.012 0.080 666 
  (-2.451,-1.953) (-0.242,-0.122) (-0.004,0.020) (-0.026,0.015) (-0.013,0.029) (-0.024,0.011) (-0.037,0.009) (-0.032,0.027)       
Poisson                        
1 0.641 -0.181 0.009 -0.005 0.007 -0.006 -0.014 -0.005 0.012 0.062 671 
  (0.440,0.854) (-0.232,-0.134) (-0.001,0.020) (-0.022,0.011) (-0.009,0.024) (-0.020,0.008) (-0.035,0.008) (-0.030,0.022)       
2 0.615 -0.174 0.008 -0.004 0.008 -0.005 -0.011 -0.004 0.012 0.061 671 
  (0.434,0.816) (-0.223,-0.133) (-0.002,0.018) (-0.020,0.012) (-0.008,0.026) (-0.018,0.007) (-0.031,0.009) (-0.028,0.022)       
3 0.649 -0.183 0.009 -0.004 0.008 -0.006 -0.013 -0.003 0.012 0.067 670 
  (0.413,0.864) (-0.236,-0.125) (-0.002,0.020) (-0.025,0.014) (-0.010,0.025) (-0.021,0.008) (-0.036,0.011) (-0.029,0.025)       
4 0.651 -0.184 0.009 -0.004 0.007 -0.007 -0.013 -0.005 0.012 0.065 672 
  (0.422,0.883) (-0.240,-0.129) (-0.002,0.020) (-0.023,0.014) (-0.012,0.025) (-0.021,0.007) (-0.036,0.010) (-0.031,0.022)       
5 0.646 -0.182 0.009 -0.003 0.008 -0.007 -0.012 -0.006 0.011 0.066 670 
  (0.441,0.888) (-0.244,-0.134) (-0.002,0.020) (-0.021,0.016) (-0.012,0.025) (-0.022,0.008) (-0.034,0.009) (-0.030,0.022)       
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α=intercept, β1=coefficient for socio-economic status, β2=coefficient for % over 45 
years of age, β3=coefficient for % overweight/obese, β4=coefficient for % daily 
smokers, β5=coefficient for % insufficient physical activity, β6=coefficient for % 
adequate fruit intake, β7=coefficient for % adequate vegetable intake, σS2=variance of 
correlated residual error, σU2=variance of uncorrelated residual error, DIC= Deviance 
Information Criteria 
 
 
Geographic Variation 
Spatially smoothed relative risks (RR) and relative excess risks (RER) and 
corresponding standard deviations and 95% credible intervals were 
obtained from the Poisson GLMMs with mean imputation and CAR priors 
fit to covariate data. The estimated RR of DM II varied between study 
regions from 0.48 (Isaac Regional) to 3.07 (Cherbourg Aboriginal Shire), 
indicating a six-fold variation (3.07/0.48 = 6.4) across regions. RER varied 
from 0.96 for Napranum Aboriginal Shire to 4.44 for Burke Shire. The 
distribution of RR and RER by quintiles from highest to lowest are 
displayed in Figure 2 along with their standard deviation. The size of 
estimated RR and RER for each region does not appear to be associated 
with the size of uncertainty for those regions. 
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Figure 2: Estimated Relative Risk (RR) and Relative Excess Risk (RER) of type 2 
diabetes for Queensland Local Government Areas 
RR=relative risk, sd=standard deviation, RER= relative excess risk) 
 
The LGAs with the five smallest and five highest RR, RER and standard 
deviation for RR and RER are ranked in Table 4. 80% of the regions in the 
top five for large RR also were in the top five for large RER, indicating 
that they are most at risk for DM II occurrence even after accounting for 
the influence of regional risk factors. 
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Table 4: Top 5 LGAs for Relative Risk (RR), Relative Excess Risk (RER) and 
uncertainty for Relative Risk and Excess Relative Risk 
Smallest estimated 
RR Smallest sd(RR) 
Smallest estimated 
RER 
Smallest sd(RER) 
LGA Estimated RR LGA sd(RR) LGA Estimated ERR LGA sd(RER) 
34 0.480 8 0.003 47 0.962 67 0.125 
16 0.573 28 0.005 32 1.021 10 0.150 
8 0.580 44 0.006 67 1.255 30 0.152 
24 0.611 60 0.006 34 1.442 32 0.161 
28 0.624 38 0.007 24 1.452 57 0.168 
                
Largest estimated RR Largest sd(RR) Largest estimated RER Largest sd(RER) 
LGA   LGA sd(RR) LGA Estimated RER LGA sd(RER) 
63 1.857 12 0.269 51 2.535 68 0.566 
35 1.933 41 0.445 35 2.627 70 0.575 
51 1.966 65 0.452 68 2.645 41 0.580 
12 2.450 70 0.465 18 3.738 23 0.587 
18 3.073 23 0.474 12 4.442 12 0.647 
 
RR=Relative Risk, RER= Relative Excess Risk, sd = standard deviation 
 
 
Figure 3 ranks regions in order of low to high RR (A) and RER (B) 
respectively with 95% CIs. As may be expected, regions with missing 
covariate data tended to have wider 95% CIs compared with regions with 
observed data. 
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 Figure 3: Ranked Relative Risk (A) and Relative Excess Risk (B) for Local Government Areas with 95% credible intervals  
 
RR= Relative Risk, RER = Relative Excess Risk) 
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DISCUSSION 
Our study describes an evaluation of three different imputation methods that are 
applicable to missing health survey data for spatial analysis. Choice of imputation 
method depends upon the particular application and is not necessarily the most 
complex method. In the application for this case study, simple imputation with 
the mean value of each missing covariate value was found to provide the most 
accurate prediction of missing values in this dataset, based on the statistical 
measures described.  
In this application, mean imputation was found to be more appropriate than 
imputation with CAR priors using spatial correlation of covariate data to impute 
missing values. For this dataset, this could be due to the large proportion of 
missingness for some covariates relative to a small number of neighbours for 
certain regions, providing insufficient observed data from neighbouring regions. 
These different imputation methods may perform comparatively differently in 
datasets with smaller proportions of missing data. 
 
Simple mean imputation was also found to be far more accurate in this case study 
than fitting a multivariate normal distribution to covariates to impute missing data 
in this dataset, despite empirical evidence of high correlation between many 
covariate pairs. This is likely due to the pattern of missingness, as LGAs tended 
to have either complete data for all covariates, or missing data for six covariates 
(proportion overweight/obese, daily smokers, aged over 45 years, proportion with 
insufficient physical activity, and sufficient fruit and vegetable intake). 
Moreover, missingness was related to population size of LGAs, as less-populated 
LGAs did not have covariate data from the Queensland self-reported health status 
survey. Thus data were not missing at random in this dataset. Multivariate normal 
imputation may provide more accurate prediction of missing values in datasets 
with missingness at random as well as high correlations between covariate pairs. 
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Our sensitivity analysis provides evidence that choice of priors, from non-
informative to more informative choices, did not affect results from the spatial 
analysis of this case study. Fitting of Binomial and Poisson models produced 
similar findings with similar goodness of fit as measured by DIC. This supports 
the estimates of DM II RR for each LGA and evidence that SES is strongly 
associated with DM II risk in this region. The sensitivity analysis described in 
this paper is readily applicable to spatial analysis of other health datasets. 
 
Several studies have examined geographic variation in DM II in the US, UK and 
Europe, however, less is known about regional variation and associated regional 
risk factors in Australia. Similar to other studies, our analysis shows marked 
geographic variation in DM II relative risk [7, 9, 11-18]. Just within Queensland, 
our study estimates a six-fold difference in DM II relative risk. Similar to findings 
from other spatial studies, we found lower socioeconomic status to be strongly 
associated with increased risk of DM II [9, 11, 13, 14].  
 
Contrary to findings from Green et al., we did not find the proportion of daily 
smokers to be associated with DM II risk [11]. In comparison with risk models 
reporting BMI to be associated with DM II risk at an individual-level, we did not 
find the proportion of residents overweight or obese to be associated with DM II 
risk at a regional level in this dataset [8]. We examined the association of obesity 
(BMI≥30kg/m2) and overweight (25kg/m2≤BMI<30kg/m2) with DM II RR 
separately in univariate models and neither were found to be significant within 
this geographic region. However, our study categorised BMI into broad 
overweight and obese categories whereas the risk models considered raw BMI 
scores. Findings may differ for spatial analyses of DM II risk in other regions. 
 
Strengths of our study include that we were able to evaluate the performance of 
three different imputation approaches using methodology which is immediately 
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applicable to other regions and health datasets outside the application of the case 
study reported. Within our case study, we were able to evaluate the geographical 
variation in DM II RR across Queensland and identify regions of high risk, and 
regional factors associated with DM II risk, accounting for missing data. We used 
Bayesian methods to fit hierarchical models accounting for different sources of 
uncertainty, to evaluate the association of geographical covariates with DM II 
RR. Spatial smoothing was performed, accounting for correlation between 
neighbouring regions and mitigating the effects of random measurement error. In 
addition, we were able to select the most accurate imputation method for this 
dataset and check the accuracy of results through sensitivity analysis.  
 
Limitations of our study include the presence of significant missing data, small 
sample sizes for test datasets in cross-validation, that diabetic counts were based 
on notification data with unknown measurement bias, and that region-level 
lifestyle data was based on self-report that is not objectively measured. Thus 
results should be interpreted with caution. 
 
Although spatial modelling of DM II relative risk at a smaller region level such 
as Statistical Local Area (SLA) may have resulted in relative risk information at 
a finer level, the difficulty is that lifestyle information is not available at this level 
and cannot be assessed for contribution to DM II risk. Furthermore, we expect 
less uncertainty from variation in notification rates when data is aggregated to a 
larger regional level. 
 
CONCLUSIONS 
In conclusion, we present a method for selection of an appropriate imputation 
method among alternative choices suited to spatial health survey data with 
varying patterns and amounts of missingness. Missing data is a common problem 
with spatial health data, and appropriate choice of imputation method depends 
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upon the particular application. As discovered for the case study considered here, 
choice of imputation method may not always be the most complex one. However 
in some cases, utilising other information such as spatial correlation in data or 
correlation between covariates may be appropriate for the purposes of imputation. 
Selection of an appropriate imputation method allows a more complete analysis 
of geographic risk factors for disease at a regional level, with the potential to 
inform resource allocation and public policy, and reduce the burden of disease to 
the community. 
 
This case study provides evidence of a six-fold difference in geographical 
variation in DM II RR across Queensland LGAs, and indicates that socio-
economic status is strongly associated with DM II risk. Our results indicate that 
a geographically targeted approach to managing DM II may be effective, and 
highlight regions most in need of additional services to manage DM II. The 
methodology used in this study is applicable to spatial analyses of diabetes in 
other regions, as well as other diseases, and has the potential to provide useful 
information for management and resource allocation decisions. 
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ABSTRACT 
Background: Hospitalisation for type II diabetes mellitus (DMII) 
complications is potentially avoidable with quality primary care of high-
risk patients. Individual and geographic factors associated with 
hospitalisation for DMII complications and adverse outcomes for these 
inpatients are examined. 
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Methods: Generalised linear mixed models were applied to 2001-2006 
hospital data for residents of a regional area of NSW. Factors associated 
with hospitalisation for DMII complications, multiple admissions, longer 
length of stay, readmissions within 28 days and ICU admission were 
examined. Covariates include age, gender, country of birth, marital status, 
comorbidity with chronic obstructive pulmonary disease (COPD), 
coronary arterial disease (CAD), hypertension (HT) and congestive heart 
failure (CHF). Participants’ Statistical Local Area of residence and its 
associated socioeconomic quintile were also included. 
 
Results: Among patients with DMII in the cohort (N=11,293), patients 
were more likely to be admitted for DMII complications if aged 70-89. 
Multiple (3+) DMII principal admissions were associated with male gender 
and comorbidity with CAD, length of stay exceeding one day with 
increasing age, male gender, being born in Australia or unmarried, or 
comorbidity with COPD, CAD, HT or CHF. 
 
Conclusions: These findings have important implications for clinicians 
within both community and hospital settings: patients with DMII who are 
older, socially isolated and comorbid with HT, CAD, CHF and/or COPD 
may be at higher risk for hospitalisation for DMII complications and 
adverse inpatient outcomes. These patients may warrant closer monitoring 
and more regular follow-up than other diabetic patients. 
 
Keywords: 
Diabetes, hospitalisation, risk factors 
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1. BACKGROUND 
There is an emerging pandemic of type II diabetes mellitus (DMII) in both 
developed and developing countries, evidenced by increasing DMII 
prevalence in every country of the world, and mounting costs from 
hospitalisation for DMII complications [1]. The estimated number of 
people with diabetes worldwide is 387 million people in 2014, projected to 
increase to 592 million by 2035, and DMII accounts for 90-95% of all cases 
of diabetes [1-3]. The direct and indirect costs of diabetes and its 
complications are estimated to exceed USD 612 billion in the US in 2014, 
£23.7 billion in the UK in 2011 and AUD 14.6 billion in Australia in 2010 
[4-7]. DMII is reported to be the seventh leading cause of death in the US, 
and the leading cause of renal failure, nontraumatic lower-limb 
amputation, new cases of blindness, and a major cause of heart disease and 
stroke [8]. A study examining temporal trends in hospitalisation incidence 
for diabetes found an exponential increase between 1981 and 2000 in Sri 
Lanka [9]. 
 
DMII is an example of an ambulatory care sensitive (ACS) condition for 
which hospitalisation can potentially be avoided among some patients with 
quality primary care, and has been suggested as the leading cause of 
avoidable hospitalisations in Australia [10, 11]. Avoidable hospitalisations 
can be defined as representative of “a range of conditions for which 
hospitalisation should be able to be avoided because the disease or 
condition has been prevented from occurring, or because individuals have 
had access to timely and effective primary care” [11]. DMII has been 
shown to be associated with other ACS conditions including chronic 
obstructive pulmonary disease (COPD) [12, 13], coronary arterial disease 
(CAD) [14-16], hypertension (HT) [17]  and congestive heart failure 
(CHF)[18, 19], and development of these conditions may be secondary 
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complications of DMII. Combined, hospitalisations for DMII, COPD and 
angina due to CAD account for almost half of all avoidable hospital 
admissions in Australia [11]. Early detection of DMII and management of 
glycaemic control and cardiovascular risk factors have the potential to 
reduce long-term complications and hospitalisation [20]. Indeed, there is 
increasing evidence from around the world that around 60% of DMII cases 
are preventable with medications and/or lifestyle changes [21]. 
 
Although individual factors associated with DMII diagnosis have been 
reported, there is still a substantial gap in knowledge around individual and 
geographic factors associated with hospitalisation for DMII complications 
among patients diagnosed with DMII. Individual risk factors for diagnosis 
with DMII are known to include increasing age, body mass index and 
waist:hip ratio, male gender, indicators of low socio-economic status 
(SES), sedentary lifestyle, physical inactivity, smoking history, and low 
levels of fruit and vegetable consumption [22-26]. In addition, there is 
increasing evidence from spatial studies conducted in the US, UK and 
Europe of spatial variation in DMII prevalence due to geographic factors 
[20, 22, 23, 25-31]. These include factors such as reduced green 
space/walkability, increased fast-food availability, decreased access to 
healthy food, car-dominated transport, reduced opportunities for exercise, 
lower SES and higher proportion of daily smokers. However, there is a 
lack of reported studies examining factors associated with hospitalisation 
for DMII complications and adverse inpatient outcomes for these patients. 
Statistical models for the prediction of DMII hospitalisation and inpatient 
outcomes that account for individual and geographic factors and highlight 
geographic inequalities in risk would be useful for closer monitoring of 
patients at risk for hospitalisation for DMII complications in primary care, 
with a view to avoiding complications. Furthermore, they would allow 
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appropriate follow-up of inpatients with DMII complications at risk of 
multiple admissions, short-term readmissions and admission to intensive 
care unit (ICU), and inform public policy regarding areas that would 
benefit most from additional services for quality primary care of DMII to 
avoid hospitalisation. 
 
For the prediction and modelling of risk at the geographic scale, spatial 
models are advantageous for risk estimation in areas with low counts, as 
they “borrow strength” from neighbouring areas, resulting in more robust 
inferences [32]. Bayesian spatial models are well-suited to modelling 
disease outcomes aggregated to small areas, as spatial correlations are able 
to be incorporated a priori [33]. 
 
Using as a case study, routinely collected hospital data from a regional area 
of  New South Wales from 2001-2006, this paper addresses a gap in current 
literature by satisfying three-fold objectives: first, to identify individual 
and geographic factors associated with hospitalisation for DMII 
complications and adverse inpatient outcomes; second, to identify high-
risk areas in the region for these outcomes; and finally, to examine 
geographic disparities in DMII outcomes. 
 
2. METHODS 
 
2.1 Data 
The analysis relied on two main sources of data. These sources are 
described in the subsections below. 
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Admissions data 
Routinely collected hospital data from all admissions among residents of 
the region to any hospital in Australia between January 2001 to June 2006. 
All private rural hospitals in this region were deidentified and aggregated 
into one category, thus the exact number of hospitals from which 
admissions records are included in the dataset is unknown. Variables 
available in the dataset for each admission include a patient identifier, 
financial year, calendar year, day of week and month of admission, hospital 
of admission, age, gender, Aboriginal and Torres Strait Islander (ATSI) 
status, country of birth, marital status, Statistical Local Area (SLA) of 
residence using 2001 SLA codes, daystay flag, readmission within 28 days 
flag, hours spent in ICU, length of stay (LOS) and International Statistical 
Classification of Diseases-10 (ICD10) codes for principal and all 
secondary diagnoses. As the precise locations of patient residences were 
unavailable, distance to a patient’s hospital of admission was unable to be 
assessed. 
 
For each admission, recorded principal and secondary diagnoses taking 
ICD10 codes between E11.0 and E11.99 inclusive were classified as 
principal DMII admissions and secondary diagnosis of DMII respectively. 
For the purposes of this paper, a principal DMII admission is synonymous 
with admission for a DMII complication. An admission with a secondary 
diagnosis of DMII indicated that the patient was comorbid with DMII but 
that the admission was not for a complication of DMII. Similarly, patients 
with any admission with a principal or secondary diagnosis taking ICD10 
codes between J41 and J44 inclusive or J47 were classified as comorbid 
with COPD, between I20 and I25 inclusive with CAD, between I10 and 
I15 inclusive with the exclusion of I11.0 with HT, and I11.0 or I50 or J81 
with CHF. 
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Demographic/Geographic Information 
Australian Bureau of Statistics (ABS) for estimated resident population 
(ERP) and socio-economic status of each SLA as measured by the Index 
of Relative Social Advantage and Disadvantage (IRSAD) in 2001 [34, 35]. 
The IRSAD is described by the ABS as a general index of socio-economic 
disadvantage [36]. A larger score indicates a relative lack of disadvantage 
and greater advantage in general, with disadvantage offset by advantage 
[37]. Some components of the IRSAD include income, education, housing, 
access to resources and type of occupation – full details of components and 
their weighting are available from the ABS [37]. Individual-level measures 
of SES were not available from the routinely collected hospital dataset; 
however, as SES has been shown to be associated with DMII outcomes at 
both an individual and geographic level, the decision was made to use the 
SES measure of each patient’s SLA of residence as a proxy for the SES 
status of each patient [23, 25-28, 38-43]. 
 
The IRSAD scores for each SLA were categorised into quintiles internal 
to the dataset to allow subgroups of patients to be compared. The cutpoints 
for IRSAD score quintiles within the dataset were 869-892, 893-915, 916-
922, 923-947 and 948-969. 
 
Covariates included in all statistical models were nine patient-level 
covariates and two covariates measured at a geographic (SLA) level. 
Patient-level covariates include age as either a categorical or continuous 
variable, gender (male, female), country of birth (Australia, other), marital 
status (married, other), Aboriginal/Torres Strait Islander (ATSI) status 
(either, neither) and comorbidity with COPD, CAD, HT and CHF (yes, no) 
as separate covariates. Geographic covariates include SLA of residence 
and its associated IRSAD quintile. The effect of ATSI status on response 
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variables was adjusted for but not reported due to ethical considerations. It 
was considered important to adjust for ATSI status within all models, as 
previous research examining the role of demographic characteristics in 
explaining variation in adverse health outcomes (acute coronary events and 
small-for-gestational-age births for example) have found indigenous status 
to have an influence on outcomes even after accounting for other variables 
such as SES [44, 45]. 
 
Exploratory analyses were performed to determine interaction terms 
between covariates that may be important for each selected outcome. 
Identified interaction terms were included in the Bayesian hierarchical 
model for that outcome. Similarly, exploratory analyses examined whether 
the relationship between age and the log odds of each selected outcome 
appeared linear or non-linear; if linearly related or not significantly 
associated then age was included as a continuous variable in the statistical 
model for that outcome, and if non-linearly related then age was included 
in five age groups (age 45-59 years, 60-69 years, 70-79 years, 80-89 years, 
90yrs+) in the Bayesian model for that outcome. The age range of patients 
within the dataset was 45-106 years of age. 
 
As part of the exploratory analyses, 𝜒2 tests were used to compare 
categorical variables and Student t-tests to compare continuous variables 
between patients with one or more DMII principal admission and those 
with DMII secondary diagnoses only. 
 
2.2 Statistical models 
Spatial generalised linear mixed models were developed to explore factors 
associated with five outcomes over the study years (A-E described below). 
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A. One or more hospital admission for principal DMII diagnosis, among 
patients with principal or secondary diagnosis of DMII (patient level 
outcome) 
B. Three or more hospital admissions for principal DMII diagnosis over 
the study period, given one or more DMII principal admission over the 
study period (patient level outcome) 
C. Length of stay two days or longer, given DMII principal admission 
(admission level outcome) 
D. Readmission to hospital within 28 days of a previous admission, given 
DMII principal admission (admission level outcome) 
E. Admission to ICU, given DMII principal admission (admission level 
outcome). 
 
Each model was developed within the Bayesian framework and estimated 
by Markov chain Monte Carlo (MCMC) using Gibbs sampling. Each 
analysis was run for 150,000 iterations with 50,000 burnin. All statistical 
analyses were performed using R 3.1.1, WinBUGS and  SAS 9.3 [46-48]. 
 
In the following sections, Models A-E are described in further detail. 
Common to all models is a binary response variable, 𝑌, equal to 1 if the 
outcome is observed and 0 otherwise. The defined outcome and associated 
subscripts are described for each model in the following subsections. For 
the prediction of each outcome, a covariate was identified as important if 
the 95% credible interval (CI) for its associated coefficient did not cover 
zero. Similarly, an SLA was flagged as having differential excess risk if 
the 95% CI for its associated random effect did not cover zero. 
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2.3 Admission for DMII principal diagnosis 
Model A considers factors associated with principal admission for DMII 
complications among all patients with a principal or secondary diagnosis 
of DMII. The aim of this model is to aid identification and monitoring of 
patients at higher risk of hospitalisation for DMII complications with a 
view to avoiding complications within a primary care setting. For patient 𝑖 
within SLA of residence 𝑗, 𝑌𝑖𝑗 is the binary outcome for a patient being 
admitted at least once with a principal or secondary DMII diagnosis and 
𝜃𝑖𝑗 is the estimated probability of this outcome. The model then takes the 
form: 
 
              𝑌𝑖𝑗~𝐵𝑒𝑟𝑛(𝜃𝑖𝑗)                  
𝑙𝑜𝑔𝑖𝑡(𝜃𝑖𝑗) = 𝛼 + 𝒙𝑖𝜷1 + 𝒛𝑗𝜷2 + 𝑈𝑖 + 𝑆𝑗  (1) 
 
where 𝛼 is a fixed intercept, 𝜷1 and 𝜷2 are vectors of coefficients, 𝒙𝑖 is the 
𝑖th row of the design matrix 𝑿, containing covariate data for observation 𝑖, 
and 𝒛𝑗 is the 𝑗th row of the design matrix 𝒁 containing spatial information 
for the region 𝑗 that observation 𝑖 belongs to. The uncorrelated error for 
observation 𝑖 is denoted 𝑈𝑖, and 𝑆𝑗 is the correlated spatial error based on 
neighbourhood information; this is described in more detail below. 
Separating the residual error into correlated (𝑆𝑗) and uncorrelated (𝑈𝑖) 
components provides an indication of how much variation in 
hospitalisation rates for DMII complications can be attributed to the effect 
of geographical region, after accounting for the effect of the covariates. 
The correlated spatial error is assumed to follow an intrinsic conditional 
autoregressive prior, as first described by Besag, York and Mollie in 1991 
[33] which assumes a priori that the mean of 𝑆𝑗 for a given region 𝑗 is equal 
to the average of its neighbours, ie: 
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𝑆𝑗|𝑆(−𝑗), 𝜎𝑆
2 ~𝑁 (
∑ 𝑆𝑘𝑤𝑗𝑘
𝑛
𝑘=1
𝑚𝑗
,
𝜎𝑆
2
𝑚𝑗
)    (2) 
 
                                      𝑤𝑗𝑘 = {
1     𝑖𝑓 𝑗 𝑎𝑛𝑑 𝑘 𝑎𝑟𝑒 𝑛𝑒𝑖𝑔ℎ𝑏𝑜𝑢𝑟𝑠
0     𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒                               
 
 
for 𝑗 = 1, … , 𝑛 with (−𝑗) denoting all regions excluding 𝑗.  
∑ 𝑆𝑘𝑤𝑗𝑘
𝑛
𝑘=1
𝑚𝑗
 is the 
average correlated random effect for the neighbours of region 𝑗, 𝑚𝑗 is the 
number of such neighbours, and 𝜎𝑆
2 is the conditional variance of 𝑺. A 
neighbour is defined as any region immediately adjacent in space to region 
𝑖. It can be seen that this type of prior induces a form of local smoothing 
across regions, where the degree of smoothing is controlled by the spatial 
correlation between regions. 
 
A 𝑁(0,100) prior was assumed for 𝛼 and each element of the vectors 𝜷1 
and 𝜷2; 𝑈𝑖𝑗 was assumed to follow a 𝑁(0, 𝜔
2) prior with 𝐼𝐺(1.0,0.01) 
priors fit to 𝜎S
2 and 𝜔2. These priors were selected as they are 
uninformative and reflect the lack of prior knowledge around values for 
the intercept and coefficients in the model. 
 
2.4 Multiple DMII principal admissions 
Model B considers factors associated with multiple admissions for DMII 
complications, defined as three or more DMII principal admissions over 
the five-year study period, among those patients with one or more DMII 
principal admission. A GLMM is fit following equations (1) and (2) above 
with the same hyperparameter priors specified above. 
 
  
179
2.5 Prolonged length of hospital stay 
Model C considers factors associated with hospital LOS in excess of one 
day among all DMII principal admissions. A GLMM model was fit as 
follows: 
 
𝑌ℎ𝑖𝑗~𝐵𝑒𝑟𝑛(𝜃ℎ𝑖𝑗)         
               𝑙𝑜𝑔𝑖𝑡(𝜃ℎ𝑖𝑗) = 𝛼 + 𝒙ℎ𝑖𝜷1 + 𝒛𝑗𝜷2 + 𝑈ℎ𝑖 + 𝑆𝑗       (3) 
 
where for admission ℎ for patient 𝑖 within region 𝑗, 𝑌ℎ𝑖𝑗 is the binary 
outcome for an admission having an LOS in excess of one day, and 𝜃ℎ𝑖𝑗 is 
the estimated probability of this outcome. 𝛼 is a fixed intercept, 𝜷1 and 𝜷2 
are vectors of coefficients, 𝒙ℎ𝑖 is the ℎth row of the design matrix 𝑿, 
containing covariate data for admission ℎ for patient 𝑖, and 𝒛𝑗 is the 𝑗th row 
of the design matrix 𝒁 containing spatial information for the region 𝑗 that 
observation 𝑖 belongs to. The uncorrelated error for admission ℎ for patient 
𝑖 is denoted 𝑈ℎ𝑖, and 𝑆𝑗 is the correlated spatial error based on 
neighbourhood information following equation (2). A 𝑁(0,100) prior was 
assumed for each element of 𝜷1 and 𝜷2, 𝑈ℎ𝑖 was assumed to follow a 
Normal distribution with zero mean and variance 𝜔2, with priors for other 
hyperparameters as described previously. 
 
2.6 Readmission to hospital 
Model D considers factors associated with a DMII principal admission 
being a readmission to hospital within 28 days of a previous admission, 
among all DMII principal admissions. A GLMM was fit following 
equation (3) above. 
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2.7 Admission to ICU 
Model E considers factors associated with a DMII principal admission 
being admitted to ICU, among all DMII principal admissions. A GLMM 
was fit following equation (3) above. 
 
2.8 Model evaluation 
Model fit was evaluated using a Deviance Information Criterion (DIC) and 
log likelihood. In addition, misclassification error rate, sensitivity, 
specificity, false positive and false negative rates were estimated using 
replicate data for the response variable in each model. 
 
The DIC, first described by Speigelhalter [49] consists of two components, 
a term that measures goodness of fit (?̅?) and a term that penalises models 
for the number of parameters (𝑝𝐷), thus favouring parsimony. 
 
𝐷𝐼𝐶 = ?̅? + 𝑝𝐷 
                   ?̅? =
1
𝑇
∑ 𝐷(𝑦, 𝜃(𝑡))
𝑇
𝑡=1
 
         𝐷(𝑦, 𝜃(𝑡)) = −2log (𝑝(𝑦, 𝜃(𝑡))) 
 
where ?̅? is the expected deviance over the course of MCMC, 𝑇 is the total 
number of iterations, 𝐷(𝑦, 𝜃(𝑡)) is the deviance of the unknown parameters 
of the model 𝜃 at iteration 𝑡, y are the data, and 𝑝(𝑦, 𝜃(𝑡)) is the likelihood 
function of observing the data given the estimated parameters of the model 
at iteration 𝑡. The expectation, ?̅? is a measure of how well the model fits 
the data – the smaller the value of ?̅?, the better the fit. Smaller values of 
DIC values are indicative of an improved model. 
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For Models A and B, 𝜃𝑖𝑗
(𝑡)
 is calculated at each iteration 𝑡 given samples 
for the parameters (𝛼, 𝜷1,𝜷2, 𝑈𝑖 , 𝑆𝑗). The likelihood for each observed 
outcome 𝑌𝑖𝑗 at each iteration 𝑡 following the Bernoulli distribution given 
the estimated parameter 𝜃𝑖𝑗
(𝑡)
 is: 
𝑝 (𝑌𝑖𝑗|𝜃𝑖𝑗
(𝑡)
) = 𝜃𝑖𝑗
(𝑡)𝑌𝑖𝑗
(1 − 𝜃𝑖𝑗
(𝑡)
)1−𝑌𝑖𝑗 
 
The log likelihood at each iteration, 𝐿𝐿(𝑡), of the model is a sum of the 
logged likelihoods for each observation: 
                     𝐿𝐿(𝑡) = ∑ ∑ log (𝑝 (𝑌𝑖𝑗|𝜃𝑖𝑗
(𝑡)
 ))
𝐼
𝑖=1
𝐽
𝑗=1
 
where 𝐼 is the total number of patients and 𝐽 is the total number of SLAs 
of residence. 
 
For Models C, D and E, the posterior likelihood for each observed outcome 
𝑌ℎ𝑖𝑗 at each iteration given the estimated parameter 𝜃ℎ𝑖𝑗
(𝑡)
 and the subsequent 
log likelihood of the model is computed as follows: 
                               𝑝 (𝑌ℎ𝑖𝑗|𝜃ℎ𝑖𝑗
(𝑡)
) = 𝜃ℎ𝑖𝑗
(𝑡)𝑌ℎ𝑖𝑗
(1 − 𝜃ℎ𝑖𝑗
(𝑡)
)1−𝑌ℎ𝑖𝑗 
                              𝐿𝐿(𝑡) = ∑ ∑ ∑ log (𝑝 (𝑌ℎ𝑖𝑗|𝜃ℎ𝑖𝑗
(𝑡)
)) 
𝐻𝑖
ℎ=1
𝐼
𝑖=1
𝐽
𝑗=1
 
 
where 𝐻𝑖 is the total number of hospital admissions for patient 𝑖, and 𝐼 and 
𝐽 are defined as above. We report the mean log likelihood, 𝐿𝐿, across all 
iterations as a measure of fit as follows: 
                                           
𝐿𝐿 =
∑ 𝐿𝐿(𝑡)𝑇𝑡=1
𝑇
  
182
The log likelihood evaluates model fit by measuring the probability of 
observed data being observed under the estimated parameters of the model. 
Higher values of log likelihood are indicative of a better fit. 
 
Replicate data for the outcome were generated for each model to compare 
with observed data as a posterior predictive check of goodness of fit. At 
each iteration, one replicate datapoint 𝑌𝑖𝑗
𝑟𝑒𝑝
 for Models A and B, and 𝑌ℎ𝑖𝑗
𝑟𝑒𝑝
 
for Models C, D and E was generated for each observation given the 
estimated parameters of the model. The observed and predicted binary 
outcomes were then compared to obtain a misclassification error rate, 
sensitivity, specificity, false positive and false negative rate across all 
observations at each iteration. The expected values of each statistic across 
all iterations are reported as measures of fit. 
 
2.9 Application 
The application of each model to selected patient profiles encountered in 
clinical practice was considered by estimating the probability of observing 
each of the five selected outcomes for a variety of patient profiles, based 
on risk factors that were substantively associated with outcomes. 
 
3. RESULTS 
 
3.1 Data 
Overall, records of 309,023 admissions among residents of the region to 
any hospital in Australia were available for 83,831 patients between 1 
January 2001 to 30 June 2006. Of these, 31,243 admissions were for 
patients with either a principal or secondary diagnosis of DMII; 11,293 
patients are represented by these admissions. Of this subset, 4870 
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admissions were for principal diagnosis of DMII, representing 3,229 
patients. 
 
Of the twenty-one SLAs of residence in the region coded by 2001 SLA 
codes, coding of SLA was ambiguous for 14% (44,090/309,023) of all 
admissions, and 13% (4,047/31,243) of admissions for patients with DMII 
principal or secondary diagnosis, and indicated one of two possible SLAs. 
These include SLAs coded as “Hastings”, “Coffs Harbour”, “Lismore” or 
“Tweed” which do not specify Part A or Part B. For these admissions, SLA 
of residence was randomly allocated to either of the two possibilities with 
probability equal to the proportion of observed admissions belonging to 
that SLA out of the two possibilities. After randomisation, SLA of 
residence was still missing for 11 patients among all admissions and 2 
patients with a DMII secondary diagnosis - these 2 observations are 
excluded from analysis in Model A. SLA of residence was not missing for 
any patients with a DMII principal admission. 
 
Hospital outcomes for DMII principal admissions are summarised in 
Figure 1. Of 4,870 principal admissions for DMII complications, 69% had 
a recorded length of stay of one day, and the remaining 31% had a recorded 
length of stay of two days or longer (range 2-177 days). Overall, 11% 
(530/4,870) were readmissions within 28 days of a previous admission, and 
1.4% (69/4,870) involved admission to ICU. Of the 3,229 patients, 62% 
(1,994) had only one admission over the five-year study period, 38% 
(1,235) had two or more admissions, and 7% (220) had three or more 
admissions. 
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Figure 1: Inpatient outcomes for patients included in the study 
 
DMII=type II diabetes mellitus, ICU=intensive care unit, N=number 
 
 
Table 1 compares characteristics of patients with DMII primary and 
secondary diagnoses at both a patient- and admission-level. For interest, p-
values are reported from t-tests for age and Chi-squared tests of 
homogeneity for other variables. For patients with multiple admissions for 
principal diagnosis of DMII complications, their age and other 
demographic information at the first admission is reported in Table 1.  
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Table 1: Patterns of admission for principal admissions for type II diabetes mellitus versus 
principal admissions for other diagnoses 
 
 
DMII principal 
admissions  
DMII 
secondary 
diagnoses 
P value 
Patient level N=3229 N=8064  
Age - mean(sd) 75.8 (7.3) 75.4 (8.2) 0.006 
Age - median(range) 76 (45-98) 75 (45-106)  
Male 1622 (50%) 4383 (54%) <0.0001 
Aboriginal/Torres Strait 
Islander 
129 (4%) 377 (5%) 0.11 
Born in Australia 2737 (85%) 6773 (84%) 0.31 
Married 1814 (56%) 4701 (58%) 0.04 
HT 990 (31%) 3590 (45%) <0.0001 
CAD 199 (6%) 1611 (20%) <0.0001 
CHF 122 (4%) 832 (10%) <0.0001 
COPD 68 (2%) 598 (7%) <0.0001 
 Frequency (% of ERP)  
Number of 
SLAs 
SLAs with ERP<10,000 176 (0.7%) 399 (1.7%) 4 
SLAs with ERP 10,000-
<20,000 
960 (0.9%) 2097 (1.9%) 8 
SLAs with ERP 20,000-
<30,000 
559 (0.7%) 1530 (1.9%) 3 
SLAs with ERP 30,000-
<40,000 
883 (0.7%) 2295 (1.7%) 4 
SLAs with ERP 40,000+ 651 (0.7%) 1741 (1.9%) 2 
Admission level N=4870 N=26376  
Financial year of 
admission 
  <0.0001 
2001 684 (14%) 4277 (16%)  
2002 845 (17%) 4577 (17%)  
2003 909 (19%) 4455 (17%)  
2004 1258 (26%) 6248 (24%)  
2005 1174 (24%) 6819 (26%)  
Month of admission   <0.0001 
January 270 (6%) 1934 (7%)  
February 386 (8%) 2171 (8%)  
March 424 (9%) 2329 (9%)  
April 349 (7%) 2109 (8%)  
May 469 (10%) 2436 (9%)  
June 443 (9%) 2370 (9%)  
July 400 (8%) 2303 (9%)  
August 440 (9%) 2257 (9%)  
September 418 (9%) 2197 (8%)  
October 449 (9%) 2109 (8%)  
November 454 (9%) 2171 (8%)  
December 368 (8%) 1990 (8%)  
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Table 1 continued 
 
 
DM II primary 
admissions  
DMII 
secondary 
diagnoses 
P value 
Admission level N=4870 N=26376  
Weekday of admission   <0.0001 
Monday 643 (13%) 4761 (18%)  
Tuesday 1002 (21%) 4534 (17%)  
Wednesday 1087 (22%) 4544 (17%)  
Thursday 1081 (22%) 4234 (16%)  
Friday 643 (13%) 4143 (16%)  
Saturday 258 (5%) 2097 (8%)  
Sunday 156 (3%) 2063 (8%)  
Length of stay   <0.0001 
1 day 3345 (69%) 6584 (25%)  
2 days or longer 1525 (31%) 19792 (75%)  
Readmission within 28 
days 
  <0.0001 
No 4340 (89%) 19902 (75%)  
Yes to same facility 310 (6%) 4184 (16%)  
Yes to another facility 220 (5%) 2290 (9%)  
    
Admission to ICU   <0.0001 
Yes 69 (1.4%) 930 (4%)  
No 4801 (98.6%) 25446 (96%)  
 
DMII=type II diabetes mellitus, HT=hypertension, CAD=chronic arterial disease, CHF=congestive heart 
failure, COPD=chronic obstructive pulmonary disease, ERP=estimated resident population, ICU=intensive 
care unit, sd=standard deviation  
 
 
In general, patients with one or more DMII principal admission were older, and a smaller 
proportion were male, married, and comorbid with COPD, CAD, HT and CHF compared with 
patients with secondary diagnosis of DMII only. Similar patterns were seen among SLAs of 
different levels of socio-economic deprivation as measured by IRSAD quintiles internal to the 
dataset (Table 2), although age and gender were no longer significantly different for certain 
quintiles, possible reflecting reduced power from smaller sample size. 
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Table 2: Descriptives by Index of Relative Social Advantage and Disadvantage  quintile; q1 indicates the most disadvantaged and q5 indicates the most 
advantaged Statistical Local Areas of residence within a regional area of New South Wales. 
 
 
IRSAD q1  
IRSAD 
q2 
  
IRSA
D q3 
  
IRSA
D q4 
  IRSAD q5  
DM II primary 
admission 
P 
value 
DM II primary 
admission 
P 
value 
DM II primary 
admission 
P 
value 
DM II primary 
admission 
P 
value 
DM II primary 
admission 
P 
value 
Patient level  Yes No   Yes No   Yes No   Yes No   Yes No  
Age, mean(sd) 
74.2 
(8.4) 
74.1 
(9.3) 
0.83 
75.2 
(7.5) 
74.2 
(8.3) 
0.05 
76.5 
(6.8) 
75.8 
(7.9) 
0.08 
76.0 
(7.2) 
75.8 
(8.0) 
0.66 
76.5 
(6.9) 
75.9 
(7.7) 
0.03 
Male, N(%) 
292 
(55%) 
722 
(53%) 
0.48 
197 
(60%) 
442 
(58%) 
0.56 
274 
(47%) 
757 
(55%) 
0.00
06 
349 
(49%) 
1010 
(54%) 
0.01 
510 
(48%) 
1450 
(54%) 
0.00
2 
ATSI N(%) 
55 
(10%) 
146 
(11%) 
0.80 
17 
(5%) 
44 
(6%) 
0.69 
16 
(3%) 
40 (3%) 0.82 
21 
(3%) 
71 
(3.8%) 
0.28 
20 
(2%) 
76 (3%) 0.11 
Born in 
Australia, N(%) 
474 
(89%) 
1198 
(88%) 
0.53 
305 
(92%) 
695 
(91%) 
0.41 
496 
(85%) 
1182 
(87%) 
0.38 
568 
(79%) 
1471 
(79%) 
0.91 
894 
(84%) 
2226 
(82%) 
0.22 
Married, N(%) 
292 
(55%) 
767 
(56%) 
0.56 
202 
(61%) 
471 
(61%) 
0.91 
312 
(54%) 
770 
(56%) 
0.24 
393 
(55%) 
1081 
(58%) 
0.14 
615 
(58%) 
1610 
(60%) 
0.32 
HT, N(%) 
157 
(29%) 
603 
(44%) 
<0.0
001 
113 
(34%) 
294 
(38%) 
0.19 
157 
(27%) 
613 
(45%) 
<0.0
001 
212 
(29%) 
919 
(49%) 
<0.0
001 
351 
(33%) 
1159 
(43%) 
<0.0
001 
CAD, N(%) 
35 
(7%) 
284 
(21%) 
<0.0
001 
13 
(4%) 
118 
(15%) 
<0.0
001 
57 
(10%) 
300 
(22%) 
<0.0
001 
43 
(6%) 
389 
(21%) 
<0.0
001 
51 
(5%) 
520 
(19%) 
<0.0
001 
CHF, N(%) 
26 
(5%) 
154 
(11%) 
<0.0
001 
6 (2%) 
74 
(10%) 
<0.0
001 
27 
(5%) 
136 
(10%) 
<0.0
001 
22 
(3%) 
207 
(11%) 
<0.0
001 
41 
(4%) 
261 
(10%) 
<0.0
001 
COPD, N(%) 
13 
(2%) 
106 
(8%) 
<0.0
001 
3 (1%) 
52 
(7%) 
<0.0
001 
17 
(3%) 
121 
(9%) 
<0.0
001 
14 
(2%) 
148 
(8%) 
<0.0
001 
21 
(2%) 
171 
(6%) 
<0.0
001 
 
IRSAD= Index of Relative Social Advantage and Disadvantage, q=quintile, sd=standard deviation, ATSI=Aboriginal/Torres Strait Islander, HT=hypertension, 
CAD=chronic arterial disease, CHF=congestive heart failure, COPD=chronic obstructive pulmonary disease
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When SLAs were categorised by population size measured by ERP, there 
was little difference in the proportion of DMII principal admissions or 
secondary DMII diagnoses per size category (Table 1). In general, both the 
number of DMII principal admissions and admissions for other causes 
among those with DMII secondary diagnosis appears to be increasing over 
time in this dataset (Table 1). The gradient of increase appears to be higher 
for DMII principal admissions compared with DMII secondary diagnoses 
with a plateau between 2004 and 2005. Among both groups, admissions 
were fairly evenly distributed among most months of the year in both 
groups, with lower numbers of admissions in January, December and 
February respectively. Both groups showed a peak in admissions on 
weekdays compared with weekends. DMII principal admissions were 
particularly common midweek, on Tuesdays, Wednesdays and Thursdays, 
and day of admission was more evenly spread across weekdays for non-
DMII principal admissions among those with DMII secondary diagnosis. 
 
 A larger proportion of patients admitted for a DMII principal diagnosis 
stayed for one day only, and a smaller proportion were readmissions within 
28 days of a previous admission and admitted to ICU compared with 
admissions for other causes among patients with DMII secondary 
diagnosis. 
 
Table 3 lists the five most common DMII principal diagnoses for each 
outcome of interest. Among all DMII principal admissions and admissions 
of one day stay, the most common diagnosis by far was for an ophthalmic 
complication. The most common diagnosis for length of stay longer than 
one day was for foot ulcers followed closely by poor DMII control. The 
two most common diagnoses for readmissions within 28 days were for foot 
ulcers and end-stage renal disease. The most common diagnoses for 
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admissions that involved ICU admission were for foot ulcers, renal and 
circulatory complications. 
 
Table 3: Top five most frequent diagnoses for type II diabetes mellitus principal 
admissions (1=most frequent), classified by International Statistical Classification of 
Diseases-10 
  Any DMII primary admission (N=4870) Frequency (%) 
1 
Type 2 diabetes mellitus with other specified ophthalmic 
complication 2896 (59%) 
2 Type 2 diabetes mellitus with foot ulcer due to multiple causes 284 (5.8%) 
3 Type 2 diabetes mellitus with hypoglycaemia 224 (4.6%) 
4 Type 2 diabetes mellitus with poor control 219 (4.5%) 
5 Type 2 diabetes mellitus with end-stage renal disease [ESRD] 206 (4.2%) 
  LOS 1 day (N=3345)   
1 
Type 2 diabetes mellitus with other specified ophthalmic 
complication 2888 (86%) 
2 Type 2 diabetes mellitus with hypoglycaemia 70 (2%) 
3 Type 2 diabetes mellitus with end-stage renal disease [ESRD] 66 (2%) 
4 
Type 2 diabetes mellitus with peripheral angiopathy, without 
gangrene 46 (1%) 
5 Type 2 diabetes mellitus with diabetic cataract 43 (1%) 
  LOS 2 days or more (N=1525)   
1 Type 2 diabetes mellitus with foot ulcer due to multiple causes 253 (17%) 
2 Type 2 diabetes mellitus with poor control 198 (13%) 
3 Type 2 diabetes mellitus with hypoglycaemia 154 (10%) 
4 Type 2 diabetes mellitus with end-stage renal disease [ESRD] 140 (9%) 
5 
Type 2 diabetes mellitus with peripheral angiopathy, without 
gangrene 139 (9%) 
  Readmission within 28 days (N=530)   
1 Type 2 diabetes mellitus with foot ulcer due to multiple causes 87 (16%) 
2 Type 2 diabetes mellitus with end-stage renal disease [ESRD] 83 (16%) 
3 Type 2 diabetes mellitus with hypoglycaemia 57 (11%) 
4 
Type 2 diabetes mellitus with other specified ophthalmic 
complication 44 (8%) 
5 
Type 2 diabetes mellitus with peripheral angiopathy, without 
gangrene 42 (8%) 
  ICU admission (N=69)   
1 Type 2 diabetes mellitus with foot ulcer due to multiple causes 11 (16%) 
2 Type 2 diabetes mellitus with other specified renal complication 8 (12%) 
3 
Type 2 diabetes mellitus with other specified circulatory 
complication 8 (12%) 
4 Type 2 diabetes mellitus with end-stage renal disease [ESRD] 7 (10%) 
5 Type 2 diabetes mellitus with hypoglycaemia 7 (10%) 
 
DMII=type II diabetes mellitus, LOS=length of stay, ICU=intensive care unit 
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3.2 Statistical models 
All models were assessed to have converged. Based on the coverage of the 
95% CIs, IRSAD quintiles did not appear to be associated with any of the 
outcomes, after accounting for other factors. Results from specific models 
are summarised below. 
 
3.3 Admission for DMII principal diagnosis 
Model A: Age at first admission for DMII principal diagnosis was included 
in the model in five age categories as previously described. Four interaction 
terms between covariates were also included in the model based on 
findings from the exploratory analysis; these are HT:CAD, HT:COPD, 
CAD:CHF and CAD:COPD interaction pairs. 
 
Among patients with a diagnosis of DMII, patients were more likely to be 
admitted to hospital for a principal diagnosis of DMII complication if they 
were aged 70-79 (posterior odds ratio (OR) 1.57, 95% credible interval 
(CI) 1.19-2.00) or 80-89 years (OR 1.39, 1.05-1.79), and less likely if they 
were comorbid with HT (OR 0.59, 0.53-0.65), CAD (OR 0.27, 0.21-0.34), 
CHF (OR 0.46, 0.35-0.59) or COPD (OR 0.31, 0.21-0.41). No interaction 
terms were found to be substantive in the Bayesian hierarchical model. The 
estimated odds ratios for hospitalisation with a principal diagnosis of DMII 
associated with each patient-level covariate and the four interaction terms 
included in the model are summarised in Table 4. 
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Table 4: Estimated odds ratios for selected outcomes associated with covariates in each model. Coefficients are summarised with regard to posterior mean and 
95% credible interval. 
 DMII principal 
admission 
3+ DMII principal 
admissions 
LOS 2+ days Readmission within 28 
days 
ICU Admission 
N in model 11,291 3,229 4,870 4,870 4,870 
10-year increase in age 
(continuous) 
- 1.21 (1.00-1.43) 1.23 (1.12-1.34) 
 
1.00 (0.80-1.10) 
 
0.99 (0.60-1.22) 
 
Age categories (years): - - - - - 
45-59 Reference - - - - 
60-69 0.99 (0.76-1.24) - - - - 
70-79 1.57 (1.19-2.00)* - - - - 
80-89 1.39 (1.05-1.79)* - - - - 
90+ 0.95 (0.71-1.17) - - - - 
Male gender 0.92 (0.84-0.99) 1.42 (1.06-1.97)* 1.48 (1.23-1.78)* 1.71 (1.39-2.11)* 1.15 (0.89-1.77) 
Born in Australia 1.04 (0.94-1.17) 1.14 (0.92-1.57) 1.19 (1.01-1.43)* 1.06 (0.90-1.31) 1.05 (0.81-1.48) 
Married 0.94 (0.86-1.03) 0.81 (0.60-1.03) 0.75 (0.65-0.87)* 0.88 (0.73-1.03) 1.07 (0.86-1.49) 
HT 0.59 (0.53-0.65)* 1.24 (0.98-1.68) 1.39 (1.10-1.76)* 1.37 (1.11-1.70)* 1.43 (0.96-2.58) 
CAD 
0.27 (0.21-0.34)* 
1.66 (1.01-2.91)* 
8.13 (5.88-
11.35)* 1.62 (1.07-2.48)* 
6.39 (3.37-
11.51)* 
CHF 
0.46 (0.35-0.59)* 
1.47 (0.94-2.94) 
19.69 (9.28-
62.18)* 3.00 (1.98-4.44)* 1.21 (0.86-2.66) 
COPD 
0.31 (0.21-0.41)* 
1.04 (0.79-1.52) 
10.32 (5.39-
21.43)* 1.80 (1.00-3.68)* 1.88 (0.91-6.43) 
Interaction terms:      
HT:CAD 0.95 (0.50-1.69) - - - - 
HT:COPD 0.97 (0.50-1.82) - - - - 
CAD:CHF 0.90 (0.36-1.82) - - - - 
CAD:COPD 0.89 (0.36-2.00) - - - - 
Male:HT - - 1.43 (1.05-2.01)* - - 
Male:CHF - - 0.76 (0.22-1.16) - - 
HT:CHF - - 0.65 (0.16-1.13) - - 
CHF:COPD - - 0.36 (0.03-1.16) - - 
Male:COPD - - - 0.95 (0.58-1.32) - 
HT:CAD - - - 0.95 (0.65-1.23) - 
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DMII=Type II diabetes mellitus, LOS=length of stay, ICU=intensive care unit, N=number, 
HT=hypertension, CAD=chronic arterial disease, CHF=congestive heart failure, 
COPD=chronic obstructive pulmonary disease 
 
 
Two SLAs of residence had substantively lower risk of DMII principal admission 
after accounting for patient-level factors. These two SLAs had posterior odds 
ratios of 0.79 (95% CI 0.63-0.97) and 0.80 (95% CI 0.71-0.91) respectively. The 
estimated mean RER, estimated by exp (𝑆𝑗), ranged from 0.79 (0.63-0.97) to 1.13 
(0.98-1.33), indicating an estimated 1.4-fold difference (1.13/0.79=1.4) between 
regions. 
 
3.4 Multiple DMII principal admissions over the study period 
Model B: Exploratory analysis suggested a linear association between age and 
probability of multiple DMII principal admissions, and age was included in the 
model as a continuous variable. No interaction terms between covariates were 
found to be substantively associated with this outcome in the exploratory analysis 
so were omitted from the model.  
 
In this model, among patients admitted with one or more DMII principal 
admission, patients were more likely to have three or more admissions over the 
five-year study period if they were older (OR 1.21 per 10 years of age, 1.00-1.43), 
male (OR 1.42, 1.06-1.97) or comorbid with CAD (OR 1.66, 1.01-2.91). The 
estimated odds ratios for three or more DMII principal admissions over five years 
associated with each patient-level covariate are summarised in Table 4. No SLAs 
of residence were found to be substantively different from the baseline expected 
value after accounting for other covariates in the model. 
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3.5 Prolonged length of hospital stay 
Model C: Exploratory analysis suggested a linear association between age at 
admission and probability of multiple DMII principal admissions, and age was 
included in the model as a continuous variable. Four interaction terms between 
covariates were also included in the model based on findings from exploratory 
analysis; these are Male:HT, Male:CHF, HT:CHF and CHF:COPD interaction 
pairs. 
 
Here, among DMII principal admissions, admissions were more likely to stay in 
hospital for two days or longer if they were older (OR 1.23 per 10 years of age, 
1.12-1.34), male (OR 1.48, 1.23-1.78), born in Australia (OR 1.19, 1.01-1.43), 
unmarried (OR 1.33, 1.15-1.54), comorbid with HT (OR 1.39, 1.10-1.76), CAD 
(OR 8.13, 5.88-11.35), CHF (OR 19.69, 9.28-62.18) or COPD (OR 10.32, 5.39-
21.43). In addition, comorbidity with HT in admissions by male patients 
increased risk further (OR 1.43, 1.05-2.01) compared with female patients. The 
estimated odds ratios for length of stay longer than one day associated with each 
patient-level covariate are summarised in Table 4. 
 
Two SLAs were found to have substantively higher risk of length of stay 2 days 
or longer, after accounting for patient-level factors. These SLAs had posterior 
odds ratios of 1.19 (95% CI 1.02-1.45) and 1.22 (95% CI 1.01-1.60) respectively. 
The estimated mean odds ratio ranged from 0.67 (0.52-0.84) to 1.22 (1.01-1.60), 
indicating an estimated 1.8-fold difference (1.22/0.67=1.8) between regions. 
 
3.6 Readmission to hospital 
Model D: Exploratory analysis suggested a lack of association between age and 
probability of readmission within 28 days; however, age was adjusted for in the 
model as a continuous variable. Two interaction terms between covariates were 
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also included in the model based on findings from exploratory analysis; these are 
Male:COPD and HT:CAD interaction pairs. 
 
Among DMII principal admissions, admissions were more likely to be a 
readmission within 28 days of a previous admission if they were male (OR 1.71, 
1.39-2.11), or comorbid with HT (OR 1.37, 1.11-1.70), CAD (OR 1.62, 1.07-
2.48), CHF (OR 3.00, 1.98-4.44) or COPD (OR 1.80, 1.00-3.68). The estimated 
odds ratio for readmission within 28 days of a previous admission associated with 
each patient-level covariate is summarised in Table 4. No SLAs of residence were 
found to be substantively different from the baseline expected value after 
accounting for other covariates in the model. 
 
3.7 Admission to ICU 
Model E: Exploratory analysis suggested a lack of association between age and 
probability of admission to ICU; however, age was adjusted for in the model as 
a continuous variable. No interaction terms between covariates were found to be 
substantively associated with this outcome in exploratory analysis so were 
omitted from the model. 
 
In this model, among DMII principal admissions, admissions were more likely to 
be transferred to ICU if they were comorbid with CAD (OR 6.39, 3.37-11.51). 
The estimated odds ratio for ICU admission associated with each patient-level 
covariate is summarised in Table 4.  No SLAs of residence were found to be 
substantively different from the baseline expected value after accounting for other 
covariates. 
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3.8 Model evaluation 
Results of goodness of fit are summarised in Table 5. Misclassification error rate 
varied between 2.8% (Model E) to 38.1% (Model A). For Model A, a large false 
positive rate (66.6%) and lower false negative rate (26.7%) was observed. The 
large value of DIC and small value of log likelihood for Model A likely reflect 
the larger sample size and higher proportion with the outcome in this model 
compared with the other four. In contrast, Models E and B have the smallest 
values for DIC and misclassification error rate and largest values of log likelihood 
likely reflecting the small proportion with the outcome and smaller sample size 
for these two models respectively. 
 
 
Table 5: Goodness of fit comparisons between five reported models. 
 
Measure of fit Model A: 
DMII 
principal 
admission 
Model B: 
3+ DMII 
principal 
admissions 
Model C: 
LOS 2+ 
days 
Model D: 
Readmission 
within 28 
days 
Model E: 
ICU 
Admission 
DIC 12732 1564 5218 3149 665 
Log likelihood -6343 -773.6 -2590 -1561 -327.4 
Misclassification 
error rate 
38.1% 
 
12.4% 35.3% 18.3% 2.8% 
Sensitivity 33.4% 8.6% 43.7% 15.8% 4.3% 
Specificity 73.3% 93.3% 74.3% 89.7% 98.5% 
False +ve 66.6% 91.4% 56.4% 84.2% 95.9% 
False –ve 26.7% 6.7% 25.7% 10.3% 1.4% 
 
DIC=Deviance Information Criteria, DMII=type II diabetes mellitus, LOS=length of stay, 
ICU=intensive care unit, +ve=positive, -ve=negative 
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3.9 Application 
Based on individual factors found to be significantly associated with the selected 
outcomes of this study, odds ratios for each outcome were estimated for fourteen 
patient profiles. Common across all profiles is the assumption that the patient is 
born in Australia, non-Aboriginal non-Torres Strait Islander, and resident of a 
SLA of IRSAD quintile 5 (the most advantaged quintile, IRSAD range 948-969). 
The fourteen profiles considered are listed in Table 6. 
 
Table 6: Characteristics of patient profiles 
 
Profile Age Gender Married HT CAD CHF COPD 
1 60 M Y N N N N 
2 60 F Y N N N N 
3 80 M Y N N N N 
4 80 F Y N N N N 
5 80 M N N N N N 
6 80 F N N N N N 
7 80 M N Y N N N 
8 80 F N Y N N N 
9 80 M N Y Y N N 
10 80 F N Y Y N N 
11 80 M N Y Y Y N 
12 80 F N Y Y Y N 
13 80 M N Y Y Y Y 
14 80 F N Y Y Y Y 
M=male, F=female, Y=yes, N=no, HT=hypertension, CAD=coronary arterial disease, 
CHF=congestive heart failure, COPD=chronic obstructive pulmonary disease 
 
 
As described above, the probability of each outcome for each patient profile are 
summarised in Figure 2. Numerical values for each estimate are available in 
tabular format in the supplementary material. 
 
197
  
 
Figure 2: Estimated probability of observing selected inpatient outcomes for fourteen patient profiles. 
Estimated probabilities are summarised with regard to posterior mean and 95% credible interval. 
 
DMII=type II diabetes mellitus, M=male, F=female, yrs=years of age, HT=hypertension, CAD=coronary 
arterial disease, CHF=congestive heart failure, COPD=chronic obstructive pulmonary disease, LOS=length 
of stay, ICU=intensive care unit 
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DISCUSSION 
In this study, we found evidence of geographic disparity for DMII outcomes 
among hospitalised patients with DMII, including principal admission for a DMII 
complication and length of stay two days or longer. The SLAs with higher or 
lower odds of these outcomes had these disparities despite the presence of 
hospitals within these areas. Two SLAs had lower odds of principal admission 
for a DMII complication compared with other SLAs and two SLAs had greater 
odds of length of stay two days or longer compared with other SLAs. Each of 
these SLAs had hospital services available. There was insufficient data within 
this analysis to assess whether road distance for each patient from their place of 
residence to the nearest hospital or general practitioner (GP), or total number of 
GPs within their SLA of residence influenced outcomes. This would be useful to 
examine in further studies. 
  
This study also identified individual demographic and clinical factors associated 
with principal admission for DMII complication, multiple admissions, 
readmission with 28 days, prolonged length of stay and admission to ICU. We 
found that among hospitalised patients with DMII, comorbidity with other 
chronic conditions was highest for HT, followed by CAD, CHF and COPD. This 
is consistent with reports from a US study examining comorbidity among 
hospitalised patient with diabetes who had multiple admissions for DMII [50]. 
Compared with reported prevalence of coronary heart disease among diabetics 
within a primary care setting in UK study, we found a smaller proportion of 
hospitalised patients with DMII that were comorbid with CAD (16% vs. 25%) 
[51]. Also, compared with the reported prevalence of HT among diabetics in the 
community in Australia and the US, we found a smaller proportion among 
patients in our study (41% vs. 50% and 71% respectively) [52, 53]. Overall, 
patients admitted with a primary diagnosis of DMII were less likely to be 
comorbid with HT, CAD, CHF and COPD compared with patients who were 
199
admitted with secondary DMII diagnosis only over the study period. The majority 
(62%) of patients hospitalised with a principal diagnosis of DMII had only one 
such admission over the study period – it is possible that some of these solitary 
admissions were for the first indication of DMII. If so, then these particular 
patients are likely to be healthier and be less likely to have comorbidities than 
patients who were admitted for secondary DMII diagnosis only. 
 
The study of temporal patterns was outside the scope of this study, however, a 
seasonal pattern of admissions with smaller numbers of DMII principal 
admissions over the summer months, December, January and February was 
observed. This may indicate that less people suffer from DMII complications over 
the holiday period due to a more relaxed lifestyle away from work, during which 
diabetic control can potentially be better managed, or that people put off visiting 
hospital for complications over the holidays. Similarly, less DMII principal 
admissions were observed during the weekend, again possibly reflecting better 
diabetes control over the weekend or putting off of admission until weekdays. 
The number of DMII principal admissions adjusted for population showed a 
general increase from financial year 2001 to 2005, consistent with trends of 
increasing prevalence of diabetes in the community over this period [54]. 
 
Compared with DMII patients hospitalised for other conditions, those admitted 
for DMII complications tended to have shorter length of stay, less readmissions 
within 28 days and less admissions to ICU, likely reflecting less severe illness in 
general. 
 
Among hospitalised patients with DMII, we found that patients were more likely 
to have been admitted for a DMII complication if they were aged 70-89, and less 
likely if they were comorbid with COPD, CAD, HT or CHF. This perhaps reflects 
that patients with these comorbidities are more likely to be admitted for principal 
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diagnosis relating to COPD, CAD, HT or CHF rather than DMII. Within a 
primary care setting, older patients may benefit from closer monitoring of 
diabetic control to avoid hospitalisation for DMII complications. The most 
common DMII principal diagnoses for which patients were admitted include 
ophthalmic complications, foot ulcers, hypoglycaemia, poor diabetic control and 
end-stage renal failure. Thus, close monitoring of the ophthalmology, peripheral 
vasculature, glycaemic control and renal function of DMII patients within 
primary care has the potential to reduce hospital admissions for DMII 
complications. The observed differences in risk of hospitalisation for DMII 
complications by age categories reflects the overall prevalence of DMII by age 
group in Australia, which peaks at age 70-85 then decreases [55]. 
 
Admissions for ophthalmic complications secondary to DMII made up 59% of 
all DMII principal admissions, and 86% of all DMII principal admissions of one 
day length of stay. Of the 2,896 admissions for ophthalmic complications within 
this dataset, 2,528 (87%) were reported to be planned admissions, and 2,877 
(99%) for principal procedure of cataract extraction. Thus the majority of DMII 
principal admissions are single-day planned admissions for cataract extraction. 
The large numbers of these planned cases may have skewed the average length 
of stay among all DMII principal admissions towards one day. Further analysis 
excluding these cases may be useful in order to examine factors specifically 
related to prolonged length of stay or emergency admissions for DMII 
complications. Furthermore, the observed decrease in DMII principal admissions 
over December through to February may potentially be explained by a reduction 
in planned admissions for ophthalmic surgery over the holiday period. 
 
Multiple DMII principal admissions, defined as three or more over the five-year 
study period, were more likely among male patients and those comorbid with 
CAD. Compared with a similar study in the US, which found that among 
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hospitalised diabetic patients, patients were more likely to have two or more 
admissions over twelve months if they were older, we found a similar trend in 
our study for older patients to have multiple admissions, however, this was not 
substantive [50]. Compared with an Australian study which found that among 
hospitalised patients with diabetes, COPD, CAD, HT or CHF who had three or 
more hospital admissions with twelve months, patients were more likely to have 
four or more admissions during that period if they were comorbid with CHF, had 
higher Charlson Comorbidity Index scores or were socially isolated, we found 
similar trends in our study for patients with multiple admissions to be comorbid 
with CAD, HT or CHF, however, this was substantive only for CAD [56]. 
Similarly, we found that a greater proportion of these patients were unmarried, 
likely indicating a larger degree of social isolation, which was not substantive. 
 
There is scarcity of information in the literature about risk factors for prolonged 
length of hospital stay, readmission in the short-term and admission to ICU 
specific to patients with DMII. We aimed to fill this gap through our study. 
Among all DMII patients with a principal admission for a DMII complication, 
we found that patients were more likely to have length of stay longer than one 
day if they were older, male, born in Australia, unmarried, or comorbid with 
COPD, CAD, HT or CHF, more likely to be a readmission within 28 days of a 
previous admission if they were male or comorbid with COPD, CAD, HT or 
CHF, and more likely to be admitted to ICU if they were comorbid with CAD. 
 
Overall, 11% of DMII principal admissions in our study were observed to be 
readmissions within 28 days of a previous admission; this is similar to the 
reported proportion in another Australian study, which reported that 8.6% of 
patients with diabetes, COPD or CHF were readmitted within 28 days of a 
previous admission [57]. The most common diagnoses among readmissions in 
our study included foot ulcers, end-stage renal disease, hypoglycaemia, 
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ophthalmic conditions and peripheral angiopathy. Patients discharged from 
hospital after being admitted for these diagnoses would likely benefit from 
follow-up in primary care or outpatient clinic a week or two after discharge to 
monitor recovery from these conditions and provide further treatment outside of 
hospital if needed and possible. 
 
Findings from this study present important implications for clinicians within both 
a community and hospital setting: patients with DMII who are older, socially 
isolated and comorbid with HT, CAD, CHF and/or COPD may be at higher risk 
for hospitalisation for DMII complications and adverse inpatient outcomes, and 
may warrant closer monitoring and more regular follow-up than other diabetic 
patients. Within a community setting, these patients may benefit from six-
monthly or more frequent GP check-ups. Within a hospital setting, these patients 
may benefit from GP follow-up within two weeks after discharge to potentially 
avoid readmission. 
 
Strengths of our study include that we were able to analyse data from a large 
number of residents from a large regional area of of NSW, Australia, and that we 
were able to account for risk factors associated with hospitalisation for DMII 
complication and subsequent inpatient outcomes at both an individual and 
geographic level. Limitations of our study include the lack of information 
regarding lifestyle factors and distance from residence to treatment facility, which 
are likely to be associated with risk of hospital admission for DMII 
complications. Also, the inferences we have made from the hospitalised cohort in 
our dataset may not be entirely generalisable to patients with DMII in the 
community and within a primary care setting. Thus recommendations should be 
treated with caution. 
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CONCLUSIONS 
In summary, we have identified individual factors associated with hospitalisation 
for DMII complications, and we estimate a 1.4-fold geographic disparity across 
geographic areas in the region for the odds of this outcome. Through closer 
monitoring and quality management of patients at risk within primary and 
inpatient care, and better allocation of resources to high-risk areas, we are better 
informed to reduce complications of DMII and subsequent costs to our 
community. 
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Supplementary Table 1: Probability of model outcomes for selected patient profiles. Estimated probabilities 
are summarised with regard to posterior mean and 95% credible interval. 
 
Patient profile DMII principal 
admission 
3+ DMII principal 
admissions 
LOS 2+ days Readmission 
within 28 days 
ICU Admission 
Male, 60yrs, 
married 
0.30 (0.27-0.32) 0.04 (0.03-0.07) 0.17 (0.15-0.21) 0.10 (0.08-0.13) 0.01 (0.01-0.02) 
Female, 60yrs, 
married 
0.32 (0.29-0.34) 0.03 (0.02-0.05) 0.12 (0.10-0.15) 0.06 (0.04-0.08) 0.01 (0.00-0.02) 
Male, 80yrs, 
married 
0.37 (0.35-0.40) 0.07 (0.05-0.08) 0.25 (0.22-0.28) 0.09 (0.08-0.11) 0.01 (0.01-0.01) 
Female, 80yrs, 
married 
0.39 (0.37-0.42) 0.05 (0.03-0.06) 0.18 (0.16-0.21) 0.06 (0.05-0.07) 0.01 (0.00-0.01) 
Male, 80yrs, 
unmarried 
0.39 (0.36-0.41) 0.08 (0.06-0.10) 0.31 (0.27-0.34) 0.11 (0.09-0.13) 0.01 (0.00-0.01) 
Female, 80yrs, 
unmarried 
0.41 (0.38-0.43) 0.06 (0.04-0.07) 0.23 (0.21-0.26) 0.06 (0.05-0.08) 0.01 (0.00-0.01) 
Male, 80yrs, 
unmarried with 
HT 
0.27 (0.24-0.30) 0.10 (0.07-0.13) 0.47 (0.42-0.52) 0.14 (0.11-0.17) 0.01 (0.01-0.02) 
Feale, 80yrs, 
unmarried with 
HT 
0.29 (0.26-0.31) 0.07 (0.05-0.09) 0.29 (0.25-0.34) 0.09 (0.07-0.11) 0.01 (0.01-0.02) 
Male, 80yrs, 
unmarried with 
HT & CAD 
0.11 (0.09-0.14) 0.15 (0.09-0.24) 0.88 (0.83-0.91) 0.20 (0.14-0.27) 0.07 (0.04-0.12) 
Female, 80yrs, 
unmarried with 
HT & CAD 
0.12 (0.10-0.15) 0.11 (0.07-0.18) 0.77 (0.70-0.83) 0.13 (0.09-0.18) 0.06 (0.03-0.10) 
Male, 80yrs, 
unmarried with 
HT, CAD & CHF 
0.07 (0.04-0.10) 0.21 (0.12-0.34) 0.99 (0.96-0.99) 0.43 (0.31-0.54) 0.08 (0.04-0.16) 
Female, 80yrs, 
unmarried with 
HT, CAD & CHF 
0.07 (0.05-0.11) 0.15 (0.08-0.27) 0.98 (0.94-0.99) 0.31 (0.21-0.41) 0.07 (0.03-0.14) 
Male, 80yrs, 
unmarried with 
HT, CAD, CHF & 
COPD 
0.03 (0.01-0.05) 0.21 (0.12-0.36) 1.00 (0.96-1.00) 0.58 (0.40-0.71) 0.16 (0.05-0.35) 
Female, 80yrs, 
unmarried with 
HT, CAD, CHF & 
COPD 
0.03 (0.01-0.05) 0.16 (0.08-0.28) 1.00 (0.94-1.00) 0.46 (0.28-0.63) 0.15 (0.05-0.32) 
 
DMII=Type II diabetes mellitus, LOS=length of stay, ICU=intensive care unit, yrs=years, 
HT=hypertension, CAD=chronic arterial disease, CHF=congestive heart failure, COPD=chronic obstructive 
pulmonary disease. 
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ABSTRACT 
Background: Three variant formulations of a spatiotemporal shared component 
model are proposed that allow examination of changes in shared underlying 
factors over time. 
 
Methods: Models are evaluated within the context of a case study examining 
hospitalisation rates for five chronic diseases for residents of a regional area in 
New South Wales: type II diabetes mellitus (DMII), chronic obstructive 
pulmonary disease (COPD), coronary arterial disease (CAD), hypertension (HT) 
and congestive heart failure (CHF) between 2001-2006. These represent 
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ambulatory care sensitive (ACS) conditions, often used as a proxy for avoidable 
hospitalisations. Using a selected model, the effects of socio-economic status 
(SES) as a shared component are estimated and temporal patterns in the influence 
of the residual shared spatial component are examined. 
 
Results: Choice of model depends upon the application. In the featured 
application, a model allowing for changing influence of the shared spatial 
component over time was found to have the best fit and was selected for further 
analyses. Hospitalisation rates were found to be increasing for COPD and DMII, 
decreasing for CHF and stable for CAD and HT. SES was substantively 
associated with hospitalisation rates, with differing degrees of influence for each 
disease. In general, most of the spatial variation in hospitalisation rates was 
explained by disease-specific spatial components, followed by the residual shared 
spatial component. 
 
Conclusion: Appropriate selection of a joint disease model allows for the 
examination of temporal patterns of disease outcomes and shared underlying 
spatial factors, and distinction between different shared spatial factors. 
 
1. BACKGROUND 
The economic and social costs of the increasing incidence of potentially 
avoidable hospital admissions are a growing burden to health services in Australia 
and internationally [1-4]. In 1990, the concept of using ACS conditions as a proxy 
for avoidable hospital admissions was proposed [5]. In Australia, diabetes 
complications are the leading cause of avoidable hospitalisation, and together 
with COPD and angina due to CAD account for almost one half (44.5%) of all 
avoidable hospital admissions [6]. DMII accounts for 90-95% of all cases of 
diabetes [7-9] and has shown to be associated with other ACS conditions 
including COPD [10, 11], CAD [12-14], HT [15]  and CHF [16, 17]. 
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 Residents of areas with indicators of socio-economic deprivation have been 
associated with increased risk of avoidable hospital admissions [18, 19] and 
emergency admissions after adjusting for other risk factors [20]. Individuals of 
lower SES are also more at risk for preventable hospitalisation even after 
adjusting for severity of illness [21]. To this end, accounting for area-level SES 
is important in joint disease spatiotemporal models exploring temporal trends in 
hospitalisation incidence for each ACS condition. Measures of SES are typically 
reported at a geographic residential scale such as a Statistical Local Area (SLA) 
or Local Government Area, so it is natural to consider this as a shared spatial 
factor. A shared spatial factor, or shared spatial component, is an underlying risk 
that is common to more than one disease. Although spatial studies have been 
performed in the US, UK and Europe to examine high-risk areas for avoidable 
hospitalisation, little is known about temporal trends in avoidable hospitalisation 
incidence in Australia specific to residential areas [20]. This paper aims to fill this 
gap in knowledge. 
 
Much work in disease mapping has focused on the role of joint spatial modelling 
of two or more diseases [22-27]. Joint spatial modelling of diseases has the 
benefits of borrowing strength across both neighbouring regions and across 
diseases with common aetiological factors [28]. This is particularly useful when 
uncertainty is present due to sparse disease counts or under-reporting of disease 
[29, 30], as well as adjusting for unmeasured confounders [31, 32]. A shared 
component is defined as an underlying spatial component common to multiple 
diseases. The incorporation of shared and disease-specific spatial and temporal 
components has three key advantages. Firstly, it highlights regions with the 
greatest exposures to aetiological factors common to all diseases being modelled 
and shared temporal patterns in these disease outcomes: these regions would be 
expected to benefit most from additional resource placement and health 
221
promotion programmes to simultaneously decrease risk for multiple disease 
outcomes in one step. Secondly, it allows the exploration of differences between 
diseases with respect to spatial and temporal trends. Finally, it improves the 
precision of estimates compared with estimates from single disease models [22]. 
 
Early work in Bayesian joint disease modelling included the two-disease shared 
component model proposed by Knorr-Held and Best (2001) [22].  This model 
partitioned the relative risk of each of the two diseases into three spatial 
components allowing for spatial clustering: one component common to both 
diseases and two disease-specific components reflecting residual spatial variation 
in each disease. A variation on this model, presented by Dabney and Wakefield 
(2005), proposed one shared and one disease-specific component and was termed 
a “proportional model”  [23]. Kim et al. (2001) proposed an alternative 
formulation using a bivariate Bayesian Poisson model to jointly model two 
diseases [24]. A shared spatial component model was extended to three or more 
diseases by Held et al. (2005) and was further developed by application to a four-
disease case study accounting for spatial variation in smoking and alcohol 
consumption [25]. Further work by Held et al. (2006) that jointly modelled four 
infectious diseases, included three shared and four disease-specific spatial 
components to account for differential risk for diseases with related aetiological 
factors [30]. 
 
The incorporation of temporal effects was introduced by Richardson et al. (2006) 
in a two-disease model with disease-specific linear temporal effects and an 
exchangeable hierarchical structure for spatiotemporal interaction [26]. An 
alternative formulation was proposed by Tzala and Best (2007) for joint 
spatiotemporal modelling of three or more diseases [27]. The authors proposed a 
model with a shared spatial component specific to each year of the study period 
and a semi-parametric autocorrelation structure for time. However, including 
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more structured temporal parameters may be useful when the focus is on 
comparing temporal trends in disease outcomes between diseases, on examining 
shared versus disease-specific temporal trends and on temporal prediction. 
Furthermore, it may be useful to examine whether the influence of underlying 
shared spatial factors may change over time for each disease. In addition, after 
adjusting for known underlying spatial factors common to all diseases studied, it 
may be useful to examine the effect of residual confounders not captured in the 
model and their influence on outcomes of each disease over time. These effects 
can be measured through the incorporation of a random error term to capture 
residual effects unexplained by variables in the model. 
 
The motivation for this paper is to present a method for comparing temporal 
trends in disease outcomes between multiple diseases and examine the effect of 
residual shared latent factors over time after adjusting for known factors. The 
proposed methodology is applied to a case study that examines the incidence of 
hospitalisation for five ACS diseases in a regional area of New South Wales 
(NSW), Australia. 
 
This paper has four objectives. First, to describe, implement and compare three 
variant formulations of a Bayesian shared component model allowing 
examination of temporal trends specific to each disease. Second, to examine 
disease-specific temporal trends in incidence of hospitalisation. Third, to 
distinguish shared and disease-specific spatial variation in hospitalisation 
incidence. The final objective is to examine geographic disparities in 
hospitalisation incidence for five ACS conditions. 
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2. METHODS 
 
2.1 Data 
The data for the aforementioned case study was collected from two main sources. 
These sources are described in the subsections below. 
 
Admissions data 
Data were routinely collected from all admissions among residents of the NSW 
region to any hospital in Australia between July 2001 and June 2006, representing 
five financial years of data. Residents belonged to one of 21 SLAs within the 
region, with an average estimated resident population (ERP) across SLAs of 
21,000 (range 4,114 to 47,112). Hospitals in the dataset included urban and rural 
hospitals both within and outside the NSW region of residence, representing 
100% coverage of hospital admissions within Australia among residents of the 
region. All private rural hospitals within the dataset were deidentified and 
aggregated into one category, thus the exact number of hospitals from which 
admissions records are included in the dataset is unknown. These linked hospital 
admissions data were made available for this study via our collaboration with the 
local health service.  The process for obtaining access to these data changed 
during the course of our research and more recent data from 2006 was not covered 
under this revised process.  Therefore, it was not possible to obtain more recent 
data from 2006 under our collaborative agreement. The rate of diabetes hospital 
admission has remained relatively stable over the past several years and so we 
believe our results are robust and indicative of more recent data [33]. 
 
Data were extracted for five ACS conditions: DMII, COPD, CAD, HT and CHF. 
Observed counts of hospital admissions for principal diagnosis of each of these 
five conditions were aggregated by SLA of residence for each financial year using 
2001 SLA codes. Using reported International Statistical Classification of 
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Diseases-10 (ICD10) coding of principal diagnosis for each hospital admission, 
an ICD10 code between E11.0 and E11.99 inclusive was classified as a DMII 
admission. Similarly, a principal diagnosis of ICD10 code between J41 and J44 
inclusive or J47 was classified as a COPD admission, between I20 and I25 
inclusive as a CAD admission, between I10 and I15 inclusive with the exclusion 
of I11.0 as an HT admission, and I11.0 or I50 or J81 as a CHF admission. 
 
Demographic/Geographic Information 
Data were obtained from the Australian Bureau of Statistics (ABS) for ERP and 
Socio-Economic Indexes for Areas (SEIFA) in 2001 specific to each of the 21 
SLAs of residence, based on information from the five-yearly Census [34, 35]. 
The ERP is based on usual place of residence, thus transient populations with a 
usual address outside the health region were excluded from the analysis. The 
small number of admissions within the region for any transient populations are 
unlikely to have a substantial impact on our analysis. 
 
The SEIFA was developed by the ABS and ranks areas in Australia according to 
relative socio-economic advantage and disadvantage. Among the five financial 
years included in this analysis, ERP and SEIFA Indices at SLA level were only 
available for 2001, and 2001 estimates were used for all time periods in models 
described below. Four different measures of SES are available through the 
SEIFA: the Index of Relative Socio-Economic Advantage and Disadvantage 
(IRSAD), Index of Relative Socio-Economic Disadvantage (IRSD), Index of 
Education and Occupation (IEO) and the Index of Economic Resources (IER). 
 
The IRSD includes only measures of relative disadvantage, including the 
proportion of residents with low income, lack of qualifications and working in 
unskilled occupations. The IRSAD includes measures of both relative advantage 
and disadvantage, including the proportion of residents with high and low income 
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and working in skilled and unskilled occupations. The IER focuses on the 
financial aspects of relative socio-economic advantage and disadvantage, by 
summarising variables related to income and wealth. This includes the proportion 
of households with high or low income, the proportion of households paying low 
rent, and the proportion of owned homes. The IEO is designed to reflect the 
educational and occupational level of communities. The education variables 
include qualification levels achieved and whether further education is being 
undertaken. The occupation variables classify the workforce into skill levels and 
the unemployed. 
 
For each of the four indices, a lower score was indicative of relative greater socio-
economic deprivation. Within the dataset, the range for each measure of SES 
differed as follows. The range was 869-969 for IRSAD, 894-990 for IRSD, 857-
946 for IER and 880-1017 for IEO. When split into quartiles, the lowest quartile 
of each range represents the greatest level of socio-economic deprivation, and the 
highest quartile represents the lowest level of deprivation. 
 
Exploratory analysis 
Descriptive analysis of the dataset was performed, including an examination of 
hospitalisation rates for each disease in each financial year, and an assessment of 
the correlation between each SEIFA Index and hospitalisation rates for each 
disease. Radar plots of SEIFA Index quartiles and hospitalisation rate quartiles 
were constructed and evaluated, as well as maps of SEIFA Index quartiles 
compared with hospitalisation rate quartiles for each SLA within the region. 
 
2.2 Fundamental models 
Three Bayesian spatiotemporal shared component formulations were compared 
for the estimation of temporal trends in hospitalisation rates for each of the five 
ACS conditions described above. Time is measured in financial years; a “year” 
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is defined as a financial year for the purposes of this paper. The first two models, 
Models A and B, examine whether the influence of shared underlying spatial 
factors changes over time by allowing different factor loadings for each disease 
for each of the five years in the analysis. Model A imposes a linear structure upon 
the relationship between year and the log hospitalisation rate for each disease; 
Model B extends on Model A by including both shared and disease-specific linear 
temporal components. Model C is a simplification of Model A and includes factor 
loadings common across all years for the shared underlying spatial factors for 
each disease. 
 
Markov chain Monte Carlo (MCMC) simulations were used to model joint 
patterns of hospitalisation rates for the five conditions studied. This was 
undertaken using R 3.1.2 and WinBUGS 14 [36, 37]. The R2WinBUGS package 
in R 3.1.2 was used to import data, specify parameter names, initial values and 
model specifications, and to invoke a BUGS model run in WinBUGS 14. Each 
model was run for a total of 200,000 iterations with the first 90,000 iterations 
discarded as the burnin period. For the prediction of each outcome, a covariate 
was identified as important if the 95% credible interval (CI) for its associated 
coefficient did not cover zero. Similarly, an SLA was flagged as having 
differential excess risk if the 95% CI for its associated random effect did not cover 
zero. A high risk area had a substantively greater risk of hospitalisation relative 
to other areas. 
 
Formulations for the three compared models are described below. 
 
2.2.1 Model A: Disease-specific temporal trends 
We assign each disease and each year an index as follows: DMII (𝑗 = 1), COPD 
(𝑗 = 2), CAD (𝑗 = 3), HT (𝑗 = 4) and CHF (𝑗 = 5); 𝑘 = 1, … ,5 for 2001-2005. 
For SLA of residence, 𝑖 = 1, … ,21, for disease, 𝑗 = 1, … ,5 and for year, 𝑘 =
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1, … ,5, the observed number of hospital admissions 𝑌𝑖𝑗𝑘 with a principal 
diagnosis for disease 𝑗 is modelled as a Poisson generalised linear mixed model 
(GLMM) with a shared spatial component 𝑠𝑖 weighted by factor 𝛿𝑗𝑘 for each 
disease in each year, a disease-specific spatial component 𝑣𝑖𝑗, and a temporal 
component 𝛽𝑗𝑡𝑘 where 𝛽𝑗 is a disease-specific coefficient for the year of 
admission, 𝑡𝑘. Let the ERP for SLA 𝑖 using 2001 estimates be denoted 𝑛𝑖, and 
𝜃𝑖𝑗𝑘 denote the estimated hospitalisation incidence rate for SLA 𝑖 for disease 𝑗 in 
year 𝑘. 
 
A sum-to-zero constraint is placed on the sum of the weighting factors for the 
shared component at each time point. This is an extension of the joint multiple 
disease model with sum-to-zero constraints for one time point as described by 
Held et al. (2005). The shared and disease-specific spatial components are 
assigned conditional autoregressive (CAR) priors as first described by Besag, 
York and Mollie (1991) [38]. A CAR specification was selected due to the 
presence of sparse data for smaller SLAs, motivating the use of local smoothing 
to borrow strength across neighbouring areas. 
 
Let 𝛼𝑗 denote a disease-specific intercept, and 𝑢𝑖𝑗𝑘 denote the uncorrelated 
residual error for each observation. We define 𝐼 = 21, 𝐽 = 5 and 𝐾 = 5. The 
model takes the following formulation: 
 
𝑌𝑖𝑗𝑘~𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝑛𝑖𝜃𝑖𝑗𝑘)             
log(𝜃𝑖𝑗𝑘) ~𝑁(𝑠𝑖𝛿𝑗𝑘 + 𝜈𝑖𝑗 + 𝛽𝑗𝑡𝑘 + 𝛼𝑗 + 𝑢𝑖𝑗𝑘 , 𝜎
2)     (1) 
                              ∑ log(𝛿𝑗𝑘) = 0
𝐽
𝑗=1
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Priors for hyperparameters in the model are as follows: 
𝑢𝑖𝑗𝑘~𝑁(0, 𝜔𝑗
2)     (2) 
 
                                  𝑆𝑖|𝑆(−𝑖), 𝜎𝑆
2 ~𝑁 (
∑ 𝑆ℎ𝑤ℎ𝑖
𝑛
ℎ=1
𝑚𝑖
,
𝜎𝑆
2
𝑚𝑖
) 
                              𝑉𝑖𝑗|𝑉(−𝑖)𝑗 , 𝜎𝑉𝑗
2  ~𝑁 (
∑ 𝑉ℎ𝑗𝑤ℎ𝑖
𝑛
ℎ=1
𝑚𝑖
,
𝜎𝑉𝑗
2
𝑚𝑖
) 
                                   𝑤ℎ𝑖 = {
1     𝑖𝑓 ℎ 𝑎𝑛𝑑 𝑖 𝑎𝑟𝑒 𝑛𝑒𝑖𝑔ℎ𝑏𝑜𝑢𝑟𝑠
0     𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒                               
 
 
for 𝑖 = 1, … , 𝑛 with (−𝑖) denoting all regions excluding 𝑖.  
∑ 𝑠ℎ𝑤ℎ𝑖
𝑛
ℎ=1
𝑚𝑖
 is the 
average correlated random effect for the neighbours of region 𝑖, 𝑚𝑖 is the number 
of such neighbours, and 𝜎𝑠
2 is the conditional variance of 𝑺. A neighbour is 
defined as any region immediately adjacent in space to region 𝑖. It can be seen 
that this type of prior induces a form of local smoothing across regions, where the 
degree of smoothing is controlled by the spatial correlation between regions. 
 
Additional priors for hyperparameters include Normal distributions for 
𝑙𝑜𝑔(𝛿𝑗𝑘), 𝛼𝑗 and 𝛽𝑗; 𝑙𝑜𝑔(𝛿𝑗𝑘)~𝑁(0,0.25) ; 𝛼𝑗, 𝛽𝑗~ 𝑁(0,100), and 𝜎S
2, 𝜎𝑉𝑗
2 , 
𝜎2, 𝜔𝑗
2~𝐼𝐺(1.0,0.01). The selected prior for 𝑙𝑜𝑔(𝛿𝑗𝑘) was based on the prior 
belief that 𝑙𝑜𝑔(𝛿𝑗𝑘) is between -0.5 and 0.5 with 95% probability for each disease 
at each timepoint, similar to foundational shared component models in the 
literature [22, 25]. Given the lack of prior knowledge surrounding estimates for 
other parameters in the model, priors for other parameters were selected as they 
are uninformative while allowing a wide range of plausible values. 
 
2.2.2 Model B: Shared and disease-specific temporal trends 
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Model B is an extension of Model A that includes coefficients for both shared 
and disease-specific temporal components, in order to examine evidence for a 
temporal trend common to all diseases. For Model B, equation (1) above is 
changed to: 
 
log(𝜃𝑖𝑗𝑘) ~𝑁(𝑠𝑖𝛿𝑗𝑘 + 𝜈𝑖𝑗 + (𝛽0 + 𝛽𝑗)𝑡𝑘 + 𝛼𝑗 + 𝑢𝑖𝑗𝑘 , 𝜎
2) 
 
Given 𝛽𝑜, the interpretation of 𝛽𝑗 has now changed to the difference between each 
disease-specific temporal trend and the shared temporal trend common to all 
diseases in the model. Priors for hyperparameters are as described for Model A, 
and 𝑁(0,100) for the new parameter, 𝛽0. As described above, priors were 
selected to be uninformative and allow a wide range of plausible values. 
 
2.2.3 Model C: Shared weighting factor 
Model C is a simplification of Model A. The year-specific weighting factor 𝛿𝑗𝑘 
is changed to a single weighting factor 𝛿𝑗 for each disease, 𝑗, across all years as 
follows: 
 
log(𝜃𝑖𝑗𝑘) ~𝑁(𝑠𝑖𝛿𝑗 + 𝜈𝑖𝑗 + 𝛽𝑗𝑡𝑘 + 𝛼𝑗 + 𝑢𝑖𝑗𝑘 , 𝜎
2)         
                    ∑ log(𝛿𝑗) = 0
𝐽
𝑗=1
 
 
Priors for hyperparameters are as described for Model A, and 
 𝑙𝑜𝑔(𝛿𝑗)~𝑁(0,0.25). 
 
2.3 Model comparison 
Model fit was compared between the three basic models described above using 
Deviance Information Criterion (DIC), the log likelihood, root mean squared 
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error and predictive concordance. Each measure is briefly described in Appendix 
A. 
 
2.4 Sensitivity analysis 
Sensitivity analysis was performed to determine the robustness of inferences from 
the selected model. Different classes of prior distributions were fit and results 
were compared. The selected model from Part 2.4 was rerun with the following 
variations of prior distribution: 
 
1. 𝜔𝑗
2, 𝜎2, 𝜎s
2, 𝜎𝑣𝑗
2 ~𝐼𝐺(1.0,0.01) - Base model 
2. 𝜔𝑗
2, 𝜎2, 𝜎s
2, 𝜎𝑣𝑗
2 ~𝐼𝐺(0.001,0.001) 
3. 𝜔𝑗
2, 𝜎2, 𝜎s
2, 𝜎𝑣𝑗
2 ~𝐼𝐺(0.5,0.0005) 
4. 𝜔𝑗 , 𝜎, 𝜎𝑠, 𝜎𝑣𝑗~Uniform(0,5) 
5. 𝜔𝑗 , 𝜎, 𝜎𝑠, 𝜎𝑣𝑗~𝑁(0,1)𝐼(0, ) 
6. 𝑙𝑜𝑔(𝜔𝑗), 𝑙𝑜𝑔(𝜎), 𝑙𝑜𝑔(𝜎𝑠), 𝑙𝑜𝑔(𝜎𝑣𝑗)~𝑁(0,0.25)  
 
For each model included in sensitivity analysis, the posterior mean estimates and 
95% CIs for model parameters were compared to check for model robustness. 
The four types of priors above represent a wide variety of classes of distribution, 
with differing means, variances and probabilities assigned to each value within 
the distribution. Thus, if similar estimates are obtained despite the choice of prior, 
this indicates that inferences are robust. 
 
Following sensitivity analysis, the selected model was utilised to examine 
temporal patterns in hospitalisation rates for each disease, the influence of SES, 
temporal patterns in the influence of the residual shared spatial component after 
accounting for SES, and the proportion of variation in hospitalisation rates that is 
explained by each spatial component. 
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 3. RESULTS 
 
3.1 Data 
Over the study period, among the five ACS conditions included in this analysis, 
hospitalisation was most frequent for CAD, followed by COPD, CHF, DMII and 
HT respectively. Among the estimated 2001 ERP of 443,199 across the region, 
there were a recorded 13,866 cases of CAD, 6,401 cases of COPD, 5150 cases of 
CHF, 4,869 cases of DMII and 804 cases of HT principal hospital admissions 
over the five-year study period. Temporal patterns in number of admissions for 
each disease in this region are shown in Figure 1. Overall, the number of 
admissions for DMII and COPD appears to be increasing over time, and the 
number of admissions for CHF appears to be decreasing over time. Numbers of 
hospital admissions for CAD and HT remained relatively stable over the study 
period. From exploratory analysis, there appear to be varying temporal patterns 
for hospitalisation for each disease by area of residence, especially for DMII, 
COPD and HT.  
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Figure 1: Temporal patterns in observed numbers of primary admissions for five diseases across a regional area of New South Wales 
 
 
CAD=coronary arterial disease, COPD=chronic obstructive pulmonary disease, CHF=congestive heart failure, DMII=type II diabetes mellitus, 
HT=hypertension
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Figure 2 shows temporal patterns in the number of admissions per 10,000 capita 
for each disease for three randomly selected SLAs. Whereas for some SLAs, the 
number of admissions per 10,000 capita appears to be consistently increasing, 
decreasing or remaining similar across the study period, a nonlinear pattern is 
observed for other SLAs in the region. The ERP and age-gender composition of 
the background population in each area remains relatively stable over the study 
period based on 2001 and 2006 Census statistics. Therefore, it is possible that 
differences in temporal patterns between areas may be related to differences in 
underlying aetiological factors between areas and may change over time, the 
investigation of which is an objective of this study. 
 
Table 1 summarises Pearson correlations between the four SES measures and 
overall hospitalisation rate per 10,000 capita across the 21 SLAs for each disease 
across the study period. All four measures of SES are negatively correlated with 
hospitalisation rates for all five diseases. Thus areas that are less deprived tend to 
have lower rates of hospitalisation for ACS conditions. In general, IRSAD and 
IEO Indexes have the strongest association with hospitalisation rates across all 
diseases, indicated by the size of the Pearson’s correlations and associated p 
values (Table 1). This suggests that variation in overall relative advantage and 
disadvantage, education and occupation may play an important part in explaining 
variation in hospitalisation rates. Among the five ACS conditions, CHF appears 
to have the strongest correlation with SES measures, followed by HT, COPD, 
CAD and DMII respectively. 
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Figure 2: Temporal patterns in number of hospital admissions per 10,000 capita for three randomly selected 
New South Wales Statistical Local Areas for five diseases 
 
DMII=type II diabetes mellitus, COPD=chronic obstructive pulmonary disease, CAD=coronary arterial 
disease, HT=hypertension, CHF=congestive heart failure  
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Table 1: Pearson’s correlations between incidence of hospitalisation for each of five diseases 
across the study period and measures of socio-economic status across Statistical Local Areas 
within the regional area of New South Wales 
 
  DMII COPD CAD HT CHF 
IRSAD 
 
-0.20 
p 0.04 
-0.24 
p 0.02 
-0.18 
p 0.06 
-0.30 
p 0.002 
-0.32 
p 0.001 
IRSD 
 
-0.11 
p 0.25 
-0.10 
p 0.30 
-0.09 
p 0.34 
-0.20 
p 0.04 
-0.34 
p <0.001 
IER 
 
-0.12 
p 0.21 
-0.21 
p 0.03 
-0.05 
p 0.59 
-0.31 
p 0.001 
-0.21 
p 0.03 
IEO 
 
-0.23 
p 0.02 
-0.24 
p 0.01 
-0.24 
p 0.01 
-0.26 
p 0.007 
-0.32 
p <0.001 
 
DMII=diabetes mellitus type II, COPD=chronic obstructive pulmonary disease, 
CAD=coronary arterial disease, HT=hypertension, CHF=congestive heart failure, IRSAD= 
Index of Relative Socio-Economic Advantage and Disadvantage, IRSD= Index of Relative 
Socio-Economic Disadvantage, IER=Index of Economic Resources, IEO=Index of Education 
and Occupation 
 
 
Figure 3 shows radar plots for each of the 21 SLAs. Quartiles internal to the 
dataset are plotted for hospitalisation rate for each disease and deprivation level 
as measured by IRSAD, IRSD, IER and IEO indexes. Quartile 4 indicates the 
largest hospitalisation rates and largest deprivation levels among the 21 SLAs, 
and quartile 1 indicates the smallest hospitalisation rates and least deprived areas. 
It is clear from the radar plots that areas with large hospitalisation rates tend to 
have greater levels of socioeconomic deprivation, and areas with small 
hospitalisation rates tend to have less deprivation. Results of this exploratory 
analysis support the inclusion of SES measures within the joint disease model as 
an additional shared spatial component common to all diseases.  
 
 
 
Figure 3 (next page): Radar plots of quartiles for incidence of hospitalisation for each of five 
diseases across the study period (4=highest incidence, 1=lowest incidence) and quartiles of 
socio-economic deprivation measured by four Indexes (4=most deprived, 1=least deprived) 
across the Statistical Local Areas within the regional area of New South Wales. Statistical 
Local Areas are ordered from highest to lowest total incidence of hospitalisation across all 
diseases.  
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DMII=diabetes mellitus type II, COPD=chronic obstructive pulmonary disease, 
CAD=coronary arterial disease, HT=hypertension, CHF=congestive heart failure, IRSAD= 
Index of Relative Socio-Economic Advantage and Disadvantage, IRSD= Index of Relative 
Socio-Economic Disadvantage, IER=Index of Economic Resources, IEO=Index of Education 
and Occupation 
 
 
3.2 Model comparison 
All models were assessed to have converged and similar estimates were produced 
for disease-specific temporal trends from all three models. Results from Models 
A and B indicate substantive variation in disease-specific factor loadings for the 
shared spatial component over time. The term for the shared temporal component 
in Model B was not substantive. 
 
Table 2 shows results of comparison of Models A-C for each disease. Overall, 
Models A and B performed equally well on all measures of fit and better than 
Model C based on DIC and log likelihood. This suggests that the influence of 
shared underlying aetiological factors common to all five diseases may have 
changed over time, and is important to account for within this application. Across 
all models, the best fit was observed for HT and the poorest fit for CAD based on 
log likelihood and RMSE; however, observed values for HT fell into predicted 
95% CIs less frequently as measured by predictive concordance. 
 
Models A and B performed equally well on posterior predictive checks, however, 
the shared temporal component in Model B was found to be negligible. Therefore, 
Model A was selected as the marginally preferred model for further analysis.  
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Table 2: Goodness of fit comparisons between basic joint disease models 
 
 Model A Model B Model C 
DIC 3690.76 3690.12 3788.06 
Log likelihood 
  DMII -336.3 -336.1 -337.3 
  COPD -360.0 -361.0 -360.2 
  CAD -394.5 -394.6 -394.8 
  HT -248.7 -248.0 -250.4 
  CHF -345.4 -345.9 -356.6 
  Overall -1685 -1686 -1699 
RMSE 
  DMII 9.65 9.64 9.62 
  COPD 11.06 11.08 11.03 
  CAD 16.12 16.10 16.17 
  HT 4.00 3.99 3.94 
  CHF 9.83 9.83 9.88 
  Overall 10.87 10.86 10.88 
Predictive concordance (95% CI) 
  DMII 1.00 1.00 0.99 
  COPD 0.98 0.98 0.98 
  CAD 0.99 0.99 0.99 
  HT 0.89 0.88 0.89 
  CHF 0.99 0.98 0.96 
  Overall 0.97 0.97 0.96 
 
DIC=Deviance Information Criteria, DMII=diabetes mellitus type II, COPD=chronic 
obstructive pulmonary disease, CAD=coronary arterial disease, HT=hypertension, 
CHF=congestive heart failure, RMSE=root mean squared error, CI=credible interval. 
“Overall” refers to the overall model. Lower values of DIC and RMSE and higher values of 
log likelihood and predictive concordance indicate a better fit. 
 
 
 
As a comparison to Model A, a model with dummy variables for year was also 
fit which did not constrain the temporal component to be linear. Coefficients for 
each year from this model followed a roughly linear trend for each disease 
matching findings from Model A, thus supporting the use of a linear temporal 
trend. 
 
 
 
239
4. EXTENDED MODEL 
Model A was extended to include an additional component to account for the 
influence of SES on hospitalisation rates. Only one of the four SES measures was 
included in the model at each time, and resulting estimates for unknown 
parameters were compared. The formulation for this extended model is as 
follows: 
𝑌𝑖𝑗𝑘~𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝑛𝑖𝑗𝑘𝜃𝑖𝑗𝑘)                                      
                      log(𝜃𝑖𝑗𝑘) ~𝑁(𝑠𝑖𝛿𝑗𝑘 + (𝜙 + 𝛾𝑗)𝑥𝑖 + 𝜈𝑖𝑗 + 𝛽𝑗𝑡𝑘 + 𝛼𝑗 + 𝑢𝑖𝑗𝑘 , 𝜎
2) 
  
where 𝑥𝑖 is the region-specific SEIFA score for one of four measures: IRSAD, 
IRSD, IEO and IER, 𝜙 is the mean random effect for the SEIFA index and 𝛾𝑗 is 
the disease-specific variation from this mean random effect for each disease 𝑗. 
SEIFA scores were included as a continuous measure in order to estimate the 
influence of each unit increase on log(𝜃𝑖𝑗𝑘). Priors for hyperparameters in the 
model are as described for Model A above, and 𝑁(0,10) for 𝛾𝑗 and 𝑁(0,100) for 
𝜃, allowing a wide range of plausible values. A sum-to-zero constraint was 
applied to 𝛾𝑗. 
 
Table 3 compares the estimated coefficients from each of the four SES models. 
The shared SES component for the SEIFA Index, 𝜙, was found to be associated 
with hospitalisation rates for IRSAD, IER and IEO but not for IRSD. Among 
IRSAD, IER and IEO models, the estimated mean and 95% CI for 𝜙 was similar 
for each of these three measures across all included diseases. There was no 
evidence of substantive disease-specific variation from ∅ (measured by 𝛾𝑗) for 
any of the five diseases. The DIC was similar for these three models indicating 
similar goodness of fit. As little difference was found in the estimated effect of 
IRSAD, IER and IEO on hospitalisation rates, IRSAD was selected to be included 
in further analysis. 
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 Table 3: Comparison of estimated coefficients from joint disease models incorporating 
measures of socio-economic status as an additional shared spatial component. Coefficients 
are summarised with regard to posterior mean and 95% credible interval. 
 
Model IRSAD IRSD IER IEO 
𝜙 
-0.008 (-0.012, -0.004) -0.002 (-0.007, 0.003) 
-0.008 (-0.013, -
0.003) 
-0.007 (-0.010, -
0.004) 
𝛾1 0.000 (-0.006, 0.007) 0.000 (-0.007, 0.010) 0.000 (-0.007, 0.008) 0.000 (-0.005, 0.006) 
𝛾2 0.002 (-0.004, 0.009) 0.004 (-0.004, 0.013) -0.000 (-0.000, 0.008) 0.002 (-0.003, 0.007) 
𝛾3 0.002 (-0.005, 0.009) 0.000 (-0.008, 0.009) 0.005 (-0.004, 0.013) 0.000 (-0.005, 0.006) 
𝛾4 -0.009 (-0.017, -0.000) -0.008 (-0.020, 0.003) 0.009 (-0.018, 0.000) -0.006 (-0.013, 0.000) 
𝛾5 0.004 (-0.001, 0.010) 0.003 (-0.005, 0.009) 0.004 (-0.002, 0.010) 0.003 (-0.000, 0.008) 
DIC 3692.760 3689.370 3694.410 3692.900 
 
IRSAD= Index of Relative Socio-Economic Advantage and Disadvantage, IRSD= Index of 
Relative Socio-Economic Disadvantage, IER=Index of Economic Resources, IEO=Index of 
Education and Occupation. 
𝜙 is the shared component associated with each measure of socio-economic status (IRSAD, 
IRSD, IER and IEO). 
𝛾1−5 is the disease-specific factor loading associated with 𝜙 for type II diabetes mellitus, 
chronic obstructive pulmonary disease, coronary arterial disease, hypertension and congestive 
heart failure respectively. 
 
 
 
4.1 Sensitivity analysis 
Similar parameter estimates were obtained from models included in sensitivity 
analysis following the model formulation with IRSAD as the measure of SES. 
However the DIC for each model varied slightly. The DIC for each model within 
the sensitivity analysis is summarised in Table 4. Overall, the model with uniform 
priors for 𝜎𝑠, 𝜎𝑣𝑗, 𝜎 and 𝜔𝑗 had the smallest DIC (3674.06 vs. 3692.76 for the 
base model) indicating the best fit. Thus, results of our final model are presented 
from the model with uniform priors. 
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Table 4: Comparison of goodness of fit of models included in sensitivity analysis 
 
Variation Hyperparameters Priors DIC 
1 𝜎S
2, 𝜎𝑉𝑗
2 , 𝜎2, 𝜔𝑗
2 𝐼𝐺(1.0,0.01) 3692.760 
2 𝜎S
2, 𝜎𝑉𝑗
2 , 𝜎2, 𝜔𝑗
2 𝐼𝐺(0.001,0.001) 3685.160 
3 𝜎S
2, 𝜎𝑉𝑗
2 , 𝜎2, 𝜔𝑗
2 𝐼𝐺(0.5,0.0005) 3692.340 
4 𝜎𝑆, 𝜎𝑉𝑗, 𝜎, 𝜔𝑗 𝑈𝑛𝑖(0,5) 3674.060 
5 𝜎𝑆, 𝜎𝑉𝑗, 𝜎, 𝜔𝑗 𝑁(0,1)𝐼(0,) 3700.160 
6 ln(𝜎𝑆), ln(𝜎𝑉𝑗), ln (𝜎), ln (𝜔𝑗) 𝑁(0,0.25) 3687.110 
 
DIC=Deviance Information Criteria 
 
 
Table 5 summarises the estimated coefficients from the final model. The mean 
hospitalisation rate per 10,000 capita for each disease across the study period is 
estimated by 10,000𝑒𝛼𝑗. Consistent with descriptive plots, Figures 1 and 2, the 
estimated rates are highest for CAD, followed by COPD, CHF, DMII and HT 
respectively.  
 
Table 5: Estimated parameters from the selected joint disease model. Coefficients are 
summarised with regard to posterior mean and 95% credible interval. 
 
Disease 𝑗 1 (DMII) 2 (COPD) 3 (CAD) 4 (HT) 5 (CHF) 
𝛼𝑗 -6.199 (-6.26,  
-6.141) 
-5.922 (-5.970,  
-5.876) 
-5.212 (-5.243, 
-5.182) 
-7.990 (-8.091, 
-7.891) 
-6.115 (-6.161, 
-6.071) 
exp(𝛼𝑗)*10,000 20 (19-22) 27 (26-28) 55 (53-56) 3 (3-4) 22 (21-23) 
𝛽𝑗 0.152 (0.113, 
0.194) 
0.045 (0.014, 
0.077) 
0.005 (-0.016, 
0.025) 
-0.064 (-0.131, 
-0.000) 
-0.035 (-0.065, 
-0.009) 
𝜎 0.066 (0.002, 0.121) 
𝜔𝑗 0.211 (0.137, 
0.286) 
0.147 (0.060, 
0.217) 
0.057 (0.004, 
0.118) 
0.242 (0.099, 
0.368) 
0.085 (0.006, 
0.159) 
𝜎𝑆 0.852 (0.581, 1.250) 
𝜎𝑉𝑗 1.008 (0.648, 
1.517) 
0.990 (0.658, 
1.460) 
1.051 (0.730, 
1.536) 
1.103 (0.728, 
1.666) 
0.863 (0.560, 
1.293) 
𝜙 -0.008 (-0.013, -0.003) 
𝛾𝑗 0.000 (-0.006, 
0.008) 
0.002 (-0.006, 
0.010) 
0.001 (-0.006, 
0.009) 
-0.008 (-0.017, 
0.002) 
0.003 (-0.003, 
0.011) 
 
DMII=diabetes mellitus type II, COPD=chronic obstructive pulmonary disease, 
CAD=coronary arterial disease, HT=hypertension, CHF=congestive heart failure 
 
 
Consistent with appearances in Figure 1, the model estimates an overall increase 
over time in hospitalisation rates for DMII and COPD, and a decrease for CHF 
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as measured by the disease-specific temporal coefficient 𝛽𝑗. Hospitalisation rates 
did not substantively change over time for CAD nor HT over the study period. 
The largest variation in hospitalisation rates across areas after accounting for 
temporal trends and effect of shared spatial components, was seen for HT and the 
lowest for CAD as measured by the standard deviation for correlated residual 
error (𝜔𝑗). Compared with variation in the shared spatial component measured by 
𝜎𝑆, variation in disease-specific spatial components measured by 𝜎𝑉𝑗 was greater. 
Similarly, compared with the common term for uncorrelated residual error, 𝜎, the 
variation in disease-specific uncorrelated error measured by 𝜔𝑗 is greater.  
 
Table 6 summarises the proportion of overall spatial variation that is explained 
by each of three components for each disease. The first component is the shared 
SES component weighted by its disease-specific factor loading, the second is the 
residual shared spatial component after accounting for the influence of SES, 
weighted by its disease-specific factor loading specific to each year, and the third 
is the disease-specific spatial component. The variation in each of these three 
components is measured by its variance across SLAs. The variance from the SES 
component measured by IRSAD Index was small for all diseases, ranging from 
0.03 for CAD to 0.24 for HT. This indicates that hospitalisation for CAD has the 
weakest and for HT has the strongest association with SES. In general, spatial 
variation explained by the residual shared spatial component was smaller than 
variation explained by the disease-specific spatial component across all years 
with the exception of 2004. In 2004, there was a decrease in disease-specific 
factor loading estimates and in the spatial variation explained by the residual 
shared component across all diseases. A similar pattern was observed in results 
from basic models A and B, all SES models and models included in the sensitivity 
analysis. Thus the proportion of spatial variation explained by each of the three 
components above varied both between diseases and across years (Table 6). 
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Table 6: The estimated proportion of spatial variation in incidence of hospitalisation for five diseases that is explained by variation in: (a) the 
shared socio-economic component weighted by its disease-specific factor loading, (b) the residual shared spatial component after accounting for 
the influence of (a), weighted by its disease-specific factor loading specific to each year and (c) the disease-specific spatial component, at each 
time point 𝑘 for each disease 𝑗. Coefficients are summarised with regard to posterior mean and 95% credible interval. 
 
Disease 𝑗 1 (DMII) 2 (COPD) 3 (CAD) 4 (HT) 5 (CHF) 
Variation in SES component 0.06 (0.00,0.22) 0.05 (0.00,0.24) 0.06 (0.00,0.21) 0.24 (0.03,0.61) 0.03 (0.00,0.13) 
Variation from residual shared spatial component, 𝜎S
2 0.65 (0.34, 1.56) 
Factor loading, 𝛿𝑗𝑘, by year  
2001 1.48 (1.20,1.78) 1.44 (1.20,1.69) 1.32 (1.17,1.49) 1.27 (0.83,1.74) 1.36 (1.15,1.61) 
2002 1.40 (1.14,1.68) 1.39 (1.14,1.63) 1.28 (1.14,1.47) 1.14 (0.70,1.62) 1.39 (1.19,1.62) 
2003 1.51 (1.23, 1.79) 1.58 (1.34,1.86) 1.33 (1.18,1.50) 1.46 (1.08,1.88) 1.39 (1.19,1.61) 
2004 0.24 (0.14,0.35) 0.20 (0.12,0.29) 0.36 (0.25,0.47) 0.43 (0.19,0.75) 0.26 (0.15,0.37) 
2005 1.39 (1.12,1.66) 1.70 (1.44,1.99) 1.26 (1.11,1.43) 1.23 (0.79,1.66) 1.55 (1.32,1.80) 
Variation from weighted residual spatial component  
2001 0.64 (0.38,1.04) 0.60 (0.36,0.88) 0.51 (0.34,0.75) 0.48 (0.18,0.84) 0.54 (0.34,0.79) 
2002 0.57 (0.33,0.92) 0.56 (0.32,0.85) 0.48 (0.32,0.69) 0.40 (0.11, 0.81) 0.56 (0.34,0.80) 
2003 0.66 (0.36,1.00) 0.72 (0.45,1.04) 0.51 (0.35,0.72) 0.63 (0.32,1.12) 0.56 (0.35,0.82) 
2004 0.02 (0.00,0.04) 0.01 (0.00,0.03) 0.04 (0.01,0.08) 0.06 (0.01,0.14) 0.02 (0.01,0.05) 
2005 0.57 (0.31,0.88) 0.83 (0.53,1.14) 0.46 (0.30,0.67) 0.46 (0.15,0.86) 0.70 (0.45,0.97) 
Disease-specific spatial variation, 𝜎𝑉𝑗
2  0.88 (0.42,2.30) 0.87 (0.43,2.13) 1.00 (0.53,2.36) 1.07 (0.53,2.77) 0.65 (0.31,1.67) 
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Table 6 continued. 
 
Proportion of spatial variation attributed to SES component  
2001 4% (0-12%) 3% (0-12%) 4% (0-12%) 13% (1-31%) 3% (0-9%) 
2002 4% (0-13%) 3% (0-12%) 4% (0-12%) 13% (1-31%) 3% (0-9%) 
2003 4% (0-12%) 3% (0-11%) 4% (0-12%) 12% (1-29%) 3% (0-9%) 
2004 6% (0-20%) 5% (0-19%) 5% (0-17%) 17% (2-38%) 4% (0-16%) 
2005 4% (0-13%) 3% (0-11%) 4% (0-12%) 13% (1-31%) 2% (0-8%) 
Proportion of spatial variation from residual shared component  
2001 38% (21-57%) 38% (21-55%) 31% (17-46%) 25% (10-43%) 42% (24-60%) 
2002 35% (19-54%) 36% (20-53%) 30% (16-45%) 21% (7-39%) 42% (25-61%) 
2003 39% (21-58%) 42% (25-59%) 31% (17-47%) 30% (15-49%) 43% (25-61%) 
2004 2% (0-5%) 1% (0-4%) 3% (1-8%) 4% (1-11%) 3% (1-7%) 
2005 35% (19-53%) 45% (27-62%) 29% (15-44%) 24% (8-42%) 48% (29-66%) 
Proportion of spatial variation that is disease-specific  
2001 58% (39-77%) 59% (41-77%) 65% (49-81%) 62% (41-82%) 56% (38-74%) 
2002 61% (41-79%) 61% (43-79%) 66% (50-82%) 65% (42-87%) 55% (37-73%) 
2003 58% (38-77%) 55% (38-73%) 65% (49-81%) 58% (37-79%) 55% (37-73%) 
2004 92% (78-99%) 94% (80-99%) 92% (79-98%) 79% (56-97%) 93% (81-99%) 
2005 61% (42-79%) 52% (35-70%) 67% (51-82%) 63% (41-84%) 50% (32-69%) 
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SES=socio-economic status measured by the Index of Relative Socio-Economic Advantage 
and Disadvantage, DMII=diabetes mellitus type II, COPD=chronic obstructive pulmonary 
disease, CAD=coronary arterial disease, HT=hypertension, CHF=congestive heart failure, 
Var=variance. 
 
 
 
Figure 4 compares the relative risk of the residual shared and disease-specific 
spatial components for each disease, with SLAs 1-21 ordered by the size of the 
relative risk associated with their shared component. Areas with small values for 
the shared spatial component tended to have large values from the disease-
specific spatial component and vice-versa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 (next page): Comparison of mean estimates of relative risk for hospitalisation for 
five diseases, separated into shared and disease-specific spatial components across Statistical 
Local Areas within the regional area of New South Wales from the selected model. Error bars 
represent 95% credible intervals for estimates. Statistical Local Areas 1-21 are ordered by the 
size of the estimated relative risk associated with their shared component, from smallest to 
largest. 
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RR=relative risk, DMII=diabetes mellitus type II, COPD=chronic obstructive pulmonary 
disease, CAD=coronary arterial disease, HT=hypertension, CHF=congestive heart failure 
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5. DISCUSSION 
We have proposed three Bayesian shared component model formulations to study 
shared and disease-specific spatial and temporal trends in hospitalisation rates for 
five ambulatory care sensitive conditions. Extending upon the two-disease and 
multiple disease spatiotemporal joint disease formulations proposed by 
Richardson et al. (2006) and Tzala and Best (2008), advantages of our selected 
model include: 
(a) The disease- and time-specific factor loadings for the shared spatial 
component allow examination of changes in underlying shared factors over time 
(b) The log-linear structure of the disease-specific temporal components is useful 
for prediction of disease counts specific to area and time and can be extrapolated 
to timepoints external to the dataset 
(c) A shared temporal component can be added to the model where appropriate 
for the application, to investigate temporal trends common to all diseases in the 
study based on changes over time in shared underlying aetiological factors 
(d) Where appropriate to the application, the model can be simplified to include 
disease-specific factor loadings for the shared spatial component common to all 
timepoints where there is no evidence of change in underlying shared factors over 
time 
(e) Where appropriate to the application, additional shared spatial components 
can be added to the model such as we have demonstrated by adding an additional 
shared component for SES. This allows spatial and temporal patterns for different 
underlying aetiological factors to be distinguished from each other, and allows 
the exploration of patterns of residual shared and disease-specific spatial factors 
after accounting for factors that are known to be shared by all or some of the 
diseases in the study. 
 
Limitations of our proposed model include that a log-linear relationship is 
assumed between disease prevalence and calendar time, and this may not be 
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suitable for certain applications. In addition, the assumption that the shared and 
disease-specific spatial components are independent of each other does not allow 
for the possibility of interaction between unobserved underlying spatial factors. 
Furthermore, there is a degree of ecological fallacy in generalising area-level 
measures of SES to all residents of each SLA. This may have obscured the true 
association between SES and risk of hospitalisation. 
 
We have demonstrated the utility of our selected model in the context of a case 
study that examines shared spatial factors for hospital admission rates for five 
ambulatory-care sensitive conditions.  Findings of this case study suggest that a 
small proportion of the geographic variation that is shared between DMII, COPD, 
CAD, CHF and HT is related to socio-economic status. We consider that the 
remainder of the shared spatial component is due to contributions from other 
shared risk factors. These are likely related to access to primary care and lifestyle 
factors, and may include distance to primary care provider, rurality, availability 
of fast food, healthy food and green spaces, walkability, prevalence of smoking 
and obesity. Further research linking the shared and disease-specific spatial 
variation to further covariates, such as the Accessibility/Remoteness Index of 
Australia (ARIA), presence of a hospital and total number of primary care 
providers within each region, and prevalence of the above lifestyle factors would 
aid interpretation. This would inform health policy decision-making to tailor 
interventions to factors found to be important. 
 
In applications where the shared risk factors are a stronger predictor of one or two 
diseases compared with other diseases being modelled, it is expected that the 
shared risk component estimated would only partially reflect the spatial pattern 
of that particular risk factor. The excess variation in the disease with the stronger 
association with this risk factor, would be captured by the disease-specific 
component for that disease. Thus, if SES is a stronger predictor of DMII 
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compared with other diseases, then we would expect that part of this effect would 
be captured in the DMII-specific spatial component. Similarly, if a putative risk 
factor such as prevalence of smoking is shared among all diseases modelled but 
is a stronger predictor of COPD compared with the other diseases, then we would 
expect that the COPD-specific spatial component would partially capture the 
spatial variation associated with this factor. More than half of all spatial variation 
was explained by disease-specific spatial factors across all years of this case 
study, reflecting varying aetiology and differential effect of risk factors for the 
five conditions under study.  
 
Within the general population, admission rates were found to be highest for CAD, 
followed by COPD, CHF, DMII and were lowest for HT, likely reflecting the 
severity of acute illness for each condition. While admission rates for DMII and 
COPD increased over the study period, potentially reflecting the need for better 
quality of primary care, they decreased for CHF and remained stable for CAD 
and HT. After accounting for SES, the effect of the remaining underlying shared 
spatial factors appeared to change over time. Further research adjusting for 
age/gender population distributions over time and examining the association of 
changes in other covariates over time with temporal variation in the shared 
component of these diseases may be useful in explaining these variations. 
 
In an epidemiological context, we found evidence of geographic disparity in 
hospitalisation rates for five ACS conditions in the region, and are able to 
highlight areas within NSW most at risk for hospitalisation for all five conditions, 
viz. those with the largest shared spatial components. These areas may benefit 
most from additional services for early detection, closer monitoring and 
management of these conditions within a primary care setting to avoid 
hospitalisation for complications. SLAs identified as having the largest shared 
underlying component for all five diseases all contain a hospital; availability of a 
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hospital may be associated with higher hospitalisation rates for residents of these 
SLAs but this was not formally assessed within this study. Further study 
examining the association between level of primary care and hospital care 
provision within each area with the shared underlying risk of hospitalisation 
would be useful in informing health policy decisions. 
 
The methodology used in this case study is immediately applicable to other 
datasets, and to any combination of diseases with shared risk factors. These could 
include dietary factors, lifestyle factors such as smoking, alcohol, physical 
activity, and access to healthcare. The model is useful to health policy planners 
to highlight regions with high values of the shared component for adverse health 
outcomes, incidence and mortality. These regions can then be targeted for suitable 
interventions relevant to the underlying shared risk factors. 
 
Strengths of our case study include that we were able to analyse data from a large 
number of residents from a large regional area of NSW, Australia and spanning 
five years, allowing examination of both spatial and temporal patterns of five 
related conditions. Limitations of our case study include that the age of the data 
limits the ability for future temporal prediction. Moreover, information regarding 
SES and ERP was available for only one year of the study and information 
regarding the prevalence of other underlying aetiological factors was not 
available at a spatial and temporal level. Therefore, it is difficult to assess whether 
the variability in spatial components over time is related to a change in underlying 
covariates or to assess the possibility of hospital data coding errors in 2004 
contributing to the variation. There is potential for further investigation of this 
with more detailed data. 
 
This case study identifies the role of SES versus other shared and disease-specific 
factors in explaining variation in potentially avoidable hospital admissions for 
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five conditions, and highlights regions most at risk. By targeting these regions for 
the provision of better quality primary care, early detection, monitoring and 
management of disease, we have the potential to reduce the costs and social 
burdens of hospitalisation for these conditions in the future. 
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GLOSSARY OF ABBREVIATIONS 
ABS  Australian Bureau of Statistics 
ACS  Ambulatory care sensitive 
CAD  Coronary arterial disease 
CAR  Conditional autoregressive 
CHF  Congestive heart failure 
CI  Credible interval 
COPD Chronic obstructive pulmonary disease 
DIC  Deviance Information Criterion 
DMII  Type II diabetes mellitus 
ERP  Estimated resident population 
GLMM Generalised linear mixed model 
HT  Hypertension 
ICD10 International Statistical Classification of Diseases-10 
IEO  Index of Education and Occupation 
IER  Index of Economic Resources 
IRSAD Index of Relative Socio-Economic Advantage and Disadvantage 
IRSD  Index of Relative Socio-Economic Disadvantage 
MCMC Markov chain Monte Carlo 
NSW  New South Wales 
SEIFA Socio-Economic Indexes for Areas 
SES  Socio-economic status 
SLA  Statistical Local Area 
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Supplementary material 
 
Appendix A: Measures of model comparison 
 
1 Deviance Information Criteria 
The Deviance Information Criteria (DIC) is a sum of two components, a term that 
measures goodness of fit (?̅?) and a term that penalises models for the number of 
parameters (𝑝𝐷), thus favouring more parsimonious models [39]. Here ?̅? is 
expected deviance over the course of MCMC, 𝑇 is the total number of iterations, 
𝐷(𝑦, 𝜃(𝑡)) is the deviance of the unknown parameters of the model 𝜃 at iteration 
𝑡, y are the data and 𝑝(𝑦, 𝜃(𝑡)) is the likelihood function of observing the data 
given the model at iteration 𝑡. 
 
𝐷𝐼𝐶 = ?̅? + 𝑝𝐷 
            ?̅? =
1
𝑇
∑ 𝐷(𝑦, 𝜃(𝑡))
𝑇
𝑡=1
 
   𝐷(𝑦, 𝜃(𝑡)) = −2log (𝑝(𝑦, 𝜃(𝑡))) 
 
A smaller value of ?̅? indicates a relatively better model fit. Smaller values of DIC 
are favoured overall. The comparison is relative; even if all models fit poorly, one 
will always correspond to the “best” as determined by the smallest DIC. 
 
2.3.2 Log likelihood 
The log likelihood (LL) for each model was calculated following each MCMC 
iteration, to reflect uncertainty in model parameters. The average log likelihood 
over all iterations is then reported, with higher values indicative of better model 
fit, relative to other models under consideration. 
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2.3.3 Root mean squared error 
Replicate data for each observation 𝑦𝑖𝑗𝑘 were generated at each iteration 𝑡 based 
on estimated parameters of the model, and compared to observed data for each 
observation 𝑦𝑖𝑗𝑘 as follows: 
?̃?𝑖𝑗𝑘
𝑟𝑒𝑝(𝑡)
~𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝑛𝑖𝜃𝑖𝑗𝑘
(𝑡)
) 
                         𝑅𝑀𝑆𝐸(𝑡) = √
∑ ∑ ∑ (?̃?𝑖𝑗𝑘
𝑟𝑒𝑝(𝑡)
− 𝑦𝑖𝑗𝑘)2
𝐾
𝑘=1
𝐽
𝑗=1
𝐼
𝑖=1
𝐼𝐽𝐾
 
 
where ?̃?𝑖𝑗𝑘
𝑟𝑒𝑝(𝑡)
 is the replicate observation for each observation 𝑌𝑖𝑗𝑘 at iteration 𝑡. 
The root mean squared error (RMSE) can be used to measure the overall 
discrepancy between predicted and observed values. Similar to LL, the average 
value of RMSE over MCMC iterations is reported, with smaller values indicative 
of improved fit. 
 
2.3.4 Predictive concordance 
The replicate data ?̃?𝑖𝑗𝑘
𝑟𝑒𝑝(𝑡)
, were used to obtain the 95% CI for each observation 
across the T iterations. The percentage of observed values, 𝑌𝑖𝑗𝑘, that fall into their 
corresponding 95% CI was then used as a measure of predictive concordance. 
Adequate model performance is inferred if 95% of observations fall within their 
respective interval. In general, lower concordance suggests that the model does 
not fit the data well, and higher concordance may suggest overfitting [40]. 
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Chapter 7: Evaluation of spatiotemporal 
predictive disease models accounting for 
missing data and non-linear trends: a type 
II diabetes case study 
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1. Australian Research Council Centre of Excellence for Mathematical and 
Statistical Frontiers, Queensland University of Technology, Brisbane, Australia 
2. Cooperative Research Centres for Spatial Information, Melbourne, Australia 
 
ABSTRACT 
 
Objectives: To predict future type II diabetes mellitus prevalence accounting 
for non-linear trends and spatiotemporal interaction 
 
Design: Case study 
 
Setting: Queensland, Australia 
 
Background: Recent papers in spatiotemporal disease models have focused on 
log-linear or semiparametric relationships between disease outcomes and 
calendar time. We propose a structured modelling approach for spatiotemporal 
future prediction that accounts for non-linear temporal trends and different types 
of spatiotemporal interaction.  
 
Methods: A number of spatiotemporal models formulated in the Bayesian 
framework, are evaluated in the context of a case study of type II diabetes 
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mellitus (DMII) prevalence across 71 Queensland Local Government Areas 
(LGAs) over five years, highlighting regions at risk of increasing prevalence. 
Three imputation methods are compared for imputation of missing data. Our 
selected model is used to predict DMII prevalence for 2015-2019 specific to 
region and year. 
 
Results: For the application, a linear relationship between time and DMII 
prevalence with unstructured space, structured time interaction provided the 
best fit for this dataset. Stratified mean imputation was selected as the most 
appropriate imputation based on multiple rounds of cross-validation. 
Geographic disparities were inferred between LGAs and there was evidence that 
these disparities varied over time. 
 
Conclusion: Careful model evaluation and choice can lead to improved 
identification of regions at risk of increasing DMII prevalence, leading to 
improved allocation of resources for the early detection and management of 
DMII. 
 
Highlights 
 Prediction of future type II diabetes mellitus prevalence specific to area and 
year 
 Comparison of several flexible models with consideration to non-linear 
trends and spatiotemporal interaction 
 Selection of most appropriate model for dataset 
 Comparison of imputation methods using cross-validation to select most 
appropriate method for dataset 
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1. BACKGROUND 
Spatiotemporal analysis of disease outcomes is increasingly important to identify 
regions at risk of changing incidence and prevalence of disease. These regions 
may benefit most from programs for early detection and management. 
Furthermore, studying variation in disease risk across both space and time may 
provide information about underlying aetiological causes and follow changes in 
these factors over time. 
 
An early application of spatiotemporal modelling approaches was provided by 
Bernardinelli (1995) who proposed a log linear model for describing the 
relationship between disease outcomes and time (1). Providing a less restrictive 
temporal approach, Waller et al. described a nested model that applied a spatial 
model to each timepoint separately (2). The proposed methodology assumed time 
was exchangeable, therefore placing emphasis on spatial patterns at each 
timepoint, as opposed to directly modelling trends over time. 
 
Knorr-Held and Besag (3) proposed an intermediate approach that combined the 
spatial model described by Besag et al. (4) with dynamic models with a random 
walk prior for temporal effects (5, 6). This dynamic modeling approach permitted 
nonparametric estimation of temporal trends in disease risk and trends in 
covariate effects over time. 
 
Four types of possible spatiotemporal interaction that may be important in 
spatiotemporal models have been described by Knorr-Held (7). Knorr-Held 
describes structured and unstructured a priori temporal effects, and structured 
and unstructured a priori spatial effects. The first form of interaction assumed 
independence between space and time through the use of unstructured random 
effects for space and time separately. The second and third types of interaction 
allowed for structured random effects in either space or time, as a way of 
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modelling spatial or temporal dependence (for example, if temporal trends varied 
between regions and neighbouring regions were not similar in temporal trends, 
or if rates of change were similar between neighbours but did not follow a 
temporal structure). Finally, the fourth form of interaction assumed structured 
terms in space and time, suitable for cases where temporal trends varied between 
regions, but were similar between neighbours. 
 
This paper builds on current literature with a focus on modelling the relationship 
between disease outcomes and time. In particular, a mixed model framework is 
adopted that considers higher-order relationships with time, with a view to 
improve the prediction of future risk for individual regions. In the development 
of these models, attention is also paid to the form of interaction between space 
and time, representing a continuation of the aforementioned research (7). 
 
1.1 Motivation for case study 
The rising pandemic in type II diabetes mellitus (DMII) prevalence, which is 
reported to be increasing in every country of the world has resulted in crises in 
service provision (8, 9). The economic burden of diabetes has reached USD 612 
billion in the US, £23.7 billion in the UK and AUD 14.6 billion in Australia, and 
DMII accounts for 90-95% of all diabetic cases (10-13). Early detection and 
management of glycaemic control can prevent long-term sequelae including renal 
failure, nontraumatic lower-limb amputation, new cases of blindness, heart 
disease and stroke, of which DMII is a leading or major cause, and there is 
evidence that around 60% of DMII cases are preventable with medications and/or 
lifestyle changes (14). 
 
There is increasing evidence from spatial studies conducted in the US, UK, 
Europe and Australia of spatial variation in DMII outcomes due to underlying 
geographic factors (15-22). Highlighting regions at risk of increasing DMII 
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prevalence has implications for resource allocation, for the early detection and 
monitoring of DMII, thereby reducing the social burden and economic costs of 
DMII complications to our community. In addition, future prediction of DMII 
prevalence specific to small regions as well as time would further facilitate 
service planning and public policy decision-making. As temporal trends in DMII 
prevalence may vary between regions, it is important to consider other types of 
spatiotemporal models that still provide sufficient spatial and temporal structure 
for future prediction and how these two dimensions interact. 
 
This paper has four objectives. The first objective is to select between three 
appropriate imputation methods for missing spatiotemporal data. Second, this 
paper seeks to evaluate the accuracy of spatiotemporal models for prediction of 
disease outcomes specific to region and time in the context of a case study, 
allowing for non-log-linear relationships between disease prevalence and time. 
The third objective is to identify geographic disparities in temporal patterns of 
DMII prevalence across Queensland LGAs. Given the final model, the final 
objective is to predict prevalence of DMII specific to Queensland LGAs over the 
short term, in this case, over the next five years. 
 
2. METHODS 
For clarity, we first introduce the case study, then consider imputation methods, 
spatiotemporal models, and finally evaluate these alternative methods within the 
context of the case study. 
 
Case study 
The case study examines spatial and temporal patterns of DMII prevalence across 
71 LGAs in Queensland, Australia with the aim to build predictive models 
specific to region and time. 
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2.1 Data 
The data for the aforementioned case study was collected from two main sources. 
These sources are described in the subsections below. 
 
Admissions data 
The National Diabetes Services Scheme (NDSS) database for diabetic 
notification data for 2007, 2011, 2013 and 2014. The NDSS monitors the 
prevalence of diabetes including DMII across geographic small regions of 
Australia and provides diabetes-related products, information and support 
services to almost 1.1 million Australians diagnosed with diabetes. Estimated 
DMII prevalence from the NDSS for 2007 and 2011 aggregated at a Local 
Government Area level (LGA) across Queensland were obtained from publically 
available data on the Diabetes Queensland website (23). Contained within this 
database is 2011 data originally from the Australian Bureau of Statistics (ABS) 
for socioeconomic status (SES) measured by average income scored 1–10 (1 
indicating the lowest and 10 indicating the highest income decile across 
Australia) which were used as a covariate for one imputation approach. 
 
Extracted data for DMII cases in 2013 and 2014 were obtained from Diabetes 
Queensland and contained information on city suburb and postcode for each case. 
From this dataset, DMII counts were aggregated to LGA level from suburb using 
the ABS locality to LGA index dataset (24). 
 
Demographic/Geographic Information 
The Australian Bureau of Statistics for estimated resident population (ERP) by 
LGA for 2007, 2011 and 2013 based on Census statistics (25). The ABS monitors 
population counts across geographic regions of Australia and collects and 
publishes Census data. The 2014 ERP for each Queensland LGA was 
extrapolated from its corresponding 2013 ERP by multiplying the 2013 ERP by 
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the same multiplicative difference observed between 2012 and 2013 ERPs for 
that LGA. 
 
Estimated DMII counts for each LGA in 2007 and 2011 were obtained by 
combining the reported prevalence of DMII in each LGA with ERP data for each 
LGA. Of the 74 Queensland LGAs, three island LGAs were excluded, leaving 71 
Queensland LGAs included in this analysis. 
 
2.2 Imputation 
A cross-validation approach was used to compare the accuracy of three 
imputation methods in producing estimates that are closest to observed values for 
DMII counts in 2007. Results from mean imputation were compared with results 
from mean imputation stratified by socio-economic status (SES) and imputation 
using conditional autoregressive (CAR) prior distributions. These methods are 
described below. The aim of imputation was to improve the model in terms of (a) 
estimating spatial and temporal patterns of DMII, and (b) building predictive 
models for the future specific to area and time. 
 
Of the 71 Queensland LGAs included in this analysis, DMII prevalence 
information was missing for four (6%) LGAs in 2011 and fourteen (20%) LGAs 
in 2007, including the four LGAs with missing data for 2011. The common 
practice of dealing with missing data by removing cases with missing values 
would have resulted in an unacceptable reduction of data (20%) and prevented 
analysis using methods for spatial smoothing across neighbouring regions. 
Instead, imputation of the missing data was considered. We evaluate the accuracy 
of these alternative methods within the context of our case study, however, the 
appropriateness of each method depends on the particular application. 
 
Methods for each of the three imputation approaches are described below. 
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Mean imputation 
For missing DMII prevalence, each missing observation was replaced with the 
mean of the non-missing values for 2007. This preserves the sample mean of 
observed data, but underestimates the standard deviation of data after imputation 
and does not account for associations between outcomes and covariates. 
 
Stratified mean imputation 
This method first stratifies LGAs by SES at a unit level (levels 1-7 observed 
within this dataset) resulting in seven strata. Missing values for DMII prevalence 
are then replaced with the mean of non-missing values for 2007 for LGA of the 
same SES stratum. This approach preserves associations between DMII 
prevalence and SES. This approach is justified as SES has been shown to be 
strongly associated with DMII relative risk in a recent Queensland spatial study 
of geographic factors associated with DMII (15). 
 
Imputation using a conditional autoregressive (CAR) prior distribution for 
the log relative risk of DMII 
This method estimates spatial correlation in relative risk between neighbouring 
regions, and uses these spatial relationships to estimate relative risk for missing 
observations based on non-missing information in neighbouring regions. A 
normal prior distribution was fit around the average of each set of neighbouring 
regions in order to estimate the expected value of each missing datum from non-
missing data. This allows borrowing of strength from neighbouring regions and 
accounts for spatial correlation between neighbours in DMII relative risk. Full 
details of the spatial model used for this form of imputation are provided in the 
supplementary material in Appendix A. 
 
Ten rounds of cross-validation were performed using only the 57 LGAs with 
complete data for 2007. For each round of cross-validation, the 2007 data were 
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split into two complementary subsets: 90% of data (51 LGAs) were randomly 
selected to form the training set, and the remaining 10% (6 LGAs) formed the 
test dataset. There is often a trade-off in selecting sizes for training and test 
datasets in cross-validation approaches, in that estimation is improved by 
including as much data as possible in the training dataset; however, this results in 
a smaller test set for testing the results of imputation against the observed values. 
Due to this limitation, imputation results for this case study should be treated with 
caution. 
 
The six randomly selected LGAs forming the test dataset in each round of cross-
validation were assigned missing values for the purpose of imputation. Each of 
the three imputation methods were then fit to the training dataset and used to 
impute DMII prevalence for the test dataset. The imputed values were compared 
to observed values of DMII prevalence using root mean squared error (RMSE). 
The RMSE measures how close imputed values are to the observed values. For 
each area 𝑖 in 2007, predicted values at each iteration 𝑡, ?̃?𝑖
𝑟𝑒𝑝(𝑡)
, were compared 
with observed values 𝑦𝑖  as 𝑅𝑀𝑆𝐸
(𝑡) = √
∑ (?̃?𝑖
𝑟𝑒𝑝(𝑡)
−𝑦𝑖)
2
𝑛
𝑖=1
𝑁
 
 
where 𝑁 = 6 denotes the total number of missing observations imputed in each 
of the ten rounds of cross-validation. The mean RMSE across T iterations was 
then computed as the overall measure of performance. 
 
The mean RMSE across all 60 imputed values (six per round of cross-validation 
for ten rounds of cross-validation) was reported as a comparison between the 
three methods of imputation. The imputation method providing the smallest 
overall RMSE was selected for further analysis. 
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2.3 Spatiotemporal Models 
Following imputation using the selected method, it was possible to fit 
spatiotemporal models suited to complete data to explore spatial and temporal 
patterns of DMII prevalence across Queensland LGAs. The spatiotemporal 
models fit are an extension of the model first proposed by Bernardinelli (1995)(1), 
and consider not only linear, but also quadratic and cubic relationships between 
time and the log prevalence of DMII. In addition, each of the four types of 
spatiotemporal interaction described by Knorr-Held are explored. (7).  
 
The observed disease count 𝑌𝑖𝑗 in region 𝑖 at time 𝑡𝑗 is assumed to follow a 
Poisson distribution as a function of the population at risk 𝑛𝑖𝑗, and the underlying 
rate of disease 𝜃𝑖𝑗 in region 𝑖 at time 𝑡𝑗 as below: 
 
𝑌𝑖𝑗~𝑃𝑜(𝑛𝑖𝑗𝜃𝑖𝑗)     
 
where 𝑃𝑜( ) denotes the Poisson distribution. The log-rate of disease is modeled 
as a linear function of space and time: 
 
    log(𝜃𝑖𝑗) = 𝜇 + 𝑆𝑖 + (𝛽 + 𝛿𝑖)𝑡𝑗   (1) 
 
where 𝜇 is the expected log-rate over all regions, 𝑆𝑖 is the spatially correlated 
random effect, 𝛽 is the mean linear time-trend over all regions, and 𝛿𝑖 is the 
interaction between the regional and time effects. An intrinsic autoregressive 
prior (4) was assumed for the vector of spatial random effects to promote the 
borrowing of information between neighbouring regions. The prior is defined by 
the following set of Normal marginal distributions, where 𝑁( ) denotes the 
Normal distribution: 
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𝑆𝑖|𝑆(−𝑖), 𝜎𝑆
2 ~𝑁 (
∑ 𝑆ℎ𝑤ℎ𝑖
𝑛
ℎ=1
𝑚𝑖
,
𝜎𝑆
2
𝑚𝑖
)   
                                    𝑤ℎ𝑖 = {
1     𝑖𝑓 ℎ 𝑎𝑛𝑑 𝑖 𝑎𝑟𝑒 𝑛𝑒𝑖𝑔ℎ𝑏𝑜𝑢𝑟𝑠
0     𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒                               
 
 
for 𝑖 = 1, … , 𝑛 with (−𝑖) denoting all regions excluding 𝑖.  
∑ 𝑆ℎ𝑤ℎ𝑖
𝑛
ℎ=1
𝑚𝑖
 is the 
average correlated random effect for the neighbours of region 𝑖, 𝑚𝑖 is the number 
of such neighbours, and 𝜎𝑆
2 is the conditional variance of 𝑺. A neighbour is 
defined as any region immediately adjacent in space to region 𝑖. Sum-to-zero 
constraints are applied to 𝑆𝑖 and 𝛿𝑖 so that 𝑠𝑖 represents the difference between 
the correlated random effect for each area and the fixed intercept 𝜇, and 𝛿𝑖 
represents the difference between the temporal trend for each area and the mean 
time-trend 𝛽.  
 
We extend upon this basic model in order to examine four different types of 
spatiotemporal interaction, and compare the predictive performance of models 
with linear, quadratic or cubic relationships between the log-rate of disease, 
log(𝜃𝑖𝑗), and time, 𝑡𝑗 in predicting values close to observed values. Overall, 
twelve models are compared which are termed Model 1A-1D, 2A-2D and 3A-
3D, with the numerical index indicating the type of coefficient for 𝑡𝑗, and the 
alphabetical index indicating the type of spatiotemporal interaction which is 
accounted for through choice of priors. 
 
The three types of coefficient for 𝑡𝑗 fit include: (1) a linear coefficient; (2) a 
quadratic coefficient; and (3) a cubic coefficient.  
 
The four types of spatiotemporal interaction modelled include: (A) unstructured 
space, unstructured time interaction; (B) unstructured space, structured time 
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interaction; (C) structured space, unstructured time interaction; and (D) structured 
space, structured time interaction. 
 
The formulation for Model 3D, the most complex form of the twelve models, is 
described below. All other models are a simplification of this model and can be 
found in the supplementary material in Appendix B. For area 𝑖 = 1,2, , … ,71, year 
𝑗 = 2007,2008, … ,2014, and 𝑡𝑗 = 0,1, … ,7 representing the number of years 
from the baseline year 2007 (ie. 𝑡2007 = 0, 𝑡2011 = 4, 𝑡2013 = 6 and 𝑡2014 = 7), 
where 𝑛𝑖𝑗 is the ERP for and 𝜃𝑖𝑗 is the estimated DMII prevalence for area 𝑖 in 
year 𝑗, the estimated number of DMII cases in each area in each year, 𝑌𝑖𝑗, is 
modelled as follows in Model 3D: 
 
                    𝑌𝑖𝑗~𝑃𝑜(𝑛𝑖𝑗𝜃𝑖𝑗) 
 log(𝜃𝑖𝑗) = 𝛼 + 𝑆𝑖 + (𝛽1 + 𝑉1𝑖)𝑡𝑗 + (𝛽2 + 𝑉2𝑖)𝑡𝑗
2 + (𝛽3 + 𝑉3𝑖)𝑡𝑗
3 + 𝑈𝑖𝑗 
 
where 𝛼 is an intercept, 𝑆𝑖 is the uncorrelated spatial error, 𝛽1, 𝛽2 and 𝛽3 are 
coefficients for overall linear, quadratic and cubic temporal effects respectively, 
𝑉1𝑖 , 𝑉2𝑖  and 𝑉3𝑖  are spatially structured coefficients for temporal effects, and 𝑈𝑖𝑗 
is the residual uncorrelated error. 
 
Priors for hyperparameters in the model are as follows: 
 
                                                     𝑈𝑖𝑗~𝑁(0, 𝜎𝑈
2) 
                                     𝑆𝑖|𝑆(−𝑖), 𝜎𝑆
2 ~𝑁 (
∑ 𝑆ℎ𝑤ℎ𝑖
𝑛
ℎ=1
𝑚𝑖
,
𝜎𝑆
2
𝑚𝑖
) 
 
                                𝑉1𝑖|𝑉1(−𝑖), 𝜎𝑉1
2  ~𝑁 (
∑ 𝑉1ℎ𝑤ℎ𝑖
𝑛
ℎ=1
𝑚𝑖
,
𝜎𝑉1
2
𝑚𝑖
) 
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                               𝑉2𝑖|𝑉2(−𝑖), 𝜎𝑉2
2  ~𝑁 (
∑ 𝑉2ℎ𝑤ℎ𝑖
𝑛
ℎ=1
𝑚𝑖
,
𝜎𝑉2
2
𝑚𝑖
) 
 
                               𝑉3𝑖|𝑉3(−𝑖), 𝜎𝑉3
2  ~𝑁 (
∑ 𝑉3ℎ𝑤ℎ𝑖
𝑛
ℎ=1
𝑚𝑖
,
𝜎𝑉3
2
𝑚𝑖
) 
 
Additional priors for hyperparameters include 𝛼, 𝛽1, 𝛽2, 𝛽3~𝑁(0,100), and 𝜎S
2, 
𝜎𝑉1
2 , 𝜎𝑉2
2 , 𝜎𝑉3
2 , 𝜎𝑈
2~𝐼𝐺(1.0,0.01) where 𝐼𝐺( ) denotes the Inverse Gamme 
distribution. Given the lack of prior knowledge surrounding estimates for 
parameters in the model, these priors were selected as they are uninformative 
while allowing a wide range of plausible values. 
 
Markov chain Monte Carlo (MCMC) was used to estimate each model, with each 
model run for 200,000 iterations excluding the first 90,000 iterations. Estimation 
of parameters and mapping of results were performed using R 3.1.2 and 
WinBUGS 14 (26, 27). Aggregation of 2013 and 2014 data from suburb to LGA 
level was performed using SAS 9.3 (28). 
 
2.4 Model comparison 
Goodness of fit was compared between the spatiotemporal models described 
above using Deviance Information Criteria (DIC), log likelihood, root mean 
squared error and predictive concordance. Each measure is briefly described 
below. 
 
2.4.1 Deviance Information Criteria 
The DIC is a sum of two components, a term that measures goodness of fit (?̅?) 
and a term that penalises models for the number of parameters (𝑝𝐷), thus 
favouring more parsimonious models (29). Here ?̅? is the expected deviance over 
the course of MCMC, 𝑇 is the total number of iterations, 𝐷(𝑦, 𝜃) is the deviance 
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of the unknown parameters of the model 𝜃, y are the data, and 𝑝(𝑦|𝜃) is the 
likelihood function of observing the data given the model: 
 
                                           𝐷𝐼𝐶 = ?̅? + 𝑝𝐷 
                                                     ?̅? =
1
𝑇
∑ 𝐷(𝑦, 𝜃(𝑡))
𝑇
𝑡=1
 
                                 𝐷(𝑦, 𝜃(𝑡)) = −2log (𝑝(𝑦, 𝜃(𝑡))) 
 
A smaller value of ?̅? indicates a better model fit. Smaller values of DIC are 
favoured overall and are indicative of a relatively improved model. 
 
2.4.2 Log likelihood 
The log likelihood for a model is the sum of log likelihoods for each observation 
𝑦𝑖  given the estimated parameters of the model. For each model, the log 
likelihood for each observation 𝑌𝑖𝑗 at each iteration 𝑡 given the estimated 
parameters of the model 𝜃𝑖𝑗𝑡 followed the Poisson distribution is 𝑝(𝑌𝑖𝑗|?̂?𝑖𝑗𝑡), as 
previously defined. 
 
The log likelihood for the entire sample is calculated at each MCMC iteration and 
the average across iterations is reported. Higher values of log likelihood are an 
indication of better fit. 
 
2.4.3 Root mean squared error 
Replicate data for each observation 𝑦𝑖𝑗  were generated at each iteration 𝑡 based 
on estimated parameters of the model, and compared to observed data for each 
observation 𝑦𝑖𝑗  as follows: 
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                                       ?̃?𝑖𝑗
𝑟𝑒𝑝(𝑡)
~𝑃𝑜(𝑛𝑖𝑗𝜃𝑖𝑗
(𝑡)
) 
                                  𝑅𝑀𝑆𝐸(𝑡) = √
∑ ∑ (?̃?𝑖𝑗
𝑟𝑒𝑝(𝑡)
− 𝑦𝑖𝑗)2
𝐽
𝑗=1
𝐼
𝑖=1
𝐼𝐽
 
 
where ?̃?𝑖𝑗
𝑟𝑒𝑝(𝑡)
is the replicate observation for each observation 𝑦𝑖𝑗  at iteration 𝑡. 
The root mean squared error (RMSE) can be used to measure the differences 
between predicted values of a model to observed values. The mean RMSE across 
T iterations is reported as a measure of model fit. Smaller values of RMSE are 
indicative of a better fit. 
 
2.4.4 Predictive concordance 
From the replicate data ?̃?𝑖𝑗
𝑟𝑒𝑝(𝑡)
, we obtain the 95%, 80% and 50% credible 
interval (CI) for each observation across T iterations. We then test the proportion 
of observed values, 𝑦𝑖𝑗 , that fall into the corresponding CIs from replicate data. 
Observed values that fall into the extreme range outside the 95% CI of replicate 
data can be considered outliers. The predictive concordance is the percentage of 
observed values that are not outliers. 
 
Gelfand (1996) suggests that in the case of the 2.5% tail area, the goal is to 
achieve 95% predictive concordance, as lower concordance suggests that the 
model does not fit the data well, and higher concordance may suggest overfitting 
(30). For 80% and 50% credible intervals, a higher predictive concordance 
indicates a better fit. 
 
Based on comparison of results from these measures of fit, the most appropriate 
model for this dataset was selected and used to build predictions specific to region 
and year for 2015-2019. 
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2.5 Spatiotemporal prediction 
Using the selected spatiotemporal model, DMII prevalence rates were predicted 
for each Queensland LGA for each year from 2015 through to 2019. The ERP for 
each LGA was estimated for 2015-2019 by using the observed percentage change 
in ERP from 2012 to 2013 at an LGA level, and multiplying the corresponding 
2013 ERP by this percentage change times the number of years since 2013. Thus, 
if 𝑥 is the percentage change in ERP for LGA 𝑖 between 2012 and 2013 and 𝑗∗ =
2015, … ,2019 is the year for prediction, then: 
                                     𝐸𝑅𝑃𝑗∗ = 𝐸𝑅𝑃2013𝑥(𝑗
∗ − 2013) 
 
Predicted DMII counts for each LGA for 2015-2019 were produced by 
multiplying the estimated ERP by the estimated prevalence of DMII for that year. 
 
3. RESULTS 
 
3.1 Data 
Of the 71 Queensland LGAs included in this analysis, DMII prevalence was 
missing for four LGAs for 2011, and fourteen LGAs for 2007. SES was available 
for all LGAs. SES ranged from 1 to 7 across all Queensland LGAs with mean 3.8 
(standard deviation 1.8). Table 1 shows variation in mean observed DMII 
prevalence by SES strata internal to this dataset. 
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Table 1: Average percentage with type II diabetes mellitus by socio-economic status 
 
 2007 2011 
Average % DMII % % 
Overall 3.54 5.47 
SES 1 5.80 8.92 
SES 2 -  
SES 3 4.20 6.36 
SES 4 3.35 4.90 
SES 5 2.95 3.41 
SES 6 3.78 3.54 
SES 7 2.29 3.17 
 
DMII=type II diabetes mellitus, SES=socio-economic status, % DMII=reported prevalence of 
DMII. 
 
A general trend is observed for higher mean DMII prevalence for lower SES 
deciles. In 2007, a mean prevalence of 5.8% is observed for the most deprived 
SES decile, SES 1, vs. 2.29% for most advantaged decile, SES 7. In 2011, a mean 
prevalence of 8.9% is observed for SES 1 vs. 3.2% for SES 7. The mean observed 
DMII prevalence increased for all SES deciles between 2007 and 2011 with the 
exception of SES decile 6. The mean observed DMII prevalence for SES decile 
1 in 2007 should be treated with caution as estimated DMII prevalence based on 
notification data was missing for 13/15 (86%) of LGAs of SES decile 1. The one 
remaining missing value of observed DMII prevalence in 2007 was missing for 
1/12 (8%) LGA of SES decile 3. In 2011, all four missing values for observed 
DMII prevalence were for 4/15 (26%) LGAs of SES decile 1. As data are not 
missing at random, and missingness appears to be correlated with SES, it is 
possible that the estimated mean DMII prevalence for LGAs of SES 1 in 2007 
are an underestimate due to the large number of missing values for this decile, 
and could be closer to the observed mean for 2011. 
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The observed association between SES and DMII prevalence supports mean 
imputation stratified by SES as an appropriate imputation approach for this 
application. 
 
An increase in DMII prevalence within Queensland, measured by the number of 
DMII cases per 10,000 capita, is observed between 2007 and 2011, followed by 
a plateau from 2011 to 2014. This is consistent with observed Australia-wide 
patterns in DMII prevalence which show that following large increases in DMII 
prevalence from financial years 1989 to 2007 there is a smaller increase from 
financial years 2007 to 2011 (31). The first parts of Table 3 and Figure 2 
summarise the observed total number of DMII cases each year from notification 
data and estimated number of cases per 10,000 capita of population prior to 
imputation. 
 
Figure 1 shows temporal patterns in observed DMII prevalence measured by 
number of DMII cases per 10,000 capita, for six randomly selected Queensland 
LGAs included in this analysis. Observed temporal patterns vary considerably 
between LGAs, with some showing an increase in DMII prevalence over time 
and some showing a stable prevalence over the study period. In addition, some 
temporal trends appear linear and some appear non-linear and may be best 
modelled allowing for a quadratic or cubic relationship between time and the log 
prevalence of DMII. This supports examination of hierarchical spatiotemporal 
models allowing for differing temporal patterns for different regions, and an 
examination of non-log-linear spatiotemporal models. 
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Figure 1: Temporal trends in observed number of type II diabetes mellitus cases per 10,000 
capita for six randomly selected Queensland Local Government Areas 
 
LGA=Local Government Area 
 
 
3.2 Imputation 
Stratified mean imputation was found to have the lowest overall RMSE (1.90) for 
this dataset. RMSE values for each imputation approach are summarised in Table 
2. Mean imputation had the second lowest RMSE of 2.05. In contrast, imputation 
using CAR priors in this application produced the highest RMSE of 3.60. 
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Table 2: Comparison of predictive accuracy of three selected imputation methods 
 
Summary RMSE 
Mean imputation 2.05 
Stratified mean imputation by SES 1.90 
CAR prior 3.60 
 
RMSE=root mean squared error 
 
As the imputation method providing the smallest RMSE and imputed values 
closest to observed values, stratified mean imputation was selected and was 
adopted for further analyses, including comparison of spatiotemporal models and 
building of a predictive model. Following imputation using stratified mean 
imputation, the estimated overall DMII prevalence for 2007 and 2011 was similar 
to that observed excluding cases with missing data (Table 3 and Figure 2).  
 
Table 3: Reported numbers of type II diabetes mellitus cases per year across Queensland 
before and after imputation 
 
Without imputed cases 2007 2011 2013 2014 
Total N DMII cases 117161 177701 168738 179822 
ERP 4140086 4459980 4648432 4738992 
Total N per 10,000 capita 282.99 398.43 363.00 379.45 
% 2.83% 3.98% 3.63% 3.79% 
 
 
With imputed cases 2007 2011 2013 2014 
Total N DMII cases 118633 178190 168738 179822 
ERP 4168934 4465429 4648432 4738992 
Total N per 10,000 capita 284.56 399.04 363.00 379.45 
% 2.85% 3.99% 3.63% 3.79% 
 
N=number, DMII=type II diabetes mellitus, ERP=Estimated resident population 
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Figure 2: Temporal patterns in number of type II diabetes mellitus cases per 10,000 capita 
across Queensland before and after imputation 
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3.3 Spatiotemporal models 
Of the twelve models fit, seven showed convergence of all estimated parameters 
- measures of fit for these seven models are summarised in Table 4.  
 
Table 4: Goodness of fit comparison of selected spatiotemporal models.  
 
 Model 
1A 
Model 
1B 
Model 
1C 
Model 
1D 
Model 
2C 
Model 
2D 
Model 
3D 
DIC 2878.96 2854.48 3009.71 2855.9 3009.58 2919.94 3033.76 
Log 
likelihood 
-1291 -1287 -1312 -1298 -1312 -1298 -1314 
RMSE 896.7 1565 715.6 1947 678.3 1762 3717 
Predictive 
concordance: 
       
95% CI 0.67 0.85 0.59 0.83 0.64 0.85 0.94 
80% CI 0.51 0.76 0.45 0.65 0.56 0.73 0.86 
50% CI 0.38 0.58 0.36 0.43 0.40 0.55 0.64 
 
DIC=Deviance Information Criteria, RMSE=root mean squared error, CI=credible interval. 
Lower values of DIC and RMSE, and higher values of log likelihood and predictive 
concordance indicate better model fit. 
 
The models that converged are 1A, 1B, 1C, 1D, 2C, 2D and 3D. The remaining 
five models, including two with quadratic and three with cubic temporal trends, 
showed poor convergence for 𝛽1, 𝛽2 and 𝛽3 estimates and are excluded from 
model comparison. Lack of convergence of these models may be due to 
overparameterisation of these models either with respect to the parameterisation 
itself, or relative to the amount of available data. The methodology may be better 
suited to larger spatiotemporally structured datasets with more than four 
timepoints of data. 
 
3.4 Comparison of spatiotemporal models 
Overall, Model 1B had the smallest DIC and log likelihood score, followed 
closely by Model 1D. The RMSE was smallest for models 2C, 1C and 1A 
respectively, however, these models performed poorly in predictive concordance 
based on 95%, 80% and 50% CIs. This reflects a trade-off between RMSE and 
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predictive concordance: narrower 95% CIs for predicted data can result in 
predicted values being closer to observed values overall, assuming unbiasedness; 
however, wider 95% CIs for predicted data favour better predictive concordance. 
The posterior mean predicted values for DMII count from the three models with 
the best measures of predictive concordance, Models 1B, 2D and 3D, are 
compared in Figure 3. 
 
Model 1B was selected, having the best DIC and log likelihood score, second-
best predictive concordance and mid-range RMSE compared with other models. 
Although Model 3D had the best predictive concordance, the RMSE and DIC 
were much higher compared with other models. Models 1A, 1C and 2C, despite 
having the smallest RMSE values, performed poorly in terms of predictive 
concordance and had higher DIC compared with the selected model, Model 1B. 
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Figure 3: Comparison of predicted versus observed values of number of type II diabetes 
mellitus cases per year for three selected models: Models 1B, 2D and 3D, with 95% credible 
intervals for estimates. 
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4. EXTENDED MODEL 
Using the selected model, Model 1B and baseline (2007) values for S and U, the 
model was extended to build a predictive model to predict disease prevalence in 
Queensland over the next five years. The DMII prevalence for region 𝑖 in year 𝑗, 
𝜃𝑖𝑗, was estimated in Model 1B as follows: 
 
                                                     𝑌𝑖𝑗~𝑃𝑜(𝑛𝑖𝑗𝜃𝑖𝑗) 
                                         log(𝜃𝑖𝑗) = 𝛼 + 𝑆𝑖 + (𝛽 + 𝑉𝑖)𝑡𝑗 + 𝑈𝑖𝑗 
                                    𝑉𝑖|𝑉(−𝑖), 𝜎𝑉
2 ~𝑁 (
∑ 𝑉ℎ𝑤ℎ𝑖
𝑛
ℎ=1
𝑚𝑖
,
𝜎𝑉
2
𝑚𝑖
) 
 
The extended model predicts DMII count for region 𝑖 in year 𝑗 for 2015 to 2019. 
At each iteration 𝑡, the predicted DMII count is computed using the estimated 
prevalence capped at 1, 𝜃𝑖𝑗
(𝑡)
, as below: 
 
                                                  ?̂?𝑖𝑗
(𝑡)
~𝑃𝑜(𝑛𝑖𝑗?̂?𝑖𝑗
(𝑡)
) 
 
The total predicted DMII count across all LGAs for each year was computed as 
the sum of regional predicted counts, ?̂?𝑗
(𝑡)
= ∑ ?̂?𝑖𝑗
(𝑡)𝐼
𝑖=1 . The posterior mean of 
?̂?𝑗
(𝑡)
across all iterations was computed as ?̂?𝑗 = ∑ ?̂?𝑗
(𝑡)𝑇
𝑡=1 /𝑇.  In Figure 4, the 
posterior mean, ?̂?𝑗, is used to represent predicted DMII counts across Queensland 
for 2015 to 2019 from the selected model, Model 1B. 
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Figure 4: Predicted versus observed number of type II diabetes mellitus cases across 
Queensland for 2007 to 2019 from selected model, with 95% credible intervals for estimates. 
 
DMII=type II diabetes mellitus 
 
The estimated rate of change in DMII prevalence for each region, exp (𝛽 + 𝑉𝑖), 
and its associated standard deviation are shown in Figure 5. Darker regions are 
estimated to have the highest rate of increase in DMII prevalence over the study 
period. The estimated rate of change varied from 0.77 (95% CI 0.68-0.86) to 1.46 
(1.34-1.58) between LGAs, indicating an almost two-fold variation in rate of 
increase (1.46/0.77=1.90).  
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Figure 5: Estimated rate of change in prevalence per year and estimated prevalence for type II diabetes mellitus across 2007, 2011, 2013 and 2014 by 
Queensland Local Government Areas from selected model 
 
DMII=type II diabetes mellitus, SD=standard deviation  
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While prevalence appeared to be decreasing for three (4%) and stable for 
four (6%) LGAs, it was increasing for the remaining 64 (90%) LGAs, with 
an overall trend for increase, measured by exp (𝛽) of 1.05 (1.02-1.08). The 
lowest rate of increase was estimated for Hope Vale Aboriginal Shire and 
the highest for Diamantina Shire. 
 
The estimated DMII prevalence for each region in each year was estimated 
by the posterior mean, 𝜃𝑖𝑗 =
∑ ?̂?𝑖𝑗
(𝑡)𝑇
𝑡=1
𝑇
.  Figure 5 maps predicted DMII 
prevalence for each Queensland LGA in 2007, 2011, 2013 and 2014 using 
𝜃𝑖𝑗 estimates and associated standard deviation. Darker regions have the 
highest and light regions have the lowest estimated DMII prevalence. In 
general, estimated prevalence increased over time for the majority of 
regions. Estimated DMII prevalence for each LGA for 2015 to 2019 is 
shown in Figure 6 with associated standard deviations. Again, estimated 
prevalence increases over time for the majority of LGAs. The uncertainty 
associated with estimates for 2015 to 2019, these being external to the 
dataset and non-reliant on observed data, are greater than those associated 
with estimates for 2007 to 2014. 
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Figure 6: Estimated prevalence for type II diabetes mellitus across 2015, 2016, 2017, 2018 and 2019 by Queensland Local Government Areas from 
selected model 
 
DMII=type II diabetes mellitus, SD=standard deviation  
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5. DISCUSSION 
In this paper, we have proposed an extension to the log-linear spatiotemporal 
model described by Bernardinelli 1995, combining an examination of 
spatiotemporal interactions as described by Knorr-Held 2000, with a view to 
building predictive future models for disease outcomes that account for non-log-
linear relationships between disease outcomes and time. Some advantages of this 
approach are as follows. First, we are able to simplify the model if spatiotemporal 
interaction turns out to be relatively non-important. Second, where 
spatiotemporal interaction is important, we are able to examine the spatial and 
temporal structure of this interaction. Third, we are able to evaluate a range of 
temporal patterns to find which best suits the data. Finally, the parametric 
structure of the temporal component is useful for making predictions specific to 
region and time external to the dataset. 
 
A limitation of this approach is that acknowledging the usual statistical caveats 
on extrapolating model prediction outside the range of the data, there must be a 
sufficient number of timepoints for which data are available relative to the degree 
of polynomial used to model the temporal trend. Thus selection of the maximum 
appropriate degree of polynomial to be considered is contingent upon the number 
of timepoints for which data are available. Model selection criteria and 
comparison through goodness of fit tests, such as those we have used in this case 
study, will be necessary in selecting an appropriate model from the many possible 
formulations. 
 
Depending upon the application, the most appropriate imputation method is not 
always the most complex. In our case study, stratified mean imputation was 
selected as the most appropriate method. For other applications, comparison of 
imputation methods through measures of predictive accuracy or cross-validation 
such as we have used in this case study, will be necessary in selecting the most 
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appropriate method from several options. Another option is to impute missing 
data directly within the spatiotemporal model, which may be appropriate for some 
datasets. In the context of our case study, we also trialled this method in addition 
to imputation methods described; however, this method resulted in seven of the 
twelve models failing to converge due to too much flexibility over which values 
missing data could take. Thus in several cases imputation with plausible values 
may prove superior to imputation directly within the model and lead to more 
appropriate inferences. 
 
Within an epidemiological context, we have identified geographic disparities in 
temporal patterns of DMII prevalence and highlighted regions in Queensland 
most at risk for increasing DMII prevalence. These regions may benefit from 
additional resources for health promotion and the early detection, management 
and monitoring of DMII to reduce the burden of DMII complications to the 
community. Overall, an increase is observed in DMII prevalence between 2007 
to 2014, but temporal patterns of DMII prevalence differ between regions and 
neighbouring regions do not necessarily share similar temporal patterns. From 
identified temporal trends, it appears likely that geographic disparities in DMII 
prevalence may increase over time. Borrowing strength across both space and 
time, we have produced spatially and temporally smoothed estimates of DMII 
prevalence specific to region and year. This information may be useful for 
informing public policy and resource allocation. 
 
Strengths of our study include that we were able to evaluate the performance of 
various spatiotemporal formulations and imputation methods using methodology 
that is immediately applicable to other regions and health datasets outside our 
reported application. Within our case study, we were able to evaluate the 
geographic variation in temporal patterns of DMII prevalence across Queensland 
and build predictive models, accounting for missing data. We used Bayesian 
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methods to fit hierarchical models accounting for different sources of uncertainty 
and spatiotemporal interaction. Spatial and temporal smoothing was performed, 
mitigating the effects of random measurement error. In addition, we were able to 
select the most accurate imputation method and spatiotemporal model for this 
dataset through measures of goodness of fit. 
 
Limitations of our study include the presence of significant missing data for one 
year of our dataset, small sample sizes for test datasets in cross-validation, that 
diabetic counts were based on notification data with unknown measurement bias, 
and that data were available for only four timepoints between 2007 to 2014, 
limiting the usefulness of models that explored quadratic and cubic relationships 
between time and disease outcomes, and limiting the scope of future predictions 
to five years into the future. 
 
This case study provides evidence of an almost two-fold difference in rate of 
change in DMII prevalence across Queensland LGAs. Our results highlight 
regions most in need of additional services to manage DMII, and indicate that a 
geographically targeted approach to managing DMII may be effective. The 
methodology used in this study is applicable to spatiotemporal analyses of 
diabetes and other diseases in other regions, and has the potential to provide 
useful information for public policy and resource allocation decisions.  
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Supplementary Material 
 
Appendix A 
The spatial model fit to 2007 DMII prevalence data for imputation using 
conditional autoregressive (CAR) priors took the following formulation: 
 
𝑌𝑖~𝑃𝑜(𝑛𝑖𝜃𝑖)     
log(𝜃𝑖𝑗) = 𝛼 + 𝑆𝑖 + 𝑈𝑖             
 
where for region 𝑖, 𝑌𝑖 is the observed number of DMII cases, 𝑛𝑖 is the ERP, and 
𝜃𝑖 is the estimated prevalence of DMII; 𝛼 is the intercept, 𝑆𝑖 is the spatially 
correlated error with a CAR prior, and 𝑈𝑖 is the uncorrelated error with a 
𝑁(0, 𝜎𝑈
2) prior. Uniform priors were fit to 𝜎𝑆 and 𝜎𝑈. An intrinsic autoregressive 
prior was assumed for the spatial random effects, as defined by the following set 
of marginal distributions: 
 
𝑆𝑖|𝑆(−𝑖), 𝜎𝑆
2 ~𝑁 (
∑ 𝑆ℎ𝑤ℎ𝑖
𝑛
ℎ=1
𝑚𝑖
,
𝜎𝑆
2
𝑚𝑖
) 
                                     𝑤ℎ𝑖 = {
1     𝑖𝑓 ℎ 𝑎𝑛𝑑 𝑖 𝑎𝑟𝑒 𝑛𝑒𝑖𝑔ℎ𝑏𝑜𝑢𝑟𝑠
0     𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒                               
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Appendix B 
Models with linear, quadratic and cubic temporal trends were compared, each 
with four different types of spatiotemporal interaction as described by Knorr-
Held et al. (1999), thus overall 12 models were compared as follows: 
 
1A. Linear temporal trend with unstructured space, unstructured time 
interaction. 𝑃𝑜( ) denotes the Poisson distribution, 𝑁( ) denotes the Normal 
distribution, and 𝐼𝐺( ) denotes the Inverse Gamma distribution. 
 
For area 𝑖 = 1,2, … ,71, time 𝑗 = 1,2,3,4 and 𝑡𝑗 = 0,1, … ,7, representing the 
years 2007, 2011, 2013 and 2014 where 𝑡2007 = 0, 𝑡2011 = 4, 𝑡2013 = 6 and 
𝑡2014 = 7: 
 
𝑂𝑖𝑗~𝑃𝑜(𝑛𝑖𝑗𝜃𝑖𝑗)                   
log(𝜃𝑖𝑗) = 𝛼 + 𝑆𝑖 + 𝛽𝑡𝑗 + 𝑈𝑖𝑗                 (1) 
𝑆𝑖|𝑆(−𝑖), 𝜎𝑆
2 ~𝑁 (
∑ 𝑆ℎ𝑤ℎ𝑖
𝑛
ℎ=1
𝑚𝑖
,
𝜎𝑆
2
𝑚𝑖
)     
                                  𝑤ℎ𝑖 = {
1     𝑖𝑓 ℎ 𝑎𝑛𝑑 𝑖 𝑎𝑟𝑒 𝑛𝑒𝑖𝑔ℎ𝑏𝑜𝑢𝑟𝑠
0     𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒                               
 
 
𝑈𝑖𝑗~𝑁(0, 𝜎𝑈
2)           
𝛼~𝑁(0,100)       
𝛽~𝑁(0,100)       
𝜎𝑈
2~𝐼𝐺(1.0,0.01)    
𝜎𝑆
2~𝐼𝐺(1.0,0.01)    
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1B. Linear temporal trend with unstructured space, structured time interaction 
Equation (1) is changed to: 
          log(𝜃𝑖𝑗) = 𝛼 + 𝑆𝑖 + (𝛽 + 𝑣𝑖)𝑡𝑗 + 𝑈𝑖𝑗 
𝑣𝑖~𝑁(0, 𝜎𝑉
2)          
𝜎𝑉
2~𝐼𝐺(1.0,0.01)   
 
1C. Linear temporal trend with structured space, unstructured time interaction 
Equation (1) is changed to: 
 log(𝜃𝑖𝑗) = 𝛼 + 𝑆𝑖 + 𝛽𝑡𝑗 + 𝑣𝑖 + 𝑈𝑖𝑗 
𝑉𝑖|𝑉(−𝑖), 𝜎𝑉
2 ~𝑁 (
∑ 𝑉ℎ𝑤ℎ𝑖
𝑛
ℎ=1
𝑚𝑖
,
𝜎𝑉
2
𝑚𝑖
)            
                         𝑤ℎ𝑖 = {
1     𝑖𝑓 ℎ 𝑎𝑛𝑑 𝑖 𝑎𝑟𝑒 𝑛𝑒𝑖𝑔ℎ𝑏𝑜𝑢𝑟𝑠
0     𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒                               
 
 
   
1D. Linear temporal trend with structured space, structured time interaction 
Equation (1) is changed to: 
log(𝜃𝑖𝑗) = 𝛼 + 𝑆𝑖 + (𝛽 + 𝑣𝑖)𝑡𝑗𝑈𝑖𝑗     
𝑉𝑖|𝑉(−𝑖), 𝜎𝑉
2 ~𝑁 (
∑ 𝑉ℎ𝑤ℎ𝑖
𝑛
ℎ=1
𝑚𝑖
,
𝜎𝑉
2
𝑚𝑖
)             
                         𝑤ℎ𝑖 = {
1     𝑖𝑓 ℎ 𝑎𝑛𝑑 𝑖 𝑎𝑟𝑒 𝑛𝑒𝑖𝑔ℎ𝑏𝑜𝑢𝑟𝑠
0     𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒                               
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2A. Quadratic temporal trend with unstructured space, unstructured time 
interaction 
Equation (1) is changed to: 
       log(𝜃𝑖𝑗) = 𝛼 + 𝑆𝑖 + 𝛽1𝑡𝑗 + 𝛽2𝑡𝑗
2 + 𝑈𝑖𝑗 
𝛽1~𝑁(0,100)               
𝛽2~𝑁(0,100)              
 
2B. Quadratic temporal trend with unstructured space, structured time 
interaction 
Equation (1) is changed to: 
                                 log(𝜃𝑖𝑗) = 𝛼 + 𝑆𝑖 + (𝛽1 + 𝑣1𝑖)𝑡𝑗 + (𝛽2 + 𝑣2𝑖)𝑡𝑗
2 + 𝑈𝑖𝑗 
𝑣1𝑖~𝑁(0, 𝜎𝑉1
2 )                   
𝑣2𝑖~𝑁(0, 𝜎𝑉2
2 )                   
𝜎𝑉1
2 ~𝐼𝐺(1.0,0.01)             
𝜎𝑉2
2 ~𝐼𝐺(1.0,0.01)             
 
2C. Quadratic temporal trend with structured space, unstructured time 
interaction 
Equation (1) is changed to: 
                      log(𝜃𝑖𝑗) = 𝛼 + 𝑆𝑖 + 𝛽1𝑡𝑗 + 𝛽2𝑡𝑗
2 + 𝑣𝑖𝑗 + 𝑈𝑖𝑗 
    𝑉𝑖𝑗|𝑉(−𝑖)𝑗 , 𝜎𝑉
2 ~𝑁 (
∑ 𝑉ℎ𝑗𝑤ℎ𝑖
𝑛
ℎ=1
𝑚𝑖
,
𝜎𝑉𝑗
2
𝑚𝑖
)        
                                  𝑤ℎ𝑖 = {
1     𝑖𝑓 ℎ 𝑎𝑛𝑑 𝑖 𝑎𝑟𝑒 𝑛𝑒𝑖𝑔ℎ𝑏𝑜𝑢𝑟𝑠
0     𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒                               
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2D. Quadratic temporal trend with structured space, structured time interaction 
Equation (1) is changed to: 
 log(𝜃𝑖𝑗) = 𝛼 + 𝑆𝑖 + (𝛽1 + 𝑣1𝑖)𝑡𝑗 + (𝛽2 + 𝑣2𝑖)𝑡𝑗
2 + 𝑈𝑖𝑗 
 𝑉1𝑖|𝑉1(−𝑖), 𝜎𝑉1
2  ~𝑁 (
∑ 𝑉1ℎ𝑤ℎ𝑖
𝑛
ℎ=1
𝑚𝑖
,
𝜎𝑉1
2
𝑚𝑖
)                  
𝑉2𝑖|𝑉2(−𝑖), 𝜎𝑉2
2  ~𝑁 (
∑ 𝑉2ℎ𝑤ℎ𝑖
𝑛
ℎ=1
𝑚𝑖
,
𝜎𝑉2
2
𝑚𝑖
)                
                         𝑤ℎ𝑖 = {
1     𝑖𝑓 ℎ 𝑎𝑛𝑑 𝑖 𝑎𝑟𝑒 𝑛𝑒𝑖𝑔ℎ𝑏𝑜𝑢𝑟𝑠
0     𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒                               
 
 
3A. Cubic temporal trend with unstructured space, unstructured time interaction 
Equation (1) is changed to: 
                         log(𝜃𝑖𝑗) = 𝛼 + 𝑆𝑖 + 𝛽1𝑡𝑗 + 𝛽2𝑡𝑗
2 + 𝛽3𝑡𝑗
3 + 𝑈𝑖𝑗 
𝛽1~𝑁(0,100)           
𝛽2~𝑁(0,100)           
𝛽3~𝑁(0,100)           
 
3B. Cubic temporal trend with unstructured space, structured time interaction 
Equation (1) is changed to: 
log(𝜃𝑖𝑗) = 𝛼 + 𝑆𝑖 + (𝛽1 + 𝑣1𝑖)𝑡𝑗 + (𝛽2 + 𝑣2𝑖)𝑡𝑗
2 + (𝛽3 + 𝑣3𝑖)𝑡𝑗
3 + 𝑈𝑖𝑗 
𝑣1𝑖~𝑁(0,100)                                                                                  
𝑣2𝑖~𝑁(0,100)                                                                                  
𝑣3𝑖~𝑁(0,100)                                                                                  
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3C. Cubic temporal trend with structured space, unstructured time interaction 
Equation (1) is changed to: 
 
log(𝜃𝑖𝑗) = 𝛼 + 𝑆𝑖 + 𝛽1𝑡𝑗 + 𝛽2𝑡𝑗
2 + 𝛽3𝑡𝑗
3 + 𝑣𝑖 + 𝑈𝑖𝑗                                
𝑉𝑖|𝑉(−𝑖), 𝜎𝑉
2 ~𝑁 (
∑ 𝑉ℎ𝑤ℎ𝑖
𝑛
ℎ=1
𝑚𝑖
,
𝜎𝑉
2
𝑚𝑖
)                                                                      
𝑤ℎ𝑖 = {
1     𝑖𝑓 ℎ 𝑎𝑛𝑑 𝑖 𝑎𝑟𝑒 𝑛𝑒𝑖𝑔ℎ𝑏𝑜𝑢𝑟𝑠
0     𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒                               
                                 
   
3D. Cubic temporal trend with structured space, structured time interaction 
Equation (1) is changed to: 
 
log(𝜃𝑖𝑗) = 𝛼 + 𝑆𝑖 + (𝛽1 + 𝑣1𝑖)𝑡𝑗 + (𝛽2 + 𝑣2𝑖)𝑡𝑗
2 + (𝛽3 + 𝑣3𝑖)𝑡𝑗
3 + 𝑈𝑖𝑗 
𝑉1𝑖|𝑉1(−𝑖), 𝜎𝑉1
2  ~𝑁 (
∑ 𝑉1ℎ𝑤ℎ𝑖
𝑛
ℎ=1
𝑚𝑖
,
𝜎𝑉1
2
𝑚𝑖
)                                                                               
𝑉2𝑖|𝑉2(−𝑖), 𝜎𝑉2
2  ~𝑁 (
∑ 𝑉2ℎ𝑤ℎ𝑖
𝑛
ℎ=1
𝑚𝑖
,
𝜎𝑉2
2
𝑚𝑖
)                                                                               
𝑉3𝑖|𝑉3(−𝑖), 𝜎𝑉3
2  ~𝑁 (
∑ 𝑉3ℎ𝑤ℎ𝑖
𝑛
ℎ=1
𝑚𝑖
,
𝜎𝑉3
2
𝑚𝑖
)                                                                               
                  𝑤ℎ𝑖 = {
1     𝑖𝑓 ℎ 𝑎𝑛𝑑 𝑖 𝑎𝑟𝑒 𝑛𝑒𝑖𝑔ℎ𝑏𝑜𝑢𝑟𝑠
0     𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒                               
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Chapter 8: Discussion and Conclusion 
The methodology developed in this thesis focussed on three applications.  
Within a primary care and inpatient care setting, models were used to 
estimate the risk of selected DMII outcomes, based on patient-level 
characteristics, enabling improved identification of patients at risk. The 
variant joint model formulations proposed allowed for changes in the 
contribution of shared, latent factors over time. The proposed 
spatiotemporal models allowed the modelling of different relationships 
between time and disease outcomes, for the prediction of region and time 
specific outcomes. 
 
The statistical modelling approaches and applications presented in this 
thesis have important implications for the management of DMII in primary 
and inpatient care settings. These approaches are immediately applicable 
to the modelling of DMII in other parts of the world and modelling of other 
chronic diseases. The development of GLMMs within the Bayesian 
framework made possible the identification of both individual and 
geographic factors associated with DMII outcomes, in addition to 
highlighting small areas with elevated risk, across both spatial and 
temporal domains. The ability to identify such regions has implications for 
service delivery for the detection and management of DMII. 
 
8.1 Research Contributions and Findings 
In this section, the main contributions of this thesis are discussed.  A 
summary of research contributions in each chapter is provided in Table 8.1.  
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The systematic review in Chapter 3 identified current literature on the 
spatial modelling of DMII outcomes. The eight steps of the Cochrane 
collaboration guidelines were followed to provide a descriptive summary 
of all spatial studies performed to model these outcomes. The spatial 
methods summarised in this review are applicable to other diseases and 
provided a base source of information for health researchers interested in 
methodology to explore various disease outcomes. These include the 
degree of geographic disparity in disease outcomes, highlighting areas 
most at risk, and examining the effect of covariates. Research gaps 
identified as a result of this review provided a basis for further analysis 
performed in Chapters 4-7 of this thesis. 
 
Studies that explored DMII outcomes were limited to the US, the UK and 
Europe, and the majority examined combined DMI and DMII outcomes. 
Although DMII makes up 90-95% of all diabetic cases, a study examining 
DMII outcomes exclusively here in Australia (or elsewhere) would provide 
a more accurate picture of geographic disparities and important covariates 
associated with these outcomes specific to these localities.  
 
Of the studies identified, only one included correlated random effects 
between neighbouring regions to encode spatial smoothing. One study 
examined temporal changes in patterns over time for each region 
independently, but did not consider spatiotemporal interactions. The 
acknowledgement of this gap motivated research in Chapters 4, 5 and 7. 
Two studies proposed joint models for the examination of multiple 
outcomes. These examined the correlation between DMII and DMI 
prevalence and DMII prevalence and study participation respectively. This 
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identified the scope to extend joint modelling methodology to examine 
spatial correlations between outcomes for DMII and other associated 
diseases, addressed in Chapter 6. The methodology considered by the 
included studies was limited to generalised linear mixed models, which 
was also the focus of this thesis. More flexible models might also be 
suitable for modelling the chosen outcomes, however were outside the 
scope of this thesis. 
 
Consistent with selected studies described in Chapter 3, the analysis in 
Chapter 4 found evidence of small area variation in DMII prevalence and 
relative risk, in this case among Queensland LGAs. There was an estimated 
six-fold difference in relative risk just within Queensland. Similar findings 
were obtained in Chapter 5, where geographic variation in DMII inpatient 
outcomes across a region of New South Wales was examined. The 
extension of spatial models adopted for these two analyses to other regions 
in Australia would be useful to further highlight geographic disparities 
across the country and to identify regions most at risk that would benefit 
from additional resources for the early detection and management of DMII. 
At a national level, comparisons in DMII prevalence could be made at a 
small area level within and between different states. This would require the 
consideration of extended random effect structures, for example, areas 
within states, each with its own level of spatial and/or temporal smoothing. 
 
The analyses in Chapters 4 and 5 extended upon current knowledge of 
DMII risk factors incorporating a larger number of geographic and 
individual covariates. The analysis in Chapter 4 was consistent with studies 
described in Chapter 3 that associated lower socio-economic status (SES) 
311
with worse DMII outcomes. After accounting for the effect of SES, other 
spatial covariates such as the proportion of daily smokers and proportion 
overweight or obese were not found to be substantively associated with 
DMII relative risk in the analysis in Chapter 4. This could be partly 
explained by the fact that low regional SES was positively correlated with 
a higher proportion of overweight/obese and a higher proportion of daily 
smokers in this dataset, which may have masked the relationship between 
these covariates and DMII relative risk. However, this contrasted with 
findings from the spatial study by Green et al., which found smoking to be 
associated with DMII prevalence even after accounting for SES, and with 
studies that found DMII risk to be associated with BMI at an individual 
level. 
 
Chapter 5 presented a substantive application of a spatial hierarchical 
model for identifying individual risk of hospitalisation for five clinically 
relevant outcomes. The findings in this Chapter were consistent with 
previous studies with respect to evidence of residual spatial variation in 
DMII outcomes, following adjusting for individual-level covariates. This 
methodology can be applied to the assessment of individual risk for other 
types of disease in other regions, and has important implications from a 
healthcare perspective. By being able to identify at an early stage, patients 
most at risk for developing disease complications within both a primary 
care and hospital setting, clinicians are better placed to treat and monitor 
these patients more closely. By doing so, the risk of hospitalisation for 
complications can be mitigated, with economic benefit for the healthcare 
system. 
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The application of the joint modelling approach presented in Chapter 6 
found evidence of shared underlying factors between DMII and four 
related chronic diseases. So far, joint disease models described in existing 
literature have focussed on semiparametric modelling of changes in shared 
spatial components over time. However, a semiparametric temporal 
structure does not easily allow a comparison of temporal trends in 
outcomes between diseases. Chapter 6 extended this methodology to a 
parametric estimation of temporal parameters, for the purposes of 
comparing differences in temporal trends between multiple disease 
outcomes. The proposed parametric structure enabled the prediction of 
disease counts specific to area and time, and provided flexibility in terms 
of the specification of shared and outcome-specific components.  For 
example, a shared temporal component could be added to the model where 
appropriate for the application, to investigate temporal trends common to 
all diseases in the study based on changes over time in shared underlying 
aetiological factors. Alternatively, the model could be simplified to include 
disease-specific factor loadings for the shared spatial component common 
to all timepoints where there is no evidence of change in underlying shared 
factors over time. Finally, shared covariate-driver components could be 
added to the model, and in Chapter 6, SES was considered. This allowed 
spatial and temporal patterns for different underlying aetiological factors 
to be distinguished from each other, and allowed the exploration of patterns 
of residual shared and disease-specific spatial factors after accounting for 
factors that were known to be shared by all or some of the diseases in the 
study.  
 
The shared component can be interpreted as a measure of the degree of 
commonality in underlying aetiology between all diseases included in the 
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study. This interpretation is not always straightforward as identification of 
which factors contribute to this shared underlying aetiology may not be 
readily apparent. In an ideal situation, all potential factors could be tested 
to identify which contributed most to the shared component, but data on all 
such factors are not always available. Future research incorporating data 
for other potential risk factors apart from SES would be useful in further 
investigating contributing factors for underlying aetiology shared by the 
chronic diseases included in this study. 
 
Chapter 7 examined the role of different types of spatiotemporal 
interaction, allowing for different temporal trends in DMII prevalence. The 
proposed model enabled the investigation of various types of space-time 
interaction. The parametric structure of the temporal component was useful 
for making predictions specific to region and time external to the dataset. 
 
The results of this course of research have important implications for 
further health research, and the methods described are immediately 
applicable to other parts of the world and to other diseases. Implementation 
of the models described have the potential to highlight areas that would 
benefit from additional resources to reduce complications of disease and 
the social and economic costs of disease. The methodology developed in 
this chapter was limited to log-linear models where smoothing was 
incorporated in the spatial dimension only. Future research could examine 
the role of temporal smoothing based on the concept of nearest neighbours 
applied to timepoints, as an extension to the spatial smoothing methods 
described in this chapter. 
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A limitation of this course of research was that the presence of missing data 
added to uncertainty around inferences made. Furthermore, for the case 
study described in Chapter 5, information around modifiable lifestyle 
factors and distance to provider were not available and not accounted for 
in models. For the joint disease spatiotemporal models described in 
Chapter 6, the influence of geographic factors was limited to SES as 
information on other geographic covariates was unavailable for the NSW 
region. 
 
These limitations provide scope for future research. Some 
recommendations for further work are described in the next section. 
 
8.2 Recommendations for future research 
The research has focussed mainly on DMII and associated conditions. 
Further research into the performance and applicability of the methods 
developed here should be undertaken in the context of other case studies in 
other parts of the world and in relation to other diseases. The imputation 
method described in Chapter 4 may provide a better fit for datasets without 
significant missing data, and it may be useful to evaluate this approach in 
the context of other case studies. 
 
Further research considering additional covariates would also be useful to 
investigate underlying aetiology for geographic variation. For example, the 
case study described in Chapter 4 examined only geographic lifestyle 
covariates associated with DMII prevalence. Further research examining 
the role of these geographic covariates after accounting for individual 
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covariates may be useful. The models described in Chapter 5 did not 
include individual lifestyle factors or distance to provider as covariates. It 
may be useful to examine the role of these factors, as well as other 
geographic factors such as availability of primary care services, such as 
number of available general practitioners, distance to hospital and primary 
care services. Future health record data collected at a geographical point 
level for area of residence and facility of treatment, would allow the 
computation of road distances between area of residence and primary care 
provider, closest hospital and other health services. This information would 
be useful to assess the impact of distance to provider on health outcomes, 
and to identify gaps in service provision. 
 
Several methodological extensions are possible for future research. 
Measurement errors are inherent in most datasets and could be modelled 
as an additional uncertainty term within the Bayesian framework, 
incorporating expert knowledge of how much uncertainty could reasonably 
be expected. Alternative models including generalised additive mixed 
models and classification and regression trees could also be explored, as 
semiparametric/nonparametric alternatives for modelling disease 
outcomes. The spatial smoothing methods utilised in this thesis could be 
extended to temporal smoothing based on the concept of nearest 
neighbours applied to individual timepoints. 
 
This thesis has examined spatial patterns of disease across relatively large 
areas, namely Statistical Local Areas and Local Government Areas. 
Further research involving smaller areas, such as meshblocks would likely 
have more power to detect associations between spatial risk factors and 
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disease outcomes, as well as spatial disparities in disease outcomes. Due 
to the large size of areas included in this research, spatial smoothing was 
only performed across areas that were directly adjacent to each other. 
Future research examining smaller areas could extend this to a comparison 
of spatial smoothing across areas that are higher order neighbourhood 
structures. Mixture modelling could also be considered to identify spatial 
clusters containing areas that are similar to each other in disease outcomes. 
Finally, the availability of data restricted the development of methodology 
to areal-level outcomes only. If available, further development of 
methodology to accommodate point-level data would facilitate inference 
at a finer resolution, to further inform decision making. 
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Table 8.1: Summary of research components and innovations 
Chapter Title Model Outcome(s) Covariates Innovation 
3 Spatial modelling of type II 
diabetes outcomes: a systematic 
review of approaches used 
Review Varied between included studies Varied between included studies First review of spatial studies 
examining DMII outcomes. 
Identified lack of Australian DMII 
spatial studies 
4 Missing in space: an evaluation of 
imputation methods for missing 
data in spatial analysis of risk 
factors for type II diabetes 
BYM DMII prevalence  SES, % aged >45 years, daily 
smokers, overweight/obese, 
insufficient physical activity, 
fruit and vegetable consumption 
First time small-area variation in 
DMII prevalence examined in 
Australia. Included lifestyle 
covariates not included in spatial 
studies reviewed in Chapter 3 
5 Indicators for hospitalisation for 
type II diabetes mellitus 
complications and adverse 
inpatient outcomes 
BYM Individual risk for hospitalisation 
and multiple admissions for DMII 
complication, greater than average 
LOS, short-term readmission and 
admission to ICU 
Age, gender, ATSI, born in 
Australia, marital status, 
comorbidity, area of residence, 
SES of area of residence 
Extension of BYM model to 
prediction of individual risk for 
adverse DMII inpatient outcomes 
within the context of their area of 
residence 
6 Joint modelling of potentially 
avoidable hospitalisation for five 
diseases accounting for 
spatiotemporal effects: a NSW 
case study 
Shared component 
flexible parametric 
relative risk 
Incidence of hospitalisation for five 
chronic diseases 
SES Extension of classic shared 
component model, flexible 
specification of different components 
7 Evaluation of spatiotemporal 
predictive disease models 
accounting for missing data and 
non-linear trends: a type II diabetes 
case study 
Spatiotemporal 
flexible parametric 
prediction of future 
prevalence 
DMII prevalence  N/A Extension of classic spatiotemporal 
model, examination of different 
types of interaction, future prediction 
 
BYM=Besag, York, Mollie model DMII=type II diabetes mellitus, SES=socioeconomic status LOS=length of stay ICU=intensive care unit ATSI=Aboriginal/Torres Strait 
Islander 
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APPENDIX A: Sources of Data 
The analyses in this thesis rely on four sources of data, including: 
 The National Diabetes Services Scheme 
 The Census of Population and Housing 
 The Queensland self-reported health status 2009-10: Local Government 
Area survey 
 Hospitalisation data specific to residents of a region of New South Wales 
The collection and quality of each of these sources of data is described below. 
 
The National Diabetes Services Scheme (NDSS)  
The NDSS delivers diabetes-related products, information and support services 
to almost 1.1 million Australian with diabetes and monitors the prevalence of 
diabetes including type II diabetes mellitus (DMII) across regions in Australia. 
Diabetic notification data for 2007 and 2011 are freely available from the NDSS 
and Diabetes Queensland websites (Diabetes Queensland 2012, National 
Diabetes Services Scheme 2012) and were used to estimate the prevalence of 
DMII across Local Government Areas (LGAs) in Queensland in those years for 
the papers in Chapters 4 and 7. The NDSS database also contains 2011 
demographic data sourced from the Australian Bureau of Statistics (ABS) 
indicating a) socioeconomic status (SES), measured by average income scored 1-
10 (1 indicating lowest and 10 indicating highest income decile across Australia) 
and b) proportion over the age of 45 years for the general population in each LGA 
in Queensland, which were used as covariates in Chapter 4. 
 
In addition, NDSS notification data specific to DMII cases within Queensland 
were obtained from Diabetes Queensland for the years 2013 and 2014 as a 
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customised data request. This dataset information relating to city suburb and 
postcode of residence for each DMII case. Cases were aggregated from suburb to 
LGA level using the ABS locality to LGA index dataset (Australian Bureau of 
Statistics 2012). These data were used in Chapter 7. 
 
Census of Population and Housing 
Estimated resident population (ERP) counts for 2011 across Queensland LGAs, 
and extrapolated ERP for 2007 and 2013 were obtained from the 2006 and 2011 
Census of Population and Housing. This information is freely available on the 
ABS website (Australian Bureau of Statistics 2013, Australian Bureau of 
Statistics 2014). The ABS monitors population counts across geographic regions 
of Australia and collects and publishes the Census data. The 2014 ERP for each 
Queensland LGA was extrapolated from its corresponding 2013 ERP by 
multiplying the 2013 ERP by the same multiplicative difference observed 
between 2012 and 2013 ERPs for that LGA. 
 
Estimated DMII counts for each LGA in 2007 and 2011 were obtained by 
combining the reported prevalence of DMII in each LGA with ERP data for each 
LGA. This is used in Chapters 4 and 7. Of the 74 Queensland LGAs, three island 
LGAs were excluded, leaving 71 Queensland LGAs included in these analyses. 
 
Data from the Census were also used to obtain ERP counts for each of 21 
Statistical Local Areas (SLAs) in the region of New South Wales in 2001, used 
in Chapters 5 and 6. In addition, the socio-economic status of each SLA as 
measured by the Socio-Economic Indexes for Areas (SEIFA) in 2001 were used 
in these Chapters. This is based on information from the Census (Australian 
Bureau of Statistics 2013). SEIFA was developed by the ABS and ranks areas in 
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Australia according to relative socio-economic advantage and disadvantage. Four 
different measures of SES are available through the SEIFA: 
1. The Index of Relative Socio-Economic Advantage and Disadvantage (IRSAD)  
2. The Index of Relative Socio-Economic Disadvantage (IRSD) 
3. The Index of Education and Occupation (IEO)  
4. The Index of Economic Resources (IER). 
 
For each of the four indices, a larger score indicates relative greater socio-
economic advantage. 
 
The Queensland self-reported health status 2009-2010: Local Government 
Area summary report 
This report is based on a 2009-2010 survey within Queensland and is used for the 
analysis in Chapter 4 (Queensland Government 2011). Survey results are 
weighted by age and gender distribution. The survey estimates the prevalence of 
key population health indicators for those aged 18 years and older for each 
Queensland LGA based on self-report. Variables include body mass index (BMI) 
from self-reported height and weight, proportion of daily smokers, proportion 
with insufficient physical activity for health benefit, adequate fruit intake (2+ 
serves/day), and adequate vegetable intake (5+ serves/day). The proportion 
overweight or obese in each LGA, defined as BMI≥25kg/m2, was estimated from 
self-reported height and weight.  
 
The survey provides a total of 16,530 completed computer-assisted telephone  
interviews across Queensland, with a response rate of 56.7% in 2009 and 64.5% 
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in 2010. The telephone numbers selected for this survey were reportedly sourced 
by random digit dialling (RDD) using a specific sample frame from the 
Association of Market and Social Research Organisations RDD sample database. 
Data are reported for LGAs that had a sample of 60 or more completed interviews 
(Brisbane LGA had the largest number of interviews at 2,561). Data are not 
reported from this survey for 28 LGAs with a sample size smaller than 60 due to 
potential inaccuracy of estimates.  
 
Hospital data for NSWNC residents 
Routinely collected hospital data from a customised data request were obtained 
for all NSWNC residents attending any hospital within Australia between 
financial years 2001/02 to 2005/06 inclusive. This data were used for the analysis 
in Chapters 5 and 6. Variables available in the dataset for each admission include 
a patient identifier, financial year, calendar year, day of week and month of 
admission, hospital of admission, age, gender, Aboriginal and Torres Strait 
Islander (ATSI) status, country of birth, marital status, Statistical Local Area 
(SLA) of residence using 2001 SLA codes, daystay flag, readmission within 28 
days flag, hours spent in ICU, length of stay (LOS) and International Statistical 
Classification of Diseases-10 (ICD10) codes for principal and all secondary 
diagnoses. As the precise locations of patient residences were unavailable, 
distance to a patient’s hospital of admission was unable to be assessed. 
 
For each admission, recorded principal and secondary diagnoses with ICD10 
codes between E11.0 and E11.99 inclusive were classified as principal DMII 
admissions and secondary diagnosis of DMII respectively. Similarly, patients 
with any admission with a principal or secondary diagnosis taking ICD10 codes 
between J41 and J44 inclusive or J47 were classified as comorbid with COPD, 
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between I20 and I25 inclusive with CAD, between I10 and I15 inclusive with the 
exclusion of I11.0 with HT, and I11.0 or I50 or J81 with CHF. 
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